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Editorial on the Research Topic
Prescribing Psychotropics: Misuse, Abuse, Dependence, Withdrawal, and Addiction
Over the last decade, the trend of drug consumption has changed dramatically. The advent of
a high number of new psychoactive substances (NPS) has contributed to the appearance and
growth of a new “drug scenario” (1, 2) characterized by an increasing number of molecules
with unknown effects; poor safety profiles and acute drug toxicity presentations; and psychiatric
consequences (3–6). In this context, medications’ misuse appears to be an increasingly concerning
phenomenon, specifically driven by the already recorded rise in the opioid use, benzodiazepines,
and other Central Nervous System (CNS) depressants (including sedatives and hypnotics),
and prescription stimulants, e.g., amphetamines, methamphetamines, methylphenidate (7, 8).
However, a range of remaining molecules have been reported as being misused; diverted;
and recorded by drug users’ online websites suggesting new trends and experimentations
specifically with medicinal compounds (9–11). An increasing awareness regarding these issues
has been contributing to the development of pharmacovigilance studies regarding the possible
potential of misuse/abuse/dependence and withdrawal of both prescription (e.g., quetiapine,
gabapentinoids, olanzapine, bupropion, etc.) and over-the-counter (OTC) drugs (e.g., loperamide,
dextromethorphan, promethazine, benzydamine etc.) (12–17). Indeed, pharmacovigilance studies
have helped in identifying signals of misuse associated with these molecules (18). For instance,
whilst both pregabalin and gabapentin are approved treatments for epilepsy and neuropathic
pain disorders, with pregabalin being prescribed as well in some countries for the treatment of
generalized anxiety disorder (19), they have increasingly been reported for their misusing potential,
especially when used in combination with opioids and sedatives (12). In 2018, after safety warnings
following an increase in deaths related to their use, the UK Advisory Council on the Misuse of
Drugs (ACMD) recommended that both had to be controlled under the Misuse of Drugs Act 1971
as Class C substances and scheduled under the Misuse of Drugs Regulations 2001 as Schedule
3, so as not to preclude legitimate use on prescription (20). Conversely, a range of factors are
thought to contribute to the non-medical use of prescription/OTC drugs, such as the perception
of these molecules being more socially acceptable/less stigmatizing; likely lack of detection in
standard drug screens; and safer than remaining illicit substances as well. “Pharming”; “pharm-
parties”; and “doctor-shopping” attitudes, involving high-/mega-dosage prescription drugs’ intake,
are trends which are increasingly being reported among young adult populations (9, 21, 22). In
parallel with this, increasing levels of access to the web over the past 15 years or so may have
boosted the current scenario of prescribed drugs’ misuse and abuse, with social networks playing
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a role in medications’ aggressive marketing/distribution from
rogue “pharmacy” websites (10, 23–25). Moreover, the web has
been contributing to the diffusion of new synthetic compounds,
such as designer benzodiazepines and illicit fentanyl analogs,
which are associated with a high abuse potential and severe
adverse effects including coma and death (26–28). Finally, since
the beginning of 2020, due to drug shortage issues resulting to
the COVID-19 pandemic, a shift in misusing behavior relating
to both prescription and OTC medicines has been recorded
(10, 13, 29–33).
Consistent with these issues, the current Research Topic has
focussed on the assessment of the misuse, abuse, dependence,
withdrawal, diversion, and addiction potential of prescribing
and OTC drugs. A range of original research papers, systematic
reviews, meta-analysis, reviews, and case reports are here made
available. This Research Topic will hopefully shed further
light on the harms associated with medications’ misuse and
abuse, highlighting the importance of this field for clinicians;
prescribers; and health professionals in general. Indeed, 13
original articles of excellent quality and likely broad impact
are here offered to the Frontiers in Psychiatry readers. A
description of prescription drugs’ misuse in “clubbers” and disco
goers in Ibiza showed that current trends of such phenomenon
may not be limited to subjects with psychiatric disorders, as
prescription drugs may be used an alternative to classic and novel
psychoactive compounds and/or may be used to tamper and
self-medicate the effects determined by the use of substances.
Considering prescription drugs misused, the diversion of the
benzodiazepine etizolam was here recorded, being characterized
by high-dosage intake and resulting dependence issues; also, the
misuse and diversion of several OTCs, including antihistamines
(e.g., diphenhydramine, promethazine, chlorpheniramine, and
dimenhydrinate); dextromethorphan- and codeine-based cough
medicines; and the nasal decongestant pseudoephedrine have
here been reported. Furthermore, a few surveys are here being
collected; the first one is a European survey investigating
psychiatry trainees’ attitudes, knowledge and training in
addiction psychiatry, while a second paper evaluated the
German addiction medicine physicians’ knowledge of both
health and psychosocial harms of 33 psychoactive substances,
including opioids and non-opioid prescription analgesics, e.g.,
gabapentinoids. Finally, using data from the RADARS R© survey
on the non-medical use of prescription drugs conducted in
five European countries, the non-medical use of gabapentinoids
resulted to have the highest prevalence in Germany and
UK compared with Spain, Italy, and France. Data related to
gabapentinoids as recorded by the French Addictovigilance
Network confirmed the importance of pharmacovigilance
monitoring for gabapentinoids due to their abuse potential and
their related health harms, including hospitalization for serious
neurologic, psychiatric or cardiac effects; requests for specific
support; and deaths. Similarly, the analysis of the FDA Adverse
Event Reporting System (FAERS) database, using big data
search analytics as a supplementary tool to detect drug abuse-
related safety signals, supported these issues. In parallel, within
a multidimensional monitoring of prescription drug abuse,
the early detection and quantification of “doctor shopping”
practices may well need to be considered essential. Moreover,
the identification of specific personality traits (e.g., hopelessness,
anxiety sensitivity, sensation seeking, and impulsivity) and
psychometric indicators (e.g., the Severity of Dependence Scale-
SDS)might be useful in providing drug abusers with personalized
interventions and strategies. Finally, the treatment of drug
intoxication, as in a case of kratom use disorder, and of
drug withdrawal through the continuous infusion of flumazenil
in the management of benzodiazepines detoxification were
here described.
In conclusion, the abuse of prescription and OTC drugs
has become an issue of increasing public concern across
the globe (34). Whilst health services are already under
unprecedented levels of strain, the current drug scenarios
have further modified, in parallel with the current pandemic-
related goods’ and people local; national; and international
restrictions of movements. At these challenging times, healthcare
professionals are recommended to both be vigilant and
develop strategies to ensure continuity of care for people
who use drugs and people with drug use disorders, whilst
preventing as well possible medicines’ misuse and diversion
issues (9).
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Background: Over the past 15 years, comparative assessments of psychoactive
substance harms to both users and others have been compiled by addiction experts.
None of these rankings however have included synthetic cannabinoids or non-opioid
prescription analgesics (NOAs, e.g., gabapentinoids) despite evidence of increasing
recreational use. We present here an updated assessment by German addiction
medicine experts, considering changing Western consumption trends–including those
of NOAs.
Methods: In an initial survey, 101 German addiction medicine physicians evaluated
both physical and psychosocial harms (in 5 dimensions) of 33 psychoactive substances
including opioids and NOAs, to both users and others. In a second survey, 36 addiction
medicine physicians estimated the relative weight of each health and social harm
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dimension to determine the overall harm rank of an individual substance. We compared
our ranking with the most recent European assessment from 2014.
Results: Illicit drugs such as methamphetamine, heroin, cocaine and also alcohol
were judged particularly harmful, and new psychoactive drugs (cathinones, synthetic
cannabinoids) were ranked among the most harmful substances. Cannabis was ranked
in the midrange, on par with benzodiazepines and ketamine—somewhat more favorable
compared to the last European survey. Prescribed drugs including opioids (in contrast
to the USA, Canada, and Australia) were judged less harmful. NOAs were at the bottom
end of the ranking.
Conclusion: In Germany, alcohol and illicit drugs (including new psychoactive
substances) continue to rank among the most harmful addictive substances in contrast
to prescribed agents including opioid analgesics and NOAs. Current laws are incongruent
with these harm rankings. This study is the first of its kind to include comparative harm
rankings of several novel abused substances, both licit/prescribed and illicit.
Keywords: gabapentinoids, psychoropic drugs use, alcohol, illicit abused substance, new psychoactive drugs
KEY POINTS
Illicit drugs such as methamphetamine, heroin, and cocaine,
and also alcohol were judged particularly harmful.
Prescribed drugs including opioids (in contrast to the USA,
Canada and Australia) and non-opioid analgesics including
gabapentinoids were judged less harmful.
Current laws are somewhat incongruent with these
harm rankings.
INTRODUCTION
Abuse of addictive psychoactive substances is characterized
by negative health and social consequences not only for the
user, but also for non-users in the community or society
(1, 2). The DSM-5 has defined various specific substance-related
dependence and addiction conditions (3), and ICD-10 coding
reflects distinct mental and behavioral disorders related to
alcohol, tobacco, opiates, cocaine, stimulants, hallucinogens,
sedatives and hypnotics, cannabis and cannabinoids, and volatile
solvents (4).
Over the past 15 years, the relative health and social harms
potential of various addictive substances has been determined
in England (5), the Netherlands (6), Scotland (7), France (8),
and most recently in Australia (9) by medical and non-medical
addiction experts. The average overall harm of various substances
is usually reported in relative rankings, based upon multi-
decision analyses (5, 9) or relying on “ad-hoc” assessments (6–8)
using validated health and social dimensions (5). These rankings
do not necessarily display congruence with legislative and law
enforcement priorities in terms of relative regulation and control
of substances, with alcohol being a prime example of dissonance
between overall harms and control efforts (5–9). Nutt et al. were
the first to demonstrate this incongruity (5).
In 2014, a group of 40 medical and non-medical addiction
experts from 21 EU countries came to the same conclusion (10).
This survey included 20 substances (10). In the interim, as in
other Western countries, there have been shifting patterns of
substance abuse trends as well as political framework conditions
in Germany, especially
• Increasing abuse of methamphetamine mainly in regions
bordering the Czech Republic (11–13).
• Increasing occurrence of new psychoactive substances (NPS),
in particular a plethora of synthetic cannabinoids and
stimulants (mostly cathinones) (12–14).
• Increasing fatal overdoses with heroin/morphine, opioid-
containing, and non-opioid analgesics, synthetic opioids,
narcotics, amphetamine, amphetamine derivatives,
methamphetamine, and NPS, accompanied by a decrease in
overdose deaths through opioid dependence treatment drugs
such as methadone and buprenorphine (11, 15).
• Increasing availability of highly potent cannabis products with
increased risk for psychosis and addiction (11, 13, 16, 17).
• Legalization of medicinal marijuana and cannabinoids for
medical prescription (18).
Given these developments, we sought to update the assessment
of the health and social harms from substances that are
commonly misused in Germany and elsewhere and also of
substances less frequently abused in our country, but already
emerging (11, 12). In this context, synthetic cannabinoids (14)
were included into harms rankings for the first time. We also
included index surveys of harms rankings for propofol, an
intravenous anesthetic (19), and some non-opioid analgesics
(NOA), i.e., gabapentinoids, non-steroidal anti-inflammatory
drugs (NSAIDs), flupirtine, and triptans (20–24). We decided
to include NOAs together with opioid analgesics into our
ratings because gabapentin and pregabalin (gabapentinoids) have
recently entered the focus of addiction medicine. In the last
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decade, several pharmacovigilance databases, population-based
studies and case reports have warned of their potential abuse
liabilities and putative contribution to fatal overdoses especially
in combination with opioids (22, 23). Even though NSAIDs
are commonly thought to be non-addictive, there are recent
case reports (25, 26) and epidemiologic (27, 28) as well as
clinical data (24) that are raising some safety concerns about
this traditional view. Other NOAs have also shown potential
abuse and dependence liability e.g., flurpirtine (21) or triptans
TABLE 1 | Participants’ characteristics.
Surveys Cohort 1 Cohort 2
(n = 101) (n = 36)
Age (years old) Mean (SD) 49.8 (9.6) 52.9 (6.9)
Median 50 55
Gender Female (n, %) 26 (25.7%) 10 (27.8%)
Male (n, %) 75 (74.3%) 26 (72.2%)
Years of professional
experience
Mean (SD) 21.6 (9.5) 24.9 (8.2)
Median 20 26
Years of tertiary care of SUD Mean (SD) 16.3 (8.4) 17.6 (7.4)
Median 15 16,5




76 (75.2%) 26 (72.2%)
Rehabilitation
hospital (n, %)
25 (24.8%) 10 (27.8%)
(20). Therefore, we felt it prudent to include the aforementioned
NOAs for the first time in a study of this kind, too. This
study is the first of its kind to include comparative harm
rankings of several novel abused substances, both licit/prescribed
and illicit.
METHODS
This cross-sectional questionnaire-study comprised two
consecutive steps (survey 1 and survey 2, see below), in which
quantitative questionnaires were distributed in written form
among German addiction medicine experts. These experts were
recruited at German addiction congresses and conferences.
Additionally, the questionnaires were sent via email to 40 heads
of German drug addiction treatment centers who were asked to
distribute them in their zone of influence among other addiction
medicine experts. Only those questionnaires which had been
filled out by physicians who (i) were specialists, i.e., had extra
expertise in at least one medical specialty and (ii) had been
working longer than 5 years in tertiary care hospitals in the field
of substance use disorders (SUD) treatment were included in
the analysis. The experts’ identity was kept anonymous with the
exception of information about their age, gender, specialties,
years of professional experience, years of work in tertiary care
of SUD, and main focus of professional work (acute care or
rehabilitation hospital) (Table 1).
FIGURE 1 | Average overall harm of 30 substances (mean values and standard deviations) as assessed by cohort 1 on a scale from 0 (‘not harmful’) to 4 (‘extremely
harmful’), shown as harmful to users and harmful to others. The relative contribution of the 5 dimensions (Supplemental Figure 1, Supplemental Table 1) had been
weighted by cohort 2.
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The first survey was conducted from March 2016 to
September 2017 and assessed the average harm of 33 substances
in in 5 dimensions (physical harm to users, psychological
harm to users, social harm to users, physical and psychological
harm to others, and social harm to others). As shown in
Supplementary Figure 1, these dimensions were defined by 16
criteria, which have been validated in several studies of this type
(5, 9, 10) (see Supplementary Materials—Methods Section).
Overall harm to users and overall harm to others comprised 3
(physical, psychological, social) dimensions and 2 (physical
& psychological, social) dimensions, respectively (for
details see Supplementary Figure 1). The assessments were
carried out using 5-point scales (from “not harmful” to
“extremely harmful”).
The questionnaire was returned by 122 physicians and from
those 101 were evaluated since 21 experts did not meet the
inclusion criteria. The physicians were allowed to decide for
themselves whether to rate a substance or not, and they were
instructed to estimate their professional experience (“no/little”
or “moderate” or “a lot”) with each substance they had rated.
This information was needed to assess the validity of the ratings
and to verify defined exclusion criteria, i.e., a substance with
<60% ratings or more than 60% “no/little experience” ratings
was excluded from further analysis. Consequently, the substances
ayahuasca, khat, and kratom had to be excluded from the harm-
evaluation (Supplementary Figures 2 and 3).
The second survey (weighting of the dimensions to determine
the overall harm in Figure 1) was conducted from September
2017 toMay 2018 by cohort 2, which were recruited only from the
emails to the aforementioned 40 heads of German drug addiction
treatment centers. This follow-up survey was administered
subsequently because the first survey was quite comprehensive,
and combining the two surveys was deemed likely to overburden
cohort 1 respondents, reducing the return quota. The second
survey asked participants to estimate the relative weight (as
a proportion between 0 and 1) of each of the 5 dimensions
TABLE 2 | Plausibility check of the overall harm ranks.
Substances/Rank in dimension PHU PSHU SHU PPHO SHO OH LD– LD+
Crack 2 2 2 1 2 1 0 1
Methamphetamine 1 1 3 3 3 2 1 1
Heroin 5 4 1 2 1 3 2 2
Alcohol 4 8 5 4 4 4 0 4
Cocaine 7 3 4 5 5 5 2 2
GHB 6 5 7 7 7 6 1 1
Amphetamines 11 6 6 6 6 7 1 4
Cathinones 9 10 10 9 8 8 0 2
Synthetic cannabinoids 13 7 9 8 11 9 −2 3
Propofol 10 18 11 13 14 10 0 8
Ecstasy 15 16 12 10 9 11 −2 5
Natural hallucinogens 8 14 18 15 17 12 −4 5
Ketamine 14 15 13 11 12 13 −2 2
Barbiturates 12 12 17 19 20 14 −2 6
Benzodiazepines 16 9 15 18 16 15 −6 3
Cannabis 21 13 8 17 10 16 −8 5
Psychotropic mushrooms 18 17 16 14 13 17 −3 5
LSD 20 11 14 16 15 18 −7 2
Nicotine 3 25 24 12 18 19 −16 6
Opioidergic Analgesics 19 19 19 23 22 20 −1 3
ZDrugs 22 20 22 22 23 21 −1 2
Codeine 23 22 20 20 19 22 −3 1
Tilidine/Tramadol 24 21 21 21 24 23 −2 1
Methadone 26 24 23 24 21 24 −3 2
Gabapentinoids 27 23 27 27 27 25 −2 2
Buprenorphine 30 27 25 25 25 26 −1 4
Methylphenidate 28 26 26 26 26 27 −1 1
Flupirtine 26 28 28 28 28 28 −2 0
NSAIDs 17 29 29 29 29 29 −12 0
Triptans 29 30 30 30 30 30 −1 0
The lower the largest difference (LD)-value the lower the variability of the 5 dimension-ranks with reference to the (individual) overall harm (OH)-rank of any substance. Discrepancies
of ≥8 ranks are marked with grey horizontal background indicating considerable variability of the single dimension-ranks with reference to the individual OH-rank requiring plausible
explanations. Abbreviations of the single dimensions: PHU – physical harm to users, PSHU – psychological harm to users, SHU – social harm to users, PPHO – physical & psychological
harm to others, SHO – social harm to others, OH – overall harm, LD− – largest difference between OH-rank and any lower dimension-rank, LD+ – largest difference between OH-rank
and any higher dimension-rank.
Frontiers in Psychiatry | www.frontiersin.org 4 October 2020 | Volume 11 | Article 59219911
Bonnet et al. Psychoactive Drugs’ Ranking
used in the first survey for the constitution of overall harm of
psychotropic substances. All of the 36 returned questionnaires
were included. We used the mean relative weight given by the
36 experts to each dimension for calculating the overall harm
of each substance (Figure 1). Further details of the overall harm
calculation of the remaining 30 substances and related data
analyses including the comparison with the previous EU-ranking
(Figure 3) are presented in the Supplementary Materials.
Validation of rankings was performed first by evaluating
the magnitude of variability between the overall harm
rating and any of the five component dimensions. A
difference between the overall harm rating and any of the 5
separate ratings in the dimensions ≥8 ranks was considered
significant and requires plausibility explanation (Table 2).
An additional validation/sensitivity test was performed
by substituting our survey-derived mean weights with
the consensus-based weights of the previous EU-study
(Supplementary Table 1) and comparing the resulting
substance-ranks of Supplementary Figure 9 with those of
Figure 1 (Supplementary Table 2).
RESULTS
Sample and Participants’ Experience
The specialist physicians had worked for a median of 15 years
(cohort 1) and 16.5 years (cohort 2) in the tertiary care of
patients with SUD. Approximately three out of four participants
worked in acute care hospitals, with the remainder working in
rehabilitation clinics (Table 1).
Average Overall Harm
Experts’ ratings in the 5 separate dimensions are shown in
the (Supplementary Figures 4–8). Regarding overall harm,
traditional drugs of abuse, i.e., cocaine (including “crack”),
methamphetamine, heroin, and alcohol were ranked as
being most harmful. The NPS, i.e., cathinones and synthetic
cannabinoids, had subordinate positions in the top harm-level
group. Ketamine, benzodiazepines, cannabis, psychotropic
mushrooms, LSD, nicotine, and opioid analgesics were in the
midrange. Methadone and buprenorphine (both preferred in
Germany for maintenance therapy of opioid dependence) fell
into the lower ranges, while methylphenidate (in Germany
the preferred medication for ADHD-treatment), and NOAs
were at the lowest ranges of the harm-ranking. Among the
NOAs, gabapentin and pregabalin (gabapentinoids) were
regarded as more harmful than flupirtine, NSAIDs and
triptans (Figure 1).
Difference Between Acute and
Rehabilitation Hospital Raters?
The assessments of the specialists from acute and rehabilitation
hospitals were very similar as shown in Figure 2.
Comparison With the Last European
Analysis
This updated German survey assessed methadone, nicotine,
cannabis and alcohol as less harmful than did the EU-raters in
FIGURE 2 | Comparison of assessments between specialists at acute
(n = 76, blue curve) vs. rehabilitation hospitals (n = 25, red curve).
2014 (10), while psychotropic mushrooms, cathinones, ecstasy,
GHB, methamphetamine, and crack were judged to be more
harmful—see Figure 3.
Plausibility Check and Sensitivity Test
The lowest discrepancies between the average overall harm-rank
and the 5 health and social dimension-ranks were found for
the traditional illegal drugs crack (and other cocaine), heroin,
methamphetamine, and also for alcohol, which were also ranked
at the top positions in terms of harms. The same applied to GHB
and NPS ranking near the top, ketamine in the midrange, opioids
at lower ranges, and most NOAs (gabapentinoids, flupirtine,
triptans) at the lowest ranks. Striking discrepancies were seen for
propofol, cannabis, nicotine and NSAIDs (Table 2). In case of
nicotine and NSAIDs disproportionate physical harm concerns
(e.g., cancer, stroke, coronary disease, COPD for the former,
and GI bleeds, renal and cardiovascular disease for the latter)
likely account for most of the discrepancy for those substances.
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FIGURE 3 | Correlation of the present assessment and the last EU-assessment (10) of the overall harm of drugs of abuse (rs = 0.73). For better orientation, the
bisector indicates perfect correlation (rs = 1).
In the case of cannabis, the German literature currently reflects
a general perception of relatively low physical harms and
conversely a perception of elevated psychosocial harms to users,
which dichotomy serves to corroborate the discrepancy here
(29–31). The discrepancy for nicotine (and perhaps also for
propofol to some extent)may be owing in part to an unexpectedly
low ranking of psychological harm to users which diverges
from empiric evidence. This potential underestimation may
therefore threaten the validity of the overall harm-ranks of these
specific substances.
When alternatively, we used the consensus-based weights
of the EU-rating study (10) as a comparison sensitivity
test, we found that the resulting ranking of overall
harms (Supplementary Figure 9) was very similar to our
survey-derived weighted rankings shown in Figure 1 (see
Supplementary Table 2 for comparison). This suggests that
the outlier/skewed weightings of individual dimensions
(Supplementary Table 1) do not critically influence the resulting
overall harm rankings in our study.
DISCUSSION
Our data corroborate the situation in many other countries
(5–10) of discordance between expert harm rankings of popular
drugs of abuse and their regulation by narcotic laws, as evidenced
most strikingly by the assessment of alcohol—judged to be
among the most harmful substances abused in our country.
The relatively high prevalence of alcohol use/abuse (compared
to that of less-frequently abused but perhaps more dangerous
substances) likely contributes to its dimension-specific ratings,
e.g., harm to others, as well as to its overall position. Similarly,
the decreasing prevalence of nicotine use in Germany (as
tobacco smoking has been banned from many public areas
such as hospitals, educational establishments, public transport,
restaurants, pubs, and discos during the last 10 years or so) may
contribute to a lower-than-expected harm ranking. In addition
it should be mentioned that nicotine use, despite its ability to
produce considerable behavioral dependence is hardly associated
with dramatic psychiatric effects, e.g., in contrast to alcohol or
hallucinogen use. This study was the first to compare the harms
of various NOAs with harms of well-characterized substances
of abuse, and as expected identifies the harms of NOAs to be
considerably lower than those of the traditional substances of
abuse. The present study was also the first to include synthetic
cannabinoids and propofol in an overall-harm ranking schema,
which may be beneficial for the psychoeducation of users, for
regulatory considerations, or for defining fields of political action
for health promotion.
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NPS (cathinones and synthetic cannabinoids) have been
assigned to the top harm-level group here. Policy-makers and
clinicians would benefit from further data about the NPS-
phenomenon, e.g., associated morbidity (32, 33) and mortality
which are on the rise (33).
Compared with the EU-rating from 2014 (10), cannabis,
methadone and nicotine were assessed as less harmful, while
crack, methamphetamine, GHB, cathinones, ecstasy, and
psychotropic mushrooms were seen as more harmful (Figure 3).
Cannabis and hallucinogens (i.e., ketamine, psychotropic
mushrooms and LSD) were considered to be on the harm level
of benzodiazepines or barbiturates. It should be mentioned that
psilocybin (in Figure 1 listed as psychotropic mushrooms) and
LSD have both enjoyed re-emerging therapeutic potential in
psychiatric diseases and appear to show low abuse potential in
that context (34).
It is interesting to note that opioid analgesics were not
within the top ranks of harmful drugs. This could perhaps
be related to the fact that an “opioid epidemic” (such as that
in the USA, Canada and Australia), is yet not apparent in
Germany or inWestern Europe (35–38). The relatively low harm
rankings of prescription opioids in our study stand in stark
contrast to the high level of stigmatization of illicit opioids.
These findings are congruent with the multi-decision analysis
of nine experts (8 from the United Kingdom and 1 from the
Netherlands) suggesting that the overall harms of non-medically
used prescription opioids are less than half that of injected street
heroin (39).
Methadone was assessed as less harmful than standard
opioid analgesics, which viewpoint might be biased by addiction
medicine physicians’ conception of methadone primarily as a
standard opioid dependence maintenance treatment, which in
this context has been repeatedly shown to reduce morbidity and
mortality (15). In the context of illicit use and abuse, methadone’s
harms (e.g., apneic and torsades-de-pointe deaths, addiction, and
diversion) are obviously considerably higher than those of several
other drugs ranked above it. This exposes a major limitation of
drug harm-ranking studies based upon subjective assessments as
they may not allow for clear differentiation between the harms
of a drug with therapeutic indication in a medical context vs.
illicit use/misuse outside of that context. These discrepancies in
ranking of analgesics among other agents suggest that perhaps
raters’ experience in pain medicine should have been surveyed
as well.
It cannot be excluded that our ratings may be biased toward
metropolitan rather than rural perception of substance use
harms; clarifying this would require further study in larger
samples. Also, a possible gender influence on drug harm
perceptions was not explicitly investigated here (40, 41). As we
had sent out the questionnaires without tracking all recipients,
requesting forwarding to other German addiction medicine
experts, we are unable to provide information about the exact
number of experts who finally received our questionnaires.
However, such modus operandi is not unusual for studies of
this kind (5). Other limitations, similar to previous studies
(5–10) include the fact that the present work cannot claim to
meet strict requirements for representativeness. We aimed to
reduce subjectivity biases by recruiting a large and homogeneous
study group (all physicians specializing in addiction medicine).
However, no official statistic exists for how many specialists
with more than 5 years of experience in tertiary care of
SUD were working in Germany at the time of the study. We
estimate that number to be somewhere between 250 and 500
physicians, thus our sample may yield a minority viewpoint. In
Germany, addiction medicine experts usually are psychiatrists
or general practitioners. Unlike the English (5), EU (10) and
Australian (9) studies, we used no consensus–feedbacks. While
this additional step may have increased the likelihood of survey
participants’ agreement (42), we decided against this course,
because consensus-based decisions per se do not eliminate
subjectivity (43) and there exists no “one-size-fits-all-method”
for benefit-risk assessment (44). Furthermore, prior consensus-
based studies utilized smaller samples comprising addiction
experts from different professions (5, 9, 10), whose heterogeneity
of experiences in the treatment of SUD more likely needed a
consensus-based decision strategy than did our homogeneous
group. Similar to the Netherlands (6), the Scottish (7), and
the French research groups (8) we performed an “ad-hoc”
assessment, using validated health and social dimensions, which
have been utilized in previous (5, 10) and recent (9) empirical
studies. This decision to use an “ad-hoc” format maximized the
return of completed questionnaires.
Apart from the novel inclusion of NOAs, synthetic
cannabinoids and propofol, there are a few strengths of the
present study: (i) the utilization of one of the largest samples
in this type of study; (ii) the considerable multidimensional
addiction medicine experience of the participants, including that
of rehabilitation clinic specialists (Figure 2), which in Germany
focuses heavily upon psychosocial dimensions and outcomes;
(iii) comparison with the previous EU-rating (Figure 3); and (iv)
the addition of comparisons of illicit and licit drug rankings to
the current literature.
The results of this cross-sectional questionnaire-study update
the average overall harm (with component harms from
various health and social dimensions) arising from use/misuse
of various psychoactive substances (including prescription
analgesics) from the perspective of German addiction medicine
specialists. It should be emphasized however that these
relative overall rankings apply to population-level risks, and
depending on the individual and situational context as well
as on the intensity of the individual misuse, nearly every
psychoactive substance can be used in a very dangerous and
harmful way.
CONCLUSION
This study provides an updated German addiction medicine
expert ranking of the average overall harms as well as harms
in specific health and social dimensions of various psychoactive
substances, including analgesics. Alcohol was estimated to be
among the most harmful addictive substances, along with heroin,
cocaine, methamphetamine, GHB, and NPS (i.e., synthetic
cannabinoids, cathinones). The elevated risks of alcohol are
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somewhat discordant with the German narcotic law, similar to
most countries. Cannabis and ketamine were ranked inmidrange
on par with benzodiazepines. Therapeutically used drugs such
as non-opioid analgesics, methylphenidate, and opioids were
estimated to be on the whole to be the least harmful at present.
Such relative safety perception however is certainly subject to
change should misuse and abuse patterns change over time (45).
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Introduction: The use of novel designer drugs has increased worldwide over the
years. Etizolam is a designer benzodiazepine (BZD) that has raised concern because
of its growing non-medical use, liability to tolerance and dependence, and related
harms. Studies exploring the abuse liability and cognitive effects of etizolam outside the
therapeutic doses are lacking.
Aims: To explore the abuse liability of etizolam and the characteristics of patients affected
by etizolam high-dose dependence in a nationwide tertiary referral addiction unit. To
document the cognitive changes to etizolam high-dose use.
Design and Methods: Sociodemographic and clinical data on subjects with etizolam
high-dose use were retrospectively collected from a database of 1,293 patients
consecutively admitted to the Addiction Medicine Unit, Verona University Hospital,
Italy for detoxification from high-dose BZDs or Z-drugs dependence. Thorough
neuropsychological testing explored the cognitive side effects of high-dose etizolam use.
Results: We found eleven etizolam high-dose users, of which eight used etizolam only,
and three used etizolam with other BZDs/zolpidem. All the patients were prescribed
etizolam for medical reasons, i.e., anxiety and/or insomnia. Neuropsychological
evaluation showed deficits of working memory, visuospatial memory and executive
function in a 27-year-old woman who used etizolam 15 mg daily.
Discussion: Our findings suggest that abuse and dependence liability of etizolam should
be considered a public health and social problem. They offer preliminary evidence on the
cognitive side effects of etizolam high-dose use.
Conclusions: This report offers new information on the potential harms of etizolam in
patients who are prescribed this drug for medical reasons.
Keywords: benzodiazepine, BZD, cognition, dependence, etizolam, substance use disorder (SUD),
neuropsychology
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INTRODUCTION
Benzodiazepines (BDZs) are gamma-amino-butyric acid type
A (GABA-A) receptor positive allosteric modulators widely
prescribed for anxiety, insomnia and other conditions (1).
The increasing use of novel designer BZD derivatives has been
recently reported in countries, where these chemical compounds
do not have marketing authorization as medicinal products (2).
Etizolam is a short-acting (half-life 5–7 h) thienodiazepine
designer BZD with high affinity for the GABA-A receptor and
anxiolytic and sedative properties (3). Etizolam is currently
approved for therapeutic use and marketed in three countries,
namely India, Italy and Japan, but available from the Internet for
research purposes worldwide (4). The few available comparative
studies reported that etizolam may induce less tolerance than
lorazepam and may have lesser sedative effects than alprazolam
and diazepam (4). The lower allosteric potency at the α1 subunit
of the GABA-A receptor has been proposed as one reason for the
reduced liability of etizolam to tolerance and dependence (5).
A consistent increase in the non-medical use and the illicit
drug market of etizolam has been reported since 2014, being this
drug implicated in several deaths in Scotland, United Kingdom,
and to a lesser extent in the United States and Sweden (4, 6). A
recent review concluded that few harms are documented with
the therapeutic use of etizolam, being predominantly related to
its non-medical use in illicitly manufactured pills and in the
context of mixed-drug toxicity, in particular in combination
with opioids (7). The World Health Organization Expert
Committee on Drug Dependence (WHO-ECDD) considered
etizolam abuse or dependence liability as an effectively public
health and social problem (4). Some questions on etizolam
side-effects profile are still unanswered. Evidence on etizolam
safety is based on preclinical studies and case reports. Common
adverse effects of etizolam include drowsiness, sedation and
slurred speech, but this drug is considered generally well-
tolerated in terms of cognitive side effects (4). The auditory
P300 was found to be prolonged with etizolam, but this
slowed brain response showed habituation, while attention and
memory appeared to be unaffected by etizolam (8). Therapeutic
etizolam doses (0.25–1mg) had no effect on cognition in
patients with anxiety (9) and on psychomotor performance and
vigilance (10). Cognitive effects to higher doses of etizolam are
still unexplored.
High-dose dependence of BZDs or related Z-drugs
(e.g., zolpidem, zopiclone, eszopiclone, zaleplon), i.e.,
daily intake ≥5 times the recommended maximum daily
dosage (1) is an emerging substance use disorder estimated
to affect 0.16% of the adult population in Switzerland
(11), associated to poor quality of life (12), and cognitive
dysfunction (13). Data on etizolam high-dose dependence
are lacking.
This report is aimed to (a) explore the liability of
etizolam to abuse and the characteristics of patients affected
by etizolam high-dose dependence in a nationwide tertiary
referral addiction unit; (b) document the cognitive changes
to etizolam in a high-dose user who underwent thorough
neuropsychological evaluation.
METHODS
Subjects with high-dose etizolam were retrospectively collected
from a database of 1,293 patients (650 men, 643 women)
aged >18 years and admitted (January 2003–December 2019)
to the Addiction Medicine Unit, Verona University Hospital,
Italy, a nationwide tertiary referral center for detoxification
from high-dose BZD/Z-drug dependence with slow flumazenil
infusion (14).
High-dose BZD/Z-drug dependence was defined according
to DSM-IV-TR criteria (15) with use lasting >6 months,
daily dosage exceeding at least 5 times the recommended
maximum intake (i.e.,>50mg of daily diazepam dose equivalent,
DDDE), otherwise problematic use of BZD/Z-drug, such as
mixing different molecules, escalating dosage, obtaining them
by illegal means, and using them to enhance the effect of other
substances (14).
We collected socio-demographic and clinical variables of the
patients. The dosage of BZD/Z-drugs was based on self-report.
DDDE (mg) was calculated according to conversion tables (14).









Marital status (single/engaged or married) 6/5
Clinical variables
Etizolam daily dosage 27.3 ± 29.3; 15; 5–100
Etizolam formulation (tablet/drops/both) 3/7/1
Concomitant abuse of other BZD/Z-drugs
(yes/no)
3/8
DDDE (mg)a 272.7 ± 263.5; 150; 70–1,000
BZD/Z-drug use duration (mos)a 36.6 ± 26.0; 24; 10–84
Age of first BZD/Z-drug intakea 24.6 ± 8.3; 21; 14–37
Reason for prescription (anxiety/sleep
disorders/both)
5/1/5






Psychiatric disorders (yes/no) 9/2
Anxiety disorders (yes/no) 6/5
Major depression (yes/no) 4/7
Other psychoses (yes/no) 1/10
Personality disorders (yes/no) 2/9
aMean ± SD; median; range. BZD, benzodiazepine; DDDE, daily diazepam dose
equivalent (sum of DDDEs for all BZDs and Z drugs in case of concomitant abuse of
other BZD/Z-drugs); Mos, months.
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FIGURE 1 | Results of the neuropsychological evaluation from one patient (woman, age 27 years, education 8 years) who took etizolam 15mg daily.
Neuropsychological findings are reported as Z-scores with negative values indicating worse performance and positive values indicating better performance than the
average value of the normal population. Abnormal values are worse than mean−1 SD; i.e., Z-scores <-1 indicate abnormal values. Shaded area indicates normal
range of values.
The diagnosis of psychiatric disorders was based on screening
tests, diagnostic interviews, and previous psychiatric assessments
or evaluations, when available.
Neuropsychological evaluation explored verbal memory,
working memory, visuospatial memory, attention and executive
function. Verbal memory was assessed by means of the Italian
versions of the Verbal Paired Association (VPA) (16) and
the Digit Span Forward Test (DSFT) (17). Working memory
was evaluated with the Digit Span Backward Test (DSBT)
(17) and Paced Auditory Serial Addition Test (PASAT-3) (18).
Visuospatial memory was explored with the 10/36 Spatial Recall
Test (SPART) (18). Attention was measured with the Trail
Making Test Part A (TMT-A) and the Symbol Digit Modalities
Test (SDMT) (18). Executive function was evaluated by means
of Trail Making Test Part B (TMT-B) (18) and the Stroop test
(19). Results were standardized as Z-scores. Cognitive testing was
performed 1 month before detoxification treatment.
All patients underwent a detoxification protocol with slow
subcutaneous flumazenil infusion (40.5 µg/h for 24 h/day for 7
days) with a prophylactic antiepileptic treatment (14).
The study was conducted according to the Declaration of
Helsinki and approved by the ethics committee of the Verona
University Hospital. All the patients gave written informed
consent to the study.
RESULTS
Among the patients admitted from January 2003 to December
2019, we found 11 patients (4 men, 7 women) who used high-
dose etizolam either as the only BZD (8 patients) or with other
BZDs or Z-drugs (3 patients; bromazepam: 1; lorazepam and
zolpidem: 1, clonazepam and triazolam: 1). All the patients were
prescribed etizolam for medical use (anxiety: 5 patients; sleep
disorders: 1; both reasons: 5) and obtained the drug through a
prescription and a pharmacy. The number of patients was stable
across years (2003–2007: 2 patients; 2008–2011: 3; 2012–2015: 4;
2016–2019: 2). Sociodemographic and clinical features of patients
are reported in Table 1.
The remaining 1,282 patients used other BZD/Z-drugs high-
doses [for further details see (12, 13)].
One patient (woman, 27 years, education 8 years; 15mg of
etizolam daily) underwent neuropsychological evaluation that
showed working memory, visuospatial memory, and executive
function to be outside normal values (i.e., >1 SD worse than
normal controls; Figure 1). No medical conditions or other
substance use disorder that could have contributed to the
cognitive deficits were reported.
DISCUSSION
To the best of our knowledge, this is the first report of etizolam
high-dose dependence in 11 patients who received etizolam for
medical reasons (anxiety and/or sleep disorders). Our patients
received on average 27.3 ± 29.3mg etizolam daily, which is
nearly ten times the maximum recommended daily dosage (i.e.,
3mg), with one patient taking 100mg daily, i.e., >30 times the
maximum daily dosage. These findings support the conclusion of
the recent WHO-ECDD report that abuse/dependence liability
of etizolam should be considered as a public health and social
problem (4). They are also in keeping with individual users
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reports on forums like Bluelight.org (20) and Erowid.org (21)
that describe tolerance, craving and withdrawal to etizolam (7).
Etizolam high-dose users represented 0.9% of our whole
sample and did not increase during the nearly 20 years covered
by our large database, suggesting some concern, but stable figures
across time. The big size difference between etizolam and other
BZDs/Z-drugs high-dose users hampered a reasonable statistical
comparison. However, when compared to high-dose users of
lormetazepam, i.e., the most common BZD of high-dose use in
Italy (22), etizolam high-dose users appear to be more frequently
women, younger, more frequently employed, with lower DDDE,
shorter BZD/Z-drug use duration, smaller age of first BZD/Z-
drug intake and more frequent poly-drug use. These findings
suggest that some populations of patients might be more prone
to non-medical use and dependence of etizolam. In particular,
they confirm the risk of etizolam harms in patients with other
substance use disorders (4).
The small number of etizolam high-dose users in our large
sample is likely related to the number of prescriptions in the
general population. Etizolam does not stand among the ten most
prescribed BZD active principles in Italy, in that its defined daily
dose (DDD) in 2018 was <0.5/1,000, while that of the most
commonly ones ranged from 13.2 for lormetazepam to 0.7 for
flurazepam (23). The absence of data on etizolam prescription
in Italian population, however, hampers the estimation of the
conversion-rate from etizolam prescription to addiction.
Etizolam negatively influenced most of the cognitive domains
in the patient who underwent neuropsychological testing, in
particular working memory, visuospatial memory, and executive
function, some of them being <2 SDs worse than normal values.
This finding, despite being preliminary since stemming from a
single patient, extends the notion that high doses of BZDs have
an impact on cognition, even in younger patients (13, 24). BZDs
cognitive side effects have been suggested to be related to the
function of the GABA-A receptor α1 (responsible for anterograde
amnesia) and the α5 subunits, which are involved in cognition,
learning and memory (25). Based on animal studies showing
etizolam lower affinity for the GABA-A receptor α1 subunit than
the α5 one (5), we speculate that the cognitive effects of etizolam
high-dose intake in our patient might be mainly mediated by the
interaction with the α5 subunit.
The strengths of this study are that it represents the first
series of etizolam high-dose users, and offers new information
on the harms of this BZD derivative from a nationwide referral
center in one of the few countries where it is marketed. The
limitations are the retrospective design, the absence of systematic
quantitative BZD measures to verify self-reported data, and
neuropsychological data from a single patient that suggest
caution in generalizing our findings on cognitive side effects
of etizolam.
In conclusion, a small number of patients who use etizolam
for therapeutic reasons appear to transition to high-dose use
requiring specialist care. This report offers new information on
the potential harms related to etizolam and extends them to
patients who are prescribed this drug for medical reasons. Future
studies should confirm our findings in larger populations and in
other countries where etizolam is marketed.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by Ethics Committee of the Verona University
Hospital. The patients/participants provided their written
informed consent to participate in this study.
AUTHOR CONTRIBUTIONS
ST, EM, AB, AF, RC, and FL designed the study and gathered
the data. ST analyzed the data. ST, EM, AB, AF, and RC drafted
the manuscript. FL and ST revised the manuscript. All authors
approved the final version of the manuscript.
REFERENCES
1. Janhsen K, Roser P, Hoffmann K. The problems of long-term treatment with
benzodiazepines and related substances. Prescribing practice, epidemiology
and the treatment of withdrawal. Dtsch Arztebl Int. (2015) 112:1–7.
doi: 10.3238/arztebl.2015.0001
2. Carpenter JE, Murray BP, Dunkley C, Kazzi ZN, Gittinger MH.
Designer benzodiazepines: a report of exposures recorded in the
national poison data system, 2014–2017. Clin Toxicol. (2019) 57:282–6.
doi: 10.1080/15563650.2018.1510502
3. Altamura AC, Moliterno D, Paletta S, Maffini M, Mauri MC, Bareggi S.
Understanding the pharmacokinetics of anxiolytic drugs. Expert Opin Drug
Metab Toxicol. (2013) 9:423–40. doi: 10.1517/17425255.2013.759209
4. World Health Organization. Expert Committee on Drug Dependence: forty-
second report. Geneva. World Health Organization (2020). Available online
at: https://apps.who.int/iris/handle/10665/331486 (accessed April 24, 2020).
5. Sanna E, Busonero F, Talani G, Mostallino MC, Mura ML, Pisu MG, et al.
Low tolerance and dependence liabilities of etizolam: molecular, fuctional,
and pharmacological correlates. Eur J Clin Pharmacol. (2005) 519:3–42.
doi: 10.1016/j.ejphar.2005.06.047
6. O’Connell CW, Sadler CA, Tolia VM, Ly BT, Saitman AM, Fitzgerald RL.
Overdose of etizolam: the abuse and rise of a benzodiazepine analog. Ann
Emerg Med. (2015) 65:465–6. doi: 10.1016/j.annemergmed.2014.12.019
7. Nielsen S, McAuley A. Etizolam: a rapid review on pharmacology,
non-medical use and harms. Drug Alcohol Rev. (2020) 39:330–6.
doi: 10.1111/dar.13052
8. Fukami G, Hashimoto T, Shirayama Y, Hasegawa T, Watanabe H, Fujisaki
M, et al. Effects of etizolam and ethyl loflazepate on the P300 event-
related potential in healthy subjects. Ann Gen Psychiatry. (2010) 9:37.
doi: 10.1186/1744-859X-9-37
9. De Candia MP, Di Sciascio G, Durbano F, Mencacci C, Rubiera M,
Aguglia E, et al. Effects of treatment with etizolam 0.5mg BID on
cognitive performance: a 3-week, multicenter, randomized, double-blind,
placebo-controlled, two-treatment, three- period, noninferiority crossover
study in patients with anxiety disorder. Clin Ther. (2009) 31:2851–9.
doi: 10.1016/j.clinthera.2009.12.010
Frontiers in Psychiatry | www.frontiersin.org 4 November 2020 | Volume 11 | Article 60182720
Tamburin et al. Etizolam High-Dose Dependence
10. Busardo FP, Di Trana A, Montanari E, Mauloni S, Tagliabracci A, Giorgetti
R. Is etizolam a safe medication? Effects on psychomotor perfomance at
therapeutic dosages of a newly abused psychoactive substance. Forensic Sci
Int. (2019) 301:137–41. doi: 10.1016/j.forsciint.2019.05.018
11. Petitjean S, Ladewig D, Meier CR, Amrein R, Wiesbeck GA. Benzodiazepine
prescribing to the Swiss adult population: results from a national survey
of community pharmacies. Int Clin Psychopharmacol. (2007) 22:292–8.
doi: 10.1097/YIC.0b013e328105e0f2
12. Tamburin S, Federico A, Faccini M, Casari R, Morbioli L, Sartore V, et al.
Determinants of quality of life in high-dose benzodiazepine misusers. Int J
Environ Res Public Health. (2017) 14:38. doi: 10.3390/ijerph14010038
13. Federico A, Tamburin S, Maier A, Faccini M, Casari R, Morbioli L, et al.
Multifocal cognitive dysfunction in high-dose benzodiazepine users: a cross-
sectional study.Neurol Sci. (2017) 38:137–42. doi: 10.1007/s10072-016-2732-5
14. Tamburin S, Faccini M, Casari R, Federico A, Morbioli L, Franchini E, et al.
Low risk of seizures with slow flumazenil infusion and routine anticonvulsant
prophylaxis for high-dose benzodiazepine dependence. J Psychopharmacol.
(2017) 31:1369–73. doi: 10.1177/0269881117714050
15. American Psychiatric Association, APA. Diagnostic and Statistical Manual
of Mental Disorders. 4th ed. Washington, DC: American Psychiatric
Press (2000).
16. Zappalà G, Measso G, Cavarzeran F, Grigoletto F, Lebowitz B, Pirozzolo
F, et al. Aging and memory: corrections for age, sex and education for
three widely used memory tests. Ital J Neurol Sci. (1995) 16:177–84.
doi: 10.1007/BF02282985
17. Orsini A, Grossi D, Capitani E, Laiacona M, Papagno C, Vallar G. Verbal
and spatial immediate memory span: normative data from 1355 adults
and 1112 children. Ital J Neurol Sci. (1987) 8:539–48. doi: 10.1007/BF023
33660
18. Goretti B, Patti F, Cilia S, Mattioli F, Stampatori C, Scarpazza C, et al. The
rao’s brief repeatable battery version B: normative values with age, education
and gender corrections in an Italian population. Neurol Sci. (2014) 35:79–82.
doi: 10.1007/s10072-013-1558-7
19. Brugnolo A, De Carli F, Accardo J, Amore M, Bosia LE, Bruzzaniti C, et al.
An updated Italian normative dataset for the stroop color word test (SCWT).
Neurol Sci. (2016) 37:365–72. doi: 10.1007/s10072-015-2428-2
20. Bluelight.org. Benzos (thienodiazepine) Etizolam Megathread V2. (2020).
Available online at: https://www.bluelight.org/xf/threads/thienodiazepine-
etizolam-megathread-v2.660685/page-97#post-14600229 (accessed April 24,
2020)
21. Erowid.org. Etizolam. (2020). Available online at: https://erowid.org/pharms/
etizolam/ (accessed April 24, 2020).
22. Faccini M, Tamburin S, Casari R, Morbioli L, Lugoboni F. High-dose
lormetazepam dependence: strange case of Dr. Jekyll and Mr. Hyde. Intern
Emerg Med. (2019) 14:1271–8. doi: 10.1007/s11739-019-02101-8
23. Agenzia Italiana del Farmaco (AIFA). The Medicines Utilisation Monitoring
Centre. National Report on Medicines use in Italy. Year 2018. Rome: Italian
Medicines Agency. (2019). Available online at: https://www.aifa.gov.it/
documents/20142/0/Rapporto_OsMed_2018.pdf/c9eb79f9-b791-2759-4a9e-
e56e1348a976 (accessed April 24, 2020).
24. Federico A, Lugoboni F, Mantovani E, Martini A, Morbioli L, Casari
R, et al. Detoxification improves multidomain cognitive dysfunction
in high-dose benzodiazepine abusers. Front Neurosci. (2020) 14:747.
doi: 10.3389/fnins.2020.00747
25. Mohler H. The legacy of the benzodiazepine receptor: from flumazenil to
enhancing cognition in down syndrome and social interaction in autism. Adv
Pharmacol. (2015) 72:1–36. doi: 10.1016/bs.apha.2014.10.008
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
The reviewer, AM, declared a past co-authorship with one of the authors,
FL, to the handling Editor.
Copyright © 2020 Tamburin, Mantovani, Bertoldi, Federico, Casari and Lugoboni.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Psychiatry | www.frontiersin.org 5 November 2020 | Volume 11 | Article 60182721
ORIGINAL RESEARCH
published: 15 December 2020
doi: 10.3389/fpsyt.2020.592594
Frontiers in Psychiatry | www.frontiersin.org 1 December 2020 | Volume 11 | Article 592594
Edited by:
Liana Fattore,
National Research Council (CNR), Italy
Reviewed by:
Daria Piacentino,
National Institutes of Health (NIH),
United States
Amira Guirguis,




†These authors have contributed
equally to this work and share first
authorship
Specialty section:
This article was submitted to
Addictive Disorders,
a section of the journal
Frontiers in Psychiatry
Received: 07 August 2020
Accepted: 16 November 2020
Published: 15 December 2020
Citation:
di Giannantonio M, Negri A,
Schiavone S, Vannini C, Pettorruso M,
De-Giorgio F, Verrastro V, Trabace L,
Corbo M, Gottardo R, Camuto C,
Mazzarino M, Barra A, De Berardis D,
Lopez JI, Del Villar CM, Schifano F and
Martinotti G (2020) Prescription Drug
Misuse in “Clubbers” and Disco Goers
in Ibiza. Front. Psychiatry 11:592594.
doi: 10.3389/fpsyt.2020.592594
Prescription Drug Misuse in
“Clubbers” and Disco Goers in Ibiza
Massimo di Giannantonio 1†, Attilio Negri 2,3†*, Stefania Schiavone 4, Chiara Vannini 1,
Mauro Pettorruso 1, Fabio De-Giorgio 5,6, Valeria Verrastro 7, Luigia Trabace 4,
Mariangela Corbo 1, Rossella Gottardo 8, Cristian Camuto 5,9, Monica Mazzarino 9,
Andrea Barra 10, Domenico De Berardis 11, Juan Iglesias Lopez 12,
Cristina Merino Del Villar 12, Fabrizio Schifano 13 and Giovanni Martinotti 1,13
1Department of Neuroscience, Imaging, Clinical Sciences, University G.d’Annunzio, Chieti-Pescara, Italy, 2Department of
Clinical, Pharmaceutical and Biological Sciences, School of Life & Medical Sciences, University of Hertfordshire, Hatfield,
United Kingdom, 3 Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan, Milan, Italy,
4Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy, 5Department of Health Care
Surveillance and Bioethics, Section of Legal Medicine, University Cattolica del Sacro Cuore, Rome, Italy, 6 Fondazione
Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 7Department of Medical and Surgical Sciences, Magna Graecia
University of Catanzaro, Catanzaro, Italy, 8Unit of Forensic Medicine, Department of Diagnostics and Public Health, University
of Verona, Verona, Italy, 9 Laboratorio Antidoping FMSI, Rome, Italy, 10 Azienda Sanitaria Locale Potenza, Potenza, Italy,
11NHS, Department of Mental Health, Psychiatric Service for Diagnosis and Treatment, Hospital “G. Mazzini,” ASL 4, Teramo,
Italy, 12Can Misses Hospital, Ibiza, Spain, 13 Psychopharmacology, Drug Misuse & Novel Psychoactive Substances Research
Unit, School of Life & Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom
Background: Prescription drug misuse and its related risks are considered a worldwide
public health issue. Current trends show that the extent of such phenomenon may not
be limited to subjects with psychiatric disorders, as it also spreads to dance party and
nightclub attendees, who often consume prescription drugs in combination with alcohol
and psychoactive substances. This study aims to report the sociodemographic data
and the psychiatric and clinical features of a sample of clubbers reporting prescription
drugs use.
Methods: Patients admitted to the psychiatry ward of the Can Misses Hospital
in Ibiza were recruited for the study during a span of four consecutive years
(2015–2018). The inclusion criteria were age 18–75 years old and the intake
of psychoactive substances or more than five alcohol units during the previous
24 h. Substance use habits, psychopathological features, and use of unprescribed
pharmaceuticals were investigated. Urine samples were collected and analyzed using
gas chromatography/mass spectrometry.
Results: A total of 110 subjects with psychoactive substance intoxication were
recruited for the study. Among these, 37 (40%) disclosed the use of prescription drugs
without medical supervision. The most common compounds were benzodiazepines
(66%), antiepileptic drugs (8%), antidepressants (6%), opioids (6%), antipsychotics (6%),
stimulants (6%), and non-steroidal anti-inflammatory drugs (NSAIDs, 2%). Prescription
drug misuse was negatively associated with the use of psychodysleptics (two-tailed
Fisher’s exact test p = 0.018, ρ = −0.262).
Conclusions: The use of prescription drugs is also common among clubbers, usually
characterized by low propensity to be prescribed benzodiazepines, antipsychotics,
or antidepressants. Prescription drugs may be an alternative to classic and novel
22
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psychoactive compounds or may be used to tamper and self-medicate the effects
determined by the use of substances. Party goers should be adequately informed about
possible risks of co-intake of psychoactive substances and prescription drugs to prevent
serious medical and psychiatric consequences.
Keywords: prescription drugs, novel psychoactive substance (NPS), club drugs, psychopathology, substance
usage disorders (SUDs)
BACKGROUND
Prescription drug misuse and related risks, including co-
ingestion with recreational drugs, have recently risen as a
worldwide public health phenomenon. They may involve
a variety of medical and social consequences that require
effective public health policies to counteract such habit, as
well as continuous updates for health professionals to promote
education and harm reduction (1, 2). Prescription medicine
misuse or non-medical use is commonly defined as the use of
medications without a prescription or in a manner other than
prescribed (3). This includes a number of conditions, such as
using these compounds for purposes other than the medical
condition they were prescribed for (i.e., recreational use or self-
harm), consuming at larger doses or higher frequencies than
intended, using an alternative route of administration (e.g.,
intravenous), or co-using with alcohol or recreational drugs (4).
Studies report that the prevalence of misuse of any prescription
drug in the United States increased by 67% from 1991–1992 to
2001–2002, while treatment-seeking for prescription drug use
disorders increased by 53% (2). In 2017, 14 countries in EU
reported on the non-medical use of such compounds (5). Among
the 10,956 drug-related acute toxicity emergency room (ER)
presentations in the Euro-DEN Plus dataset, approximately 29%
involved at least one prescription medicine (most commonly
benzodiazepines and opioids), and 45% of these involved only
prescription drugs, with no illicit compounds involved (6).
Current trends show that the extent of prescription drug
misuse is not limited to subjects with psychiatric disorders or
co-occurring substance use disorders (SUDs). Admissions to
ER and psychiatric intensive care units due to psychotropic
pharmaceutical intoxications involve a heterogeneous cohort
of users, including traditional drug users, “psychonauts” [from
the Ancient Greek ψυχή (soul) and ναύτης (sailor), i.e.,
subjects who define themselves as explorers of the human soul
through the use of psychoactive substances], clubbers, students,
marginalized populations, and individuals with patterns of
non-habitual recreational drug consumption (7). In this context,
the phenomenon of co-ingesting prescription drugs in order
to imitate, potentiate, modulate, or counteract the effects
of prohibited psychoactive substances has been increasingly
reported (8). This trend involves not only novel highly potent
opioid, such as fentanyl and its derivatives, or designer
benzodiazepines but also antipsychotics, antidepressants,
stimulants, performance-enhancing drugs (PEDs), hormones,
vitamins, beta-blockers, gabapentinoids and over-the-counter
(OTC) drugs (8).
For example, students and workers may consume attention
deficit hyperactivity disorder (ADHD) medications such as
methylphenidate to improve their academic performance or
working tasks (1). Gamma hydroxybutyrate (GHB), a drug
used for many conditions, has been increasingly associated with
practices such as “chemsex” (9). Furthermore, compounds such
as benzodiazepines (e.g., diazepam and alprazolam) or atypical
antipsychotics (e.g., quetiapine and risperidone) are often used
by club goers to counteract the effects of psychostimulant
drugs, such as cocaine or methylenedioxymethamphetamine
(MDMA) (10, 11). Venlafaxine, a selective noradrenaline
reuptake inhibitor, has been associated with recreational use
at high dosages, earning for itself the name of “baby ecstasy”
(i.e., MDMA) (8). With regard to the nightlife and clubbing
scene, the situation shows peculiar characteristics. The growing
offer of novel and traditional prescription drugs has found
a fertile ground in this scenario. Summer holiday periods in
popular resorts have historically represented an opportunity for
excesses and experimentation, especially among young people
who find an environment in which hedonistic partying is socially
accepted and drugs are typically easily available (12). Alcohol use,
particularly during binge drinking, and psychoactive substance
use are commonly reported among festival-goers and clubbers
in holiday resorts; practices such as poly-substance abuse and
prescription drug misuse have also been reported (13–16). The
use of a variety of pharmaceuticals including benzodiazepines
(17, 18), stimulants (19, 20), opioids (21), antidepressants (8), and
sedatives such as GHB (22) has been associated to dance music
party attendees. Such heterogeneous cohort of compounds,
presented in different forms and with various ways of intake (e.g.,
ingested, snorted, or intravenous), may lead to potential negative
medical outcomes, including acute intoxications, SUD, and other
psychiatric disorders. Nevertheless, pharmaceuticals are often
perceived as less harmful and less stigmatizing than illicit drugs,
particularly among young people, partly due to these substances’
legitimate medical purposes (23, 24). Moreover, information
on the actions of these drugs is widely available in package
inserts, advertisements, and on the internet; therefore, their
effects (including adverse reactions) and dosages are considered
more predictable (25).
Such phenomenon is further complicated by the rise on
the nightlife market of novel psychoactive substances (NPS). A
number of these substances were originally developed as research
chemicals and diverted for recreational purposes, as they often
mimic the pharmacological effect of traditional drugs of abuse
or popular prescription drugs (4). Their effects and related
risks are often unknown to both users and health professionals,
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due to the scarcity of evidence-based information regarding
their toxicological profiles and to the ever-changing nature of
this market (7, 26–28). Nevertheless, growing evidence reported
potential acute and chronic psychiatric risks associated to NPS
consumption, including confusion; paranoid thoughts; auditory
and visual hallucinations; dissociation; delusions of reference,
persecution, grandeur, and jealousy; cognitive impairment;
hypomanic states; aggressiveness and irritability; violence; and
suicidal thoughts (8, 29–31).
The current dynamic of recreational substance use is a serious
matter of concern for public health institutions worldwide. In
particular, the threats posed by psychoactive compounds and
concomitant prescription drug misuse require updated policies
provided by local and supranational regulatory agencies, as well
as appropriate approaches by health professional, to prevent
negative outcomes and reduce associated harms (32), including
deaths (33). In such context, Ibiza and the Balearic Islands,
two of the most popular destinations with nightlife resorts for
summer holidays in Europe, may be considered as an interesting
real-life scenario to explore such phenomenon. Previous studies
confirmed a higher prevalence of risky behaviors for both
residents and tourists in Ibiza, including problematic alcohol
use, substance use, and sexual disinhibition (34–36). Moreover,
it has been reported that traffickers and dealers have introduced
NPS and pharmaceuticals into the Ibiza drug market to test new
compounds and drug combinations on unaware customers (36).
This study aimed to assess patients admitted to the
psychiatric ward of the Can Misses Hospital in Ibiza for
psychoactive substance intoxication, in order to (1) identify
which psychotropic prescription drugs are mostly involved in
cases of concomitant psychoactive substance use and (2) report
the psychopathological features and patterns of consumption
associated to prescription drug use in a nightlife resort setting.
MATERIALS AND METHODS
Patients admitted to the psychiatry ward of the Can Misses
Hospital in Ibiza during summer when nightclubs are open
(May–October) were recruited for the study during a span
of four consecutive years (2015–2018). The subjects were
evaluated according to the DSM-5 diagnostic classification. The
inclusion criteria were age 18–75 years old and the intake
of psychoactive substances or more than five alcohol units
(i.e., 10ml or 8 g of pure alcohol) during the previous 24 h.
Clinical conditions such as delirium tremens, epilepsy, liver
encephalopathy, dementia, and other neurological diseases,
severe cardiac failure, diabetes mellitus, severe liver impairment,
kidney failure, or neoplastic diseases were among the exclusion
criteria, as the presence of such conditions could present a
confounding factor. Demographic (age, gender, family, and
nationality) and socioeconomic data (living status, job status,
and level of education) were collected, as well as recent and
past medical and psychiatric history, current pharmacological
treatment, and alcohol and substance use habits (including
NPS), with a specific focus on prescription drugs misuse.
Among these, recent and lifetime use of benzodiazepines (e.g.,
diazepam, alprazolam, and lorazepam), ADHDmedications (e.g.,
amphetamine/dextroamphetamine and methylphenidate), and
opioid painkillers (e.g., morphine, methadone, oxycodone, and
fentanyl), as well as other popular prescription drugs (e.g., GHB
and gabapentinoids) was investigated.
To explore the different psychopathological aspects related to
substance use, such as depressive or manic symptoms, anxiety,
psychosis negative and positive symptoms, somatic disorders,
aggressiveness, and suicidality, the following psychodiagnostic
tests were administered to patients during their hospitalization:
Timeline Follow-Back (TLFB) for psychoactive substances and
alcohol; Brief Psychiatric Rating Scale (BPRS); Positive and
Negative Symptoms Scale (PANSS); Mania Rating Scale (MRS);
Hamilton Depression Scale (HAM-D); Hamilton Anxiety Scale
(HAM-A); and Modified Overt Aggression Scale (MOAS).
TLFB was used to identify the main substance of abuse
for each patient. The subjects were divided in three macro-
groups according to the TLFB and the results of the
urinalysis: psychostimulants (e.g., cocaine, amphetamines, and
synthetic cathinones), depressors (e.g., opioids, alcohol, and
benzodiazepines), and psychodysleptics (e.g., cannabinoids,
psychedelics, and dissociatives). This classification was derived
from our previous reports on the topic (7, 36).
Data collection was carried out in an anonymous and
confidential way; all participants received a detailed explanation
of the design of the study and a written informed consent was
systematically obtained from every subject, according to the
Declaration of Helsinki. Ethics approval was granted by the
University of Hertfordshire Health and Human Sciences ECDA,
protocol no. aPHAEC1042(03); by the CEI Illes Balears, protocol
no. IB 2561/15 PI; and by the University “G. d’Annunzio”
of Chieti-Pescara, no. 7/09-04-2015. Majorcan local ethics
committee also gave approval to the study.
Urine Sample Analysis
A urine sample was collected at admission, stored at−30◦C, and
subsequently analyzed at the laboratory of the Department of
Forensic Toxicology of the Università Politecnica delle Marche,
at the FMSI Antidoping of Rome, and at the University of
Verona, Italy. The urine samples were analyzed at the FMSI
Antidoping of Rome using a routine screening test for drugs
of abuse. The urine samples were extracted with a solid-phase
cartridge (OasisMCX), and the obtained solution was evaporated
until dry and reconstituted with mobile phase. An Agilent
1290 Infinity II UHPLC with a binary gradient system and an
automatic injector (Agilent Technologies, Cernusco sul Naviglio,
Milano, Italy) was used for the chromatographic separation. The
instrument was equipped with an Agilent ZORBAX Eclipse Plus
C18 column (100 × 2.1mm i.d., particle size 1.8µm) (37). The
detector was an Orbitrap Q Exactive (Thermo Fisher Scientific)
with an ESI source. The method was validated according to
WADA guidelines and for a screening method in antidoping
test defining selectivity, limit of detection (LOD), recovery, carry
over, and repeatability (38). The method showed no interference
or carry over, LOD < 1 ng/ml, recovery >70%, and repeatability
estimated as CV% < 1% for all the analytes.
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A comprehensive screening of urine samples was performed
at both the Unit of Forensic Medicine of the University of
Verona and at the Politecnico of Ancona, by using a ToxtyperTM
LC/IT-MS platform (Bruker Daltonics, Bremen, Germany)
consisting of an ultra high performance liquid chromatography
(UHPLC) coupled to a high-speed ion trap mass analyzer
(IT-MS). The instrument applied the analytical protocols
provided by the manufacturer, and compound identification
was provided by using the Maurer/Wissenbach/Weber (MWW)
library containing as many as 4,500 therapeutic, toxic/illicit drugs
and their metabolites (including NPS) (39). Prior to injection,
urine sample were diluted 1/10 (v/v) with water (40).
Data Analysis
Statistical analysis was performed by using IBM SPSS R© Statistics
software, version 20 and GraphPad 5.0 software forWindows (La
Jolla, CA, USA). Fisher’s exact test was used to determine whether
or not there was a significant association between the categorical
variables “abuse of prescription drugs” and “use of distinct
categories of psychoactive substances.” Spearman’s correlation
value (ρ) was calculated to determine if variables (abuse of
prescription drugs and categories of substances) were positively
or negatively correlated. Independent samples t-test was used
to determine whether or not there was a significant difference
in scale scores between subjects who abused and subjects who
did not abuse prescription drugs. One-way analysis of variance
(ANOVA) followed by Tukey’s post-hoc test was used to assess
whether or not there was a significant difference in scale scores
among subjects who abused different classes of prescription
drugs. For all tests, a two-tailed p-value <0.05 was considered
statistically significant.
RESULTS
A total of 110 subjects were recruited for the study, with most of
them being of European nationality (n = 76, 71.8%). Age ranged
from 19 to 63 years old, with the majority of patients (n = 57,
51.8%) under 30 years old. The median age of the 110 patients
was 32.57 years. A higher percentage of males (n = 76, 69.1%)
was reported in our sample. Nine patients were full-time or part-
time students (8.1%), 52 (47.3%) were employees, and 40 (36.4%)
were unemployed.
All the subjects of the sample were diagnosed with substance
intoxication at admission. Although the majority of patients
declared multiple substance use (n = 77, 70.0%) and 33%
of them reported the use of more than two substance, the
participants were divided in three macro-groups according to
their responses to the TLFB test and their urinalysis results to
identify a category of substances “of choice” for each patient.
Thus, 17 (15%) depressors users, 44 (40%) stimulant users, and
49 (45%) psychodysleptics users were identified.
When asked about lifetime use of specific groups of
substances, stimulant use was disclosed by 74 patients (32%)
and cannabinoid use by 68 patients (29%). These were followed
by depressors (n = 32, 14%), empathogens–entactogens (n =
28, 12%), dissociatives (n = 15, 6%), opioids (n = 9, 4%), and
psychedelic drugs (n = 7, 3%). Almost half of the participants
TABLE 1 | The most common substances used by patients who declared
prescription drug misuse.
Prescription Drug N %
Benzodiazepines (e.g., diazepam and alprazolam) 32 66
NSAIDs (e.g., paracetamol) 1 2
Antidepressants (e.g., paroxetine and clomipramine) 3 6
Antipsychotics (e.g., risperidone and clotiapine) 3 6
Anticonvulsants (e.g., valproate and pregabalin) 4 8
Opioid derivatives and synthetic opioids (e.g., methadone and fentanyl) 3 6
Stimulants (e.g., methylphenidate) 3 6
FIGURE 1 | Percentage of patients abusing (Yes%) or not abusing (No%)
prescription drugs stratified for the following substance categories:
psychodepressors, psychostimulants, or psychodysleptics.
(46%) declared to have used a substance without knowing what it
was at least once in their life. These results will be described in a
separate manuscript (31).
In our sample, 37 patients (40%) disclosed a lifetime
misuse of prescription drugs. The most commonly reported
compounds were benzodiazepines, which were used by 32
subjects. Table 1 presents the complete information on the type
of pharmaceuticals reported by users.
Prescription drug misuse was reported for 8 psychodepressor
(e.g., non-prescription opioids and alcohol) users, 19
psychostimulant (e.g., cocaine and amphetamines) users,
and 10 psychodysleptic (e.g., cannabis and dissociatives) users.
The percentage for each group of substance users is reported in
Figure 1. Abuse of unprescribed pharmaceuticals was negatively
associated with the use of psychodysleptics (two-tailed Fisher’s
exact test p= 0.018, ρ =−0.262).
According to their lifetime use of specific compounds,
prescription drug consumption without medical supervision
was reported by 31 stimulant users, 21 cannabinoid users, 10
depressor users, 7 opioid users, 7 empathogen–entactogen users,
5 dissociative users, and 1 psychedelic user.
The severity of psychiatric symptoms according to HAM-A
Psychotic Anxiety scale, PANNS BPRS, andMRS was comparable
among users and non-users of unprescribed pharmaceuticals.
Patients who disclosed prescription drug misuse tended to report
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FIGURE 2 | (A) HAM-D total score of subjects abusing (YES, n = 37) or not abusing (NO, n = 56) prescription drugs. Independent samples t-test, p > 0.05; (B)
HAM-A Somatic Anxiety scale score of subjects abusing (YES, n = 37) or not abusing (NO, n = 56) prescription drugs. Student’s t-test, p > 0.05.
FIGURE 3 | HAM-D total score stratified for the following classes of abused
prescription drugs: benzodiazepines (n = 32), methylphenidate (n = 3), opioid
derivatives and synthetic opioids (n = 3), anticonvulsants (n = 4), neuroleptics
(n = 3), and antidepressants (n = 3). One-way ANOVA, followed by Tukey’s
post-hoc test, F = 3.032, *p < 0.05 methylphenidate vs antidepressants.
higher scores in HAM-D andHAM-A Somatic Anxiety, although
this tendency did not reach the statistical significance (Figure 2).
One-way ANOVA for HAM-A total score (F = 0.6808, p >
0.05), PANNS (F = 1.487, p > 0.05), MRS (F = 0.4402, p > 0.05),
and BPRS (F = 3.094, p > 0.05) did not report any statistically
significant difference among users of benzodiazepines,
methylphenidate, prescription opioids, anticonvulsants,
antipsychotics, and antidepressants. A statistical difference
was found for HAM-D scores between methylphenidate and
antidepressant users (one-way ANOVA, followed by Tukey’s
post-hoc test, F = 3.032, ∗p < 0.05 methylphenidate vs.
antidepressants) (Figure 3), with higher scores of depression in
the group of patients taking antidepressants.
The most common diagnosis at discharge among the patients
who disclosed prescription drug use was substance or alcohol
use disorder (n = 26, 48%), followed by schizophrenia spectrum
disorders (n= 10, 18%) (Figure 4).
DISCUSSION
Our study evaluated the use of prescription drugs among a
sample of clubbers, who were mainly composed of young
subjects (more than 50% of the participants being aged under
30) with a medium-high socioeconomic status. Many subjects
(40%) reported the use of prescription drugs. Therefore, our
results show that such use is not only limited to subjects
with psychiatric disorders and co-occurring SUD but can also
involve subjects who are usually not considered as typical
psychoactive substance users. This data pave the way for serious
considerations on the possible pharmacological interactions
with alcohol and other substances, as well as on other short-
and long-term consequences, both physical and psychiatric.
As users may concomitantly consume various prescription
drugs and substances of abuse, an increased risk of drug–
drug interactions may be observed, both pharmacokinetic (e.g.,
between prescription opioids and heroin) and pharmacodynamic
(e.g., between opioids of abuse and benzodiazepines or other
CNS sedative drugs) (41). This involves not only depressors,
such as benzodiazepines, opioids, and alcohol, but also stimulant
drugs commonly used by clubbers. For example, metabolic
pathways of synthetic cathinones, antidepressants, and ADHD
medications have been shown to overlap, including metabolism
via cytochrome P450 enzymes and their inhibition (42).
Benzodiazepines were the most prevalent class of prescription
drugs reported in our sample. This result may be explained by
the use of benzodiazepines as a “trip terminator” to calm down
the strong experience caused by the use of multiple substances.
This confirms the data from Messina et al. (10), who showed
that benzodiazepines and atypical antipsychotics are often used
by club goers to counteract the effects of psychostimulant drugs,
such as cocaine or MDMA. In terms of preventive strategies, the
use of benzodiazepines in the context of a multiple substance use
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FIGURE 4 | Discharge diagnosis (expressed both as raw number and %) of patients abusing prescription drugs.
could be dangerous as it causes respiratory depression and risk
of overdoses, specifically in combination with opiates, alcohol,
ketamine and derivatives, and inhalants (18, 43, 44). Specific
policies and harm-reduction approaches should be advised for
these potentially lethal combinations, particularly with the intake
of large amounts of long half-life compounds, such as diazepam.
Furthermore, a number of novel designer benzodiazepines,
with undisclosed toxicological profiles and variable potencies,
have recently been made available in the drug market. They
are developed in order to mimic prescription benzodiazepines
and Z-drugs, but they may lead users to adverse events of
various severities, particularly if used in combination with other
substances (4, 45, 46).
Among the different categories of substances,
psychodepressors were the most commonly associated with
the use of prescription drugs, whereas only a small percentage
of psychodysleptic users reported such habit. The typology
of subject using psychodysleptics such as LSD, psilocybin,
MDMA, ayahuasca, and other plants, is characterized by the
search for a strong inner experience, spirituality, and high
level of emotionality (47, 48). The use of benzodiazepines and
antipsychotics can inhibit or temper the perception of these
experiences and therefore may not be chosen by users. With
regard to antidepressants, which can determine affective blunting
and enhance the distance from emotional experiences, the same
consideration can be reported.
Interestingly, patients who disclosed prescription drug misuse
tended to report higher scores in HAM-D and HAM-A Somatic
Anxiety. This finding emphasizes how those patients are the most
vulnerable in terms of psychopathological load. In this regard,
those who report taking prescription drugs may actually be the
subjects with a psychiatric history. A prescription drug may
have already been tested for therapeutic purposes and therefore
may have made the patient more accustomed to its use out of
indication. Moreover, the high level of depression is an issue that
needs to be considered and can represent a significant suicidal
risk factor in people who misuse alcohol and psychoactive
substances. In fact, the use of psychotropics can represent an
additional risk factor, given the possibility of a consistent increase
in the levels of impulsivity, violence, and self-directed aggression
due to such drugs. Therefore, it is very relevant to evaluate these
patients and to put specific strategies in place to manage these
psychopathological manifestations, with a specific focus on the
prevention of anti-conservative behaviors.
A further point of interest, although expected, is the presence
of high levels of depressive symptoms on the Hamilton scale
in relation to the use of antidepressants without a specific
medical prescription. This fact suggests how sometimes the use
of prescription drugs may be related not only to the goal to
“get high” or to the management of an intoxication but also
to the self-medication need of patients who perceive a sub-
leveling of their mood. For this reason, a shared strategy could
be justified, even more than in other types of patients with dual
disorders. Conversely, methylphenidate use was associated with
lower scores at the Hamilton depression scale. This prescription
drug with stimulant properties (49, 50), usually indicated for
attention deficit hyperactivity disorder, can probably be chosen
by users of psychostimulants as a cheaper alternative to cocaine
and amphetamine. In the short run, it could also show some
antidepressant properties, thus explaining the data observed
at the HAM-D. The detection of methylphenidate among the
prescription drugs reported in our sample may indicate some
level of comorbidity between adult ADHD and SUD, as recently
reported (51).
In terms of the role of the discharge psychiatric diagnosis,
alcohol or substance use disorder showed a high prevalence,
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although the diagnoses of schizophrenia and bipolar spectrum
disorder were also significantly reported. In some cases,
the presence of a psychiatric comorbidity could justify the
use of prescription drugs such as antidepressants, mood
stabilizers, and benzodiazepines. However, the presence of a
relevant percentage of addiction diagnoses (alcohol use disorder
and/or substance use disorder) further confirms that these
patients do not typically represent pure psychiatric patients
who increase their dosages of prescribed drugs but are
instead classical party-goers who use prescription drugs for
other purposes.
Limitations of this study are represented by a low and
heterogeneous sample size, with a high prevalence of
benzodiazepine as the main prescription drug. Moreover,
although the target of the study is that of young clubbers, a
significant subgroup of participants were middle-aged adults.
In conclusion, in this study, we have highlighted how the
use of prescription drugs is common also among clubbers
and disco-goers. These subjects usually do not have a
previous psychiatric history and share a low propensity
to be prescribed with benzodiazepines, antipsychotics, and
antidepressants by a mental health professional. These data
confirm that prescription drugs may be an alternative for
classic and novel psychoactive compounds, may be used to
modulate and temper the experience, and, in some cases, may
be used to reduce the negative effects determined by the use
of substances. From the treatment prospective and as a useful
preventive strategy, a specific psycho-education process should
be indicated for subjects at risk. Party-goers should be adequately
informed about the possible risks of co-intake of NPS, classical
substances, and prescription drugs to prevent serious medical
and psychiatric consequences.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.
ETHICS STATEMENT
The studies involving human participants were reviewed
and approved by University of Hertfordshire CEI Illes
Balears University G. d’Annunzio of Chieti-Pescara. The
patients/participants provided their written informed consent to
participate in this study.
AUTHOR CONTRIBUTIONS
MdG and AN wrote the manuscript. CV, JL, MC, CD, AN, and
GM recruited patients inside the CanMisses Hospital of Ibiza. SS
and LT performed the statistical analysis. MP, VV, FS, and GM
elaborated the study protocol and performed the translation for
scales and questionnaire. FD-G, RG, CC, and MM executed the
urine analysis in the different centers. AB and DD performed
literature search about the topic and elaborated all the ethical
procedures required for the study approval in both countries. GM
coordinated all the study processes. All authors contributed to the
article and approved the submitted version.
ACKNOWLEDGMENTS
This study was partly funded by the European Project entitled
Analysis, Knowledge dissemination, Justice implementation
and Special Testing of Novel Synthetic Opioids—JUST-2017-
AG-DRUG.
REFERENCES
1. YoungAM,Glover N,Havens JR. Nonmedical use of prescriptionmedications
among adolescents in the United States: a systematic review. J Adolesc Health.
(2012) 51:6–17. doi: 10.1016/j.jadohealth.2012.01.011
2. Blanco C, Alderson D, Ogburn E, Grant BF, Nunes EV, Hatzenbuehler ML, et
al. Changes in the prevalence of non-medical prescription drug use and drug
use disorders in the United States: 1991–1992 and 2001–2002. Drug Alcohol
Depend. (2007) 90:252–60. doi: 10.1016/j.drugalcdep.2007.04.005
3. National Institute on Drug Abuse (NIDA), National Institute of Health, USA.
Misuse of prescription drugs. Available online at: https://www.drugabuse.
gov/publications/research-reports/misuse-prescription-drugs/summary
(accessed May 25, 2020).
4. Bersani FS, Imperatori C. Misuse, recreational use and addiction in relation
to prescription medicines. In: Corazza O, Roman-Urrestarazu A, editors.
Handbook of Novel Psychoactive Substances: What Clinicians Should Know
About NPS. New York, NY: Routledge (2018).
5. United Nations Office for Drug and Crime. World Drug Report 2019. United
Nations (2019).
6. European Monitoring Center for Drugs and Drugs Addiction (EMCDDA).
Hospital Emergency Presentations and Acute Drug Toxicity in Europe: Update
From the Euro-DEN Plus Research Group and the EMCDDA. (2016).
doi: 10.2810/894142
7. Martinotti G, Merino del Villar C, Giorgetti R, Schifano F, Di Giannantonio
M. Novel and traditional club substances are associated to psychopathological
and medical sequelae: the Ibiza project. In: Corazza O, Roman-Urrestarazu A,
editors. Handbook of Novel Psychoactive Substances, What Clinicians Should
Know About NPS. New York, NY: Routledge (2018).
8. Schifano F, Chiappini S, Corkery JM, Guirguis A. Abuse of prescription drugs
in the context of novel psychoactive substances (NPS): a systematic review.
Brain Sci. (2018) 8:73. doi: 10.3390/brainsci8040073
9. Edmundson C, Heinsbroek E, Glass R, Hope V, Mohammed H, White M,
et al. Sexualised drug use in the United Kingdom (UK): a review of the
literature. Int J Drug Policy. (2018) 55:131–48. doi: 10.1016/j.drugpo.2018.
02.002
10. Messina BG, Dutta NM, Silvestri MM, Diulio AR, Garza KB, Murphy
JG, et al. Modeling motivations for non-medical use of prescription
drugs. Addict Behav. (2016) 52:46–51. doi: 10.1016/j.addbeh.2015.
07.024
11. Vento AE, Kotzalidis GD, Cacciotti M, Papanti GD, Orsolini L,
Rapinesi C, et al. Quetiapine abuse fourteen years later: where are
we now? A systematic review. Subst Use Misuse. (2020) 55:304–13.
doi: 10.1080/10826084.2019.1668013
12. Kelly D, Hughes K, Bellis MA. Work hard, party harder: drug use and
sexual behaviour in young British casual workers in Ibiza, Spain. Int J
Environ Res Public Health. (2014) 11:10051–61. doi: 10.3390/ijerph1110
10051
13. Esser MB, Guy GP Jr, Zhang K, BrewerRD. Binge drinking and prescription
opioid misuse in the U.S., 2012–2014. Am J Prev Med. (2019) 57:197–208.
doi: 10.1016/j.amepre.2019.02.025
14. BustoMiramontes A,Moure-Rodríguez L, Díaz-Geada A, Rodríguez-Holguín
S, Corral M, Cadaveira F, et al. Heavy drinking and non-medical use of
Frontiers in Psychiatry | www.frontiersin.org 7 December 2020 | Volume 11 | Article 59259428
di Giannantonio et al. Prescription Drugs and Clubbers
prescription drugs among university students: a 9-year follow-up. Int J
Environ Res Public Health. (2019) 16:2939. doi: 10.3390/ijerph16162939
15. Grigg J, Barratt MJ, Lenton S. Double dropping down under: correlates of
simultaneous consumption of two ecstasy pills in a sample of Australian
outdoor music festival attendees. Drug Alcohol Rev. (2018) 37:851–5.
doi: 10.1111/dar.12843
16. Martins D, Barratt MJ, Pires CV, Carvalho H, Vilamala MV, Espinosa IF, et al.
The detection and prevention of unintentional consumption of DOx and 25x-
NBOMe at Portugal’s boom festival. Hum Psychopharmacol. (2017) 32:e2608.
doi: 10.1002/hup.2608
17. Kurtz SP, Inciardi JA, Surratt HL, Cottler L. Prescription drug
abuse among ecstasy users in Miami. J Addict Dis. (2005) 24:1–16.
doi: 10.1300/J069v24n04_01
18. Kurtz SP, ButtramME, Surratt HL. Benzodiazepine dependence among young
adult participants in the club scene who use drugs. J Psychoact Drugs. (2017)
49:39–46. doi: 10.1080/02791072.2016.1269978
19. Butler R, Sheridan J. Innocent parties or devious drug users: the views
of primary healthcare practitioners with respect to those who misuse
prescription drugs. Harm Reduct J. (2010) 7:21. doi: 10.1186/1477-7517-7-21
20. León KS, Martínez DE. To Study, to party, or both? Assessing risk factors
for non-prescribed stimulant use among middle and high school students. J
Psychoact Drugs. (2017) 49:22–30. doi: 10.1080/02791072.2016.1260187
21. Palamar JJ. Use of “lean” among electronic dance music party attendees. Am J
Addict. (2019) 28:347–52. doi: 10.1111/ajad.12897
22. Brennan R, van Hout MC. Gamma-hydroxybutyrate (GHB): a scoping review
of pharmacology, toxicology, motives for use, and user groups. J Psychoactive
Drugs. (2014) 46:243–51. doi: 10.1080/02791072.2014.921746
23. Hernandez SH, Nelson LS. Prescription drug abuse: insight into the epidemic.
Clin Pharmacol Ther. (2010) 88:307–17. doi: 10.1038/clpt.2010.154
24. Kelly BC, Vuolo M. Social network ties to nightlife and healthcare
professionals and prescription drug misuse among young adults. Int J Drug
Policy. (2019) 66:48–56. doi: 10.1016/j.drugpo.2019.01.007
25. United Nations Office on Drugs and Crime (UNODC). The non-medical use
of prescription drugs, policy direction issues. United Nations Office on Drugs
and Crime, 96. (2010). Available online at: http://www.unodc.org/unodc/en/
drug-prevention-and-treatment/non-medical-use-prescription-drugs.html.
(accessed March 25, 2020).
26. Schifano F, Leoni M, Martinotti G, Rawaf S, Rovetto F. Importance of
cyberspace for the assessment of the drug abuse market: preliminary results
from the Psychonaut 2002 project. Cyberpsychol Behav. (2003) 6:405–10.
doi: 10.1089/109493103322278790
27. Corazza O, Assi S, Simonato P, Corkery J, Bersani FS, Demetrovics Z, et al.
Promoting innovation and excellence to face the rapid diffusion of novel
Psychoactive substances in the EU: the outcomes of the reDNet project. Hum
Psychopharmacol. (2013) 28:317–23. doi: 10.1002/hup.2299
28. Simonato P, Corazza O, Santonastaso P, Corkery J, Deluca P, Davey Z, et al.
Novel psychoactive substances as a novel challenge for health professionals:
results from an Italian survey.Hum Psychopharm Clin Exp. (2013) 28:324–31.
doi: 10.1002/hup.2300
29. Kehr J, Ichinose F, Yoshitake S, Goiny M, Sievertsson T, Nyberg F, et al.
Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly
increases both dopamine and 5-HT levels in nucleus accumbens of awake
rats. Br J Pharmacol. (2011) 164:1949–58. doi: 10.1111/j.1476-5381.2011.0
1499.x
30. Lovrecic B, Lovrecic M, Gabrovec B, Carli M, Pacini M, Maremmani
AGI, et al. Non-medical use of novel synthetic opioids: a new challenge
to public health. Int J Environ Res Public Health. (2019) 16:E177.
doi: 10.3390/ijerph16020177
31. Martinotti G, De Risio L, Vannini C, Schifano F, Pettorruso M, Di
Giannantonio M. Substance related exogenous psychosis: a post-modern
syndrome. CNS Spectr. (2020) 25:1–20. doi: 10.1017/S1092852920001479
32. Santacroce R, Ruiz Bennasar C, Sancho Jaraiz JR, Fiori F, Sarchione F, Angelini
F, et al. A matter of life and death: substance-caused and substance-related
fatalities in Ibiza in 2015. Hum Psychopharmacol Clin Exp. (2017) 32:e2592.
doi: 10.1002/hup.2592
33. Corkery JM, Schifano F, Martinotti, G. How deaths can help clinicians and
policy-makers understand the risks of novel psychoactive substances. Br J Clin
Pharmacol. (2020) 86:482–98. doi: 10.1111/bcp.14183
34. Bellis MA, Hale G, Bennett A, Chaudry M, Kilfoyle M. Ibiza uncovered:
changes in substance use and sexual behaviour amongst young people
visiting an international night-life resort. Int J Drug Policy. (2000) 11:235–44.
doi: 10.1016/s0955-3959(00)00053-0
35. Bellis MA, Hughes K, Lowey H. Healthy nightclubs and recreational
substance use. From a harm minimisation to a healthy settings
approach. Addict Behav. (2002) 27:1025–35. doi: 10.1016/s0306-4603(02)
00271-x
36. Martinotti G, Cinosi E, Santacroce R, Papanti D, Pasquini A, Mancini
V, et al. (2017). Substance-related psychopathology and aggressiveness in
a nightlife holiday resort: Results from a pilot study in a psychiatric
inpatient unit in Ibiza. Hum Psychopharmacol. 32:e2586. doi: 10.1002/hup.
2586
37. Chieffi C, Camuto C, De-Giorgio F, de la Torre X, Diamanti F, Mazzarino
M, et al. Metabolic profile of the synthetic drug 4,4
′
-dimethylaminorex
in urine by, LC–MS- based techniques: selection of the most suitable
markers of its intake. Forensic Toxicol. (2020). doi: 10.1007/s11419-020-0
0544-9. [Epub ahead of print].
38. Camuto C, Pellegrini S, De-Giorgio F, de la Torre X, Marti M, Mazzarino
M, et al. Urinary excretion profile of methiopropamine in mice following
intraperitoneal administration: a liquid chromatography-tandem mass
spectrometry investigation. Drug Test Anal. (2020) 1–10. doi: 10.1002/dt
a.2900
39. Gottardo R, Murari M, Bertaso A, Bortolotti F, Tagliaro F. Drug screening
by using the ToxtyperTM LC-ion trap MS: optimization of its application on
serum samples in DUID context. Clinica Chimica Acta. (2020) 510:537–43.
doi: 10.1016/j.cca.2020.08.009
40. van der Schaar JA, Attema-de Jonge ME, Gresnigt FM, Franssen
EJ. Toxicological screening in the Amsterdam acute setting becomes
more relevant if the standard panel of the drug-of-abuse point-of-care
test is expanded with GHB ketamine. Toxicol Rep. (2020) 7:539–46.
doi: 10.1016/j.toxrep.2020.04.007
41. Pérez-Mañá C, Papaseit E, Fonseca F, Farré A, Torrens M, Farré M. Drug
interactions with new synthetic opioids. Front Pharmacol. (2018) 9:1145.
doi: 10.3389/fphar.2018.01145
42. Contrucci RR, Brunt TM, Inan F, Franssen EJF, Hondebrink L. Synthetic
cathinones and their potential interactions with prescription drugs. Ther Drug
Monit. (2020) 42:75–82. doi: 10.1097/FTD.0000000000000682
43. Riley ED, Evans JL, Hahn JA, Briceno A, Davidson PJ, Lum PJ,
et al. A longitudinal study of multiple drug use and overdose among
young people who inject drugs. Am J Public Health. (2016) 106:915–7.
doi: 10.2105/AJPH.2016.303084
44. Andersson JA, Brekke M, Vallersnes OM. Acute poisoning from
substance abuse of benzodiazepines. Akutt forgiftning ved rusrelatert
bruk av benzodiazepiner. Tidsskr Nor Laegeforen. (2020) 10.
doi: 10.4045/tidsskr.20.0035
45. Orsolini L, Corkery JM, Chiappini S, Guirguis A, Vento A, De Berardis
D, et al. ‘New/designer benzodiazepines’: an analysis of the literature
and psychonauts’ trip reports. Curr Neuropharmacol. (2020) 18:809–37.
doi: 10.2174/1570159x18666200110121333
46. Batisse A, Eiden C, Peyriere H, Djezzar S. French Addictovigilance Network.
Use of new psychoactive substances to mimic prescription drugs: The
trend in France. Neurotoxicology. (2020) 79:20–4. doi: 10.1016/j.neuro.2020.
03.015
47. Hupli A, Berning M, Zhuparris A, Fadiman J. Descriptive assemblage
of psychedelic microdosing: netnographic study of YoutubeTM videos
and on-going research projects. Perfor Enhanc Health. (2019) 6:129–38.
doi: 10.1016/j.peh.2019.01.001
48. Orsolini L, Ciccarese M, Papanti D, De Berardis D, Guirguis A,
Corkery JM, et al. Psychedelic fauna for psychonaut hunters: a
mini-review. Front Psychiatry. (2018) 9:153. doi: 10.3389/fpsyt.2018.
00153
49. Guthrie SK, Teter CJ, McCabe SE, Boyd CJ. Illicit methylphenidate use in an
undergraduate student sample: prevalence and risk factors. Pharmacotherapy.
(2003) 23:609–17. doi: 10.1592/phco.23.5.609.32210
50. Sussman S, Pentz MA, Spruijt-Metz D, Miller T. Misuse of “study drugs:”
prevalence, consequences, and implications for policy. Subst Abuse Treat Prev
Policy. (2006) 1:15. doi: 10.1186/1747-597X-1-15
Frontiers in Psychiatry | www.frontiersin.org 8 December 2020 | Volume 11 | Article 59259429
di Giannantonio et al. Prescription Drugs and Clubbers
51. Özgen H, Spijkerman R, Noack M, Holtmann M, Schellekens ASA, van de
Glind G, et al. International consensus statement for the screening, diagnosis,
and treatment of adolescents with concurrent attention-deficit/hyperactivity
disorder and substance use disorder. Eur Addict Res. (2020) 26(Suppl 4–
5):223–232. doi: 10.1159/000508385
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 di Giannantonio, Negri, Schiavone, Vannini, Pettorruso,
De-Giorgio, Verrastro, Trabace, Corbo, Gottardo, Camuto, Mazzarino, Barra, De
Berardis, Lopez, Del Villar, Schifano and Martinotti. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Psychiatry | www.frontiersin.org 9 December 2020 | Volume 11 | Article 59259430
ORIGINAL RESEARCH
published: 08 January 2021
doi: 10.3389/fpsyt.2020.585607







Swansea University, United Kingdom
Diana Martinez,





This article was submitted to
Addictive Disorders,
a section of the journal
Frontiers in Psychiatry
Received: 21 July 2020
Accepted: 29 October 2020
Published: 08 January 2021
Citation:
Orsolini L, Rojnić Palavra I,
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Kuiters JP, Gondek TM, Panfil A-L,
Borovcanin MM, San Roman Uria A,
Biskup E, Sönmez Güngör E,
Casanova Dias M, Tomori S, Banjac V,
Marinova-Djambazova P and Pinto da
Costa M (2021) Psychiatry Trainees’
Attitudes, Knowledge, and Training in
Addiction Psychiatry—A European
Survey. Front. Psychiatry 11:585607.
doi: 10.3389/fpsyt.2020.585607
Psychiatry Trainees’ Attitudes,
Knowledge, and Training in Addiction
Psychiatry—A European Survey
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Diego Quattrone 6, Matis Martens 7, Sandra Sklenářová 8,9, Jonna Levola 10, Leslie Grichy 11,
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Background: Although psychoactive substance use disorders (PSUDs) are a domain of
mental health, addiction psychiatry is only formally recognized as a subspecialty in a few
European countries, and there is no standardized training curriculum.
Methods: A 76-item questionnaire was developed and disseminated through an online
anonymous data-collecting system and hand-to-hand amongst psychiatric trainees from
the 47 European countries of the Council of Europe plus Israel and Belarus.
Results: 1,049/1,118 psychiatric trainees from 30 European countries completed
the questionnaire. Fifty-nine-point nine percent of trainees stated to have training in
addictions. Amongst the trainees who described having training in addictions, 43%
documented a not well-structured training and 37% an unsatisfactory training, mainly due
to poor acquired knowledge. Overall, 97% of trainees stated that addiction represents a
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core curriculum for their training. Overall, general adult psychiatric trainees reported a
better knowledge in addictions, compared to trainees in child and adolescent psychiatry.
Conclusion: Despite a growing spread of PSUDs in European countries, addiction
psychiatry is a relatively poorly trained field within psychiatry training programs. Further
research should investigate reasons for poor training and timings of the educational
activities to optimize experiential education training in addiction psychiatry.
Keywords: addiction psychiatry, addiction, EFPT, psychiatry trainees, psychiatry training
INTRODUCTION
According to the Global Burden Disease study (1), alcohol,
tobacco, and illicit substance use significantly determine the
global burden of disability, morbidity and mortality, being
considered amongst the top four health burdens across many
upper-middle and high-income countries. Mental and behavioral
disorders due to psychoactive substance use include different
conditions caused by the intake of medically or not medically
prescribed psychoactive substances (2). Psychoactive substance
use disorder (PSUD) was firstly coded as a discrete diagnostic
category both in the American Psychiatric Association (APA)
Diagnostic and Statistical Manual (DSM)-3rd edition (DSM-III)
and in the World Health Organization (WHO) International
Classification of Diseases and Related Health Problems (ICD)-
9th edition of the (2–4). The current Diagnostic and Statistical
Manual-5th edition (DSM-5) (5) amalgamated the abuse and
dependence under a single category named “Substance Use
Disorder” whilst the ICD-11 beta draft (6) described substance
dependence (not substance use) (ICD: F10.xx to F19.xx)
as a “disorder of regulation of the use of a psychoactive
substance arising from repeated or continuous use of the
substance [. . . ]” (5, 6). Overall, PSUD may largely differ in
severity and intensity in their psychopathological and clinical
manifestation, i.e., ranging from an uncomplicated intoxication
to the development of clinically significant psychotic disorders or
other psychopathological and/or clinical manifestations) (2).
People with PSUD, including those classified as affected
with a dual disorder, have been considered, compared to
the general population, at higher risk of developing a range
of medical and psychiatric disorders in comorbidity (7–9).
Overall, PSUD subjects, particularly those with concurrent
mental disorders, are overall associated with poorest outcomes,
higher psychopathological severity and an increased rate of
risky behaviors (i.e., hypersexuality, syringes/needles sharing,
etc.) which can predispose them to an increased occurrence
of serious infection diseases like Human Immunodeficiency
Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) and
Hepatitis C Virus (HCV), compared to the general population
(10). Moreover, people with PSUD display a worsen psychosocial
impairment (e.g., unemployment and homelessness) and they
can more likely be involved in criminal and antisocial behaviors,
compared to people affected by other mental disorders with a
concurrent substance and/or alcohol use disorder (8, 11, 12).
However, although the PSUDs are fully considered among
the mental and behavioral disorders, the contribution of
psychiatrists, early career psychiatrists (ECPs) and psychiatry
trainees into this clinical and research field, should be better
developed. For instance, addiction psychiatry (sometimes named
as addiction medicine) appears not to be adequately and
homogeneously incorporated within the psychiatric training,
across all European countries. Furthermore, psychiatry trainees’
levels of knowledge and experiences in addiction psychiatry may
greatly vary across European countries and cultures. As already
documented by the 2014 WHO Global Survey on Resources
for Prevention and Treatment of Substance Use Disorders,
around 37% of the 155 responding countries do not provide
adequate access to the post-graduate training programme for
professionals working in PSUD treatment (13). Globally almost
30% of countries did not report a dedicated training programme
for the treatment and the management of PSUD patients (52% of
low-income countries vs. 16% of high-income countries), being
mainly included in a short cycle tertiary education programme
(48%). Overall, 95% of countries documented that psychiatrists
are commonly involved in the treatment of people with PSUD,
followed by psychologists, who are involved in PSUD treatment
and management in around 86% of the countries. Furthermore,
more than 80% of European countries reported the availability
of a post-graduate training programme for the treatment and
management of PSUD for psychiatrists (14).
Contextually, psychiatrists and psychiatry trainees’ attitudes
toward PSUD patients largely differ across different countries
and cultures, where people with PSUD are generally more
exposed to psychiatrists’ and health professionals’ negative
attitudes/perception as well stigmatizing behaviors, and
language (15). Stigmatizing behaviors and attitudes displayed
by both psychiatrists and other physicians may lead to an
inadequate and inhomogeneous physical, mental health care
and treatment, including prescribing non evidence-based
pharmacological/not pharmacological treatments, prescribing
an inadequate/insufficient posology and duration of therapy.
Moreover, use of potentially stigmatizing language may lead
mental health professionals to a poor/inadequate communication
with their PSUD patients, displaying an overall judgmental and
unempathetic attitude, and other problematic and potentially
stigmatizing behaviors (16–19).
The present study aimed at evaluating the organization of
the addiction psychiatry training, trainees’ satisfaction, trainees’
attitudes toward people who use psychoactive substances and
addiction psychiatry, and how psychiatric trainees manage
psychopharmacology and pharmacotherapy in the most
common clinical presentations of people with PSUD and
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The EFPT-PSUD Study has been an international cross-sectional
survey of European psychiatry trainees carried out in the context
of the European Federation of Psychiatric Trainees (EFPT), the
umbrella organization of the national trainees’ associations in
psychiatry in Europe (20, 21). Among the framework of the EFPT,
a working group specifically dedicated to the PSUD developed a
self-administered survey that was disseminated at European level,
by involving both Child and Adolescent Psychiatry (CAP) and
General Adult Psychiatric (GAP) trainees.
Pilot Phase
All active members of the EFPT-PSUD Working Group,
constituted during the 2014 EFPT Forum in London (22) and
initially comprising national representatives from 5 countries
(Italy, Croatia, Lithuania, Denmark, and Estonia), firstly
conducted a preliminary overview about the current state-of-the-
art regarding the training in addiction psychiatry in the European
CAP/GAP training programs, and subsequently developed the
survey. The survey was initially piloted amongst the members of
the EFPT-PSUDWorking Group.
Full Study Phase
The previously developed survey was circulated at the European
level both to CAP and GAP trainees. The survey was circulated
to the national representatives of each 47 European countries of
the Council of Europe plus Israel and Belarus.
The European countries not represented in the survey were
those not able to identify a National Coordinator who would take
over the responsibility of the study or those unable to collect at
least 10 completed questionnaires from their own country.
Instrument
The questionnaire was a 76-item self-report survey (Appendix 1
in the Supplementary Material). The questionnaire consisted
of: (a) single answer and/or multiple answer questions (i.e.,
for evaluating trainees’ knowledge in a specific field); (b) an
increasing five-item Likert scale (i.e., for evaluating attitudes
and interests toward the addiction medicine and psychiatry);
and, (c) a series of open-ended questions (i.e., asking for
further specification and/or clarification of the provided
answers). In particular, the section on general knowledge on
addiction consists of 36 items in which each question correctly
answered gave 1 point (range score: 0–36). This section was
developed by GDP, following the evidence-based practices of
the Substance Abuse and Mental Health Services Administration
(SAMHSA) (https://www.samhsa.gov/ebp-resource-center).
For the present article, we have focused on the following
sections of the survey:
• General socio-demographic section;
• General information about training in GAP (General Adult
Psychiatry) or Child and Adolescent Psychiatry (CAP),
including experiences (if any) on addiction psychiatry;
• General attitudes and interest toward addictions,
addiction psychiatry;
• Level of knowledge about addictions, addictive disorders,
including treatment.
Data Collection
One national coordinator per each of 47 European countries
of the Council of Europe plus Israel and Belarus facilitated the
delivery of the survey through an online data collecting system
(https://www.surveymonkey.com/r/EFPT-PSUDstudy) and/or, if
necessary, delivering the questionnaire hand-by-hand, in a
paper form (Appendix 1). The questionnaire was circulated in
English across all European countries (in French language in
France) and no translation in other languages was deemed
necessary, as psychiatric trainees were deemed by their
national coordinators to have sufficient command of English
to reliably answer the questions (i.e., this was preliminarily
evaluated by each national coordinator). Data were collected
from 15th August 2015 to 15th October 2016. Annual
EFPT forum as well as European and national congresses
or educational events were chosen to reach out to all
CAP/GAP trainees in each country or to involve national
coordinators, needed for those countries still not represented
in the sample of the survey. Moreover, European contact
e-mail databases were periodically used to disseminate the
link for the online survey (https://www.surveymonkey.com/r/
EFPT-PSUDstudy). All hand-to-hand questionnaires completed
were subsequently entered into the online study database
by the National Coordinator via the online survey tool
Survey Monkey. The online survey link was only accessible
by invitation.
Inclusion Criteria
The inclusion criteria were: (i) being a CAP/GAP trainee, defined
as a fully qualified medical doctor enrolled in a nationally
recognized specialist training programme in CAP or GAP; (ii)
belonging to one of the 47 European countries of the Council of
Europe plus Israel and Belarus.
The participant countries included in the present analysis were
those countries of whom each CAP/GAP National Coordinator
was able to collect at least 10 completed questionnaires [not
considering the last section regarding Novel Psychoactive
Substances (NPS)]. Those countries with a National Coordinator
who took responsibility to take part in the study but did not reach
an enough minimum number of completed questionnaires were
excluded in the present analysis (Greece, Belgium, Germany,
Slovakia, Ukraine, Sweden, Denmark, and Israel). Amongst
these, the following European countries participated in the
present survey with a valid number of filled questionnaires:
Albania, Austria, Azerbaijan, Belarus, Bosnia and Herzegovina,
Bulgaria, Croatia, Czech Republic, Estonia, Finland, France,
Hungary, Ireland, Italy, Kosovo, Latvia, Lithuania, Moldova,
Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia,
Slovenia, Spain, Switzerland, Turkey, and UK.
Frontiers in Psychiatry | www.frontiersin.org 3 January 2021 | Volume 11 | Article 58560733
Orsolini et al. Addiction Psychiatry—A European Survey
Ethics Approval and Consent
The survey was conducted according to the principles of good
scientific practice, which was supported by previous EFPT-
sponsored psychiatry trainees’ surveys (23). Ethical approval
for the study has been sought and granted by the School of
Pharmacy Ethics Committee at the University of Hertfordshire
(December 15, 2010, reference code PHAEC/10-42), with a
further extension of the approval granted in November 2013.
The patients/participants provided their written online informed
consent to participate in this study.
Before filling out the survey which was self-administered
anonymously, all participants were asked to give written online
informed consent before, as legally and ethically required.
Statistical Analysis
Data was analyzed using the Software Package for Social
Sciences for Windows v. 24.0 (SPSS 24) (IBM Corp, Armonk
NY). Categorical variables were summarized as n (%), and
continuous variables as means [standard deviation (SD)].
Pearson’s χ2-tests were used to compare demographic and
categorical variables, such as the trainees’ attitudes toward
addiction psychiatry. Student’s t-tests and one-way analysis
of variance (ANOVA)-tests were used to compare continuous
variables, including comparisons of training experiences. Ordinal
regression was used to model the predictors of trainee
satisfaction. Variables added to the model included trainees’
sub-specialty and percentage of training completed. The
significance level was set a priori at p ≤ 0.05, and all hypotheses
were two-tailed.
RESULTS
Sampling and Sample Characteristics
The total number of questionnaires correctly filled during
the collection process and afterwards included in the analysis
was of 1,118, amongst all trainees in Europe who took part
in the survey. However, after excluding missing data (i.e.,
including only complete questionnaires) only 1,049 responses
were included (Table 1). There were differences in the gender
distribution, being most of them women (68.7%) and this
difference is statistically significant when we stratified the
sample by subspecialty (χ2 = 25, p < 0.001), being 84.6% of
the CAP sample represented by women, whilst in the GAP
sample, a percentage of 64% was represented by women, by
reaching a total amount of GAP and CAP trainees of 936 (after
excluding those trainees in forensic psychiatry or others with
an unspecified other psychiatry training). The mean age of
respondents was 30.48 (±4.84) years, without any statistically
significant differences between GAP and CAP samples. The
majority (73.8%) were GAP trainees, whereas 15.4% were CAP
trainees, whilst around 10.6% of the sample did not specify
if they are GAP or CAP trainees. Amongst the respondents,
the total number of years required to complete GAP and CAP
training programs may largely differ across European countries.
To adjust the analysis for this confounder, it was calculated the
percentage of progression/completeness of individual training
for each country, in order to measure the most reliable and
objective variable. This variable reported that in an average
of 67.4% of the total sample, CAP/GAP trainees were in
the last quantile of their training programme, without any
statistically significant difference between GAP and CAP (see
Figure 1). The CAP/GAP trainees overall belong to 30 different
countries, with the highest proportion of respondents amongst
those training in France (16.3%), followed by Italy (5.7%),
Spain (5.1%) and the UK (5.0%). See Table 1 for further
demographic features.
Trainees’ Experience, Satisfaction, and
Training in Addiction Psychiatry
Amongst those who answered the question “Have you performed
part of your psychiatric training in the treatment of patient
with substance use disorder?”, only 59.9% of trainees reported
to have spent part of their training in addiction psychiatry
settings, with a statistically significant difference between GAP
and CAP trainees (p = 0.018). Amongst those trainees who
declared to have received training in addiction psychiatry during
their psychiatry training, only 43% described that the PSUD
training was not well-structured due to several reasons. First, the
addiction training program is often too short to allow trainees
to deepen knowledge on all theoretical and practical aspects
of addiction psychiatry; second, during the addiction training
program, CAP/GAP trainees are often alone in the management
of PSUD patients (often without a dedicated supervisor/mentor);
third, the addiction training program usually consists in a
mere observership experience (without a practical frontline
experience). Amongst those trainees who had training in
addictions only 37% of them declared that they were not
satisfied about the level of training offered, mainly stating lack of
enough acquired skills and knowledge in the field, largely below
their initial expectations. There was no significant difference in
the percentage of training completed amongst those trainees
who reported being satisfied with their addiction psychiatry
training, compared to those trainees who did not document
an enough level of satisfaction [F(1,555) = 2.244, p= 0.135].
Trainees with larger caseloads had generally progressed further in
their training, compared to those trainees with smaller caseloads
[F(5,551) = 6.487, p < 0.001]. Most of the sample (97%) agreed or
strongly agreed that addiction represents a core curriculum for
training. Subspecialty was a significant predictor of satisfaction
with training (β = 1.713; p = 0.042), being GAP trainees overall
more satisfied, compared to CAP trainees, even though this
finding is not strictly correlated by the percentage of training
completed (β = 1.005; p= 0.176).
Trainees’ Attitudes Towards People Who
Use Psychoactive Substances and
Addiction Psychiatry
Approximately one third of the sample (33.27%) agreed
or strongly agreed to be confident with their basic skills
needed/requested necessary to work in addiction settings after
their training (χ2 = 82.864; p< 0.001). Interestingly, on the other
hand, around 66.9% of the trainees agreed or strongly agreed
that “Addiction psychiatrists are usually less skilled than their
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TABLE 1 | Demographic characteristics.
Total GAP (N = 774) CAP (N = 162) Significance
Mean (SD) Mean (SD) Mean (SD) t
Age 30.48 (4.84) 30.43 (4.58) 30.79 (5.24) p = 0.899
Training completed (%) 67.37 (28.01) 67.77 (28.44) 66.95 (28.64) p = 0.716
Frequency (%) Frequency (%) Frequency (%) χ2
Gender p < 0.001
Male 328 (31.3%) 269 (34.8%) 25 (15.4%)
Female 721 (68.7%) 505 (65.2%) 137 (84.6%)
Country of training p = 0.221
Croatia 38 (3.6%) 26 (3.4%) 5 (3.1%)
Czech Republic 36 (3.4%) 28 (3.65%) 8 (4.9%)
Finland 44 (4.2%) 32 (4.1%) 8 (4.9%)
France 171 (16.3%) 101 (13.0%) 30 (18.5%)
Ireland 40 (3.8%) 20 (2.6%) 5 (3.1%)
Italy 57 (5.4%) 50 (6.5%) 7 (4.3%)
Lithuania 45 (4.3%) 35 (4.5%) 10 (6.2%)
Netherlands 35 (3.3%) 23 (3.0%) 3 (1.9%)
Poland 47 (4.5%) 38 (4.9%) 6 (3.7%)
Portugal 42 (4.0%) 37 (4.8%) 5 (3.1%)
Romania 45 (4.3%) 39 (5.0%) 6 (3.7%)
Slovenia 33 (3.1%) 22 (2.8%) 9 (5.6%)
Spain 53 (5.1%) 47 (6.1%) 1 (0.6%)
Switzerland 34 (3.2%) 27 (3.5%) 7 (4.3%)
Turkey 40 (3.8%) 31 (4.0%) 9 (5.6%)
UK 52 (5.0%) 30 (3.9%) 5 (3.1%)
Other 237 (22.6%) 188 (24.3%) 38 (23.5%)
GAP, General Adult Psychiatry; CAP, Child and Adolescent Psychiatry; SD, Standard Deviation; UK, United Kingdom.
FIGURE 1 | Distribution of training completion.
colleagues working in GAP/CAP” (Table 2). Moreover, around
75.7% disagreed or strongly disagreed that addictions are mental
disorders; similarly, 77.8% of the sample agreed or strongly
agreed that people with drug addiction cannot be recovered
(Table 2).
Over three-quarters of respondents (76.1%) knew/had
previously known someone outside of their workplace with an
addiction-related problem (Table 3). The findings showed that
those who knew/had known someone with addiction related
problems were significantly associated with a stronger desire to
work in the addictions after their training [χ2(4) = 16.311, p =
0.003] (Figure 2).
Trainees’ Basic Knowledge and
Confidence/Perceived Competence in
Addiction Psychiatry
Respondents who had treated someone with an addiction-related
condition significantly declared to have almost completed their
training, compared to those trainees who had not [F(1,991) =
99.155, p < 0.001] (Figure 3). Figure 4 represents the graphical
distribution of the knowledge score, by indicating that most
trainees responded correctly to most of the questions regarding
their general and specific knowledge of addiction psychiatry
(mean average 25.77 ± SD 3.59), with a minimum score of
7 and a maximum score of 34 (skewness = −0.956). There
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TABLE 2 | Attitude of trainees who have/haven’t performed part of their training in the treatment of a patient with addiction.
Have you performed part of your psychiatric
training in the treatment of patients with addiction?
Yes No
Illicit drugs (e.g., heroin) addicted
are good people
Strongly agree 9 3 χ2 = 8.773
p = 0.067Agree 33 22
Neither agree or disagree 303 236
Disagree 101 52
Strongly disagree 62 60
I don’t feel confident with my
skills to work in addiction
Strongly agree 36 22 χ2 = 82.864
p < 0.001Agree 178 44
Neither agree or disagree 125 84
Disagree 146 181
Strongly disagree 23 42
I think that people with drug
addiction cannot recover
Strongly agree 138 88 χ2 = 3.872
p = 0.424Agree 257 188
Neither agree or disagree 87 75
Disagree 25 19
Strongly disagree 1 3
Addiction is a mental disorder Strongly agree 5 4 χ2 = 6.263
p = 0.180Agree 25 15
Neither agree or disagree 59 61
Disagree 262 198
Strongly disagree 15 95
Addiction psychiatrists are
usually less skilled than their
colleagues working in general
adult and child adolescent
psychiatry
Strongly agree 159 130 χ2 = 6.565
p = 0.161Agree 181 140
Neither agree or disagree 104 73
Disagree 57 24
Strongly disagree 7 6
was no significant difference in terms of the most prevalent
addiction-related condition that was treated/observed during
their addiction psychiatry training [F(4,479) = 1.523, p= 0.194].
However, those trainees who had treated alcohol withdrawal
syndrome, delirium tremens, opioid withdrawal syndrome, or
substance induced-psychosis were significantly more senior
in their level of training completeness, compared to those
trainees who had not treated these addiction-related conditions
who were more junior (all p-values < 0.001). Similarly, those
trainees prescribing acamprosate, naltrexone, methadone, and
buprenorphine were also significantly further in their training
than those who did not prescribe a medication for an addiction
(all p-values < 0.001). In addition, GAP trainees more likely
reported to have treated a person affected with an addiction
during their training, compared to CAP trainees [χ2(1) = 8.328,
p = 0.004]. Likewise, GAP trainees more likely reported to
have prescribed medication for an addiction-related condition,
compared to CAP trainees [χ2(1) = 9.482, p = 0.002].
Furthermore, GAP trainees reached higher scores, compared to
those undergoing CAP training, when questioned about their
general and specific knowledge of addictions [F(1,802) = 14.181, p
< 0.001]. Moreover, GAP trainees were more likely aware of the
existance of legal highs/smart drugs/novel substances, compared
to CAP trainees [χ2(2) = 25.663, p < 0.001]. However, when the
knowledge score includes in the analysis also those questions
about legal highs/smart drugs/novel substances, there was no
significant difference in the total score between GAP and CAP
trainees [F(1,531) = 0.524, p= 0.470].
DISCUSSION
Key Findings and Comparison With the
Literature
PSUD have been historically perceived as personal, family,
social, moral, or criminal issues rather than a health condition
(24). Therefore, subjects with PSUD have been supposed
to be better managed at the individual, family or justice
level (i.e., through existing social infrastructure or civil and
criminal justice interventions) (24). Indeed, criminalization of
people with PSUD exacerbated their perceived and experienced
stigma, avoidant attitudes and behaviors of contempt, by
worsening their marginalization and poor access to adequate
treatment and care (24). People with PSUD tend to be
stigmatized due to their use of drugs and drug-seeking
behaviors (24). Moreover, other PSUD-related risky behaviors,
such as speeding/dangerous driving, violence, aggressiveness,
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TABLE 3 | Attitude of trainees who have/haven’t known someone outside their workplace with addiction related problems.
I know/had known someone outside my workplace
(family, friends, relatives, neighborhood) who
has/had addiction related problems
Yes No
I am afraid to work with persons
with cocaine addiction
Strongly agree 204 39 χ2 = 14.623
p = 0.006Agree 309 101
Neither agree or disagree 92 42
Disagree 62 20
Strongly disagree 7 5
I am afraid to work with persons
with alcohol
Strongly agree 283 68 χ2 = 8.305
p = 0.081Agree 298 97
Neither agree or disagree 64 30
Disagree 25 11
Strongly disagree 4 1
Addiction is a mental disorder Strongly agree 8 1 χ2 = 14.525
p = 0.006Agree 34 6
Neither agree or disagree 83 37
Disagree 339 121
Strongly disagree 210 42
Individual psychotherapy should
be preferred in treating addiction
Strongly agree 14 1 χ2 = 12.680
p = 0.013Agree 125 45
Neither agree or disagree 236 93
Disagree 238 52
Strongly disagree 61 16
and impulse dysregulation, are barely seen as part of a
complex disorder, so that people with PSUD are usually
rejected by the society due to the supposed moral valence
of these behaviors (24, 25). These patients may also be seen
as a burden for the healthcare system, by indeed increasing
the disparities of cares, the risk to not adequately provide
evidence-based and effective treatments (19, 25). Due to
this disadvantageous framework, patients with PSUD may
develop a self-stigmatizing attitude as well (e.g., a subjective
process characterized by negative feelings about own self,
maladaptive behaviors, stereotype endorsement resulting from
individual’s experiences/perceptions/feelings and anticipation
of negative social reactions) (26–29). In fact, potentially
“stigmatized” attitudes and behaviors, overly provided by
healthcare professionals, including psychiatrists and psychiatry
trainees, may be potentially trigger and maintain these
self-stigmatizing attitudes, as already reported in the literature
and confirmed by our findings (16, 19, 26–29). Furthermore,
subjects with PSUD are symbolically associated with a range
of other stigmatized health conditions, including HIV/AIDS,
HCV, risk and disinhibiting behaviors such as impaired driving,
prodigality, criminality, risky sexual behaviors, and social issues
(30, 31). Stigmatizing beliefs and behaviors about PSUD may be
influenced by the level of knowledge (and education) about these
mental health conditions and the personal experience with people
affected with PSUD. Furthermore, it has been reported that
media portrayal of people with PSUD and media coverage/level
of news disseminated about significant and impactful related
events, mainly occurring due to a drug intoxication and/or
drug dependence/abuse/misuse, can significantly increase these
stigmatizing beliefs and attitudes (29, 32).
Furthermore, addictions have not been historically
recognized as conditions requiring a medical, psychological
and psychopharmacological treatment (19). This is in line
with our findings in which most GAP and CAP trainees
declared that the addictions are not mental disorders. In
fact, as previously documented in the literature, this overall
consideration regrading PSUD appears to be widely spread
not only at the general population level but also amongst
mental health professionals who overall reported negative
and pessimistic views about PSUD, people with PSUD
and do not routinely screen patients in daily practice for
addictions (15, 26, 33, 34).
However, the individual perceptions and attitudes towards
people with PSUDmay largely vary according to different factors.
For instance, people are less likely to endorse the stereotype
of violence together with a negative connotation of addiction
disorders, if they have had direct contact with people (or also
familymembers or close friends) whowere affected with PSUDor
did not experience violent acts by people affectedwith PSUD (35).
This is comparable with our findings which demonstrated that
those trainees who have/had experience with people with a PSUD
significantly declared to have a stronger desire to work in the
addiction field and with subjects with PSUD after their training.
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FIGURE 2 | Frequency of trainees who would like to work in addiction
following completion (by those who have/haven’t known someone outside the
workplace who has had an addiction related problem).
FIGURE 3 | Mean percentage of training completed in those who
have/haven’t worked with patients with psychoactive use disorders during
their training (by sub-specialty).
Furthermore, despite a compelling need for PSUD treatment
in Europe, mental healthcare professionals (including psychiatry
trainees) overall appear poorly or neither trained, nor especially
eager to accept/tolerate patients with PSUD (15, 33, 34, 36).
In general, psychiatrists do not feel competent/confident in
treating addiction disorders, do not like working with patients
affected with PSUD and do not find rewarding treating patients
with PSUD (33, 37, 38). A lack of (practical) experience
and/or an inadequate (theoretical and practical) training in
FIGURE 4 | Distribution of the knowledge score.
addiction psychiatry may indeed result in an endless loop of
incompetence and neglect regarding the addiction psychiatry,
amongst mental health care professionals. However, despite
the evidence demonstrating the need to improve addiction
medicine’s training not only amongst psychiatry trainees but
also amongst all physician trainees, most medical students and
CAP/GAP trainees generally receive an inadequate (practical and
theoretical) training in the field of addiction medicine/psychiatry
(33, 39, 40). Moreover, most CAP/GAP trainees generally
display lacking core clinical and therapeutic competences,
as required for working with patients with PSUD (33, 39,
40). Although formal addiction training within the medical
field has been closely tied to psychiatry, psychiatric training
generally provides a poor improvement and a limited level
of knowledge over medical school, about addictions (39,
40). These considerations are particularly significant in the
European countries, whereas there are several inequalities
and heterogeneous training levels in addiction psychiatry, as
documented by our findings. Furthermore, most CAP and
GAP trainees reported to be less skilled in the addiction field,
compared to other fields of psychiatry. Interestingly, there are
not statistically significant differences between GAP and CAP
trainees regarding this finding. This appears particularly relevant
if we consider that CAP trainees should possess a comprehensive
experience including behavioral, psychosocial and addiction
problems particularly amongst youngsters/adolescents who have
been well-demonstrated to be those patients more frequently
exposed to drugs and/or other addictive behaviors, but also
those patients more vulnerable toward the new onset of mental
disorders associated with a PSUD (41).
Furthermore, an insufficient training experience with patients
with PSUD, along with the lack of a highly-specialized
faculty (i.e., short addiction training experience, lack of a
supervisor/mentor during the addiction training, and poor
quality of addiction training), may overall lead to a discouraging
training experience amongst CAP/GAP trainees, as reported
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in our study. Overall, one could argue that this general
psychiatry trainees’ attitudes and perceptions towards the
addiction psychiatry might discourage trainees’ interest and
willingness to deepen the management and therapy of patients
with PSUD, independently by their level of psychiatry training,
as well as their interests in working in addiction psychiatry
(38). Renner et al. (38) described the following main predictors
of poor perception of careers in addiction medicine by GAP
trainees: (a) the poor/not enough/lacking experience with
patients with PSUD; (b) the perceived sensation and feeling
to work with “difficult” patients; (c) the lack of a competent
training in the addiction; (d) an overemphasis, during psychiatry
training, about the detoxification process rather than a long-
term rehabilitative and care program for the addiction-related
conditions. Miller et al. (33) identified the following hypothesized
barriers/determinants explaining the different attitudes and
practices of medical students, trainees and physicians towards
addiction psychiatry: (a) lack of acceptance of a medical model
for addictive disorders; (b) lack of positive and/or optimistic
attitudes about patients with PSUD, by accepting the prevalent
stereotype of subjects with PSUD as those patients whose social
and medical prognosis is poor; (c) curricula deficits throughout
the Continuum Medical Education (CME) in the field of
the addiction psychiatry/medicine, particularly the total time
devoted to addictive disorders during the medical school and
psychiatry training; (d) lack of parity and physician advocacy in
medical education; (e) prejudices and misunderstandings about
addictive disorders, along with ungrounded fears of huge costs
connected with addiction treatment and the perception that
addiction treatment owns a low ratio of benefits to costs; (f)
personal and/or family history of drug and/or alcohol disorders.
Conversely, Rush et al. (42) found that the factors associated
with more positive attitudes towards the treatment of addictive
disorders and subjects with PSUD may be represented by: (a) the
number of subjects with PSUD treated/visited; (b) the physicians’
perceived effectiveness in the management of the addictive
disorders; and, (c) the numbers of hours of CME specifically
addressed on the addictive disorders.
However, as widely reported in the literature, the level of
knowledge and education about PSUD and addiction psychiatry
can positively influencemental health professionals’ attitudes and
interests towards the field of addictions, limit the misdiagnosis
and potentially reduce improper and inadequate treatment
regimens for these disorders (43–45), even though other studies
demonstrated a deterioration in attitudes throughout medical
school years and suggested a continued decline throughout the
years of training, mainly due to time and resources spent for
those subjects with PSUD (19, 46–49). The enhancement of
these beliefs appears to be more significant when we compared
those subjects with PSUD with those with AUD (49). As
proposed by Miller et al. (33), to achieve an adequate level
of education and training in addiction psychiatry, it should
be ensured that all trainees reach an enough and adequate
knowledge and skills in the diagnosis and treatment of the
addictive disorders, by favoring the development of curricula for
the addictive disorders in all medical schools, residency training
programs and CME; by supporting the research and revising all
discriminatory policies that create barriers to the implementation
of curricula in addictive disorders; by providing the detection
and intervention for students, trainees and physicians who have
addictive disorders; and, by supporting the parity between the
addictive disorders and other medical and psychiatric diseases.
Main Strengths and Limitations
To the best of our knowledge, this has been the only study
specifically investigating the levels of training, experiences,
attitudes and perceptions as well as the level of perceived
confidence and capacity in the management of people with
a PSUD, carried out amongst European CAP/GAP trainees.
The present survey also included a large sample size of
CAP/GAP trainees in Europe (n = 1,118) which comprises
many European countries (n= 30). Furthermore, collecting data
from different European countries might lend strength to the
generalization of these findings also to other WHO Regions,
beyond European Region. Moreover, our study identifies gaps in
knowledge by demonstrating that addiction psychiatry appears
not to be adequately and homogeneously incorporated within
the psychiatric training, across all European countries. Moreover,
a key finding is represented by the significant number of
recruited psychiatry’s trainees who do not consider addiction as a
psychiatric disorder.
Despite its original and poorly investigated topic, there
are several limitations that should be here drawn up. Firstly,
being a self-report questionnaire and partly online administered,
potential recall, social desirability, and reporting biases may
occur. Secondly, the sampling method may be hugely affected
both by the fact that not in all European countries we reached
an enough number of completed questionnaires or reached an
available official national coordinator. In fact, some European
countries initially included have been a posteriori excluded in our
analysis as they did not reach an enough number of completed
questionnaires (cut-off of 10 for each country), like Greece,
Belgium, Germany, Slovakia, Ukraine, Sweden, Denmark, and
Israel. Furthermore, sampling rates largely vary within different
European countries, being some countries (i.e., Croatia, Finland,
France, Ireland, Italy, Lithuania, Poland, Portugal, Romania,
Slovenia, Spain, Turkey, and UK) most represented in our
sample compared to Albania, Bosnia, Bulgaria, Czech Republic,
Estonia, The Netherlands, Serbia, and Switzerland. The level of
perceived confidence and knowledge in addiction psychiatry,
being mainly based on a set of questionnaires, may also be
susceptible to the updated information and new available and
emerging pharmacological and not pharmacological treatments,
may not completely reflect the current situation occurring
at the time of writing of the present study. Moreover, the
present study does not examine what happens once GAP/CAP
residency is completed and the GAP/CAP enters career’s
practice. It should be relevant to document further data
particularly regarding the level of attitude or perception of
PSUD patients with added experiences and added continuing
educational opportunities during their clinical career. Finally,
the present study does not specifically define whether psychiatry
trainees’ attitudes differ towards caring for subjects with AUD
and/or SUD.
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Relevance of the Findings and Implications
for Practice, Policies, and Research
The present study provides significant and valuable information
on the current European CAP/GAP trainees’ level of experiences,
training, perceived knowledge/competence, and subjective
attitudes/perceptions towards the addiction psychiatry. These
findings not only serve to investigate the current European
situation in terms of level of subspecialty offered in the
addiction psychiatry as well as the potential differences across
all analyzed European countries, but they might also investigate
those situations which should be implemented/enhanced as
lacking in providing opportunities both in terms of internship
(practical training) and knowledge (theoretical training) in
the field of the addictions. Moreover, addressing the identified
reasons/factors determining a different level of training in
addiction psychiatry as well as a different level of interest
CAP/GAP trainees, in strenghtening knowledge in this field
might be a way to modulate and act on these factors, to improve
the CAP/GAP training conditions in the field of addiction
psychiatry (50). Regarding the need to improve all CAP/GAP
training programmes, the standardization of curricula would
be important to produce both GAP and CAP trainees able
and capable (self-confident) in the management and correct
identification of both physical and mental/behavioral PSUD-
related conditions. This should be part of the essential core
knowledge that should be indispensable for all psychiatric
practice. In terms of the enhancement of GAP/CAP trainees’
education/knowledge in the addiction medicine and psychiatry,
an implementation of a mandatory addiction rotation during
the CAP and GAP training program, could greatly improve
the level of trainees’ confidence and competence in identifying
and dealing with all different addictive disorders. Furthermore,
in CAP and GAP training, the need to develop and satisfy
objective measurable educational criteria must be balanced
with the acquisition of subjective skills needed to treat subjects
with PSUD effectively (e.g., increasing empathy and not
judgmental approach as well as addressing stigma), as well as
reaching an enough comfort in working with PSUD patients
and obtaining a minimum sense of mastery in the field of
the addictions. Finally, it might be suggested to all European
GAP and CAP training programmes to administer to all
psychiatry trainees at the end of their training program, validated
tools for assessing addiction psychiatry training and early
identify potential deficits, such as the Addiction Training
Scale (ATS) (51).
These findings may assist the decision-makers to implement
strategies to adapt their national diversities in CAP/GAP training
programmes and make them homogenous especially at the
European level. The need for psychiatry trainees’ education
and experience in treating patients with addiction problems
has been outlined. Lastly, although these preliminary findings
may help in mapping the reality of this field of psychiatry,
further studies are needed to focus on the main motivations
underpinning the existing differences across European countries
in terms of level of training in addiction psychiatry (i.e.,
cultural and/or religious factors, epidemiological motivations,
etc.) and consequences of different experiences/training in the
level of knowledge of a CAP/GAP trainees as well as their
attitude/perception towards addictions in general and people
who use psychoactive substances. Moreover, it would also
be of interest to repeat the present survey with identical
methodology every 4 or 5 years (being the average duration
of CAP/GAP European training) to assess potential trends
in these findings and attitudes/opinions of psychiatry trainees
over time and evaluate if any enhancing intervention has been
provided at European and national level concerning addiction
psychiatry training and evaluate if any positive/neutral/negative
impact was reached amongst psychiatry trainees’ attitudes
and knowledge.
CONCLUSIONS
Despite the growing dissemination of addictive disorders across
all European countries, addiction psychiatry seems to be an
underdeveloped part of psychiatry within psychiatry training
programmes. However, we found substantial consensus among
all European psychiatry trainees that more education and
experience in treating patients with addictive disorders should be
guaranteed and be part of the core curricula in GAP and CAP
training. Further research needs to be directed towards the causes
of poor training as well as timings of these educational activities
to optimize experiential education programs to be implemented
within GAP and CAP training programs.
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Introduction: Gabapentinoid drugs (gabapentin and pregabalin) are widely used
worldwide for epileptic and pain disorders. First signals of gabapentinoid abuse occurred
in the last decade. This study aims to describe clinical characteristics of gabapentinoid
use related disorders and health consequences in France.
Materials and Methods: We designed a multisource investigation reviewing data
reported to the French Addictovigilance Network (FAN) with pregabalin and gabapentin
from 2010 to 2019. Information was obtained through the analysis of Spontaneous
Reports (SRs) notified by health professionals and the pharmacoepidemiological
surveys OSIAP (suspicious prescriptions forms indicators of potential abuse), OPPIDUM
(observation of illicit drugs and misuse of psychotropic medications), DRAMES (death
related to prescription drugs and other substances), and DTA (toxic deaths due
to analgesics).
Results: Over 2010–2019 period, were collected: (i) 265 SRs (258 pregabalin;
7 gabapentin); (ii) 816 forged prescription forms (805 pregabalin, 10 gabapentin,
1 involving both drugs); (iii) 145 cases of gabapentinoid use in people who use
drugs (121 pregabalin; 24 gabapentin) and (iv) 31 cases of gabapentinoid-related
deaths (25 pregabalin; 6 gabapentin). Risk factors of gabapentinoid abuse were
opioid use disorders or psychiatric history, but cases of primary abuse in subjects
without any substance abuse history were observed. Adverse outcomes concern
almost exclusively pregabalin, with coma, dyspnea, convulsion, and conduction
disorders. Treatment demands increased from 10.6% in 2018 to 23.1% in 2019,
with pregabalin cited as the first substance leading to addictological care in
the 2019 OPPIDUM survey. Gabapentinoid-related deaths increased over time.
Pregabalin has become the first drug mentioned in forged prescriptions in
2019 (23.8% of OSIAP), while it ranked at the 15th position in 2017 (2.6%).
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Discussion: This study shows the importance of addictovigilance monitoring for
gabapentinoids. Addictovigilance data helped to make visible the gabapentinoid-abuse
related health harms (hospitalization for serious neurologic, psychiatric or cardiac effects,
requests for addictological support and deaths) and to confirm the intrinsic abuse
potential of pregabalin. These data highlight new points of vigilance considering observed
primary abuse. At this point in France, the risk of abuse and related complications is very
apparent with pregabalin. Still, it is identical to that observed elsewhere with gabapentin.
Keywords: addictovigilance, gabapentinoids, psychotropic adverse effects, addiction, prescription drug abuse
INTRODUCTION
Gabapentin and pregabalin are two pharmacologically closely
related drugs, belonging to the class of gabapentinoids
[mirogabalin, only available in Japan, represents the third
member (1)]. This class present structural similarities with
gamma-amino-butyric acid (GABA) without acting on its
receptor. The mechanism of action of gabapentinoids is generally
described as binding on the alpha2-voltage-dependent calcium
channels in the central nervous system, reducing central
neuronal excitability. This action is believed to contribute to
the antinociceptive, anticonvulsant and anxiolytic properties
of these drugs. Gabapentin (approved in the early 1990s) and
pregabalin (approved in 2004) are widely used for epilepsy
and neuropathic pain (gabapentin is indicated for post zoster
pain). Pregabalin is also approved for generalized anxiety
disorder and for fibromyalgia and gabapentin for restless leg
syndrome only in the US. The European commercial success
of pregabalin since its marketing authorization in 2004 has led
to the expansion of its use in off-label indications [any type of
pain or to manage benzodiazepines or alcohol withdrawal (2, 3)].
In 2010, toxicology and pharmacovigilance data as clinician
reporting in Europe [Scandinavian countries, Germany and
Southern Europe (4–7)] first reported involvement of pregabalin
in deaths related to substance abuse. Since then, an increasing
number of reviews have been published on the subject, arguing
the evidence of gabapentinoid misuse and abuse. A minority of
these reviews concluded that gabapentinoids has no appearing
addictive potential themselves and may lead to abuse only by
persons with opioid use disorders (8, 9). It should be noted
that subjects with a history of psychiatric or substance use
disorders are overall more at risk of such behaviors. Most
of these reviews suggest that misuse and abuse occur more
frequently in users of pregabalin compared with gabapentin
(10–12). In France, only a few cases of gabapentin misuse and
abuse have been reported until 2014 (13–15). In 2011, a first
case of recreational use of pregabalin has been reported by a
general practitioner in 2011 and received particular attention by
the French Addictovigilance Network (FAN) as an early signal
for pregabalin abuse potential. Data have been since collected
leading to further evidence that pregabalin misuse and abuse is
now widespread in France, with visible harmful consequences in
terms of treatment demands, somatic complications, and even
risk of death.
Based on data collected through the French addictovigilance
system from 2010 to 2019, this study aims to describe clinical
characteristics of pregabalin and gabapentin use related disorders
and their health consequences, focusing on primary dependence
potential, life-threatening complications and management of
abuse and dependence.
MATERIALS AND METHODS
We designed a multisource investigation reviewing data reported
to the FrenchAddictovigilanceNetwork (FAN). The FAN ismade
up of 13 Addictovigilance Centers, it was set up in 1990 under
the supervision of the French Medicines Agency (“ANSM” for
Agence Nationale de Sécurité desMédicaments et des Produits de
Santé) to monitor the abuse potential of psychoactive substances
(with the exclusion of tobacco and alcohol) (16–18).
Data Related to Spontaneous Reports
(SRs) Notified by Health Professionals
All cases of pregabalin/gabapentin-related disorders reported
between 2010 and 2019 were analyzed with data on individual
features (age, gender, past medical history) and clinical features
(clinical signs related to substance use, patterns of substance use).
All psychoactive substances included, over the 2010–2019 period,
the FAN has recorded more than 41,500 SRs.
Data Related to Forged/Falsified
Prescriptions Forms Reported by
Community Pharmacists (OSIAP Survey)
This survey aims to identify drugs liable to be diverted from their
medical use or at risk of abuse or dependence. Prescription forms
recorded from 2010 to 2019 including citations of pregabalin
and gabapentin were analyzed. All prescription drugs included,
over the 2010–2019 period, the FAN has recorded about 11,000
prescription forms (19, 20).
Data Related to Patterns of Psychoactive
Drug Use Reported by People Who Use
Drugs (PWUD) Visiting Specialized
Addiction Care Centers (OPPIDUM Survey)
This annual, cross-sectional survey aims to collect information
on self-reported drug use by PWUD. Data of individuals
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reporting pregabalin and gabapentin use between 2010 and 2019
were analyzed. All psychoactive substances included, over the
2010–2019 period, the FAN has recorded data on around 52,000
individuals (21).
Data Related to Drug-Related Deaths From
Toxicological and Medico-Legal Data
(DRAMES and DTA Surveys)
These surveys aim to identify cases of death related to
prescription drugs and other substances (DRAMES survey) or
toxic deaths due to analgesics (DTA survey, since 2013). For a
given case, each substance identified in the blood is subjected to a
causality assessment, establishing the link between the substance
and the cause of death. The strength of causal connection is
determined by a score, from high (level 1) to low (level 4).
The causal link is made on blood concentrations (or other
matrices if no blood) quantification and relies on analysis of
toxicology experts and different published references (22). For
pregabalin, the retained therapeutic concentration is from 2 to 5
mg/L, toxic concentration is at 10 mg/L and lethal concentration
at 25 mg/L and above (23), whether pregabalin is alone or
in combination with other drugs. Cases of death for which
pregabalin and gabapentin were confirmed and quantified, were
analyzed, over the 2010–2018 period for DRAMES survey and
over the 2013–2018 period for DTA survey. All psychoactive
substances included, over the 2010–2018 period, the FAN has
collected data on almost 4,000 deaths. The 2019 DRAMES/DTA
data were not complete at the time of our study (because delay
for forensic context); available information was analyzed.
Other data used into the multisource approach include the
level of drug exposure in the French general population from the
French Health Insurance System (Système National des Données
de Santé, SNDS https://www.snds.gouv.fr/SNDS/Accueil) and
the French Pharmacovigilance database for all reports of any
adverse drug reaction (including misuse and abuse). Figure 1
presents the partnership involved in the network providing
field/post-marketing data and the sources of addictovigilance
data used in this study (16). The level of exposure to pregabalin
and gabapentin in the French general population for the 2010–
2019 period was computed as the number of people living in
France who received at least one prescription of these drugs
each year.
To describe gabapentinoid use related disorders, the following
terms and definitions were used in the manuscript:
- Misuse: use in a manner that is non consistent with the
summary of the product characteristics (regarding therapeutic
indications, route of administration or posology) or a
nontherapeutic use of prescription drug (24)
- Abuse: misuse or illicit drug use leading to health harms
(somatic or psychiatric, hospitalization, death, etc)
- Dependence: condition according to which, upon
cessation, a withdrawal syndrome (somatic or psychiatric
symptoms) emerges
- Substance use disorder: defined by the DSM-5 (25), when the
level of available information is sufficient to conclude this or
reported as such by a specialist in addiction.
As this study was performed retrospectively using routinely
collected anonymous data, it did not require any ethics
committee approval, in line with the French regulations for
mandatory reporting of addiction cases by health professionals.
RESULTS
Over the 2010–2019 period, the following data were collected:
(i) 265 SRs of gabapentinoid abuse (258 with pregabalin and
7 with gabapentin); (ii) 816 forged/falsified prescription forms
(805 involving pregabalin, 10 gabapentin and 1 involving both
drugs) from OSIAP survey; (iii) 145 cases of gabapentinoid use
in people who use drugs (PWUD) (121 with pregabalin and
24 with gabapentin) from OPPIDUM survey; and (iv) 31 cases
of gabapentinoid-related deaths (25 with pregabalin and 6 with
gabapentin) from DRAMES and DTA surveys.
Evolution of Gabapentinoid Abuse
Phenomenon in France From 2010 to 2019
During the study period, the consumption of both pregabalin
and gabapentin increased significantly, with gabapentin level
remaining about four times lower compared to pregabalin
(Figure 2). In contrast, the proportion of falsified prescriptions
with pregabalin increased sharply from 2018 onwards with a
citation rate (number of pregabalin citations among all forged
prescriptions collected) below 3.0% up to 2017 and increased to
11.9% in 2018 and 23.8% in 2019 (Figure 2). A similar pattern has
been observed in other surveys (Figure 3). From 2010 to 2017,
a gabapentinoid abuse has been reported in 24 cases (<0.5% of
total of SRs per year). In 2018 and 2019, this figure increased
significantly to 71 in 2018 (1.2% of total SRs) and 117 (2.0%)
in 2019. In 2013, the first gabapentinoid-related deaths were
reported with one case involving pregabalin. The number of
reported deaths was at its maximum in 2018 (n = 10, data for
2019 being not completely collected at the time of the study).
The number of gabapentinoid users among PWUD reached the
highest level in 2019 with 40 (0.7% of the surveyed population)
users, i.e., 2.6 times higher than in 2018. The gabapentinoid
abuse phenomenon involved almost exclusively pregabalin and
remained marginal for gabapentin.
Socio-Demographic Profiles of
Problematic Users of Gabapentinoids
According to SRs, a total of 258 individuals with pregabalin abuse
and 7 with gabapentin were reported. This population mainly
consisted of men (72.5%). The median age was 30 years old over
the period but dropped to 24 years old in 2019. The proportion
of subjects under the age of eighteen was of 22.3%. Psychiatric
history was reported in 70 (26.4%) patients, chronic pain in 69
(26.0%) and epilepsy in 6 (2.3%) patients. An existing substance
use disorder was documented in 143 patients (54.0%, missing
data 45.7%); but one reported case confirmed the absence of any
substance use disorder for this patient. Substance use disorder
data were available for 88 (61.5%) patients, with 61.3% of them
(N = 54) having opioid use disorder.
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FIGURE 1 | The multidimensional French Addictovigilance Network: collaborative relationships and data sources involved in the national system (A) and the data
sources used for the evaluation of gabapentinoid abuse potential (B).
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FIGURE 2 | Gabapentinoid abuse phenomenon in France from 2010 to 2019 through the monitoring of forged/falsified prescription forms (OSIAP survey) with regard
to number of gabapentinoid users.
Given the limited data collected with gabapentin compared to
pregabalin, the results presented in the following paragraphs 3.3
and 3.4 focus on pregabalin cases (gabapentin cases are excluded)
(Table 1).
How Pregabalin Is Used in the Context of
Abuse
According to the 258 SRs, pregabalin was use in combiation with
other psychoactive substance (including alcohol) by 69 (26.7%)
individuals (Figure 4). Among the desired non-therapeutic
effects, euphoria ranked first reported by 28 (10.9%) individuals.
It was followed by research of high in 23 (8.9%) individuals.
Criteria related to substance use disorders were found: 20
(7.8%) individuals continued taking pregabalin to prevent the
occurrence of withdrawal symptoms, and 3 (1.2%) took it
by craving or routinely. Pregabalin was either used as a
substitute or to prevent alternative drug use by 12 (4.7%)
subjects [mainly benzodiazepines (5/12), opioids (5/12) and
cocaine (2/12)] or to potentiate effects of other drugs [opioids
(2/3) and cocaine (1/3)]. Pregabalin was used in the context
of a drug experimentation for 2 (0.8%) subjects, including
one by intranasal route. Oral administration was preferred
but intranasal use was reported occasionally. Also, one subject
inhaled (“smoked”) pregabalin by a process similar to that used
to prepare free-base cocaine. Regarding frequency intake, 138
(53.5%) individuals used pregabalin daily. From detailed cases
(68.8%) the median dose was of 900mg per day [Q1 = 450; Q3
= 1,200], with a maximum reported dose of 12.6 grams per day
after 4 months of pregabalin exposure in a context of substance
addiction transfer from buprenorphine to pregabalin. There were
71 (27.5%) cases relative to acute exposure of pregabalin; in
these cases, the maximum reported dose (out of deliberate self-
poisoning contexts) was 3.6 grams per intake to reach high
and hypnotic effects. In 20 (7.8%) cases, the subjects consumed
pregabalin occasionally or over a few days. The information on
frequency or doses consumed was missing in 29 (11.2%) cases.
Pregabalin was obtained illegally by 94 (57.7%, 95 missing data)
subjects through illicit market, forged/falsified prescriptions
or medical/pharmaceutical nomadism. In 70 (42.9%) cases, a
valid prescription form was used. In one case, pregabalin was
purchased in pharmacy without prescription (outside France).
Data from 2019 OSIAP survey have shown that pregabalin has
become the first drug mentioned in forged/falsified prescriptions
forms presented in pharmacy (citation rate of 23.8%), while
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FIGURE 3 | Number of individuals affected by gabapentinoid related disorders through addictovigilance data sources (A) (orange): number of gabapentinoid related
disorders from Spontaneous Reports (SRs). (B) (green): number of gabapentinoid users in people who use drugs (OPPIDUM survey). (C) (blue): number of
gabapentinoid-related deaths (DRAMES and DTA surveys) - data collection uncompleted for 2019.
TABLE 1 | Main characteristics based on the 258 NotS (spontaneous reports) of pregabalin use disorders collected by the French Addictovigilance Network from 2010 to
2019.
1 The dynamics of pregabalin problematic use phenomenon intensified in France from 2018 and still growing in 2019. Among the 258 collected NotS, 183 (70.9%)
occurred in 2018 and 2019.
2 Subjects were mainly men (72.5%), young (median age of 24 years in 2019). An existing substance use disorder was documented in 54% patients, including
subjects with no opioid use disorder, and one reported case confirmed the lack of any substance use disorder for this patient.
3 Pregabalin was preferentially misused by the oral route, at high dose [median daily dose at 900mg (Q1: 450; Q3: 1,200)]; occasional intakes until (3.6 grams) and
illegally obtained (false prescription forms and street market). Among desired non-therapeutic effects, euphoria ranked first cited by 28 (10.9%) individuals
followed by research of high in 23 (8.9%) of them.
4 Pregabalin abuse frequently led to neurological (81.6%) and psychiatric (34.4%) complications alone or in combination. A convulsive episode and a cardiac
serious complication (atrioventricular block) occurred with pregabalin alone.
5 Ninety patients (34.9%) presented criteria of pregabalin use disorder, whether the subjects used it to obtain therapeutic effects or not. Between 2018 and 2019,
the proportion of individuals demanding for specialized addiction care have increased from 10.6 to 23.1%. Withdrawal strategies were instituted by health
professionals (hospitalization, gradual tapering off, medication support).
it ranked at the 15th position in the 2017 survey (citation
rate of 2.6%) (Figure 2). The 300mg dosage was the most
concerned (67.3% of citations of pregabalin, missing data in
20.1%). Pregabalin street names have been reported: “l’extase”
(bliss), “saroukh,” “fusée” (rocket) or “taxi,” and street prices:
for the 150mg dosage, 10 euros per 14 capsules, for the 300mg
dosage, 1–2 euros each capsule or 30 euros the box of 56 capsules.
Pregabalin-Related Complications in the
Context of Abuse
Clinical Symptoms
Among the 258 patients presenting a problematic use of
pregabalin, a hospital based care was needed in 100 (38.8%) cases
and 125 (48.4%) have presented clinical complications: 106 in a
context of polydrug use and 19 with pregabalin alone (Table 2).
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FIGURE 4 | Context of use or users’ motivations to misuse pregabalin, in number of citations out of the 258 subjects with a pregabalin use disorder.
Among complications with pregabalin alone as in combination,
neurological complications ranked first, concerned 81.6% of
patients, mainly represented by consciousness impairment.
Coma occurred in 12 patients in polydrug use context only,
with benzodiazepine being co-ingested in 10/12 cases. The
convulsive episode with pregabalin alone occurred in a 15-
year-old girl without any history of epilepsy after an intake of
1,200mg. Psychiatric complications came second with pregabalin
alone as in-combination, concerned 34.4% of patients, and
particularly behavioral issues such as agitation, aggressiveness,
impulsiveness or disinhibition. Among psychotic symptoms,
hallucinations were reported three times, all occurred with
pregabalin combinations (1 case with alcohol after occasional
pregabalin intake of 400mg, 1 case with buprenorphine and
oxazepam and 1 case with cannabis), in subjects without
any psychotic history. Euphoria was reported with pregabalin
alone (after an intake of 600mg by oral route). Clinical
presentations of opioid overdose (not included in impaired
consciousness/miosis/dyspnea categories) concerned 11 (8.8%)
patients, exclusively in the context of polyconsumption but
not exclusively with opioid substances. Dyspnea (out of opioid
overdose presentation) concerned 4 (3.2%) patients who have
used pregabalin with other drugs, mainly opioids (3/4 cases).
Two serious cardiac complications have been reported: an
atrioventricular block in a male aged 35 using pregabalin
by intranasal route for several months and hypertrophic
cardiomyopathy in a male aged 17 who regularly used
clonazepam and cannabis.
Addictological Complications and Demands for
Specialized Care
Among the 258 pregabalin abuse SRs, 90 (34.9%) presented
criteria of a pregabalin use disorder, whether the subjects used
it to obtain therapeutic effects or not. Time to onset was
specified in 48 (53.3%) cases, and the shortest was about 2
months. Over the 2010–2019 period, 49 (19.0%) subjects have
requested addictological support due to pregabalin problematic
use or were referred to specialized addiction care. Between 2018
and 2019, the proportion of subjects demanding for specialized
addiction care have increased from 10.6 to 23.1%. Withdrawal
strategies consisted in hospitalization to stop using pregabalin
[12 (24.5%) subjects] or ambulatory, in gradual tapering off (9,
18.4%) or by introducing medication such as benzodiazepine,
sedative antipsychotic or antidepressant (5, 10.2%). A prior







































(%) Co-consumed reported substances (n)
Number of patients 258 73 185
Number of patients with
reported clinical
complications
125 48.4% 19 26.0% 106 57.3%
Neurological complications 102 81.6% 16 84.2% 86 81.1%
Impaired consciousness (out of
clinical “triad” of opioid
overdose*)
68 66.7% 11 68.8% 57 66.3% Benzodiazepine (33); Opioids (17); Psychostimulants (19); Alcohol (18); Other
psychotropic drugs (15); Cannabis (14)
Incl. Coma (GSC < 9) 12 11.8% 0 12 14.0% Benzodiazepine (10); Other psychotropic drugs (6); Opioids (5); Psychostimulants (5);
Alcohol (5); Cannabis (3)
Psychomotor retardation -
Dizziness - Ataxia





8 7.8% 0 8 9.3% Cannabis (3); Alcohol (3); Benzodiazepine (2); Opioids (2); Psychostimulants (2); Other
psychotropic drugs (2)
Convulsion 7 6.9% 1 6.3% 6 7.0% Opioids (3); Psychostimulants (3); Other psychotropic drugs (3); Alcohol (3);
Benzodiazepine (2); Cannabis (2)
Miosis (out of clinical ‘triad’ of
opioid overdose)
10 9.8% 0 10 11.6% Cannabis (6); Benzodiazepine (5); Psychostimulants (4); Other psychotropic drugs (4);
Alcohol (4); Opioids (3)
Mydriasis 7 6.9% 1 6.3% 6 7.0% Alcohol (4); Psychostimulants (3); Cannabis (3); Benzodiazepine (2); Opioids (2)




27 62.8% 3 60.0% 24 63.2% Benzodiazepine (11); Psychostimulants (8); Cannabis (8); Opioids (7); Alcohol (5);
Other psychotropic drugs (4)




6 14.0% 0 6 15.8% Opioids (2); Alcohol (2); Cannabis (2); Psychostimulants (1); Other psychotropic drugs
(1); Benzodiazepine (1)
Anxiety 4 9.3% 1 20.0% 3 7.9% Psychostimulants (2); Benzodiazepine (1); Cannabis (1); Other psychotropic drugs (1)
Euphoria 2 4.7% 1 20.0% 1 2.6% Opioids (1)
Clinical presentation of opioid
overdose* (uncounted
elsewhere)
11 8.8% 0 11 10.4% Benzodiazepine (8); Opioids (8); Psychostimulants (7); Cannabis (6); Other
psychotropic drugs (2); Alcohol (1)
Respiratory complications 4 3.2% 0 4 3.8%
Dyspnea (out of clinical ‘triad’ of
opioid overdose)
4 100.0% 0 4 100.0% Opioids (3); Psychostimulants (2); Benzodiazepine (1); Cannabis (1); Other
psychotropic drugs (1)
Cardiac complications 2 1.6% 1 5.3% 1 0.9%
Atrioventricular block 1 50.0% 1 100.0% 0
Hypertrophic cardiomyopathy 1 50.0% 0 1 100.0% Benzodiazepine (1); Cannabis (1)
Others 3 2.4% 1 5.3% 2 1.9%
Hyperglycemia 1 33.3% 0 1 50.0% Opioids (1); Psychostimulants (1); Cannabis (1); Alcohol (1)
Hypoglycemia 2 66.7% 1 1 50.0% Benzodiazepine (1); Psychostimulants (1); Cannabis (1)
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withdrawal attempt was reported in 13 (26.5%) subjects. Data
from 2019 OPPIDUM survey have shown the highest level of
pregabalin consumption in individuals seeking addiction care
(Figure 3). In 2019, for the first time since the beginning of the
OPPIDUM investigation, two subjects reported pregabalin as the
first psychoactive substance that leads to dependence.
Pregabalin Related Deaths
From 2010 to 2018, pregabalin was detected and quantified
in 51 cases of death. Pregabalin was responsible for death
(level 1 of causal connection) in 17 cases (Table 3); alone (case
12) or in combination with other drugs (all other cases). The
most frequently detected drugs assessed as co-responsible for
death were opioids involved in 12/16 cases (with tramadol and
methadone, respectively, involved in 5 and 4 cases). The blood
concentrations were lethal in 8 cases, ranged from 26 to 154
mg/L (cases 1–8) and toxic in 9 cases (cases 9–17), ranged from
9 to 21 mg/L. The first pregabalin-related death was recorded
in 2013. From 2013 to 2017, one to three pregabalin related
deaths were reported each year, whereas the year 2018 counted
8 deaths (which represents 1.4% of all deaths due to drugs in
2018). Among the 17 cases, 9 have been reported in a context
of substance use disorders and exclusively concerned men with a
median age of 34 years old while the remaining 8 cases without
substance use disorder context concerned mainly women (6/8
cases) with a median age of 50 years old. In the same period,
only 4 cases of gabapentin-related deaths were reported over the
2010–2018 period. The data of the year 2019 were not completely
available at the time of this study (because delay for forensic
context), but 8 cases involving pregabalin and 2 cases involving
gabapentin had already been reported in that year (Figure 3).
DISCUSSION
This paper aims to describe gabapentinoid use related disorders
and their health consequences in France using multi-sourced
information and pharmacological expertise. From 2010 to 2019,
the general French population has been increasingly exposed
to gabapentinoids and particularly pregabalin, which has led to
an expanding risk level of adverse events including substance
use disorders. The dynamics of gabapentinoid, particularly
pregabalin, abuse phenomenon is recent, intensified from
2018 and still grown in 2019. Indeed, over the 2010–2019
period, 70.9% of abuse cases reported to the FAN occurred in
2018 and 2019. Health indicators were reflecting this growth:
hospital based care for serious neurologic, psychiatric or cardiac
complications, demands for addiction care and deaths. Over
a year (between 2018 and 2019), the proportion of subjects
demanding for addiction care increased from 10.6 to 23.1%.
French practitioners are currently facing the management
of gabapentinoid withdrawals and have initiated strategies
(hospitalization, tapering off, introducing medication), despite
having proper guidelines (26). Based on the rise of pregabalin
involved in overdose deaths worldwide (27–33), the FAN worked
jointly with the French Society of Analytical Toxicology (Société
Française de Toxicologie Analytique) to include gabapentinoids
in toxicological investigations in clinical situations involving new
psychoactive substances and deaths encountered in the practice
of forensic toxicology (34). Such awareness could have explained
the increase of reported gabapentinoid-related deaths. It certainly
helped to better assess gabapentinoid use disorders related harms
(35). Experimental studies have shown that the combination of
pregabalin with opioids has an additive effect or reverse tolerance
to depress respiration and therefore increases the risk of acute
overdose death (36); this was also observed in observational
studies with gabapentin and pregabalin in patients exposed to
opioids (for maintenance therapy) or for pain (37–40).
Gabapentinoids (gabapentin and pregabalin) exhibit calcium
channel antagonism and attenuate calcium influx, which can
explain unwanted electrophysiological effects. By this way, they
present a similar spectrum of adverse drug reactions, which
are dose-dependent. Some studies highlighted the implication
of gabapentin and pregabalin in cardiac conduction disorders
(15, 41). These deleterious cardiac outcomes were observed in
case of misuse and abuse of high doses of pregabalin in our study
even if rarely reported in the literature (42). We also cannot
exclude the implication of gabapentinoids in overdose death
not only through exacerbating respiratory depression but also
through dysrhythmic disorders.
Along with the population approach, published data
and those collected in this study have demonstrated that
pregabalin presents a true abuse potential by its own. Clinical
and experimental studies have shown the “drug-liking” and
reinforcing effects of pregabalin (37, 43), not correlated with
the mesolimbic dopaminergic system but potentially mediated
through a possible glutamatergic mechanism (44–46). This
rewarding effect is supported by data collected by the FAN
through spontaneous reports with 10.9% of problematic users
searching for euphoria, 8.9% to get high, 5.4% searching for
psychostimulation and 1.2% feeling a craving for pregabalin
or routinely use it. Of note, two subjects used pregabalin in
the context of drug experimentation. These elements are in
favor of an intrinsic attractiveness of pregabalin. Concerning
gabapentin, experimental studies have shown that gabapentin
induced drug-seeking behavior but only with the highest dose
(47). This has also been demonstrated with mirogabalin (48).
Published literature has shown that the risk of gabapentinoid
abuse increased in subjects with a history of substance use
disorder, particularly in those with opioid use disorder (8, 9, 49–
54). The present data suggest that abuse could be observed
in subjects without any opioid abuse history; within the 265
spontaneous reports of gabapentinoid abuse collected, 38.7%
of subjects with a substance abuse disorder had no opioid use
disorder. In addition, a case of pregabalin abuse concerned a
patient without any substance use disorder, which constitutes an
early signal given the well-known under-reporting phenomenon
(14, 55). Other elements are in favor of the possible occurrence
of pregabalin de novo dependence; in the 2019 OPPIDUM
survey, for the first time, two subjects cited pregabalin as the
first psychoactive substance that led to dependence (implying
that the pregabalin use disorder was at the cause of the demand
for addiction care), which is also an emerging signal. Some
international studies in the general population have shown
that from 8 to 12% of subjects initiating prescribed pregabalin






























TABLE 3 | Pregabalin-attributed deaths: data from DRAMES and DTA surveys.
Case Gender,
Age (y)
Drug responsible for death and blood concentrations Other drugs
detected
Autopsy data Context of death, individual
health history











Found at his home, injection
drug use equipment next to him.
Prescribed pregabalin.












Psychiatric history, found at his
home in a state of putrefaction.
Notion of alcohol abuse.
Prescribed pregabalin.







History of chronic back pain.
Died at his home. Prescribed
pregabalin.













History of methadone abuse
(intranasal use and doctor
shopping behavior), ongoing
drug withdrawal, found in his
vehicle, alcohol, methadone
packages and intranasal
equipment next to him.















therapy. Increased drug use in
the context of traumatic pain 6
months ago with doctor
shopping behavior.









Pink foam on lips
and nose.
History of bipolar disorder and
alcohol addiction. Context of
suicide with drug medications
next to her and a suicide note.















Psychiatric, epileptic and drug
addiction history, died at his
home. Medication drugs next to
him.






Not known Context of abuse/dependence.
Found in a state of putrefaction
with drug medications next to
him.
















Context of suicide. Pregabalin
















































































TABLE 3 | Continued
Case Gender,
Age (y)
Drug responsible for death and blood concentrations Other drugs
detected
Autopsy data Context of death, individual
health history








History of cardiac issues.














Died at her home. Prescribed
pregabalin. Pregabalin used by
oral route.









History of depressive syndrome.
Prescribed pregabalin.










No Context of abuse/dependence.
On buprenorphine, died
in detention.







Not known Context of abuse/dependence.
History of cannabis and alcohol
abuse. No information available
on methadone use.











History of depression, found at
his home, alcohol and
medication drugs next to her. No
notion of pregabalin treatment.










History of depressive syndrome
and cocaine use, died at his
home. Notion of alcohol use the
day before.
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TABLE 4 | International regulatory status, amendments or monitoring of dispensing for pregabalin and gabapentin.
Year Month Country Measure
2005 July United States of
America (USA)
Pregabalin: Drug Schedule V Controlled Substances (Federal law).
2015 May Saoudi Arabia Pregabalin: Limited prescription, dispensing only in state health-care structures and use of a prescribing register.
October Russia Pregabalin: Listed as controlled medicine
December United Arab Emirates Pregabalin and Gabapentin: List of Controlled Medicines and Medications, Narcotic and Controlled Prescriptions.
Limited prescription to 3 days for general practioners, 2 weeks for specialists, 4 weeks in hospital. Prescription
validity: once (no possible renewal). Register for prescribers and pharmacies and specific prescription support
provided by the Ministry of Health.
2016 August Minnesota (USA) Gabapentin: Mandated reporting to a PDMP
December Argentina Pregabalin: Listed as Other Substance for Special Control
Ohio (USA) Gabapentin: Mandated reporting to a PDMP
2017 February Virginia (USA) Gabapentin: Mandated reporting to a PDMP
May Wyoming (USA) Gabapentin: Mandated reporting to a PDMP
July Armenia Pregabalin: Listed as controlled substance
Kentucky (USA) Gabapentin: Drug Schedule V Controlled Substances with mandated reporting to a PDMP (State law)
West Virginia (USA) Gabapentin: Mandated reporting to a PDMP
August Massachusetts (USA) Gabapentin: Mandated reporting to a PDMP
North Dakota (USA) Gabapentin: Mandated reporting to a PDMP
November Turkey Pregabalin: Prescription validity for 1 year. Specialized opinion (neurologist or psychiatrist) for chronic prescription.
Electronic prescription since January 2018.
November Jordan Pregabalin: Listed as controlled substance, second table (Drugs, Psychotropic substances and Precursor
chemicals appended to the Narcotic Drugs and Psychotropic Substances Law no. 23 of 2016). Limited packaging
to 64 tablets. Precribing and dispensing register.
2018 January Nebraska Gabapentin: Mandated reporting to a PDMP
April Norway Pregabalin: Schedule B (alongside benzodiazepine)
May New Jersey (USA) Gabapentin: Mandated reporting to a PDMP
June West Virginia (USA) Gabapentin: Drug Schedule V Controlled Substances (State law)
July Sweden Pregabalin: List of substances to be considered narcotics under the Penal Law on Narcotics.
Tennessee (USA) Gabapentin: Drug Schedule V Controlled Substances
Kansas (USA) Gabapentin: “Drug of concern,” mandated reporting to a PDMP
2019 January Michigan (USA) Gabapentin: Drug Schedule V Controlled Substances (State law)
April United-Kingdom Pregabalin and Gabapentin: Category C (prescribing and dispensing restrictions comparable to benzodiazepine)
June Washington (USA) Gabapentin: Mandated reporting to a PDMP
July Virginia (USA) Gabapentin: Drug Schedule V Controlled Substances (State law)
PDMP, Prescription Drug Monitoring Program.
presented a misuse (56–58). In the French cohort study, a
possible evolution toward a primary addiction was found for
11% of the gabapentinoid misusers without previous any history
of drug use disorder before drug initiation, whereas it was 1.6
times lower for duloxetine misusers (56).
At this stage in France, the risk of abuse of pregabalin
is indisputable, and its harmful consequences are becoming
problematic on a population scale. The potential of gabapentin
abuse exists and has been observed elsewhere, in the USA
and the UK (8, 11, 12, 38, 39, 59). It is still not very
apparent in France (13); this discrepancy could be due to the
level of use, which is about four times lower for gabapentin
than pregabalin. Moreover, geographical variations must be
interpreted with caution and could be partly explained by the
health professionals’ awareness regarding the abuse potential of
these drugs (37–39, 59–61).
This paper shows the importance of specific post-marketing
monitoring on substance use related disorders (that is
addictovigilance). The isolated analysis of pregabalin exposure
data could not have revealed the suspected misuse behaviors
to obtain this drug highlighted by OSIAP survey. Along with
spontaneous reports, these data support the growing ease of
access to pregabalin through street market with falsified or
valid prescription forms. Moreover, at the time of pregabalin
marketing approval, pre-clinical and clinical studies on abuse
potential were limited, and states decisions were different in
the USA and Europe. Based on a clinical abuse liability study
showing that pregabalin (450mg) could be as attractive as
diazepam (30mg) leading subjective effects of “drug-liking” and
higher reported euphoria as an adverse reaction in clinical trials
compared to placebo (4 vs. 1% of patients), the FDA scheduled
pregabalin as a controlled substance (Schedule V) indicating that
Frontiers in Psychiatry | www.frontiersin.org 12 February 2021 | Volume 12 | Article 63978054
Tambon et al. Gabapentinoid Abuse in France
it had abuse potential, while the EMA did not at once, even in
2006 when extending market approval to generalized anxiety
disorder was submitted and concluded to a low abuse potential
in analogy with gabapentin (62, 63). Since, the phenomenon
of abuse of gabapentinoids has spread to an international
level (Europe, Australia, USA). Since 2015, a dozen countries
around the world have regulated the prescription and dispensing
procedures for pregabalin, and several have extended these
restrictions to gabapentin (Table 4) (64). In France, proposals
for regulatory measures have been made and are currently being
considered by the French Medicines Agency. Health damages
due to gabapentinoid abuse are to balance with their clinical
efficacy. Precisely, after a growing enthusiasm for the multiform
therapeutic virtues claimed by various promoters of this drug,
a growing number of publications highlight the insufficient or
unproven effectiveness of pregabalin in neuropathic pain and
fibromyalgia (65), as well as in the management of substance
use disorders (66, 67) or long-term beneficial impact in post-
traumatic stress disorder (68). Finally, recent observations
from population-based studies, and animal models, have
demonstrated that association of gabapentinoids and opioids
(analgesics, maintenance drugs, or illicit opioids) significantly
increase the risk of opioid death, with the reversibility of
tolerance for opioid respiratory depression (36–38, 40).
In clinical practice, based on available guides (69, 70), results
of this study and published data, some recommendations may be
proposed at different steps. Before prescribing gabapentinoids,
the medical questioning should search for possible psychiatric
or substance abuse (including alcohol and tobacco) history.
To consider other drugs taken, whenever prescribed or not,
should avoid potentially dangerous drug-drug interactions such
as gabapentinoid-opioid interaction on respiratory distress.
Or, at least get to know the patients/users of respiratory
distress symptoms and the first emergency actions. During a
gabapentinoid medication, the minimal effective dose should
be taken and the benefits/risks balance evaluated at each
prescription and refill. Considering substance disorders-related
risks, the following signs should be monitored and raised
prescriber’s attention: tolerance (that is, the reduction of effects
as exposure continues at constant dose, or the corollary of
this, the need to increase doses to achieve the desired effects),
searching for psychoactive effects other than those of the
initial indication, drug-seeking behavior (71) or the occurrence
of withdrawal symptoms during discontinuation/between
gabapentinoid intakes. If possible, due to withdrawal syndrome,
gabapentinoid discontinuation may be planned and used
schedules. A hospitalization could be proposed if experiencing
withdrawal difficulties or existing substance use disorder or
psychiatric co-morbidities. The absence of a substance use
transfer at the time of discontinuation should be monitored
(68). To improve the knowledge on the evaluation of drugs
in real life, at any time of management, to report any adverse
event, including those related to substance use disorders, to the
territorial vigilance systems.
The strength of this study is to cross results of different
data sources collected over a recent 10 years’ period, for both
pregabalin and gabapentin drugs. However, there are limitations
related to the four addictovigilance data sources used. The level
of reported information in SRs could be different from one
case to another, on individuals or clinical features, depending
on the person filling the reporting form and available/patient-
provided information at time of reporting. Moreover, it could
exist an awareness bias with pregabalin compared to gabapentin,
with first specific sensitizations of French health professionals on
pregabalinmisuse since 2016 (72). The pharmacoepidemiological
studies OSIAP, OPPIDUM, and DRAMES/DTA could presented
bias related to participation and reported information. It has
to be note that the results of DRAMES/DTA surveys should
not be considered as an exhaustive description of drug-related
deaths in France. They are based on voluntary participation of
expert toxicologists, requested toxicological analysis carried out
by judicial authorities and the spectrum of substances analyzed
(73). Besides these limits, DRAMES/DTA surveys are currently
references for the assessment of drug-related deaths in France.
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the Management of Benzodiazepines
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An effective approach in the treatment of benzodiazepine (BZD) overdosing and
detoxification is flumazenil (FLU). Studies in chronic users who discontinued BZD in
a clinical setting suggested that multiple slow bolus infusions of FLU reduce BZD
withdrawal symptoms. The aim of this study was to confirm FLU efficacy for reducing
BZD withdrawal syndrome by means of continuous elastomeric infusion, correlated to
drugs plasma level and patients’ compliance.
Methods: Seven-day FLU 1 mg/day subcutaneously injected through an elastomeric
pump and BZDs lormetazepam, clonazepam, and lorazepam were assessed by
HPLC-MS/MS in serum of patients before and after 4 and 7 days of FLU continuous
infusion treatment. Changes in withdrawal severity were assessed by using the BZD
Withdrawal Scale (BWS).
Results: Fourteen patients (mean age ± SD 42.5 ± 8.0 years, 5 male and 9 female),
admitted to the hospital for high-dose BZD detoxification, were enrolled in the study.
Serum FLU concentrations significantly decreased from 0.54 ± 0.33 ng/ml (mean ± SD)
after 4 days of treatment to 0.1 ± 0.2 ng/ml at the end of infusion. Lormetazepam
concentrations were 502.5 ± 610.0 ng/ml at hospital admission, 26.2± 26.8 ng/ml after
4 days, and 0 at the end of treatment. BWS values decreased during FLU treatment
temporal period. FLU was well-tolerated by patients.
Conclusions: Elastomeric FLU infusion for BZD detoxification is a feasible
administration device to maintain adequate, constant, and tolerated FLU concentrations
for reducing BZD withdrawal symptoms.
Keywords: benzodiazepine, flumazenil, withdrawal, high dose, detoxifcation
INTRODUCTION
Although benzodiazepines (BZDs) constitute one of the most broadly prescribed drug classes
worldwide, the frequent and often inappropriate use is a problem that remains considerably
underestimated by practitioners and most regulatory agencies (1). BZD can produce tolerance
and dependence; thus, their use is recommended for a limited time (2). Surveys carried out in
the 1990s in France, Germany, Italy, and the United Kingdom showed that 3.9% of hypnotic
drug users and 3.2% of anxiolytic drug users had been taking a dose exceeding the recommended
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one (2–4). In Italy, about 7.5–10% of adult population are BDZ
users, half of these being long-term users (LTU) with a diagnosis
of BZD use disorder (5). Another study conducted in Italy
showed that 14.0% of patients visiting general practitioners were
taking BZDs, with 4.7% of the total sample being LTU, using
BZDs daily for at least 12 months (6).
BZD tolerance was first reported in 1961 (7), but this
phenomenon has been often obscured by the enthusiastic use
of these drugs, which were able to replace barbiturates. The low
toxicity coupled to a high potential of tolerance can lead to
very high-dose misuse (8). From a clinical point of view, the
only proposed solution of a gradual reduction of BZD is too
simplistic. For long-term users, in general, if properly applied,
gradually reducing the dosage works, but it is much less effective
for high-dose users (2, 8, 9). This is worth mentioning because
withdrawing from high doses of BZD carries significant risk for
the health of the patient (2, 10).
It is in this area of HDUs that the use of flumazenil
(FLU), used worldwide to treat the overdose of BZD, has been
demonstrated as effective (9, 11–13). Experimental findings have
shown that FLU acts as a BZDpartial agonist with a weak intrinsic
activity, when administered by slow intravenous infusion. While
withdrawal symptoms may be brought on by the use of FLU,
BZD-tolerant patients only reported mild symptoms (14, 15).
BZDs positively modulate γ-aminobutyric acid (GABA)
through distinct binding sites on GABAA receptors, and there is
little variation among BZDs in pharmacodynamical factors such
as selectivity and efficacy. Consequently, the choice of a particular
BZD for clinical use is primarily based on pharmacokinetic
features. Only one drug, flumazenil (FLU), is currently approved
to reverse the effects of BZDs. FLU is a BZD partial agonist
commonly used in the treatment of BZD overdose. Studies
in chronic users who have discontinued BZDs suggested that
multiple slow bolus infusions of FLU reduce the symptoms of
BZD withdrawal when compared to placebo (9). The mechanism
of FLU action remains, however, unclear: its action may
facilitate the coupling of GABAA and BZD receptor complexes,
presumably by reversing the down-regulation/uncoupling that
occurs with long-term BZD use (16). This mechanism is
supposed to underlie FLU’s weak agonist action and may explain
its ability to attenuate BZD withdrawal symptoms (9). FLU does
not antagonize the effects of other CNS sedative-hypnotics, such
as ethanol, opioids, or general anesthetics (17).
FLU owns a rapid and extensive distribution phase with high
volume of distribution and a second phase with fast metabolic
elimination and short half-life (18). Its brief BZD-antagonism
duration is due to a rapid hepatic elimination, determining its
short half-life (60–90min) and high plasma clearance (31–78
l/h). The low plasma protein binding of FLU (about 50%) does
not limit its wide distribution (apparent distribution volume
0.6–1.6 l/kg) or its partly flow-dependent hepatic elimination
(19, 20). Pharmacokinetic parameters of FLU do not change
whether the drug is administered alone or in combination with
other BZDs (18). For BZD detoxification, a viable method is
the intravenous administration of FLU by using multiple bolus
infusions either alone (14, 21) or in combination with tapering
doses of BZDs (11).
The pharmacodynamical mechanisms of FLU are therefore
crucial to determine its clinical effect, which could be achieved
thanks to specific FLU infusion parameters in order to guarantee
timing and extent of receptor occupancy (14). Thus, the
choice of the most appropriate mode of delivery must be
based on the correlation between FLU infusion parameters,
plasma levels, and clinical endpoint. Our addiction unit has
been employing FLU for high-dose BZD detoxifications since
2003, initially by means of endovenous continuous infusion
administered by day. Such mode of delivery was both inconstant
at maintaining adequate serum levels, being unfeasible for the
night, and uncomfortable for the patient. In order to maintain
constant serum concentration of FLU and to reduce modality of
administration from multiple to single, we aimed to deliver FLU
by slow subcutaneous infusion by using an elastomeric infusion
pump at constant flow. In this study, we correlated the efficacy
of continuous elastomeric FLU infusion on BZD withdrawal
clinical endpoint to both drugs’ (FLU and BZDs) plasma levels
and, of equal importance, to patients’ compliance and tolerance
to treatment.
MATERIALS AND METHODS
This study was approved by the Ethical Review Board of
the University Hospital (protocol number: 50771; prog. n.
683CESC). Informed consent was obtained from each subject.
Subjects
Five male and nine female patients (mean age ± SD 42.5 ±
8.0 years), admitted to the hospital for BZD detoxification, were
enrolled in the study (see Table 1 for patients’ characteristics).
The BZD use was stopped on day 1 of admission. The therapy
with antidepressants, if any (Table 1), was maintained and
continued after discharge.
All patients reported a history of BZD dependence according
to the Diagnostic and Statistical Manual of Mental Disorders,
Fifth Edition (DSM-5) criteria (22). Before hospitalization, all
patients were interviewed by a physician to assess degree of
BZD dependence and general health conditions. All patients had
voluntarily contacted the Addiction Unit of Verona University
Hospital and were aware of their BZD dependence.
Inclusion criteria were as follows: (i) age older than 18 years;
(ii) diagnosis of BZD use disorder according to the DSM-5
criteria; (iii) BZD abuse lasting more than 6 months; and (iv)
high dose of BZD abuse, meaning BZD intake exceeding at
least five times the recommended daily amount (e.g., >50mg in
diazepam equivalents). Individuals were excluded if presenting
the following: (i) current substance use disorder, defined as a
history of illicit drug dependence or abuse within the previous
6 months; (ii) active medical illnesses or psychosis; and (iii)
previous history of seizures, but not due to BZD withdrawal.
Elastomeric Pump
Patients were treated with a solution containing 7mg of
flumazenil (Anexate R©, Roche), available commercially in 0.5
mg/5ml vials at pH = 4. The elastomeric pump (Infusor LV 1.5,
code 2C1087K, Baxter S.p.A., Rome, Italy) was arranged with a
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1 M 38 LRZ 25 mg/day Agomelatine
CLO 2 mg/day
2 M 44 LRM 75 mg/day None
3 F 42 LRM 75 mg/day Duloxetine
4 F 55 ALP 35 mg/day Escitalopram
5 F 47 CLO 12 mg/day Mirtazapine











7 F 47 LRM 400 mg/day Agomelatine
DLZ 12 mg/day
8 F 37 LRM 40 mg/day Agomelatine
9 M 36 LRM 150 mg/day None
10 F 43 LRZ 50 mg/day Citalopram
11 F 31 LRM 100 mg/day Paroxetine
12 F 30 LRM 75 mg/day Sertraline
13 M 38 ALP 15 mg/day Escitalopram
14 M 32 LRM 150 mg/day Citalopram
ALP, aprazolam; CLO, clonazepam; DLZ, delorazepam; DZP, diazepam; F, female; FLZ,
flurazepam; LRM, lormetazepam; LRZ, lorazepam; M, male; TRZ, triazolam.
maximum capacity of 250ml and constant release of 1.5 ml/h
for 7 days. The pump was connected to the patient’s anterior
abdominal wall via a butterfly needle inserted subcutaneously.
The pump, releasing 1mg of flumazenil every 24 h, was then
placed in a small bag that could be carried attached to the belt
or on the shoulder. Patients’ tolerance for the infusion device
was investigated on a daily basis, through clinical examination
and interview.
Throughout the detoxification, FLU subcutaneous infusion
(FLU-SI) was associated with therapeutic doses of clonazepam,
orally administered every day in the evening and gradually
tapered from 6mg on the 1st day to 0.5–2.0mg on the last day
of treatment. The different speed in the tapering of clonazepam
was due to clinical criteria, in particular we considered the quality
of sleep and the intensity of withdrawal symptoms. In this way, at
the end of hospitalization, 3/14 patients were discharged with no
clonazepam, and 11/14 (78.6%) patients were discharged with a
low dose of clonazepam ranging from 0.5 to 2.0 mg/day; these
patients were recommended to gradually taper it in a few weeks
(8). Unfortunately, patients were not followed-up as outpatients,
and we cannot be sure whether they succeeded in tapering and
eventually stopping clonazepam.
Ten days prior to the admission, anti-epileptic prophylaxis (1
g/day valproic acid or levetiracetam) was given to all patients
in order to prevent seizures during treatment. Anti-epileptic
treatment wasmaintained during the hospital stay and for further
20–40 days after discharge.
Patients under concurrent treatment with antidepressant
(12/14 patients, see Table 1) were maintained under
this pharmacotherapy.
Sampling Protocol
Blood samples were collected without anticoagulant at the
moment of admission, after 4 days of FLU treatment, and at
the end of the 7 days of treatment, before discharge from the
addiction unit.
Samples were centrifuged (3,000 rpm, 10min) and sera were
frozen at−80◦C until HPLC-MS analysis.
Flumazenil and Main BZD Concentration
Analysis
Blank serum samples, used for the development and validation of
the procedure, were obtained from healthy volunteers abstinent
from any drug during the week before sampling. A 250-µl aliquot
of serum was added to an equal volume of 0.1M phosphate
solution (pH 8.8), and the mixture was spiked with the IS
(diazepam-D5) to have a final concentration of 40 ng/ml. The
mixtures were added with 1.5ml of ethyl acetate, then extracted
by vortex-mixing for 1min, and centrifuged at 4,000 rpm for
15min. The organic phase was then evaporated to dryness
under nitrogen stream and the residue dissolved in 50 µl of
ultrapure water.
The determination of FLU and lormetazepam was obtained
by using a model 1290 UHPLC coupled to a model 6450
triple quadruple mass spectrometer (Agilent Technologies,
Waldbronn, Germany) operating in positive ionization mode.
Gradient elution was performed on a UHPLC ZORBAX
Eclipse reversed-phase column (RRHD 2.1mm × 100mm,
1.8µm) (Agilent) by mixing 5mM aqueous ammonium formate
containing 0.01% formic acid (eluent A) and acetonitrile added
with 0.01% formic acid at a flow rate of 0.5 ml/min (eluent
B) from 10 to 95% B in 7min. The analyses were performed
in multiple reaction ion monitoring (MRM) mode using the
following ion transitions: FLU 304 217, 232, and 258 (collision
energy: 20 eV); lormetazepam 335 317, 289, and 177.0 (collision
energy: 20 eV); and diazepam-D5 290 262 (collision energy:
27 eV).
Method was linear in the concentration range of 78–5,000
pg/ml for FLU and of 3–200 ng/ml for lormetazepam. Lower limit
of quantification (LLOQ) corresponded to 78 pg/ml for FLU and
3 ng/ml for lormetazepam.
Precision (% CV) of the assay was ≤9.8% for both the
analytes, whereas the inter-assay accuracy was ≤3.8 and ≤4.7%,
respectively. The accuracy and CVs for day-to-day tests resulted
always below 7.93%.
Withdrawal Assessment
A Benzodiazepine Withdrawal Scale (BWS) form exploring
withdrawal symptoms (33 items each with a score of 0–4 from
best to worst) was given to each patient for daily report (23).
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Statistical Analysis
Statistical analysis was performed using the software Graph
Pad PRISM version 6.0. The results were expressed as mean ±
standard error of the mean (SEM). Student’s t-test was utilized
for statistical analysis by comparing different treatment times of
the same group of patients.
RESULTS
Drug plasma levels are shown in Figure 1. Plasma FLU
concentrations were 0.54 ± 0.089 ng/ml (mean ± SEM) at T1
after 4 days of continuous subcutaneous infusion, ranging from
0.14 to 1.4 ng/ml. Values recorded at T2 (end of therapy) were
0.09 ± 0.05 ng/ml, with FLU concentrations below limits of
detection in 10 patients out of 14.
Lormetazepam (LRM) levels were 502.5 ± 163.0 ng/ml at T0
baseline. A significant decrease (11.2 ± 5.7 ng/ml; p = 0.008) in
LRM levels was recorded at T1 and 0.43± 0.43 ng/ml at T2. High
LRM plasma levels recorded at T0 are in agreement with patients’
self-report of BZD use at admission, whereas low T1 and T2 levels
confirmed compliance to detoxification treatment.
Lorazepam (LRZ) levels showed a similar pattern, with
high initial plasma concentrations (83.1 ± 27.4 ng/ml), then a
significant decrease to 20.4 ± 11.4 ng/ml (p = 0.01) at T1 and
9.4± 5.6 ng/ml at T2 after 7 days of FLU administration.
Clonazepam (CLN) plasma levels were low at T0 (14.0 ±
8.6 ng/ml), 35.5 ± 5.0 ng/ml at T1, and 25.4 ± 3.9 ng/ml at T2.
Note that three patients were treated with CLN before hospital
admission (see Table 1).
According to different BZD behaviors, BWS showed a
decrease from 26.4 to 17.7 points, as portrayed in Figure 2.
During the treatment, 10/14 subjects (71.4%) completed the
Benzodiazepine Withdrawal Scale (BWS) with scores ranging
from 0 to 132 on a daily basis, in order to subjectively assess
their withdrawal symptoms. Four out of 14 patients could not
complete the BWS. As shown in Figure 2, BWS improved
significantly during FLU treatment in all subjects. Nomajor event
(i.e., convulsive crisis) occurred.
The elastomeric pump was well tolerated by patients. Since
FLU is further diluted in a saline solution inside the device,
no skin irritation around the insertion of the needle was
noticed. Since elastomeric pumps are light and compact, patients
appreciated the freedom ofmovement and rated them as painless,
safe, and comfortable, with no bound to the pump and respecting
the privacy about the therapy, whereas nurses acknowledged they
required less time to manage them.
DISCUSSION
BZD represents a class of drugs characterized by low acute
toxicity even at high doses in the absence of any concurrent
drug abuse such as alcohol and opioids (2). Literature data
on the toxicity of high-dose BZD are old and mostly based
on anecdotal case reports. The lack of clinical studies and the
high tolerability of these drugs have produced the erroneous
perception that the administration of high doses of BZD for
a prolonged time, although not recommended, could be not
harmful. However, several complications have been associated
to chronic BZD consumption, such as memory and attention
deficit, inability to learn, increased risk of falls, road accidents,
depression, and reduced quality of life (Lugoboni DAD 2014).
Thus, although the prolonged use of high dose of BZD seems not
to induce liver toxicity, it remains a serious health concern (24).
The severe discomfort experienced by patients stopping long-
term BZD use led to the development of treatment strategies
for discontinuing these medications (1, 10). The common
management of BZD withdrawal syndrome includes, either
individually or in combination: (i) a gradual tapering of the
drug; (ii) switching to an equivalent dose of a long half-life BZD
before tapering withdrawal (10, 25); and (iii) adding medications
prior to detoxification and continuing those medications after
BZD discontinuation (1, 10). A potential approach is the abrupt
discontinuation of themedication and a rapid BZDdetoxification
using FLU. FLU is commonly used in the treatment of BZD
overdose; it is usually considered a BZD antagonist (9). When
compared to placebo, bolus infusion of flumazenil (1mg in
5min) produced effects similar to BZD withdrawal in BZD users
(23, 26). Nonetheless, results of studies in chronic BZD users
who have discontinued BZD use suggest that multiple slow
bolus infusions of flumazenil reduce the symptoms of withdrawal
(9, 11, 21, 27).
Subcutaneous route of FLU administration was previously
described only in three patients (14), suggesting the usefulness of
this route for its excellent tolerability, efficacy, and improvement
on measure of psychological distress. According to these data,
we decided to administer FLU by subcutaneous route utilizing
elastomeric pumps normally used for pain control in cancer
patients or, more recently, for continuous infusion of antibiotics
(28) or for treatment of idiopathic hypersomnia (29).
To our knowledge, the results present in this paper are the
first data of FLU serum concentrations following subcutaneous
infusion by elastomeric pump described in literature. FLU serum
concentrations were low, but consistent with data of FLU
administered by i.v. route (14).
FLU is characterized by short half-life (0.8–1.2 h) (30) and
requires repeated doses or continuous infusion to reverse BZD
overdose. In spite of its low lipophilicity, FLU has a large volume
of distribution, and its weak binding to plasma proteins explains
its rapid distribution. Moreover, FLU is extensively metabolized
by hepatic cytochromes P450 3A4, 3A5, and 2C9 and readily
eliminated. Maximum brain concentrations are reached 5 to
8min after i.v. administration (31).
Subcutaneous administration of flumazenil eliminates some
problems with first-pass hepatic metabolism observed orally
and is likely to facilitate better absorption. Subcutaneous
administration also provides continuous dosing, which would be
hard to achieve with oral or sublingual administration, and the
slow absorption may abrogate side effects related to high serum
concentrations. The subcutaneous route is easier to establish
than the intravenous administration, and there is no risk for
patient’s veins. Study data suggested that flumazenil administered
by the s.c. route might have equitable clinical benefits to i.v.
administration, but it might be superior in that it requires less
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FIGURE 1 | Drugs plasma levels. Individual plasma levels (ng/ml; ordinates) for flumazenil, lormetazepam, clonazepam, and lorazepam at different time-points
(abscissa), i.e., at admission (T0), four (T1) and seven days after flumazenil start of elastomeric infusion.
FIGURE 2 | Withdrawal Symptom Scores from day 1 to day 7 of FLU-SI treatment.
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clinical monitoring and is likely associated with less equipment
problems (i.e., dislodged or blocked i.v. needle/line) and adverse
events (i.e., venous tissue irritation). These advantages, as well as
an improved patient mobility over the treatment period, will also
likely result in increased patient satisfaction (9, 14).
The subcutaneous route of administration may be associated
to the absence of adverse events associated with i.v. FLU
administration. In fact, our patients did not report any kind of
adverse events such as those frequently reported during or after
FLU administration (8, 14, 32).
Our results demonstrated low and constant serum
concentrations during all treatment and a prompt decrease
nearly to 0 at the end of treatment, protecting patients from peak
serum levels. We utilized an elastomeric infusion pump mostly
utilized in our hospital for analgesic purposes.
Several elastomeric pumps are commercially available, and
they are calibrated in different conditions, including operating
temperature and pressure, viscosity of fluid, backpressure, and
time recommended between filling of the device and beginning
of the infusion. All of these factors affect the infusion rate of
pumps. Elastomeric infusion pumps are feasible to use and less
bed bounding for patients, although a little less precise than
other pumps.
Moreover, Höjer et al. (33) studied the stability of infusion
solutions of flumazenil in concentrations of 1.0 and 5.0µg/ml
stored for periods of up to 9 months and concluded that the
stability of flumazenil in infusion solution was satisfactory.
Importantly, serum levels of other BZDs (such as LRM and
LRZ) are 0 after 4 days of FLU administration, proving both the
efficacy of FLU and patients’ compliance despite the elevated BZD
plasma levels measured at the beginning of the treatment. The
good patients’ compliance was confirmed by CLN concentrations
in serum that showed a trend to decrease after 7 days. Most
interestingly, during the detoxification process, all patients
reported low levels of craving for BZD, which might represent
a rarely seen feature in the spectrum of drug detoxification.
According to previous studies, high-dose BZD chronic use
determines a severe impairment of psychological, physical, and
social functioning, along with a significant reduction of quality of
life (34, 35).
The main limitation to this study is the lack of a follow-up
phase to determine whether all patients were successfully able
to taper and suspend clonazepam and to assess the relapse rate.
Another limitation of the study is its monocentric design. The
problem is not new. Although more than 30 years have passed
since the first studies of the efficacy of FLU in the treatment
of addiction to high doses of BZD, to our knowledge, there are
no more than five centers worldwide offering this treatment.
This continues to represent a major obstacle to the definition
of more shared and standardized protocols. Currently, FLU
protocol is the same for all patients, regardless of sex, age, BMI,
and BZD daily intake. Future prospects should include further
investigations of the individual variables and clinical outcomes in
order to individualize the detoxification therapy.
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Kratom or Mitragyna speciosa (Korth.) is an evergreen tree of the coffee family native
to South-East Asia and Australasia. It is used by locals recreationally to induce
stimulant and sedative effects and medically to soothe pain and opiate withdrawal.
Its leaves are smoked, chewed, or infused, or ground to yield powders or extracts
for use as liquids. It contains more than 40 alkaloids; among these, mitragynine and
7-hydroxymitragynine are endowed with variable mu, delta, and kappa opioid stimulating
properties (with 7-hydroxymitragynine having a more balanced affinity), rhynchophylline,
which is a non-competitive NMDA glutamate receptor antagonist, but is present in
negligible quantities, and raubasine, which inhibits α1-adrenceptors preferentially over
α2-adrenceptors, while the latter are bound by 7-hydroxymitragynine, while mitragynine
counters 5-HT2A receptors. This complexity of neurochemical mechanisms may account
for kratom’s sedative-analgesic and stimulant effects. It is commonly held that kratom at
low doses is stimulant and at higher doses sedative, but no cut-off has been possible
to define. Long-term use of kratom may produce physical and psychological effects that
are very similar to its withdrawal syndrome, that is, anxiety, irritability, mood, eating, and
sleep disorders, other than physical symptoms resembling opiate withdrawal. Kratom’s
regulatory status varies across countries; in Italy, both mitragynine and the entire tree
and its parts are included among regulated substances. We describe the case of a
patient who developed anxiety and dysphoric mood and insomnia while using kratom,
with these symptoms persisting after withdrawal. He did not respond to a variety of
antidepressant combinations and tramadol for various months, and responded after
1 month of clomipramine. Well-being persisted after discontinuing tramadol.
Keywords: kratom, mitragynine, substance use disorder, clomipramine, withdrawal syndrome
INTRODUCTION
The interest of the medical world in Mitragyna speciosa Korthals (MsK) dates back to the
1950s (1–6). MsK (kratom) was first described by the Dutch colonial botanist Pieter
Korthals in 1839 and is indigenous to Thailand, Indonesia, Malaysia, Myanmar, and
Papua New Guinea, where it has been used in traditional medicine and religious
(7) contexts since at least the 19th Century, as well as a voluptuary substance
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use (a surrogate to opium) well before Korthals’ description
(8, 9). In these countries, leaves of MsK are first dried and then
chewed or consumed as smoke in long pipes, extract, or powder,
or brewed into a tea (10). Mixtures with other substances are
also made, thus increasing dangerousness of consumption. Some
of them are confectioned into pills (11). Concern over its use
was not raised until recently, when it became largely available
in Western countries and its toxic potential realized. A first
Malaysian report found kratom consumers to develop addiction
and psychiatric symptoms (12), while its psychoactive properties
were detailed in the late 1980s (13).
MsK alkaloids were quantitatively determined in its leaves
after separation by thin-layer chromatography, with ultraviolet
spectrophotometry (14), with colorimetry (15), densitometry
(16); indoles and oxindoles were identified in the first place (17).
Since then, more than 25 significant alkaloids were identified
(11). The corynanthe-type indole mitragynine contributes 66%
to MsK alkaloids, paynantheine 9%, 7-hydroxymitragynine 2%,
and speciociliatine 1%; other alkaloids contribute <1% each
(11). However, their contribution varies across locations (18)
and products sold across the world might not always contain
MsK at all (19). The first whose structure was determined
in 1958 was mitraphylline (20), with many other alkaloids
following suit (18). The MsK alkaloids may differ in their brain
accessibility and crossing of the blood-brain barrier; for example,
mitragynine penetrates in the brain significantly more than 7-
hydroxymitragynine, at least in the rat (21). However, the latter
is held to be responsible for almost all kratom effects on opioid
receptors, and despite low content, it is produced by cytochrome
P450 (CYP3A4 isoenzyme) conversion from mitragynine (22).
Other biochemically and neurochemically interesting
compounds include rhynchophylline derivatives (23, 24),
which down-regulate NMDA-mediated responses in animals
(25–27), and a yohimbine and mitragynine analog, ajmalicine
or raubasine (28), which differently from mitragynine (29),
inhibits α2-adrenoceptors, although less than α1-adrenoceptors
(30–32). Of note, kratom alkaloids closely interact with α2
adrenoceptors, and mitragynine and 7-hydroxymitragynine
bind them (33). Furthermore, mitragynine inhibits the activity
of 5-HT2A receptors, although indirectly so (29, 34, 35), as it
shows a K i > 10µM for the 5-HT2A receptor (36). It is possible
that the interplay between these receptor effects and between
MsK alkaloids underpin the different effects of kratom at low vs.
high doses.
Although kratom was reportedly used to substitute for opiate
addiction and cure it (37), the demonstration of their binding
by MsK had to await the discovery of opioid receptors (38,
39). Mitragynine and other kratom alkaloids were shown to be
possibly allosteric (40) agonists to opioid receptors (41–44), to
possess analgesic properties thanks to their binding to brain µ-
and δ-opioid receptors, and to induce ileal and vas deferens
distention through the same receptors at peripheral sites (43, 45).
These properties were long harnessed by traditional healers in
the countries where kratom grows. In South-East Asia kratom
is used to alleviate muscle aches, and sometimes to heal wounds
and cure worm infections, while some users support they assume
it to increase resistance to fatigue and to stimulate sexuality
(46). Indeed, mitragynine and kratom alkaloids are likely to be
associated with “dependence” signs and symptoms which are less
severe than those usually associated to opiates and they may be
used to alleviate classical opiate withdrawal (47, 48). This is not
surprising, since they act as agonists on opioid mu receptors.
Legislations concerning kratom varies across countries. In
Europe it is illegal in Denmark, Finland, Ireland, Latvia,
Lithuania, Poland, Romania, and Sweden (49), while in the UK
it has been included in the Psychoactive Substances Bill 2015
(50), hence it is illegal since March 2016, being regulated through
the Psychoactive Substances Act 2016 (51). In Italy, it became
illegal in 2016. In Canada and Australia, kratom is illegal, while
in New Zealand it is a regulated substance. In the United States
it is forbidden in some States and not in other (49). Many
US state legislations are likely to change their attitude toward
kratom in the near future. Similarly, Thailand, one of kratom’s
major producers, which prohibits since 1943 the cultivation of
new plants and mandates the abatement of the existing ones,
while restricting possession and use and establishing sanctions
for quantities superior or inferior to 10Kg, is on the verge
of changing its legislation. In Malaysia, Bhutan and Myanmar
kratom is illegal, and in Indonesia it will be banned by 2022 (52).
Discrepancies among the various legislations internationally, as
well as the increase in the use of internet and globalization
have resulted in an increased use of kratom for voluptuary
purposes (53) indicating the need for international coordination
of scientists and legislators (54). That kratom could induce an
opioid-like withdrawal syndrome, therefore it can be included
among addictive substances, is shown by the fact that it may
be present in neonates exposed to the substance due to their
mothers’ heavy use during pregnancy (55–61). In fact, the World
Anti-Doping Agency placed mitragynine on its Monitoring List
since 2014, and 1 year later, four cases of mitragynine use among
strength sportsmen were detected (62). Kratom use has been also
reported in fitness settings (63).
The effects of the use of kratom are variable and may depend
on the cultural and genetic background of the user as well as on
differences in product composition. Product conservation and
transport factors may also be involved, as are co-administered
sedative ormultisubstance use. In a US-Thailand comparison, for
example, symptoms were more severe andmortality higher in the
US sample, with drowsiness, irritability-agitation and tachycardia
being the most common in order of increasing frequency (64).
Kratom may be used according to users’ taste and adjusted
according to the desired effects, with low doses producing
stimulant and activating effects and high doses sedative and
tranquilizing effects (65–67), although these dose-related effects
were not confirmed in a recent study and was unrelated to the
amount and duration of kratom use (68). Many people, especially
in South-East Asia, get to use kratom after being addicted to
opioids and in the attempt to quit; others are prompted to
use kratom due to its anxiolytic and mood enhancing effects
(69–71). It is expected that upon discontinuing, rebound mood
and anxiety symptoms emerge. In regular users, withdrawal
symptoms may occur which are more intense in long-time users
or after stopping heavy use, and involve usually moderate anxiety
and depression (72), as well as aching and disordered sleep (73).
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However, kratom withdrawal syndromes are usually mild and
transient (72–74), similar to but milder than those of opiate
withdrawal (74, 75), but may be complicated in some users (54).
We here report the case of an adult man who used kratom and
developed withdrawal symptoms while trying to quit. He did well
on clompipramine just 1 month after initiation and, 9 months
later, is currently symptom-free.
CASE REPORT
A 44-year-old man, married to a 44-year-old, currently pregnant
woman, with a 5-year-old son, a graduate in economy and
employed as a researcher at a University, sought help at
a community psychiatric service for symptoms of kratom
withdrawal and elevated anxiety.
The patient was collaborative at interview, appropriately
dressed and well-oriented in time and space; he showed
free-floating and somatic anxiety, with tachycardia, profuse
sweating, psychomotor agitation, insomnia, dysphoric mood,
and emotional lability. His thoughts were focused on anxious
experiences and hopelessness. He reported being treated during
the last few months with various benzodiazepines and selective
serotonin reuptake inhibitors (SSRIs), first paroxetine 40mg/Day
and then sertraline 200 mg/day, to which he associated cognitive-
behavioral therapy, with no clear benefit.
The patient had experienced two important major depressive
episodes coinciding with stressful life events, which he overcame
through the use of SSRIs and long-term psychotherapy. When
he was young, he had engaged in polysubstance use, while in
his adult life he first used cannabis and alcohol, but later turned
to benzodiazepines, alcohol, and kratom, which he obtained
through dark internet sites. The patient has been vague as to
when and how he started consumption, and also very unclear
regarding dosing. His internet-related kratom sources varied, so
we are not in a position to determine the purity of the samples
he received. During the last 10 months preceding the visit, he
had scheduled daily kratom infusions, but had discontinued
quite sharply during the last 2 months. The patient used to
continue drinking the infusion until he reached the desired effect.
Having realized in the last 2 months he was becoming severely
dependent, he decided to quit kratom and to no longer seek it on
the internet.
Urinary drug testing was positive for benzodiazepines. Blood
chemistry showed no abnormal values. However, kratom could
not be quantified due to the unavailability of routine laboratory
tests. The electrogram (ECG) showed no abnormalities, with a
QTc of 385ms and a heart rate of 60 beats/min. We established
treatment with pregabalin 25mg b.i.d., gradually tapering off
sertraline and substituting it with 150 mg/day bupropion,
taken in the morning, and 300mg controlled-release trazodone,
administered in the evening. His next visit was scheduled after
2 weeks.
During the second visit, his clinical conditions were
unchanged. The patient was restless, anxious, agitated,
insomniac, dysphoric, with frequent cry spells and unstructured
ideation of self-harm. He craved for benzodiazepines and alcohol
and often abused them. Bupropion was increased to 300 mg/day
and pregabalin, 75mg b.i.d. was initiated.
During his third visit, after further 15 days, the above clinical
picture persisted. The patient reported to be able to relax, but
observed no symptom improvement. We agreed to add 50
mg/day tramadol in the evening. He noted since the first days of
tramadol addition a mild reduction in craving and restlessness,
with disappearance of self-harm ideas, while anxiety, which the
patient reported as paralyzing, dysphoric mood, cry spells, and
avolition remained unchanged. The patient asked for a medical
certificate to abstain from work, since he considered teaching
at the University a complex and stressful activity. We agreed
to increase tramadol to 100mg b.i.d., gradually introducing
clomipramine to a target dose of 75 mg/day, while gradually
discontinuing bupropion.
Three months after the first visit and about 1 month after
introducing clomipramine, the clinical picture was on the way
to resolution; the patient himself asked to discontinue tramadol.
Free-floating and somatic anxiety had subsided and craving for
all substances, including alcohol, benzodiazepines, and kratom,
was significantly attenuated, while mood was stable and in the
normal range (euthymic).
In the following months, given the clear clinical improvement
and the remission of withdrawal symptoms, it was possible to
gradually discontinue both pregabalin and trazodone.
Currently, the clinical picture is stable; the patient continues
on clomipramine 75 mg/day and about 9 months after its
introduction reports to have resumed normal life.
The patient signed free informed consent for the publication
of his case and all treatments received.
DISCUSSION
In this report we presented the case of an adult Italian
man in his forties, who deliberately used kratom to soothe
his anxiety symptoms. The patient was well-educated and
upper socioeconomic class. He had started kratom after
engaging in multisubstance use and psychotherapy, while
completing steps toward reaching a high social status. He
used the internet to obtain kratom, but had no available
supplies when he came to our attention, so we could not
analyse any kratom specimen he used. After trying several
therapeutic strategies, including pharmacotherapy, he was unable
to resolve his anxiety symptoms, either during kratom use or
during abstinence, and was switched to low-dose clomipramine
eventually discontinuing all other psychotherapeutic drugs;
1 month after initiating clomipramine, his symptoms had
resolved and so were his anxiety symptoms that had originated
psychiatric visits.
There have been several case reports of kratom use toxicity
and withdrawal in literature, but clomipramine treatment had
not been reported to date. Cases vary in severity and symptom
presentation. One of the first described cases of mitragynine
toxicity was of severe seizures and come occurring in a 64-year-
old man, that resolved soon with symptomatic treatment, that
is, intubation to preserve airway integrity (76). In another case,
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seizures occurred when a 43-year-old man tried to self-treat his
opiate dependence with a kratom-modafinil combination (69);
the case resolved with few kratom-related withdrawal symptoms.
A further case presenting with seizures occurred in a 18-year old
man and treated with antiepileptic drugs. Magnetic resonance
imaging showed bilateral alterations in the striatum, cerebral
peduncles, and subthalamic nuclei in this chronic kratom
user, indicating possible permanent effects of kratom in brain
structure (77). Finally, a 27-year-old nab with history of anxiety,
attention-deficit/hyperactivity disorder, substance use disorders
(benzodiazepines and opioids) developed seizures while using
kratom and opioids and recovered with anti-anxiety agents (78).
Another 36-year-old man was unresponsive to external stimuli
and near comatose, did not respond to naloxone and was treated
with respiratory support and symptomatic management (79).
Another kratom overdose case occurred in a 38-year-old woman
who resented with respiratory depression at the emergency
department and resolved with naloxone (80). A 33-year-old male
polysubstance user exhibited cardiovascular shock features and
high procalcitonin levels promptly treated with vasopressors
(81). An otherwise healthy 35-year-old man suffered a cardiac
arrest after using kratom alone and was found with small brain
infarcts, but recovered spontaneously (82). Finally, a 62-year-old
woman who used kratom for the first time to soothe traumatic
pain presented at the emergency room with intractable vomiting
and nausea that responded to ondansetron, promethazine, and
famotidine (83).
Cases of kratom-related deaths are usually linked to
simultaneous assumption of kratom with other drugs, as in the
above described case. Initial death reports regarded associations,
but more recent cases show that people who only take kratom are
at risk. One case of death of a 20-year-old man occurred with
propylhexedrine and kratom; the latter was not determined to
have caused the death, which has been associated to accidental
propylhexedrine (84). Nine cases of death occurring in one
year were described in Sweden in 2011 with the simultaneous
intake of mitragynine and O-desmethyltramadol. Decedents’ age
ranged 22–35; seven were men and two were women (85).
The authors concluded that mitragynine-related herbal mixes
are not so safe as per internet propaganda. Another death
case in which mitragynine was involved, but the death was
attributed to quetiapine overdose, has been described in a
27-year-old man succumbing to hyperthermia associated with
seizures. One case of a 17-year adolescent male who was
trying to quit opioid use by self-medicating with kratom, points
to kratom being occasionally toxic; the boy was found dead
with pulmonary congestion and oedema, as well as urinary
bladder distension, which are typical of opiate intoxication (86).
The case was labeled as “probable kratom toxicity.” Another
case of kratom intoxication-related death was found to be
associated with high blood amounts of mitragynine and 7-
hydroxymitragynine and unremarkable pathological finding at
autopsy in a middle-aged man with psychiatric history and
illicit drug use disorder (87). Another report of death related
to kratom use was one of a 24-year man with opiate and
alcohol use disorders, who was found dead with high peripheral
alkaloid concentrations, pulmonary oedema and congestion,
and urinary retention, compatible with opioid intoxication; the
patient was using several psychiatric medications that were
found at therapeutic blood levels (88). Further two cases of
young men could not be attributed to the documented kratom
use, despite high mitragynine levels in femoral blood (89).
One of the patients had attempted suicide just after taking
kratom with prescription drugs, while the other took a mix of
drugs. Another fatality was due to 3-methoxyphencyclidine, and
mitragynine was just one of many other substances the 58-year-
old man had taken (90). An emergency case presenting with
cardiorespiratory arrest could not be rescued despite the use of
intralipid, that nevertheless improved somehow the conditions
of a 26-year-old man, but proved ineffective in avoiding exitus,
attributed to cardiorespiratory failure and hypoxic brain damage
(91). A Canadian 56-year-old woman with chronic obstructive
pulmonary disease, after skipping hermedication and consuming
kratom purchased from Indonesia, died due to respiratory failure
(92). Her mitragynine levels in the femoral vein were found to
be substantial but sublethal (under the reporting laboratory’s
threshold of fatality, which was 0.21 mg/L). Another case
of multiple drug use ensuing in death has been related to
mitragynine due to the very high doses found in inferior cava
blood of a 33-year-old man (93). In general, fatality case studies
suffer from heterogeneity in kratom alkaloid detection methods
and sites.
Cases of chronic kratom used followed by withdrawal
symptoms have been reported to resolve with gabapentin in
a 26-year-old woman and gabapentin and clonidine in a 27-
year-old man (94). A case similar to ours has been described
in a 44-year-old man with a history of alcohol use and
anxiety; gradually tapered-off dihydrocodeine and lofexidine
were followed by rapid withdrawal symptom resolution (95). In
our case, the psychiatric symptoms of our patient were more
prominent and stubborn, and briefly trialed clonidine in the
past had sorted no effect. Hence the need for something more
specific for anxiety disorders. Cases of kratom withdrawal in
a 47-year-old woman (96) and in a 24-year-old man with an
autism spectrum disorder (97) have been treated with clonidine
and hydroxyzine, similarly to ordinary opiate withdrawal
syndromes. The latter case and four other cases of kratom
withdrawal were treated successfully with buprenorphine-
naloxone maintenance (98–100). A further withdrawal from
combined kratom-tilidine addiction has been successfully treated
with retarded morphine (101). Finally, a recent paper reported
an unusual presentation of obsessive-compulsive disorder-
like syndrome during kratom withdrawal that responded to
lorazepam (102). We did not use treatments aimed at treating
patient’s kratomwithdrawal, since the syndromewasmild despite
being obstinate, but rather focused on the anxiety disorder, which
usually responds to antidepressants. By treating our patient’s
background psychological symptoms, we were successful in
reducing withdrawal symptomatology.
Kratom use has been often linked to liver toxicity. Kratom
has been associated with biliary cholangitis and cholestasis in
several cases (67, 103–110) and with one case of hepatomegaly
(111), but also with acute hepatitis (112). Mitragynine inhibits
hepatic and intestinal cytochrome P450 3A activities (113) and
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hepatic microsomal CYP2D6 (114), thus increasing blood levels
of other concomitantly administered drugs that are metabolized
by these isoenzymes, that is, most psychiatric drugs. This may
expose to further hepatotoxicity (115, 116). Our patient did not
develop liver abnormalities during his kratom use period, despite
the fact he was concurrently using alcohol. We did not perform
kratom quantification analyses in our patient throughout the
treatment period. This was because the patient refused to provide
organic specimens or leaves for forensic analyses. There are
reliable methods for detecting mitragynine and its derivatives
in the urine (117) and in plant and extracts (118) for forensic
purposes, but these are not currently routine practice. There is
need for standardizing methods of kratom alkaloid detection in
reported users.
A limitation of the current review is that the supposed
benefits-to-risk ratio of kratom use cannot be currently addressed
adequately. There is insufficient epidemiological documentation
as to the extent of kratom use worldwide and in specific
countries (119), so to estimate how many people use it
and how many develop unwanted effects. Besides this, risks
may increase, as many kratom users have concurrent other
substance use (120), and this is difficult to disentangle. The
most recent estimates in indicate kratom use in the adult US
population is 0.8% for the past year and 1.3% lifetime (120).
The debate on epidemiological issues is strong and ongoing, and
points to the evergreen “more studies are needed” (121, 122).
The advocates of kratom use to ease opioid dependence and
harness its effects on strength and endurance while involved
in work activities do not publish in scientific literature, but
put forward their uncontrolled views and opinions in sites of
their own property. Hence, it is an impervious task to try
to respond to the question whether kratom use is relatively
safe, but it appears it is not (123). Currently, there is not
sufficient evidence to recommend changes in kratom regulation,
nor to recommend the use of clomipramine in cases of
kratom withdrawal.
Our patient showed while withdrawing from kratom
mitigated signs and symptoms typical of opiate withdrawal,
which were mixed with other psychiatric symptoms presumably
linked to his background psychopathology. Knowing that
the withdrawal is generally time-limited and mild, we
chose to use an anxiety-specific agent, clomipramine, with
preference for serotonin transporter over noradrenaline
transporter inhibition, which is a tricyclic antidepressant
used in anxiety disorders and obsessive-compulsive disorder
and has shown good evidence in these disorders. We used
it at 75 mg/day, which is on the lower range of clinical
effectiveness for these disorders. Mitragynine counters
serotonin 5-HT2A receptors (29) and clomipramine down-
regulates the same receptors after chronic treatment (124, 125);
furthermore, it has pain supressing effects even at low doses
through spinal mechanisms (126). Hence, it is possible that
some mitragynine withdrawal symptoms were alleviated
concomitantly with clomipramine’s anxiety relieving effects.
However, this is not the most likely mechanism whereby
clomipramine reduced our patient’s symptomatology. In fact,
clomipramine may obviate for the opiate-like mitragynine
withdrawal syndrome through interference with opioid
receptors, which it was shown to bind (127); chronic,
but not subacute clomipramine administration, induced
a mu receptor down-regulation in the rat (128). In this
case, clomipramine could reduce the quantity of opioid
receptors in the need for occupation, as it occurs in opiate
withdrawal. However, the response of human opioid receptors
to chronic clomipramine appears to be weak (129). We
are unsure about how improvement was obtained, but the
timeline appears to match the usual onset of clomipramine
antidepressant effects.
CONCLUDING REMARKS
Summarizing the above evidence, we may conclude that kratom
may induce addiction, acute toxicity which may be sometimes
lethal and, upon discontinuation, it induces a withdrawal
syndrome, which may vary in intensity. In many instances
that appeared in literature, kratom was regularly used by
patients with psychiatric history and/or substance use disorders.
Legislations should take very seriously peer-reviewed published
evidence and regulate the substance. In parallel, we need to
enforce kratom detection methods in consent-providing users
for forensic purposes. International drug policies should be
coordinated and inform the public about kratom and other novel
addictive drugs.
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Objective: Investigate the psychometric properties of the Severity of Dependence Scale
(SDS) for codeine and its association with aberrant codeine related behaviors.
Design: A voluntary and uncompensated cross-sectional online survey.
Setting: Online population (≥18 years).
Respondents: Two hundred and eighty-six respondents (66% women) who had used
codeine containing medicines in the last 3 months and were living in the UK.
Results: Of the respondents (mean age = 35.4 years, SD = 12.5), more than
half were employed. Only 3.5% respondents reported no income. The majority of
respondents (45.1%) primarily obtained prescription-only codeine from a consultation
with a health professional, whilst 40.9% mainly purchased “over-the-counter” codeine
containing medicines in a pharmacy without a medical prescription. Principal component
analysis indicated a single factor solution accounting for 75% of the variance. Factor
loadings ranged from 0.83 to 0.89. Cronbach’s Alpha was high (α = 0.92). Several
behaviors relating to codeine use were found to significantly predict probable codeine
dependence. These included: daily codeine use in the last 3 months (OR = 66.89,
95% CI = 15.8–283.18); tolerance to codeine (OR = 32.14, 95% CI = 13.82–74.75);
problems with role responsibility due to intoxication (OR = 9.89, 95% CI = 4.95–19.78);
having sought advice on the internet to manage codeine use (OR = 9.56, 95%
CI = 4.5–20.31); history of alcohol or drug treatment (OR = 3.73, 95% CI = 1.88–7.43).
Conclusions: The SDS was acceptable and feasible to use to assess probable
psychological codeine dependence in an online sample of people using codeine
containing medicines. SDS scores were associated with behaviors known to be
indicators of codeine dependence. Studies are needed in well-defined populations of
people who use codeine to test the different aspects of psychometry of the scale
compared against “gold standard” criterion [a diagnosis according to the Diagnostic and
Statistical Manual of Mental Disorders (DSM-5)].
Keywords: psychometric validation, Severity of Dependence Scale, opioid misuse, codeine, addiction
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STRENGHTS AND LIMITATIONS OF THIS
STUDY
• Advances the understanding of the use of screening tools and
scales to assess dependence on codeine containing medicines
for research purposes.
• The study recruited a broad cross-section of codeine users in
the UK, providing an initial investigation of the psychometric
properties of the Severity of Dependence Scale for codeine.
• Online purposive samples have unknown population
characteristics which must be recognized when interpreting
the findings of the present study.
• Studies in well-defined populations of people using codeine
are needed to test different aspects of psychometry of the scale
compared against independent “gold standard” criterion.
INTRODUCTION
In the UK, the use of codeine containing medicines and the
resulting possibility of dependence and severe health outcomes
(1) pose a burden on primary and secondary care, specialized
addiction treatment (2) and mortality (3). Codeine is used in
form of codeine-based Prescription-Only Medicines (POM) or
Pharmacy medicines (P), which contain a lower amount of
codeine and may be sold under the supervision of a pharmacist
without a medical prescription (sold “over-the-counter”) (4).
Codeine is currently controlled under the Misuse of Drugs
Regulations 2001 classified as Schedule 5 (Controlled drugs
excepted from the prohibition on importation, exportation and
possession) (5).
Many codeine containing medicines include a combination
of codeine and a non-opioid analgesic such as ibuprofen or
paracetamol (6). In 2014, the UK accounted for nearly one-
sixth of the global consumption of codeine (7). Sales of codeine
containing “over-the-counter” products in packs of 32 tablets
more than doubled in the period of 2006 to 2008 from 5.3 to 11.1
mn (8).
During 2007 to 2016, the number of registered drug-related
deaths involving codeine increased from 60 to 131 in England
and Wales (9). In Scotland, codeine or a codeine-containing
compound was implicated in an average of 19 deaths per year
between 2003 and 2007, 27 deaths per year between 2008
and 2012, and 33 deaths per year between 2011 and 2015
(10). The accessibility to codeine is under scrutiny in many
countries, including the UK, due to concerns of dependence and
severe harm from excessive use and overdose of accompanying
paracetamol and ibuprofen (11–13). The recent indicators of
an emerging “codeine problem” in the UK expose the need for
reliable and accurate instruments to identify and treat early signs
of codeine dependence to reduce long-term use, mortality, and
the economic burden of addiction treatment.
The Severity of Dependence Scale (SDS) is a simple and
practical 5-item, 15-point scale used to assess the degree of
psychological dependence across several substance classes (14).
In research to date, the psychometric properties of the SDS
have been investigated in populations using illicit drugs (14–
16), alcohol (17), and nicotine (18). Optimal cut-off scores
on the SDS for probable psychological dependence, when
measured against the presence of a diagnosis obtained from the
Diagnostic and Statistical Manual of Mental Disorders (DSM-5),
have been determined for amphetamine (19), cocaine (20, 21),
benzodiazepines (22), alcohol (23), and cannabis (24). The scale
has previously been used to determine the level of probable
codeine dependence amongst adults in Australia reporting use
of “over-the-counter” codeine (25). Further investigation of the
psychometric properties of the SDS for codeine would add
understanding and value to the use of the scale for research
purposes and possibly in clinical settings.
Using data collected from a cross-sectional, self-completed,
online survey of adults who used codeine, the article presents a
preliminary investigation of (i) the psychometric properties of
the SDS for people living in the UK and (ii) the relation between
the scale and behaviors known to be indicators of codeine
dependence. Scales to identify people who are codeine dependent
which are reliable and simple to administer are currently needed
to promote public health.
METHODS
Ethics
The study received ethics approval granted by the Psychiatry,
Nursing, and Midwifery Research Ethics Subcommittee
(PNM RESC), King’s College London. REC Reference
Number: PNM/14/15-110.
Recruitment
The survey was advertised on Facebook, Twitter, health and drug
related websites and e-mail circulars to include a broad sample
of people using codeine resembling the general population.
Recruitment lasted between July 2015 andMarch 2016. The main
inclusion criterion was use of codeine containing medicines,
prescribed or “over-the-counter,” on at least one occasion in the
last 3 months. Only respondents over the age of 18 were asked to
participate. Participation in the study was voluntary, anonymous
and uncompensated. A more detailed account of the survey has
previously been published (26).
Sample
The survey was embedded within the CODEMISUSED
collaboration aiming to carry out national and international
studies to estimate levels of codeine use, misuse and dependence
in partner countries (Ireland, South Africa and the UK) (27).
For this reason, the online survey was open to respondents
from all countries. However, in these re-analyses of the data in
the present study, it was decided to only include respondents
living the UK for several reasons: (i) There is great disparity
between levels of codeine consumption, availability of codeine as
“over-the-counter” medicines or POM, the amount of codeine
included in codeine containing medicines and regulation of
advertising of codeine containing medicines across countries
around the world (11, 28–30) which may affect aberrant
codeine behavior differently. By limiting the sample to the
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UK, respondents completing the SDS were sourcing and using
codeine under similar conditions and regulation; (ii) conducting
analysis of the SDS according to nationality was not feasible as
some nations were represented by very few respondents; and (iii)
the survey was only available in English. Limiting the analysis
to respondents living in the UK presumably reduces the risk of
misunderstanding due to potential language barriers.
Procedure
The online survey was developed in Bristol Online Surveys (BOS)
and consisted of 49 questions about demographic information,
codeine use, codeine dependence, social factors, treatment
history, and other substance use (26).
The SDS was included as part of this larger study
questionnaire, with the scale items included as questions 28–32
out of a total of 49 questions. The wording of each item of the
scale was adapted to enquire about the use of codeine in the last
3 months. Respondents were asked:
(i) In the last 3 months did you think your use of codeine
was out of control? (Responses: “Never/almost never” = 0;
“Sometimes”= 1; “Often”= 2; “Always/nearly always”= 3).
(ii) In the last 3 months did the prospect of not taking codeine
make you anxious? (Responses: “Never/almost never” = 0;
“Sometimes”= 1; “Often”= 2; “Always/nearly always”= 3).
(iii) In the last 3 months did you worry about your use
of codeine? (Responses: “Never/almost never” = 0;
“Sometimes”= 1; “Often”= 2; “Always/nearly always”= 3).
(iv) In the last 3 months did you wish you could stop
taking codeine? (Responses: “Never/almost never” = 0;
“Sometimes”= 1; “Often”= 2; “Always/nearly always”= 3).
(v) In the last 3 months how difficult did you find it to stop
using codeine? (Responses: “Not difficult” = 0; “Quite
difficult”= 1; “Very difficult”= 2; “Impossible”= 3).
Responses were scored from 0 to 3 for a total score between 0
and 15.
Likely indicators of codeine dependence included frequency
of use in the last 3 months, reported as a dichotomous variable
(daily or non-daily use). Additional questions were asked about
tolerance to codeine and withdrawal symptoms after the use of
codeine. Respondents were asked to report if they had sought
help to control their use of codeine from (i) a community
pharmacist, (ii) a general medical practitioner (GP), or (iii)
from the internet. Respondents were also asked about past
treatment for alcohol and illicit drug use. The survey included
items from the Alcohol, Smoking and Substance Involvement
Screening Test (ASSIST) to investigate problems with role
responsibility due to the use of codeine (31). Questions from
a scale designed to measure reasons for substance use were
included to investigate use of codeine for anxiety (32). Several
questions about tampering of codeine containing medicines were
developed for the study, including about extraction of codeine
(otherwise known as “cold water extraction”) (33) and drinking
codeine cough syrups mixed with soft drinks or with alcohol.
A question about life-time use of illicit drugs, such as cannabis,
amphetamines, ecstasy, cocaine, and heroin was included in
the survey.
The complete survey was reviewed by experts in codeine
misuse and dependence and piloted amongst addiction treatment
service users. The survey took between 15 and 20min
to complete.
Data Analysis
Data were downloaded from the online questionnaires and
imported to SPSS. All data analyses were conducted using
SPSS, version 24. Before undertaking analyses, all respondents
living in countries other than the UK were removed from the
dataset. Principal Component Analysis (PCA) was conducted
for the five SDS items as proposed by Gossop et al. (14).
PCA was applied to determine the number of dimensions and
item loading structure. The Cronbach’s Alpha coefficient was
used to assess the internal consistency of the scale. Mono-
variate logistic regression analyses were conducted to estimate
the associations between the presence of codeine dependence
and individual behaviors relating to codeine use. Comparisons
were made between a baseline comparison group consisting of
non-dependent codeine users and codeine dependent users. For
this part of the analysis, a SDS score of five or above indicated
probable psychological dependence on codeine, consistent with
previous use of the scale to assess dependence to codeine (25, 34).
A score of below five indicated non-dependence. Independent
variables were demographic characteristics, frequency of codeine
use, tolerance, seeking help tomanage codeine, past treatment for
alcohol or drug use, social problems, codeine use for emotional
distress, tampering of codeine containing medicines, and other
substance use.
Missing Data
To reduce the amount of missing data, most items were
mandatory in the computerized survey and respondents could
not proceed to the next question without providing an answer.
Missing data was therefore uncommon. However, data was
missing for amount of codeine consumed on last occasion
of use precluding an analysis of this item in the logistic
regression model.
RESULTS
Between July 2015 and March 2016, 472 respondents using
codeine in the last 3 months and over the age of 18 completed the
survey online. Respondents from outside the UK were removed,
leaving a total of 286 respondents in the final analysis. As Table 1
shows, 66.4% of these were female. The mean age of the sample
was 35.4 years (SD= 12.5) with a range of 18–71 years.More than
half of the respondents were employed full or part-time (60.5%).
The main source of obtaining codeine containing medicines was
prescribed following a face-to-face consultation with a doctor
(45.1% of respondents). The second most common source was
purchased “over-the-counter” in a pharmacy without a medical
prescription (40.9% of respondents). In the 3 months prior to
completing the survey, 39.2% (n = 112) of the respondents had
consumed codeine daily. A majority of 219 respondents (76.6%)
took less or equal to the maximum recommended daily dose of
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TABLE 1 | Respondent characteristics (n = 286).
Characteristic






Student allowance 38 (13.3%)
Dependent on other 17 (5.9%)
Disability allowance 17 (5.9%)
No income 10 (3.5%)
Temporary benefit 8 (2.8%)
Pension 7 (2.4%)
Other 8 (2.8%)
Main type of codeine, n (%)
Prescription codeine 129 (45.1%)
“Over-the-counter” codeine 117 (40.9%)
Otherc 40 (14%)
SD, Standard Deviation.
aFour respondents did not say (1.4%).
bEight respondents did not say (2.8%).
cPurchased online and obtained from friends and family.
TABLE 2 | Factor loadings and percentage of variance accounted for.
Respondents (use of codeine in past 3 months)
n = 286
SDS score, mean (SD) 2.2 (SD = 3.5)
Range 0–15
Principal components analysis







Item % variance accounted for 75
Cronbach’s alpha 0.92
codeine (240mg), 31 (10.8%) took more and 36 (12.6%) did not
provide this information or answered the question incorrectly.
Variance and Consistency of the SDS
The respondents answered all required questions for the SDS.
The responses to the scale produced a full range of scores from 0
to 15 (Mean score= 2.2, SD= 3.5). Principal component analysis
(PCA) was undertaken, indicating a single factor solution which
accounted for 75% of the variance in codeine dependence
(Table 2). The SDS had high internal consistency (Cronbach’s
alpha= 0.92).
Associations With Aberrant Codeine Use
Mono-variate logistic regression analyses were used to investigate
the relation between codeine dependence and aberrant behaviors
in themselves indicating codeine dependence. Non-dependent
codeine users were the reference category (Table 3).
Compared with those who were not dependent on codeine,
the group of people with probable codeine dependence were
significantly more likely to report daily use of codeine (96.1
vs. 26.8%, p < 0.01). In relation to experiences of physical
dependence, there was a significantly higher proportion of
codeine dependent respondents (58.8%) who reported tolerance
to codeine in comparison with non-dependent (4.3%) (p < 0.01).
SDS scores were investigated in relation to seeking help to
control the use of codeine and specialized addiction treatment
history. In the logistic regression model, independent variables
that were found to significantly predict probable codeine
dependence were having sought help on the Internet (OR= 9.56,
95% CI = 4.5–20.31) and having sought help from a GP
(OR = 9.31, 95% CI = 3.21–27.01). Codeine dependent
respondents were more likely to have received treatment to
manage alcohol and illicit drug use than non-dependent users
(35.3% compared to 12.8%, p < 0.01).
Those who were dependent on codeine were more likely
to report problems with role responsibility, such as missing
appointments at work or at home due to intoxication, compared
to those who were not dependent (52.9 vs. 10.2%, p < 00.1). SDS
scores were investigated in relation to whether a friend or relative
or anyone else had expressed concern about the respondents’
use of codeine, which was found to significantly predict codeine
dependence (OR= 8.74, 95% CI= 4.39–17.38).
Non-medical use of codeine relating to depression and anxiety
were found to significantly predict probable codeine dependence,
including using codeine to stop worrying about a problem
(OR = 6.03, 95% CI = 2.83–12.83) and using codeine to feel
better when down or depressed (OR = 5.41, 95% CI = 2.77–
10.55).
The group of people with probable codeine dependence had
a high proportion of respondents who had consumed codeine
cough syrups mixed with soft drinks, juice or alcohol (25.5%)
compared to the group of non-dependent respondents reporting
this behavior (9.4%) (p < 0.01).
There was no significant association between probable
codeine dependence and consuming codeine extracted from
codeine containing medicines or life-time illicit drug use.
DISCUSSION
This study demonstrates the feasibility of screening 286
respondents to an online cross-sectional survey for probable
codeine dependence using the SDS. Pilot testing of the survey
indicated that the five SDS items were easy to understand and the
assessment easy to complete. The high questionnaire completion
rate to the scale (all items of the scale were completed by all
286 respondents) shows that the SDS was acceptable to use
as part of a larger survey study. PCA showed a single factor
solution accounting for 75% of the variance. The alpha value
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TABLE 3 | SDS score and its association with aberrant codeine related behaviors.
Respondents scoring <5 on





Respondents scoring ≥5 on





% % OR (95% CI)
Codeine consumption
Daily use in last 3 months 26.8% 96.1%** 66.89 (15.8–283.18)
Physical dependence
Codeine tolerance 4.3% 58.8%** 32.14 (13.82–74.75)
Sought advice to manage the use of codeine
On the Internet 6.8% 41.2%** 9.56 (4.5–20.31)
From a GP 2.6% 19.6%** 9.31 (3.21–27.01)
Drug addiction treatment
Received treatment to help control alcohol or drug use 12.8% 35.3%** 3.73 (1.88–7.43)
Impact on social life
Problems with role responsibility due to codeine 10.2% 52.9%** 9.89 (4.95–19.78)
Others expressed concern about use of codeine 10.6% 51%** 8.74 (4.39–17.38)
Emotional distress
Used codeine to feel better when down or depressed 13.2% 45.1%** 5.41 (2.77–10.55)
Used codeine to stop worrying about a problem 7.7% 33.3%** 6.03 (2.83–12.83)
Codeine tampering
Consumed codeine extracted from codeine containing medicines 14.5% 25.5% 1.78 (0.86–3.7)
Drinking codeine cough syrups mixed with soft drink, juice or alcohol 9.4% 25.5%** 3.33 (1.55–7.14)
Illicit drug use
Life-time substance use 52.8% 64.7% 1.54 (0.85–2.79)
**P < 0.01; OR, odds ratio; CI, confidence interval.
was high (Cronbach’s alpha = 0.92). Using a score of five and
above to indicate probable psychological dependence to codeine,
the study demonstrated associations between SDS scores and
measures in themselves indicating probable codeine dependence,
including daily consumption, tolerance, and problems with role
responsibility due to codeine intoxication (25, 35). This compares
favorably with a previous study using a similar online research
design where probable codeine dependence (indicated by a cut-
off score≥5) was associated with past alcohol and drug addiction
treatment, chronic pain, and exceedingmedical guidance for dose
consumption (25). Online purposive samples have unknown
population characteristics (36), but have in this study provided
useful preliminary data and indication of using the SDS to assess
probable codeine dependence.
PCA and Consistency of the Scale
PCA has been used to investigate the dimensionality of the SDS
for heroin, cocaine, amphetamine and cannabis (14, 37). In this
study, PCA indicated a single factor solution accounting for 75%
of the variance, suggesting that the five SDS items are suitable as
a single measure of psychological dependence. Previous research
on the SDS, comparable to findings presented here, found single
factor solutions accounting for a range of 45.5–80% of the
variance (14, 17, 37).
Cronbach’s alpha was used as a measure of internal
consistency. According to previous research, values of≥0.70 were
considered adequate (38). An alpha value of 0.92 in the study is
equal to or slightly higher than in previous investigations of the
scale (14, 24, 37). In addition to the PCA analyses, a high alpha
value is also a necessary condition for unidimensionality (14).
While the conducted analyses, including the PCA, satisfy a
number of criteria to account for the SDS as a single measure
of psychological dependence on codeine, they do not account for
how well the SDS determines if respondents have the condition
or not. As such the diagnostic properties of the SDS are unclear
until further analyses can be completed comparing SDS scores
against indicators of codeine dependence from the DSM-5.
External Validation
Using a cut-off score of five or above, the validity of the SDS score
is supported by the association with codeine related behaviors
known to be related to the severity of codeine dependence. These
include exceeding dose recommendations, daily use, chronic
pain, psychological distress, past alcohol and drug addiction
treatment, and codeine use to prevent withdrawal symptoms
(25, 34, 35). The results obtained in this study show that probable
codeine dependence was associated with daily use over the
past 3 months, having sought advice and treatment to manage
dependence, drinking codeine cough syrup mixed with juice and
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alcohol, having experienced that other expressed concern about
codeine use and using codeine for emotional distress.
A well-known limitation of the SDS is that it was designed
to measure psychological elements of dependence, such as
compulsion or craving, whilst excluding components relating
to physical dependence like tolerance and withdrawal caused
by neuroadaptation (14). It is notable in this respect that
respondents who were codeine dependent according to the SDS
were significantly more likely to report tolerance to codeine than
those who were not codeine dependent, supporting the validity
of the SDS by its association with this central component of
physical dependence.
Limitations
Whilst, to our knowledge, this is the first study to report on
the psychometric properties of the SDS for codeine, the sample
size restricts inference of these results to wider populations of
people who are using codeine. The sample size is relatively small
when considering the time during which the survey was open
for recruitment. Lack of data and understanding of codeine
dependent populations in the UK impede the construction
of a sampling frame and make the representativeness of our
sample difficult to measure. Furthermore, it must be noted
that online purposive sampling has biases due to unknown
characteristics of people who participate in online communities
and forums (36). Using online recruitment potentially excludes
those with no immediate access to the Internet and may
restrict respondents to those with a certain income, social
situation and level of education. The differences between levels
of codeine dependence and associated problems in online
and non-online populations are currently unclear. Missing
data precluded an analysis of codeine dose consumption
amongst non-dependent and dependent respondents, although
dose is a well-known indicator of problematic medicine
use (25). Though our findings suggest that a score of 5
and above is an acceptable indicator of probable codeine
dependence, the SDS was not designed as a screening tool to
decide categorically between non-dependence and dependence
(14). Further research is therefore required to compare the
adopted cut-off score of 5 against a validated screening tool
diagnosing substance dependence. Further research should also
explore the use of the SDS compared against a validated
diagnostic assessment in different age groups and according
to gender.
Implications for Research
Further studies are needed in well-defined populations to test
the different aspects of psychometry of the SDS for codeine
to determine its feasibility and validity in research settings.
Studies should also investigate the validity of the SDS within
different settings, such as primary care, community pharmacies
and specialized addiction services. The test-retest reliability of the
SDS for codeine is not known. Data that provides an indication
of the stability of SDS scores across occasions (39) would add
additional value to the scale.
Implications in Practice
Previous studies have determined a cut-off point on the
SDS that discriminates between the presence and absence
of a DSM-5 diagnosis for substance dependence suggesting
its implementation and usefulness in clinical settings. These
studies found a SDS score of 3 or above optimal for
characterizing a DSM-5 diagnosis of alcohol dependence
(23), whereas a cut-off score of 7 was found to be the
appropriate threshold for dependence to benzodiazepines (22).
In this study, several factors relating to aberrant codeine
use were associated with probable codeine dependence when
using a cut-off score of 5. Research with people attending
specialized drug addiction treatment for codeine would enable
a comparison between SDS scores and DSM-5 diagnosis,
possibly enabling its use in clinical settings as a quick way
of determining possible psychological dependence on codeine.
Obtaining good assessment amongst people presenting with
substance use typically improves care and use of screening,
assessment and monitoring tools is recommended (40). This
study demonstrated that the SDS is useful as a screening tool
for research purposes, which can be included in larger study
questionnaires with an excellent response rate presumably due
to its short length.
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Background: Fifteen to 25-year-olds are the age groupmost likely tomisuse prescription
drugs. Few studies have tested theory-driven models of adolescent risk for prescription
drug misuse. Moreover, rarely are distinct pathways to different forms of prescription drug
misuse considered.
Methods: We tested mediational paths from personality to mental health symptoms
to prescription drug misuse, informed by etiological models of addiction. We specified
pathways from particular personality traits to unique forms of prescription drug misuse
via specific mental health symptoms. We used semi-longitudinal data collected across
two waves of the Co-Venture Trial. Our sample included students from 31 Canadian
high schools tested in Grade 9 (n = 3,024) and again in Grade 10 (n = 2,869; 95%
retention). Personality (hopelessness, anxiety sensitivity, impulsivity, sensation seeking)
was assessed in Grade 9. Mental health symptoms (depression, anxiety, ADHD, conduct
disorder) and prescription drug misuse (opioids, sedatives/tranquilizers, stimulants) were
assessed at both time points.
Results: Consistent with the negative affect regulation model, hopelessness was
specifically associated with opioid misuse via depressive symptoms, and anxiety
sensitivity was specifically associated with sedative/tranquilizer misuse via anxiety
symptoms. Consistent with positive affect regulation, sensation seeking was directly
associated with stimulant misuse. Consistent with the psychological dysregulation
model, impulsivity was associated with stimulant misuse via ADHD symptoms. And
consistent with the deviance proneness model, impulsivity was also associated
with unconstrained (i.e., all three forms of) prescription drug misuse via conduct
disorder symptoms.
Conclusions: Screening for adolescents high in hopelessness, anxiety sensitivity,
sensation seeking, or impulsivity and providing them with personality-matched
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cognitive-behavioral interventions may be helpful in preventing or mitigating prescription
drug misuse. Our results point to the specific mental health symptoms that are important
to target in each of these personality-matched interventions.
Keywords: adolescents, personality risk, prescription drug misuse, anxiety sensitivity, hopelessness, sensation
seeking, impulsivity, mental health symptoms
INTRODUCTION
The National Survey on Drug Use and Mental Health defines
prescription drug (PD) misuse as use of PDs “in any way that a
doctor did not direct you to use them” including (a) use without a
prescription of one’s own; (b) use in greater amounts, for longer,
or more often than prescribed; or (c) use in any other way
that was not prescribed by a physician (1). Many young people
consider PDs to be less harmful than illicit drugs (2). Due to
their potency, potential for addiction, and overdose potential,
however, PD misuse can be injurious or even fatal (3).
Of any age group, 15–25-year-olds are the most likely
to misuse PDs (1). After cannabis, PDs are the drugs most
commonly misused by North American adolescents (1, 4).
One study showed that among adolescents aged 12–17, 5%
reported past year PD misuse (5). PDs are readily accessible
to adolescents through legitimate medical prescriptions (6),
diversion (7, 8), and online pharmacies (9, 10). These trends
are concerning for several reasons. First, prescription opiate
misuse increases risk for serious injury (11), respiratory
depression, and death (12). Moreover, the prevalence of
adolescent misuse of sedatives/tranquilizers, including novel
designer benzodiazepines, is significantly increasing (13–15), co-
use with opioids is common (16), and sedative/tranquilizer-
related deaths increased by 137% from 2007 to 2016 (17).
Stimulant misuse is associated with adverse short-term (e.g.,
headaches, sleep problems, academic difficulties) and long-term
effects [e.g., decreased likelihood of college graduation; (18)].
Adolescent-onset PDmisuse is linkedwith elevated substance use
disorder rates in adulthood (18, 19).
While several risk and protective factors for adolescent PD
misuse have been identified [see review by (20)], few studies have
tested theoretical models of adolescent risk for PD misuse (21).
And although the predictors of PDmisuse may vary considerably
by drug class (22), little work has examined unique pathways to
specific forms of PD misuse. One potential risk factor that may
help fill both these identified gaps is personality: specific traits
may present risk for particular classes of PD misuse via unique
theory-informed pathways.
Personality as a Risk Factor
Personality is a robust predictor of addictive behavior [e.g.,
(23)]. Internalizing and externalizing traits have been reliably
associated with an increased susceptibility for alcohol and illicit
substance misuse in adolescence (24). Pihl and Peterson (25)
developed a model that delineates four such traits. The first
two traits in this model are internalizing. Hopelessness (HOP)
involves the trait-like tendency to expect aversive events but not
desirable ones (26, 27). Anxiety sensitivity (AS) involves the fear
of anxiety-related sensations, due to an unrealistic expectation
that such sensations will have catastrophic consequences (28).
In adolescents, both HOP and AS are associated with coping
motives for substance use (29). Young people high in these traits
tend to preferentially misuse depressant drugs (30, 31). In adults,
HOP uniquely predicts opioid dependence and AS uniquely
predicts anxiolytic dependence (30, 32). The specificity of these
paths has yet to be tested in adolescents.
The remaining two traits in Pihl and Peterson’s (25) model
are externalizing. Impulsivity (IMP), or impulsiveness, is the
tendency to act without sufficient forethought (33). IMP has been
associated with a pattern of polysubstance use (34, 35). Deficits
in response inhibition make high IMP teens more susceptible
to early experimentation and to later compulsive substance use
(36). Sensation seeking (SS), or novelty seeking (37), involves the
desire for novel and intense stimulation (38). High SS substance
users are sensitive to the rewarding properties of drugs (39)
and tend to specifically misuse stimulants (40) to study, stay
awake/alert, “get high,” “party,” and experiment (41).
Traits from Pihl and Peterson’s (25) four-factor personality
vulnerability model have proven useful in predicting adolescent
alcohol (42) and illicit drug use (43, 44), emerging adult PD use
(31, 45), and adult PD use (30). This model has yet to be applied
to adolescent PD misuse.
Etiological Models of Addiction
Theoretically, these four traits exert their influence on substance
use via negative and positive affect regulation, deviance
proneness, and/or psychological dysregulation processes (39).
The models most relevant to linking HOP, AS, SS, and
IMP with PD misuse are described below (see also Table 1).
These theoretical models have informed the mediators in the
hypothesized paths from personality to PD misuse.
Affect Regulation Models
Affect regulation models theorize that drugs are taken to regulate
emotions—either for negative reinforcement (i.e., a drug’s ability
to relieve negative affect) or positive reinforcement (i.e., a drug’s
hedonic effects) (31). Negative affect regulation involves PD use
to avoid or control negative emotional states whereas positive
affect regulation involves PD use to increase positive emotional
states. This dichotomy is in keeping with McCabe et al.’s (46)
work on PDmisusemotives, which suggests that PDs aremisused
for self-medication (negative affect regulation) or recreation
(positive affect regulation).
Negative Affect Regulation
Individuals high in HOP or AS are theoretically most prone to
PD misuse for negative affect regulation (29). First, those high in
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HOP, AS Negative affect
regulation
H1: HOP → depressive symptoms → opioid
misuse




H3: SS → stimulant misuse
IMP Deviance
proneness
H4: IMP → CD symptoms → opioid misuse
IMP → CD symptoms →
sedative/tranquilizer misuse
IMP → CD symptoms → stimulant misuse
IMP Psychological
dysregulation
H5: IMP → ADHD symptoms → stimulant
misuse
HOP are thought tomisuse opioids to control or avoid symptoms
of depression. High HOP adults preferentially misuse opioids
over other substances (30–32). HOP also predicts adolescent
depression (47), and depression increases risk of PD misuse (21).
The negative affect regulation model suggests that depressive
symptoms shouldmediate HOP’s specific effect on opioidmisuse.
Those high in AS are also theoretically prone to PD misuse
for negative affect regulation but through a distinct pathway.
Specifically, they are thought to misuse sedatives/tranquilizers
to control or avoid anxiety symptoms. High AS adults
preferentially misuse anxiolytics over other substances (30,
31). AS incrementally predicts anxiety disorder symptoms in
children and adolescents (48, 49) and anxiety disorders are
associated with increased risk for sedative/tranquilizer misuse
(50). In sum, the negative affect regulation model supports
two distinct and specific pathways: HOP to opioid misuse via
depressive symptoms vs. AS to sedative/tranquilizer misuse via
anxiety symptoms.
Positive Affect Regulation
Stimulants activate mesolimbic dopamine activity and increase
positive mood (51). High SS individuals are theoretically most
prone to stimulant misuse for positive affect regulation. SS
is robustly related to sensitivity to drug reward (39) and to
enhancement motivated substance use (31). High SS individuals
preferentially misuse stimulants (32, 40). The positive affect
regulation model suggests this is because SS underlies sensitivity
to stimulant reinforcement (52). The positive affect regulation
model suggests a direct pathway from SS to stimulant misuse that
is not mediated through mental health symptoms.
Deviance Proneness Model
Another model relevant to understanding PD misuse is the
deviance proneness model (53). High IMP individuals are
thought to be prone to a broad, unconstrained pattern of PD
misuse (opioid, sedative/tranquilizer, and stimulant), occurring
amidst other “deviant” or antisocial behaviors. IMP is associated
with comorbid addictive and antisocial behaviors (54). IMP in
elementary school students is concurrently and prospectively
associated with conduct problems (55). Conduct disorder
(CD) symptom severity is associated with greater substance
involvement (56), including unconstrained PD misuse (57), in
adolescence. The deviance proneness model suggests that CD
symptomsmediate IMP’s effect on unconstrained PDmisuse (i.e.,
all three types of PD misuse).
Psychological Dysregulation Model
The psychological dysregulation model is an alternative model
for explaining the specific link of IMP to stimulant misuse.
Individuals high in IMP are most prone to PD misuse
resulting from an adverse environment triggering a heritable
tendency toward psychological dysregulation (58). ADHD is
an externalizing disorder characterized by high IMP (59).
Individuals with ADHD (60) or high IMP levels (24) are more
likely to misuse stimulants. While only 4% of 10–18-year-olds
endorse past-month stimulant misuse (61), 14% of 4–17-year-
olds with ADHD endorse past-2-week stimulant misuse (62).
IMP’s effect on stimulant misuse may be attributable, at least
in part, to an inability to inhibit pre-potent responses (63).
ADHD symptoms are associated with stimulant misuse even
after controlling for prescribed use (64). The psychological
dysregulation model suggests that symptoms of ADHD mediate
IMP’s specific effect on stimulant misuse.
Objectives
Nargiso et al. (20) reviewed 50 articles on adolescent PD misuse
and identified the following limitations. First, most studies
were cross-sectional. Second, non-demographic risk factors (e.g.,
personality, mental health symptoms) were understudied. Third,
there was a lack of specificity regarding predictors of misuse
across PD classes. The present study sought to address these
limitations by examining predictors of different forms of PD
misuse (i.e., opioid, sedative/tranquilizer, stimulant) in a large
sample of Canadian adolescents, tested prospectively in Grades
9 and 10 through a “semi-longitudinal design.” In this design,
one part is longitudinal (i.e., tests of personality to mental health
symptoms and personality to PD misuse) and the other part
is cross-sectional (i.e., tests of mental health symptoms to PD
misuse). We used a broad definition of PD misuse in the present
study, involving use of a PD in any way not directed by a
physician (1).
See Table 1 for a summary of our hypotheses. Based on
the theories described above, we hypothesized that: in keeping
with the negative affect regulation model, (H1) Grade 9 HOP
would specifically predict Grade 10 opioid misuse via Grade 10
depressive symptoms, and (H2) Grade 9 AS would specifically
predict Grade 10 sedative/tranquilizer misuse via Grade 10
anxiety symptoms; in keeping with the positive affect regulation
model, (H3)Grade 9 SS would directly predict Grad 10 stimulant
misuse; in keeping with the deviance proneness model, (H4)
Grade 9 IMP would predict Grade 10 opioid misuse, sedative
tranquilizer misuse, and stimulant use, all via Grade 10CD
symptoms; and in keeping with the psychological dysregulation
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model, (H5) Grade 9 IMP would also predict Grade 10 stimulant
misuse via Grade 10 ADHD symptoms.
METHODS
The present study’s data was archival. It was collected as
part of the Co-Venture Trial (65) examining the longer-term
efficacy of personality-targeted substance misuse prevention.
Assenting students from 31 high schools (public and private;
English and French) in Montreal, Canada participated. Data was
collected annually (during the fall and spring terms) beginning
in September 2012. A web-based platform (Delosis Ltd., London,
U.K.) was used to survey students during regular class times.
At baseline, students were in Grade 7. The present study
used data collected prospectively in Grade 9 (September 2014-
May 2015) and Grade 10 (September 2015-May 2016). Risk
increases as adolescents transition from middle to high school
(66). In Canada, high school normally runs from Grades 9-
12 (67). We therefore excluded Grade 7-8 (i.e., middle school)
data. Ethical approval was granted by Sainte-Justine Hospital’s
Research Ethics Board (approval number= 2012-396, 3427) and
by each administrative school board.
Participants
Sample sizes were n = 3,024 in Grade 9 and n = 2,869 of




The 23-item Substance Use Risk Profile Scale (SURPS; 30) was
used to assess personality as part of the Co-Venture Trial.
The SURPS has four subscales: HOP (7 items; “I feel that
I’m a failure”), AS (5 items; “It is frightening to feel dizzy or
faint”), SS (6 items; “I like doing things that frighten me a
little”), and IMP (5 items; “I usually act without stopping to
think”). Participants responded using a 5-point Likert scale (1
strongly disagree to 5 strongly agree). Following reverse scoring
of certain negatively keyed items, subscale scores were generated
by summing component items. The SURPS was chosen for use
in the large-scale Co-Venture survey given its brevity and its
strong psychometric properties in both English (43) and French
(73). These include acceptable to good internal consistency,
factorial validity, convergent and discriminant validity (e.g., with
similar personality measures), and concurrent, predictive, and
incremental validity in relation to substance use and substance-
related problems in youth [e.g., (31, 43, 74)]. In the present
sample, the subscales were internally consistent (see Table 2).
Internalizing Symptoms
The 18-item Brief Symptom Inventory-18 [BSI-18; (70)] was used
to assess depression and anxiety symptoms. It measures past-
week psychological distress. In this study, only the Depression
(6 items; “feeling blue”) and Anxiety (6 items; “nervousness or
shakiness inside”) subscales were used. Participants responded
using a 5-point Likert Scale (0 not at all to 4 extremely often).
Subscale scores were generated by summing component items.
The BSI-18 has strong psychometric properties in both English
(75) and French (76). In our sample, the subscales were internally
consistent (see Table 2).
Externalizing Symptoms
The 25-item Youth Self-Report Strengths and Difficulties
Questionnaire (SDQ; 73) was used to assess ADHD and CD
symptoms. It measures symptoms over the past 6-months. In
this study, only the Hyperactivity/Inattention (5 items; “restless,
cannot sit still for long”) and Conduct Problems (5 items;
“often accused of lying or cheating”) subscales were used
(77). The remaining subscales were excluded as they pertain
instead to prosocial (Prosocial Behavior) and internalizing
(Emotional Symptoms, Peer Relationship Problems) behaviors
(77). Participants responded using a 3-point Likert Scale (0 not
true to 2 certainly true). Following reverse scoring of certain
items, subscale scores were generated by summing component
items. The SDQ has strong psychometric properties in both
English (78) and French (79). In our sample, the subscales were
internally consistent (see Table 2).
Prescription Drug Misuse
Amodified and validated version of the Detection of Alcohol and
Drug Problems in Adolescents (DEP-ADO; 77) assessed lifetime
PD misuse for: (1) Opioids: e.g., “Codeine, Demerol, Morphine,
Percodan, Methadone, Darvon, Opium, Dilaudid, or Talwin”;
(2) sedatives: e.g., “barbiturates, sedatives, downers, or sleeping
pills like Seconal and Quaaludes”; (3) tranquilizers: e.g., “Valium,
Librium, or Ativan”; and (4) stimulants: e.g., “stimulants, speed,
methamphetamine, amphetamine, or Benzedrine.” Participants
responded using a 6-point frequency scale (0 never to 5
every day). To deal with zero-inflation, items were scored
dichotomously (i.e., 1 = had used that PD class, 0 = had
not). In keeping with our previous research (45), sedatives
and tranquilizers were collapsed into a single category. The
DEP-ADO has strong psychometrics and is available in both
English (69) and French (80). It was developed for and validated
with adolescents aged 14-17 years (i.e., Grades 9–11). It has
a strong test-retest reliability (r =0.94), acceptable to good
internal consistency (Cronbach’s alpha=0.61–0.86), and content,
convergent, and criterion-related validity (sensitivity =0.84;
specificity=0.91) (69).
Alcohol Misuse
Alcohol misuse was also assessed using the modified DEP-ADO
(69). This scale includes 10 yes/no items that pertain to lifetime
issues with: physical health, psychological health, familial
relationships, intimate relationships, academics, finances,
delinquency, risky behavior, alcohol tolerance, and treatment
seeking, attributable to one’s alcohol use. This sole focus on
alcohol was a change from the original DEP-ADO which asked
these items for alcohol and other drugs combined (69). Items
were summed to create a 0–10 total score. Only those indicating
a frequency of drinking greater than or equal to “weekends or
once or twice during the week” on a previous DEP-ADO item
were asked these alcohol misuse items; the others were skipped
over these items and automatically assigned an alcohol misuse
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TABLE 2 | Frequencies and descriptive statistics.
Grade 9 Grade 10
n % M (SD) α N % M (SD) α
Age 3,024 14.79 (0.47) 2,869 15.83 (0.42)
Gender
Male 1,463 50.7 1,374 50.1
Female 1.425 49.3 1,371 49.9
Ethnicity
Canadian or American 2,535 87.8 2,413 87.9
European 64 2.2 63 2.3
African 57 2.0 46 1.7
Caribbean 28 1.0 26 0.9
East Asian 81 2.8 82 3.0
South Asian 17 0.6 17 0.6
Middle Eastern 21 0.7 21 0.8
South or Central American 44 1.5 39 1.4
Other 27 0.9 23 0.8
Don’t know 14 0.5 15 0.5
Socioeconomic status 5.36 (1.69) 5.37 (1.66)
Alcohol misuse 0.09 (0.59) 0.79 0.17 (0.79) 0.81
Hopelessness 12.51 (3.92) 0.89 12.73 (3.83) 0.89
Anxiety sensitivity 11.09 (2.95) 0.70 11.02 (2.97) 0.73
Sensation seeking 16.14 (3.63) 0.70 16.37 (3.70) 0.71
Impulsivity 11.66 (2.91) 0.75 11.55 (2.87) 0.75
Depression 5.32 (5.98) 0.90 5.45 (5.93) 0.90
Anxiety 2.81 (4.03) 0.90 2.82 (3.99) 0.89
ADHD 4.12 (2.40) 0.72 4.12 (2.38) 0.74
CD 2.18 (1.64) 0.62 2.09 (1.61) 0.64
Opioids 54 1.8 88 3.1
Sedatives/tranquilizers 95 3.1 100 3.5
Stimulants 50 1.7 63 2.2
Socioeconomic Status was rated using a 10-point Likert scale (68) with higher scores representing greater wealth. Alcohol Misuse was assessed using the DEP-ADO (69); internal
consistency values for the DEP-ADO alcohol misuse scale was calculated only among the more frequent drinkers as others were skipped over these items and assigned a score of zero.
Personality was assessed using the SURPS (31). Depression and Anxiety were assessed using the BSI-18 (70). ADHD, Attention-Deficit Hyperactivity Disorder; CD, Conduct Disorder.
Both were assessed using the SDQ (71). PD misuse was assessed using the DEP-ADO (69) and scored dichotomously. For short scales with 10 items or less, an alpha of ≥ 0.60 is
considered acceptable (72).
score of 0. In the present sample, the alcohol misuse scale was
internally consistent (see Table 2).
Statistical Analyses
Sample descriptive statistics were first calculated in SPSS 20.0. T-
tests and chi square tests were used to compare baseline (Grade
9) characteristics of those retained (n = 2,869) vs. lost to follow-
up (n = 155) in Grade 10. Correlations were specified between
the personality, mental health, and PD misuse variables. The
hypothesized model was then run in MPlus 7.11 (81). Because
our dependent variables were categorical, a robust weighted
least squares approach was used [ESTIMATOR = WLSMV;
(82)]. Missing data was handled using pairwise deletion such
that only those with data at both timepoints were used in
hypothesis testing. We controlled for school and for Grade 9
mental health and PD misuse. Our model therefore accounts
for new users. We also controlled for age, sex, ethnicity, and
socioeconomic status (68), given their known effects on PD
misuse (20, 83). Because high-intensity drinking is associated
with PDmisuse (84), we controlled for alcohol misuse as assessed
on the DEP-ADO. These covariates were regressed onto all the
outcome variables.
Standard indices were used to assess model fit. RMSEA ≤
0.05 and CFI/TLI ≥0.95 indicate good fit. RSMEA ≤ 0.08 and
CFI/TLI≥0.90 indicate adequate fit (85). Since chi-square values
are often significant when the sample size is large (86), we did
not interpret the chi-square as a fit statistic. Instead, we used the
χ
2/df ratio where a value < 3.0 indicates good fit. Significant
effects were detected at a 95% confidence interval. Bootstrapped
confidence intervals were used to determine the significance of
indirect effects (i.e., significant if the confidence intervals did not
cross zero).
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RESULTS
Sociodemographic Features
On average, students were 14.8 (SD = 0.5) years of age in Grade
9. There was a relatively equal split of the sample across gender at
both waves. Most students were middle class and of Canadian or
American descent (see Table 2).
Personality
Sample mean scores on the four subscales of the SURPS
were relatively consistent with norms on the measure from a
previously tested sample of adolescents (31). Scores remained
relatively stable from Grade 9 to Grade 10 (see Table 2).
Mental Health
Sample mean scores on the BSI-18 measure of internalizing
mental health symptoms indicated that levels of anxiety and
depression symptoms were both relatively low, on average, in
our non-clinical sample at baseline (Grade 9), with depression
symptom scores somewhat higher than anxiety symptom scores
overall. Sample mean scores on the SDQmeasure of externalizing
mental health symptoms similarly indicated that levels of ADHD
and CD symptoms were both relatively low, on average, in
our non-clinical sample at baseline (Grade 9), with ADHD
symptom scores somewhat higher than CD symptoms scores
overall. Scores remained relatively stable on all four measures of
mental health symptoms from Grade 9 to Grade 10 (see Table 2).
Substance Misuse
In Grade 10, lifetime PD misuse rates were: 3% for opioids, 4%
for sedatives/tranquilizers, and 2% for stimulants (see Table 2).
Rates of misuse of each type of PD rose between Grade 9 and
Grade 10 with the sharpest increase observed for opioid misuse.
Levels of alcohol misuse also rose between Grade 9 and Grade 10
(see Table 2).
Comparison of Students Retained vs. Lost
to Follow-Up
T-tests and chi-square tests suggested that, at baseline (Grade
9), those who were later lost to follow-up (Grade 10) were
older, more likely to attend certain schools, and endorsed
more personality vulnerability (HOP, SS, IMP), mental health
symptoms (depression, CD, ADHD), alcohol misuse, and
PD misuse.
Correlations
Bivariate correlations between study variables are displayed in
Table 3. With respect to correlations between Grade 9 personality
and Grade 10 mental health symptoms, HOP was most strongly
associated with depressive symptoms, AS was most strongly
associated with anxiety symptoms, and IMP and SS were most
strongly associated with ADHD and CD symptoms (with IMP
showing much stronger associations than SS in this regard).
With respect to correlations between Grade 10 mental health
symptoms and Grade 10 PD misuse, the strongest correlations
were between CD symptoms with all three forms of PD misuse,
anxiety and depressive symptoms with sedative/tranquilizer
misuse, and ADHD symptoms with stimulant misuse. Grade
9 alcohol misuse was significantly associated with all Grade 9
personality factors save AS, with all four measures of Grade 10
mental health symptoms, and with all three forms of PD misuse
in Grade 10, underlining the importance of alcohol misuse as
a covariate.
Hypothesis Tests
Our hypothesized model (see Figure 1) showed good fit across
fit indices: χ2(71) = 158.07, p < 0.001; χ2/df = 2.23; RMSEA
=0.02, 90% CI [0.02, 0.03]; CFI=0.98; TLI=0.96. Indirect effects
are reported in Table 4.
Grade 9 HOP significantly predicted Grade 10 depressive
symptoms which in turn were significantly associated with
Grade 10 opioid misuse. Consistent with H1, the indirect
effect was statistically significant (p < 0.05). Grade 9 AS
significantly predicted Grade 10 anxiety symptoms which in turn
were significantly associated with Grade 10 sedative/tranquilizer
misuse. Consistent with H2, the indirect effect was statistically
significant (p < 0.01).
Consistent with H3, the direct path from Grade 9 SS to
Grade 10 stimulant misuse was statistically significant. Grade
9 IMP significantly predicted Grade 10CD symptoms which
in turn were significantly associated with Grade 10 opioid
and sedative/tranquilizer misuse and marginally associated with
Grade 10 stimulant misuse (p = 0.06). Consistent with H4, all
three indirect effects were statistically significant (p < 0.05 for
opioid and stimulant misuse; p < 0.01 for sedative/tranquilizer
misuse). Grade 9 IMP also significantly predicted Grade 10
ADHD symptoms which were in turn associated with Grade 10
stimulant misuse. Consistent with H5, the indirect effect was
statistically significant (p < 0.05).
Tests of Pathway Specificity
To determine the specificity of the HOP to opioid misuse
pathway via depression symptoms [H1] and the AS to
sedative/tranquilizermisuse pathway via anxiety symptoms [H2],
we examinedmodification indices (MIs). These indicated that the
inclusion of paths from AS to depression (MI: 0.23) and HOP
to anxiety (MI: 2.47) did not improve model fit (values > 3.84
indicate that the model would be improved). Thus, for the sake
of model parsimony, these were not added to the model.
DISCUSSION
Main Findings
In the present study, we sought to address the limitations of the
extant literature on adolescent PDmisuse, as outlined by Nargiso
et al. (20). We applied the four-factor personality vulnerability
model (25) to understanding risk for misuse of specific classes
of PDs in adolescents. Moreover, we applied different theoretical
models of addiction (39) to understanding specific pathways
from personality to adolescents’ future PD misuse, as mediated
through specific sets of mental health symptoms.
Different personality traits showed effects on specific
types of PD misuse through unique sets of mental health
symptoms, consistent with different theoretical models of
addiction, namely the negative and positive affective regulation,
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TABLE 3 | Correlation matrix.
1 2 3 4 5 6 7 8 9 10 11 12
Grade 9
1. Hopelessness 1.00 0.27 −0.03 0.32 0.11 0.46 0.35 0.33 0.22 0.07 0.11 0.09
2. Anxiety sensitivity 1.00 –0.12 0.19 0.02 0.23 0.33 0.14 0.05 −0.03 −0.01 −0.01
3. Sensation seeking 1.00 0.25 0.14 −0.01 −0.02 0.12 0.16 0.13 0.11 0.11
4. Impulsivity 1.00 0.11 0.22 0.18 0.45 0.41 0.11 0.11 0.12
5. Alcohol harms 1.00 0.08 0.06 0.08 0.13 0.12 0.17 0.20
Grade 10
6. Depression 1.00 0.73 0.29 0.24 0.07 0.16 0.10
7. Anxiety 1.00 0.29 0.20 0.06 0.11 0.07
8. ADHD 1.00 0.40 0.09 0.09 0.10
9. CD 1.00 0.14 0.14 0.14
10. Opioids 1.00 0.21 0.30
11. Sedatives/tranquilizers 1.00 0.17
12. Stimulants 1.00
ADHD is attention-deficit hyperactivity disorder; CD is conduct disorder. Bold correlations are significant at p < 0.05.
FIGURE 1 | Model results. H1-H5 represent numbered hypotheses. Solid arrows represent statistically significant hypothesized pathways; dotted arrows represent
hypothesized but non-significant pathways. Numbers represent standardized coefficients. *p < 0.05, **p < 0.01, ***p < 0.001.
†
represents marginal significance at
p = 0.06.
deviance proneness, and psychological dysregulation models.
Two internalizing personality traits (HOP and AS) followed
a negative affect regulation model for predicting specific PD
misuse, while SS (an externalizing trait) followed a positive
affect regulation model. First, depressive symptoms mediated
the relationship between HOP and future opiate misuse.
Second, anxiety symptoms mediated the relationship between
AS and future tranquilizer misuse. While both these paths are
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TABLE 4 | Tests of hypothesized indirect effects.
Hypothesis Predictor Mediator Outcome Indirect effect 95% confidence interval
H1 Hopelessness Depression Opioids 0.003 [0.000, 0.007]*
H2 Anxiety sensitivity Anxiety Sedatives/tranquilizers 0.005 [0.002, 0.012]**
H4 Impulsivity CD Opioids 0.005 [0.001, 0.010]*
Impulsivity CD Sedatives/tranquilizers 0.008 [0.004, 0.014]**
Impulsivity CD Stimulants 0.005 [0.000, 0.014]*
H5 Impulsivity ADHD Stimulants 0.005 [0.000, 0.012]*
ADHD is attention-deficit hyperactivity disorder; CD is conduct disorder. *p < 0.05, **p < 0.01.
consistent with negative affect regulation, they suggest that
high HOP adolescents may be using opiates to self-medicate
their depressive symptoms—while high AS teens may be using
tranquilizers to self-medicate their anxiety symptoms. Third,
SS was predictive of future stimulant misuse suggesting high SS
adolescents may be using stimulants to enhance positive affect.
This suggests that adolescents high in HOP and AS are prone to
PD misuse via negative affect regulation pathways while those
high in SS are prone to PD misuse via a positive affect regulation
pathway. Fourth, CD symptoms mediated the relationship
between IMP and future opiate, sedative/tranquilizer, and
stimulant misuse, consistent with a deviance proneness pathway.
Unlike the other three traits, IMP therefore seems to be a more
general predictor of PD misuse, rather than a specific predictor
of a particular form of PD misuse. Higher IMP adolescents
appear to more prone to misusing PDs indiscriminately—in
the same way that they are prone to engaging in broadband
antisocial behaviors. Finally, ADHD symptoms also mediated
IMP’s effect in the case of future stimulant misuse. We have
suggested that this unique personality-to-PD misuse pathway
may represent self-medication of psychological dysregulation.
In the next section, we look at each of these main findings in
relation to the extant literature.
Comparison With the Literature
H1 predicted that HOP would specifically predict future opioid
misuse via depressive symptoms. This hypothesis, informed by
the negative affect regulation model, was supported through a
significant indirect effect from Grade 9 HOP to Grade 10 opioid
misuse 1 year later as mediated through Grade 10 depressive
symptoms. Depression has been identified as the mental health
issue most strongly related to opioid misuse (odds ratios from
1.2 to 4.3) (87). Zullig and Divin (88) found that students who
endorsed HOP, depression, and suicidality were 1.18–1.43 times
more likely to misuse opioids. Opioids possess psychic pain-
numbing properties (89), which may make them particularly
attractive to highHOP adolescents—who are prone to depression
and may be looking to dull their psychological pain. Our
mediational findings are consistent with a mechanism where
HOP confers risk for opioid misuse in adolescence via negative
affect regulation. More specifically, high HOP adolescents may be
self-medicating their depressive symptoms by misusing opioids.
Given that opioids are prescribed for the management of physical
pain (89) but not for the management of depression (90), any use
of opioids for depression self-medication would be considered
opioid misuse since it would involve taking the medication for
a non-prescribed purpose (91). To help establish the specificity
of this HOP risk pathway to opioid use, we tested an additional
personality to PDmisuse pathway informed by the negative affect
regulation model involving AS (i.e., H2).
H2 predicted that AS would specifically predict future
sedative/tranquilizer misuse via anxiety symptoms. This
hypothesis, also informed by the negative affect regulation
model, was supported through a significant indirect effect
from Grade 9 AS to Grade 10 sedative/tranquilizer misuse 1
year later as mediated through Grade 10 anxiety symptoms.
While sedatives/tranquilizers are commonly prescribed for
anxiety (92), the relevant DEP-ADO items (69) specify use
“without a prescription,” suggesting that high AS adolescents
may be taking non-prescribed sedatives/tranquilizers that
they have obtained from family, friends, dealers, or online
pharmacies (15) to self-medicate their anxiety symptoms.
Taken together, support for H1-2 suggests that there are two
distinct negative affect regulation paths from personality to PD
misuse. The first is specific to opioid misuse through HOP and
the self-medication of depression, and the second specific to
sedative/tranquilizer misuse through AS and the self-medication
of anxiety. Furthermore, modification indices indicated that the
inclusion of paths from AS-to-depression and HOP-to-anxiety
did not improve model fit, providing further evidence of the
specificity of these pathways.
Informed by the positive affect regulationmodel,H3 predicted
that SS would lead to future stimulant misuse. This hypothesis
was supported through a direct path from Grade 9 SS to
Grade 10 stimulant misuse. SS is strongly related to sensitivity
to positive reinforcement and enhancement motives (31). It
predicts substance misuse (93) that is driven by a need for
positive affect and psycho-stimulation (29). Previously, we found
that SS predicted undergraduate stimulant misuse (45). Other
studies also support a robust association between SS and
adolescent alcohol misuse (74). Finn et al. (94) found that SS
was both directly linked to alcohol problems as well as indirectly
linked through alcohol use and positive alcohol expectancies.
Castellanos-Ryan et al. (95) concluded that SS’s effect on binge
drinking was mediated by a reward response bias. Thus, SS
likely confers risk for adolescent stimulant misuse as well as
excessive drinking via a positive affect regulation pathway. Taken
together, the support for H1-H3 suggests that three distinct
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affect regulation paths predict PD misuse in adolescence: two
involving negative affect regulation (i.e., HOP to depression
to opioid misuse and AS to anxiety to sedative/tranquilizer
misuse) and one involving positive affect regulation (i.e., SS to
stimulant misuse).
Unlike the specific associations of each of HOP, AS and SS
with particular forms of PD misuse, we expected IMP to have
a more general association with PD misuse, including future
opioid, sedative/tranquilizer, and stimulant misuse.H4 predicted
that Grade 9 IMP would be associated with all three forms
of PD misuse in Grade 10 via Grade 10CD symptoms. These
hypotheses, informed by the deviance proneness model, and
IMP’s centrality as a characteristic of CD (59, 96), were all
supported in tests of indirect effects. This pattern is in keeping
with previous research with other substances. Mackie et al. (93),
for instance, found that IMP predicted adolescent alcohol use
via CD symptoms. This result also replicates and extends prior
research linking CD symptoms to unconstrained PD misuse in
adolescents, including misuse of opioids (97) and stimulants
(64). IMP’s relationship with substance misuse is motivationally
undefined (31) in that it is more reflective of a general inability
to inhibit behavior (98). IMP is associated with deficits in
response execution and inhibition (95). Poor response inhibition
is a risk factor for both CD (99) and substance misuse (100).
Paths from IMP to both CD and alcohol problems are also
partially mediated by deficient response inhibition (94, 95). In
sum, we know that high IMP adolescents struggle to regulate
and inhibit their impulses. This makes them more vulnerable
to deviance (including CD and PD misuse). Our results are
consistent with the idea that IMP confers risk for broadband
PD misuse (including all three types of PD misuse) via a general
proneness toward deviance in adolescence.
In addition to these general IMP to CD symptoms to PD
misuse pathways, H5 predicted a second indirect pathway
specifically linking IMP to later stimulant misuse via ADHD
symptoms. This hypothesis, informed by the psychological
dysregulation model, was supported by a significant indirect
effect from Grade 9 IMP to Grade 10 stimulant misuse via
Grade 10 ADHD symptoms. IMP is a prominent symptom
of ADHD (101) for which stimulants are prescribed (102).
Previously, we showed that IMP was concurrently associated
with both medically sanctioned stimulant use and stimulant
misuse in university students (45). Prescription stimulants are
classified as Schedule III under the Canadian Controlled Drugs
and Substances Act (S.C. 1996, C. 19) due to their high potential
for misuse (103). Their use is legal only when prescribed by
a licensed practitioner and taken by the person for whom
they were prescribed. For those high in IMP, availability is the
best motivational predictor of misuse (34). Adolescents who
report symptoms of ADHD are more likely to have stimulant
prescriptions, which they can then misuse [e.g., by taking their
stimulants in greater amounts or more often than prescribed,
via non-intended routes, for non-prescribed reasons, and/or
with contraindicated substances; (91)]. While rates of stimulant
misuse are relatively low in general adolescent samples, rates
are much higher among adolescents who: have symptoms of
ADHD, have ADHD diagnoses, are receiving treatment for
ADHD, or have stimulant prescriptions (104). Interestingly,
some research suggests that the young people most likely to
misuse prescription stimulants are those with markers of a
possible mental health disorder (e.g., ADHD) but without a
formal diagnosis or prescription (105). Our results suggest
that some young people may misuse stimulants to cope with
their ADHD-related disorganization, poor time management,
forgetfulness, and distractibility (64). Thus, in adolescence, IMP
may confer risk for stimulant misuse, in part, via self-medication
of psychological dysregulation—a form of self-medication that is
theoretically distinct from the self-medication of negative affect
pathways described above for AS and HOP.
Strengths and Limitations
Our study has several important strengths. These include the
large sample size, inclusion of both French- and English-speaking
students, the longitudinal component (personality to mental
health symptoms and personality to PD misuse paths) over a 1-
year follow-up across the developmentally challenging transition
to high school, the excellent retention rate (95%), the control
of baseline levels of mediators and outcomes in all models, and
the theoretically driven hypotheses. Moreover, the topic of the
paper is likely to be of interest to both a general and specialty
audience of mental health professionals, particularly those that
work with youth.
These findings should be interpreted in the context of several
potential study limitations. First, we measured personality in
Grade 9—and mental health symptoms and PD misuse in Grade
10. As such, the final pathways in our semi-longitudinal model
(from mental health symptoms to PD misuse) were cross-
sectional. Methodologically, we set up our semi-longitudinal
model in this manner because H1-H3 pertain to self-medication.
We considered assessing PD misuse in Grade 11, in a three-
wave design, but this would have meant testing whether students
misused PDs to cope with the mental health symptoms they had
reported a year earlier. We wanted to measure mental health
symptoms and PD misuse in closer proximity. Self-medication
models posit that the mental health-to-PD misuse relationship
is unidirectional (50). There are data, however, that suggest
that it may be bidirectional. PD misuse, for example, has been
shown to exacerbate students’ mental health symptoms (106).
Our data do not allow us to compare these possibilities and
our model does not allow for causal inference. Nonetheless,
mediation analyses with even partially cross-sectional data can
be a useful starting point (107) and our model had the advantage
of being semi-longitudinal (i.e., where part of the design was
longitudinal—specifically personality to mental health symptoms
and personality to PD misuse). To demonstrate reliability
and address these limitations, however, our model should be
replicated in a fully longitudinal design that uses shorter (e.g.,
6 month) lags between waves. Future research could also use
ecological momentary assessment to examine these relationships
day-to-day [e.g., (108)].
A second potential limitation pertains to our measure of PD
misuse. The DEP-ADO was chosen because it is standardized,
has been demonstrated reliable and valid in the measurement
of Canadian high school students’ substance use (69), and
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can be use with both English- and French-speaking Québécois
adolescents (73). Despite these strengths, the DEP-ADO has
some shortcomings. For example, we assessed each type of PD
misuse with a single item, introducing measurement error. It also
provides little information about students’ means of access (e.g.,
diversion sources, online pharmacies), administration routes, or
motives for use. Moreover, different definitions of PD misuse
abound (109), and it has been suggested that none of the
instruments published to date can adequately assess PD misuse
(110). When improved PD misuse measurement tools become
available, our model should be replicated. This would reduce
measurement error, allowing for a more accurate and refined test
of personality’s effects on PD misuse generally and on specific
classes of PD misuse specifically.
Third, our sampling was limited. While our study was
bolstered by its large sample size, this increases the likelihood
that small effects will be statistically significant. And some
of our effects were relatively small in magnitude, calling for
evaluation of their clinical significance (see below). In addition,
the students who did not complete our Grade 10 measures were
more likely to report Grade 9 personality vulnerability, mental
health symptoms, and alcohol and PD misuse, and were more
likely to come from specific schools. Some of these results are
in keeping with previous studies, in which adolescents lost to
follow up were more likely to be involved in drug use and other
deviant behavior (111–113). Moreover, we controlled effects of
school in our analyses. It still bears noting, however, as samples
and findings can be biased when the individuals who drop out
differ substantially from those who are retained (114).
Finally, while the use of our brief personalitymeasure [SURPS;
(31)] allowed for brevity in the context of a large-scale survey,
it did not allow for nuanced assessment of the components of
each of our traits. For example, the longer Childhood Anxiety
Sensitivity Index (115) would have allowed for examination of
the relative contributions of the AS Physical, Social/Control, and
Psychological concerns dimensions (116) to the anxiety symptom
mediated pathway to sedative/tranquilizer misuse observed in
the present study. Similarly, the longer Barratt Impulsiveness
Scale (117) would have allowed for examination of the relative
contributions of the Attentional, Motor, and Non-planning
Impulsiveness components (118) to the CD andADHD symptom
mediated pathways to PD misuse observed in the present study.
Future Research Directions
The present study focused on the mediating effects of mental
health symptoms. Motives for PD misuse were not assessed.
Bennett and Holloway (119) have concluded that opioids,
sedatives/tranquilizers, and stimulants tend to be misused in one
of twoways. PDs aremisused for self-medication ofmental health
(e.g., more sleep, less anxiety) or physical health (e.g., to manage a
pre-existing illness) problems. They are also misused for pleasure
(e.g., to party, get high, or experiment). Boyd et al. (22) and
McCabe et al. (46) have published measures of motives for PD
misuse. Negatively and positively reinforcing motives are both
associated with increased PD misuse frequency (120). Follow-up
studies might test whether personality predicts specific motives
for PD misuse just as personality predicts specific motives for
alcohol use (121). Previously, in the alcohol field, we found
chained mediation from personality to mental health symptoms,
to drinking motives, to alcohol outcomes (122). The results of the
present study suggest that a four-variable chained mediational
model might be equally applicable to PD misuse. For example,
HOPmay predict opioid misuse via symptoms of depression and
in turn self-medication motives.
There are also several other areas of future research that
are worthy of investigation in the field of personality and PD
misuse risk more broadly. First, given that online marketplaces
are an accessible source of PDs for young people [e.g.,
largely uncontrolled, not requiring a prescription, allowing for
anonymous access; (123, 124)], and thus a significant public
health concern, we need more information on the types of
adolescents who are accessing PDs via these sites. While the
demographic characteristics of the typical customers of such
online marketplaces have been identified [i.e., young, male,
Caucasian; (125)], we have not yet identified their personality
or mental health characteristics, which would be helpful for
targeting prevention efforts. Second, given the well-established
role of social influence in young people’s drug misuse [e.g.,
(126)] and emerging data concerning online drug forums
and social networking sites where those experimenting with
psychotropics, including PDs, share drug-related information
(9), it would be interesting to study whether involvement in
such communities might be related to personality. For example,
are these experimenters or “psychonauts” higher in sensation
seeking? Finally, personality and mental health factors may be
relevant when it comes to pre-marketing assessment trials of the
abuse liability of new prescription drugs. Current practices in this
regard have been criticized for excluding those with a previous
history of drug misuse or addiction [e.g., (8)]. Given the present
findings of significant links of four factor personality model
traits and mental health symptoms to different forms of PD
misuse, there could be utility to testing a new compound’s abuse
potential using these more substance-misuse prone individuals
in pre-marketing assessment trials to get at the compound’s truer
abuse liability.
Clinical Implications
Our model suggests that treatment of opioid misuse in
adolescents might benefit from a specific targeting of HOP
and IMP youth. Cognitive-behavioral therapy (CBT) could
benefit teens high in HOP, by teaching them to better
cope with their symptoms of depression (127). Motivational
approaches could benefit antisocial teens high in IMP, by
increasing their future-oriented thinking and teaching them
to weigh the short vs. long term consequences of their
behavior (128). Because we substantiated paths from IMP to
CD symptoms, to opioid, sedative/tranquilizer, and stimulant
misuse—a focus on this personality factor would theoretically
reduce misuse of a variety of types of PDs. The results
of our specificity tests further suggest that treatments of
sedative/tranquilizer misuse be targeted toward youth high
in AS and include techniques drawn from CBT for anxiety
(128). To treat stimulant misuse, our model suggests we should
be targeting adolescents high in externalizing traits. Those
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high in SS could be encouraged to pursue other stimulating
yet prosocial activities (129). “Alternate rebellions” including
hair dyeing, getting a tattoo, or getting a piercing (130) are
safer activities that might meet these adolescents’ need for
excitement. In contrast, psychologically dysregulated, high-
IMP teens could be trained in behavioral ADHD-management
techniques (131).
Treating PD misuse is, of course, important. But, given the
ongoing PD crisis in North America (132), preventing it is
critical. Adolescent overdoses from prescription opioids rose
95% from 1999 to 2016 (133). The likelihood of reporting
PD misuse during adolescence, increases with age (83), as we
saw across each PD type from Grade 9 to 10 in our sample.
Research has shown that PD misuse rates rise consistently
between Grade 8–12 and ages 12–17 (134). Thus, prevention
efforts geared toward at-risk youth are especially vital. Our
results suggest that identifying high personality-risk adolescents
(i.e., those high in HOP, AS, SS, or IMP) would benefit
both early intervention and targeted prevention strategies for
PD misuse.
Personality-matched interventions have effectively reduced
illicit drug use in adolescence (135) and PD misuse in
adulthood (136). The present study was embedded within a
larger trial, which evaluated the longer-term efficacy of the
Preventure Program (65). This personality-matched prevention
program targets teens with elevated four-factor trait scores
(25). It is rooted in the cognitive-behavioral model and
incorporates psycho-educational and motivational interviewing
components. When applied to alcohol and illicit drug use,
the Preventure Program has resulted in delayed onset and
reduced escalation of misuse (65). Our study suggests that
personality is related to PD misuse in a similar manner to
its relations with alcohol and illicit drug use, through mental
health symptoms. Thus, personality-matched interventions may
have the potential to reduce PD misuse and even prevent
PD uptake, if administered prior to PD misuse onset. Our
results suggest that the Preventure Program should next be
investigated in relation to its utility in targeting adolescent
PD misuse.
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Background: Non-medical use (NMU) of prescription GABA analogs (pregabalin and
gabapentin) has been reported especially in opiate dependent persons. However, by
now the prevalence of NMU of gabapentinoids in the general population has not been
sufficiently evaluated. The aim of this research paper is to determine the prevalence of
prescription GABA analog NMU and associated demographics in five European countries
with special detail of Spain.
Methods: The RADARS Survey of Non-Medical Use of Prescription Drugs Program
(NMURx) is a harmonized series of contemporaneous cross-sectional surveys of adults
conducted in multiple countries. NMURx collects data from the general population in
each participating country about NMU of prescription drugs, illicit drugs, and associated
demographics. NMU was defined as “using a medication without a doctor’s prescription
or for any reason other than what was recommended by their doctor.” Responses from
Spain (4Q2017, n=10,062) were analyzed in detail. Comparative data were available
from France, Germany, Italy, and UK. Responses were collected using non-probability
quota sampling and post-stratification population weighting was applied to reflect the
national distributions of adults, based on age, gender, and census region. Rates of NMU
and associated demographics were reported as rate of past 90-day NMU per 100,000
adult population with 95% confidence intervals.
Results: Germany (1,197 per 100,000 adult population [95% CI: 1,004.3–1,379.1])
and United Kingdom (1,067 per 100,000 adult population [95% CI: 851.3–1,283.2])
presented the highest prevalence of gabapentinoids NMU. In Spain the prevalence
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of past 90 days GABA analog NMU was: 344.4, 95% (CI 204.8–484.0), with male
predominance. Those who non-medically use GABA analogs had a higher prevalence
of lifetime chronic pain, lifetime illicit drug use, and previous substance abuse treatment.
In Spain, 20% of respondents who ever have used gabapentinoids, reported a lifetime
NMU; the prevalence was higher for pregabalin 624 (6.2%) than for gabapentin 444
(4.4%). The main reasons for use were to self-treat pain and other medical conditions.
Conclusions: The risk of NMU of gabapentinoids should not be neglected. Subjects
with a history of chronic pain and lifetime substance use disorders had an increased risk
of NMU of gabapentinoids.
Keywords: gabapentin, pregabalin, non-medical use, prescription drugs, misuse
INTRODUCTION
Gabapentinoids, pregabalin and gabapentin, are widely
used for the treatment of neuropathic pain and epileptic
disorders according to the United States (US) Food and Drug
Administration (FDA). Both gabapentin and pregabalin have
been approved by the European Medicine Agency (EMA) for
neuropathic pain and generalized anxiety disorder, respectively.
Additionally, some off-label uses of gabapentinoids include
treatment for chronic lower back pain, insomnia, migraine,
social phobia, panic disorder, mania, bipolar disorder, and
alcohol withdrawal (1, 2).
Gabapentinoids are now among the most commonly
prescribed medications in most countries (3). For instance, the
overall rate of pregabalin prescriptions use increased from 1.0
per 1,000 individuals in 2013 to 22.0 per 1,000 individuals in
2014 in Ontario, Canada (4). Also, there has been a progressive
increase in the reported cases of misuse and dependence to
the European Medicines Agency’s EudraVigilance database,
specifically in subjects with previous history of substance
use disorders (3).
At the pharmacological level, gabapentinoids selectively
bind to the α2δ-subunit of voltage-gated calcium channels
in central nervous system neuronal tissues. This in turn
increases the GABA levels and decreases other excitatory
neurotransmitters (5). This mechanism is associated with
their antinociceptive, anticonvulsant, anxiolytic, and sleep-
modulating effects (6). Gabapentinoids have significant risks
despite their reputation as safe drugs. Sedation, dizziness, gait
instability, and feeling of intoxication are quite common side
effects; as many as one in three patients taking therapeutic
doses experience dizziness or somnolence (7). Although, both
substances share some mechanisms of action, they also have
some pharmacokinetic differences that could explain differences
in their abuse potential; for instance, pregabalin is absorbed more
rapidly by oral route, with maximum plasma concentrations
attained within 1 h, whereas, maximum plasma concentrations
of gabapentin are detected 3–4 h after oral administration.
Pregabalin absorption is linear, and gabapentin absorption is
saturable (non-linear –zero-order- process) with less predictable
pharmacokinetics. Bioavailability is also different; pregabalin
has a 90% bioavailability independently from the dosage, but
gabapentin bioavailability changes with dosage, from 60% at 900
mg/day to 33% at 3,600 mg/day. On the other hand, similarities
in pharmacokinetics are: both can be given without regard
of meals, they do not bind to plasma proteins and both are
excreted renally with an elimination half-live of 6 h (7). The linear
pharmacokinetics of pregabalin and its greater potency explains
its steep dose-response relationship and differences in abuse
potential and severe adverse events as respiratory depression.
Evidence regarding misuse and diversion of gabapentinoids
has grown in recent years (8–10). The first description of their
misuse and abuse were published in 2010 (11). Prevalence of
misuse and abuse in the general population is an estimated 2.5%
(12) but, the rates in people suffering a substance use disorder
(SUD) is higher (pregabalin: 3–68%; gabapentin: 15–22%) (1).
In a systematic review aimed to evaluate the abuse liability of
gabapentin and pregabalin, the authors found that pregabalin
had a greater potential for addiction than gabapentin based on
the magnitude of behavioral dependence symptoms, transitions
from prescription to self-administration, and the durability of the
self-administrations (8).
Current research suggests that the addictive potential of
gabapentinoids is primarily a concern among patients with
other substance use disorders, especially opioid use disorder (8).
The reasons that motivate gabapentinoid misuse and abuse are
not clearly described. Also, the subjective effects described by
people who report non-medical use are multiple: self-treatment
of pain and other medical conditions, pursuit of changes in
states of consciousness, and “to get high” (1, 13). According
to a recent systematic review (13), one of the most predictive
factors associated with gabapentinoid use was the concomitant
use of opioids.
The neurobiological mechanism involved in the abuse liability
of gabapentinoids has not been yet clearly investigated. The
usual increase in the dopamine levels at the mesolimbic
brain circuits has not been proved in preclinical studies
(14, 15). Gabapentinoids have been reported to produce
alcohol/gamma hydroxybutyrate (GHB)/benzodiazepine-type
effects mixed with euphoria. Rates of euphoria have been
reported at between 1 and 12% but this has been for
therapeutic doses. Other reported effects include dissociative
feeling, improved sociability, relaxation and sense of calm, and
psychedelic effects (10, 16).
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On the other hand, however, there are studies indicating that
gabapentin could be an useful treatment for alcohol use disorder.
For instance, a recent randomized controlled trial showed efficacy
of gabapentin in the treatment of alcohol use disorder, improving
the alcohol withdrawal syndrome, reducing the heavy drinking
days andmore total abstinence in the group treated with 1,200mg
of gabapentin (17). Also, in a meta-analysis of seven studies,
gabapentin showed efficacy in the treatment of alcohol use
disorder, reducing the number of heavy drinking days (18).
In countries as United Kingdom gabapentinoids have been
reclassified as Class C controlled drugs under theMisuse of Drugs
Act, from 1 April 2019 (19). That means that it is illegal to
dispense them without a signed prescription, but that they do not
require safe custody in controlled drug cabinets. In Spain, Italy,
Germany, and France, gabapentin and pregabalin are available
both only under a medical prescription. Alternatively, in the
USA, the Drug Enforcement Administration (DEA) classifies
pregabalin as a Schedule V controlled substance, or the lowest
abuse potential among controlled substances, and gabapentin as
a non-controlled substance (20).
The aim of this study is to determine the prevalence of
prescription gabapentinoids non-medical use and associated
demographics in five European countries (France, Germany,
Italy, Spain, and the United Kingdom) and to evaluate the main
factors related with its misuse in Spain.
MATERIALS AND METHODS
Design and Participants
The data were obtained from the Researched, Abuse, Diversion
and Addiction Related Surveillance (RADARS R©) System Survey
of Non-Medical Use of Prescription Drugs (NMURx) Program
that collects data on respondent demographics and the
prevalence, reasons of use, routes of administration, and method
of drug acquisition for NMU of prescription drugs across
multiple countries. The methodology and the validity of this
program is explained in its validation study (21, 22).
The whole program collects information from France,
Germany, Italy, Spain, and the United Kingdom. Recruitment
and data collection are delivered to country-based members
through a global survey panel company, in the native language
of the country where the survey is undertaken and in English.
Each launch has a “soft launch” of around 500 participants to
ensure proper data collection. The surveys were available during
the following timeframes: In France: from 2017 December 13 to
2018, January, 7: in Germany: from 2017 December 12 to 2018,
January, 16; in Italy: 2017, from December 14 to December 26; in
Spain: From 2017 December 12 to 2018, January, 4; and in UK:
2017, from September 28 to December 1.
The inclusion criteria were: agree to be included and give
informed consent at the beginning of the survey; adult age that
was defined as ages 15–110 years in Spain, 16–110 years in the
United Kingdom, and 18–110 in France, Germany, and Italy; in
order to reflect the geographical and gender distribution of the
country, surveys from different countries and regions have been
included if region/sex sampling strata that has not yet met its
sampling quota; and have completed the survey in its entirety.
Respondents and/or surveys were excluded from the analysis if
the respondent met criteria for careless response as defined by
the validation study (21).
Calibration weights were applied to the survey population to
be representative of the distribution of the adult population of
each of the countries included in the study based on geographic
region, age, sex, limitations in daily activities, and smoking
status (21). National data utilized for this weighting scheme
was calculated from estimates from Eurostat and the European
Social Survey; NMURx was approved by the Colorado Multiple
Institutional Review Board (Protocol Number: 13-2394) and
locally by the Parc de Salut Mar Ethics Committee (Protocol
Number: 2017/7331/I). Data used in this analysis is from the
surveys launched in the second half of 2017 (17Q4).
Measures
Respondents were asked if they had ever used prescription
gabapentin or pregabalin for any reason in their lifetime; a “yes”
response classified lifetime use. If respondents reported lifetime
use, they were asked about last 12- month use and last 12-month
NMU, where NMU was defined as “in a way not directed by your
healthcare provider.”
Basic demographics (age and gender) were collated together
with data on prevalence of last 12-month gabapentin/pregabalin
use and NMU.
Analyses
The weighted proportion and 95% confidence intervals (CIs)
of select demographic and respondent characteristics were
calculated to describe the population. Weighted prevalence
estimates and 95% CIs were calculated for last 12-month use
and NMU of prescription gabapentin only, pregabalin only, and
pregabalin and gabapentin. The prevalence of prescription or
NMU in the last 12 months was estimated by gender and age.
Differences in prevalence of prescription and were compared
by gender and age range (18–24, 25–34, 35–44, 45–54, 55–
64, 65+ years). Analyses were conducted in SPSS Version 25.0
(Armonk, NY).
RESULTS
Survey Termination and Completion for the
Five Countries
In the last quarter of 2017, approximately 63,450 French panelists
were invited to participate in the survey. Of the 16,903 who
initiated the survey, the inclusion and exclusion criteria below
were applied and a total of 10,072 respondents were included in
the analysis (5,058 (50.2%) females, 46.8±15.17 years).
In Germany, ∼64,982 German panelists were invited to
participate in the survey. Of the 21,977 who initiated the survey,
15,051 completed it and fulfilled the inclusion criteria (7,531
(50.0%) female, mean age 46.8± 14.24 years).
In Italy, 41,167 Italian panelists were invited to participate
in the survey. Of the 12,766 who initiated the survey, the
inclusion and exclusion criteria below were applied and 10,019
surveys were included (5,019 females (50.1%), mean age 43.5 ±
13.72 years).
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FIGURE 1 | Final analytic sample flowchart.
In Spain, 26,498 panelists were invited to participate in the
survey. Of the 15,798 who initiated the survey, the inclusion and
exclusion criteria below were applied (Figure 1). Finally, 10,062
people completed the survey (5,030 (50.0%) female, mean age:
41.6± 12.74 years).
In the United Kingdom, there were 108,633 panelists invited
to participate in the survey, of which 13,036 initiated the survey
and 10,004 were included in the analysis (5,003 (50.0%) females,
mean age 51.6± 15.33 years).
Comparison of Five Countries
Prevalence of past 90 day GABA analog NMU was highest
in Germany (1,191.7 per 100,000 population, 95% CI 1,004.3–
1,379.1) and the UK (1,067.2, 95% CI 851.3–1,283.2), and lowest
in Spain (344.4, 95% CI 204.8–484.0) and Italy (366.2, 95% CI
207.7–524.6) (Table 1).
NMU was evenly distributed between genders except in
Spain which showed a male predominance (Table 2). Those who
non-medically use GABA analogs were estimated to have higher
incidence of lifetime chronic pain, lifetime illicit drug use, and
previous substance abuse therapy (Table 2).
Spanish Respondents Characteristics
Approximately 26,498 Spanish panelists were invited to
participate in the survey. Of the 15,798 who initiated the
survey, the inclusion and exclusion criteria below were applied
(Figure 1). Finally, 10,062 people completed the survey (5,030
(50.0%) female, mean age: 41.6 + 12.74 years). The main
characteristics (unweighted and weighted) of the respondents
are described in Table 3. The responses are weighted to represent
the population above 15 years old in Spain by region, gender
and age.
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A total of 1,003 (10.0%) respondents referred a lifetime use
of gabapentinoids; after weighting the responses a 9.9% (95% CI:
9.2–10.6) (Table 4).
From the total Spanish sample, 444 (4.4%) respondents
have ever used gabapentin and 624 (6.2%) pregabalin. Out of
them, 84 (18.9%), and 126 (20.6%) reported non-medical use
of gabapentin and pregabalin, respectively (cave: according to
Table 4 the % of respondents with NMU of gabapentinoids
should be something higher >>2.9 out of 9.9.% = 29.3%. The
others respondents were not sure (40 (9.0%) for gabapentin and
33 (5.3%) for pregabalin) about their NMU (that means, that they
were not sure whether they followed the recommendations of
the prescriber) or answered that they do not use for NMU (320
(72.1%) for gabapentin and 465 (74.5%) for pregabalin).
Characteristics of Non-medical Use in
Spain
The main reasons for non-medical use were to self-treat pain and
other medical condition different from pain (Table 5).
Respondents who declare NMU of gabapentinoids, usually
used the oral route of administration (either swallowed or
chewed and then swallowed). Those of them who used to
get high, reported to inject gabapentin (41%) and pregabalin
(14.3%) (Table 6).
TABLE 1 | Last 90 day non-medical use of GABA analogs by country.






































aRates based on the weighted estimated number of adults who reported NMU of each
drug class in the last 90 days per 100,000 adult population.
bRates are based on the weighted estimated number of adults who reported NMU of
each drug class in the last 90 days per 100,000 standard units sold.
Respondents said that they main method of drug acquisition
in Spain was by a prescription of a doctor/dentist (61.3% for
gabapentin and 69.8% for pregabalin), however, they used several
methods to acquire them including family or friends (either
bought or given), taken from family, friends and other people,
bought outside the country, by internet or to a dealer (Table 7).
Finally, in Table 8, is described the last purchase of gabapentin
and pregabalin where respondents said that they have obtained
the substances from a dealer of bought in internet. The median
price paid for both was similar (10 e).
DISCUSSION
The main finding of this study is that it confirms the potential
abuse liability and then non-medical use of the gabapentinoids
gabapentin and pregabalin. When comparing the five European
countries, those who non-medically use gabapentinoids were
estimated to have a higher likelihood of chronic pain, use of illicit
substances, and history of substance abuse treatment compared
to the general population. These results are in concordance with
country surveys, reviews and metanalyses published previously
(8, 23, 24).
There are differences in the rate per 100,000 people among
the five countries, with Germany and UK the countries having
a higher rate compared to France, Italy and Spain. Reasons for
these differences could be related to the availability of other
sedative type substances in those countries. According to the
European Drug Report of the same year that the information
of this study was recorded (25), the prevalence of cannabis
use in France, Italy, and Spain was higher than 15%, whereas,
in Germany and United Kingdom the prevalence was lower
than 15%. We can hypothesize that some reasons for using
cannabis and gabapentinoids could be similar: to treat pain
and anxiety symptoms; in countries with higher availability
of cannabinoids and opioids, subjects could prefer them to
gabapentinoids. Also, in some countries, gabapentinoids might
replace partially benzodiazepines; in Spain, a general population
survey performed every 2 years, showed data on life-time NMU
of benzodiazepines about 3.0% in male and 3.1% in female (26).
TABLE 2 | Demographics of those who have non-medically used GABA Analogs in the last 90 days vs. the general adult population demographics.
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Male 5,032 (50.0%) 48.8 (47.6, 49.9)
Age (years)
Mean (STD) 41.6 (12.74) 45.7 (0.2)
Median (IQR) 41.0 (32.0, 50.0) 46.0 (33.6, 56.9)
Range (15.0, 90.0) (15.0, 90.0)
Age categories (years)
15–24 1,008 (10.0%) 0 (0.0, 0.0)
25–34 2,021 (20.1%) 0 (0.0, 0.0)
35–44 2,999 (29.8%) 14.4 (13.8, 15.0)
45–54 2,391 (23.8%) 19.8 (19.0, 20.5)
55+ 1,643 (16.3%) 18.2 (17.5, 19.0)
Territory of residence
Andalucía 1,813 (18.0%) 18.0 (17.1, 18.9)
Aragón 570 (5.7%) 5.7 (5.2, 6.3)
Canarias 467 (4.6%) 4.7 (4.2, 5.1)
Cantabria 51 (0.5%) 0.5 (0.3, 0.7)
Castilla y León 617 (6.1%) 6.1 (5.5, 6.7)
Castilla-La Mancha 424 (4.2%) 4.1 (3.6, 4.6)
Cataluña 1,673 (16.6%) 17.1 (16.3, 18.0)
Ciudad Autónoma de Ceuta 2 (0.0%) 0.0 (0.0, 0.0)
Ciudad Autónoma de Melilla 10 (0.1%) 0.2 (0.1, 0.3)
Comunidad de Madrid 1,380 (13.7%) 13.7 (12.9, 14.5)
Comunidad Foral de Navarra 65 (0.6%) 0.6 (0.5, 0.8)
Comunidad Valenciana 1,105 (11.0%) 10.4 (9.8, 11.1)
Extremadura 188 (1.9%) 1.9 (1.5, 2.2)
Galicia 643 (6.4%) 6.2 (5.6, 6.7)
Illes Balears 131 (1.3%) 1.3 (1.1, 1.6)
La Rioja 39 (0.4%) 0.4 (0.2, 0.5)
País Vasco 290 (2.9%) 2.9 (2.5, 3.3)
Principado de Asturias 283 (2.8%) 3.0 (2.6, 3.5)
Región de Murcia 311 (3.1%) 3.1 (2.7, 3.5)
Region of residence
Noroeste 977 (9.7%) 9.7 (9.0, 10.5)
Noreste 964 (9.6%) 9.6 (9.0, 10.3)
Comunidad de Madrid 1,380 (13.7%) 13.7 (12.9, 14.5)
Centro 1,229 (12.2%) 12.1 (11.3, 12.9)
Este 2,909 (28.9%) 28.9 (27.9, 29.9)
Sur 2,136 (21.2%) 21.3 (20.3, 22.2)
Canarias 467 (4.6%) 4.7 (4.2, 5.1)
Net monthly household income
Under e499 404 (4.0%) 4.0 (3.5, 4.4)
Between e500 and e799 430 (4.3%) 4.6 (4.1, 5.1)
Between e800 and e999 588 (5.8%) 5.9 (5.3, 6.4)
Between e1.000 and e1.499 2,145 (21.3%) 20.5 (19.6, 21.4)
Between e1.500 and e1.999 1,723 (17.1%) 16.6 (15.8, 17.5)
Between e2.000 and e2.499 1,472 (14.6%) 14.4 (13.5, 15.2)
Between e2.500 and e2.999 1,105 (11.0%) 11.1 (10.4, 11.9)
Between e3.000 and e4.999 1,116 (11.1%) 11.5 (10.7, 12.2)
Between e5.000 and e6.999 204 (2.0%) 2.1 (1.8, 2.5)
(Continued)





e7.000 or more 92 (0.9%) 0.8 (0.7, 1.0)
Prefer not to say 783 (7.8%) 8.5 (7.8, 9.2)
Marital status
Single 3,709 (36.9%) 32.3 (31.3, 33.3)
Married 5,463 (54.3%) 55.5 (54.3, 56.6)
Separated/divorced 760 (7.6%) 9.5 (8.7, 10.3)
Widowed 130 (1.3%) 2.7 (2.2, 3.2)
Education achieved
No studies or incomplete primary studies 25 (0.2%) 0.3 (0.2, 0.5)
Comprehensive primary education 174 (1.7%) 2.3 (1.9, 2.7)
Secondary studies 1st stage 1,481 (14.7%) 15.8 (14.9, 16.7)
Secondary studies 2nd stage 3,544 (35.2%) 35.9 (34.8, 37.0)
Middle University studies 2,274 (22.6%) 22.0 (21.0, 22.9)
Higher University studies 2,564 (25.5%) 23.7 (22.7, 24.6)
Student within the last 3 months
Yes 1,403 (13.9%) 13.6 (12.8, 14.3)
No 8,659 (86.1%) 86.4 (85.7, 87.2)
A member or former member of the armed forces
Yes 479 (4.8%) 4.6 (4.2, 5.1)
No 9,583 (95.2%) 95.4 (94.9, 95.8)
Currently a healthcare professional
Yes 615 (6.1%) 5.6 (5.1, 6.1)
No 9,447 (93.9%) 94.4 (93.9, 94.9)
Pregnancy statusb
Yes 250 (5.0%) 3.3 (2.9, 3.8)
No 4,780 (95.0%) 96.7 (96.2, 97.1)
Gestationc (months)
Mean (STD) 4.8 (2.08) 4.8 (0.1)
Median (IQR) 5.0 (3.0,6.0) 4.4 (2.6,5.9)
Range (1.0, 9.0) (1.0, 9.0)
Survey language
English 197 (2.0%) 2.1 (1.8, 2.5)
Spanish 9,865 (98.0%) 97.9 (97.5, 98.2)
CI, Confidence Interval; STD, Standard deviation; IQR, Interquartile range.
aResponses are weighted to represent the distribution of adults (ages 15+) in Spain by
region, gender, and age.
bAmong females only (n = 5,030).
cAmong pregnant females only (n = 250).
Some studies have tried to analyze the possible usefulness of
pregabalin and gabapentin in the treatment of benzodiazepine
use disorder, but there are no clear results regarding this (27, 28).
When evaluating the rates by drug, as described before,
pregabalin has more endorsements than gabapentin, for example,
in a recent paper describing data from addictovigilance
monitoring for gabapentinoids (24). Some publications have
described a higher abuse liability for pregabalin compared to
gabapentin. One of the explanations of this difference could be
the higher prevalence of euphoria in pregabalin compared to
gabapentin. The studies that have described this effect reported
that this is a dose-dependent effect and it is not related to
treatment indication, nor previous abuse of substances; its
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prevalence varies among different studies from 1 to 40% (10, 29).
The theory of people taking pregabalin to experience euphoria
and to get high it is not completely explained by our results,
as the majority of the respondents used pregabalin as self-
treatment. The differences between the two substances could
also be explained by the different pharmacokinetic characteristics
of both molecules; pregabalin has more rapid absorption than
gabapentin; also, the peak plasma concentration is more rapidly
achieved with pregabalin (1 h compared to 4–5 h) and has a
longer half-life (7).
In the subsample of Spanish population evaluated, about 20%
of all persons ever using gabapentinoids report on NMU of these
substances. A risk for NMU that should not be neglected. The
main reason for non-medical use was in both medications for
self-treat any pain, followed to treat othermedical conditions; few
respondents used them to get high or to come down; also, there
were a percentage of people using them to prevent withdrawal
symptoms. Another article, based on data of pharmavigilance
(24), found that the use of pregabalin was not only related
to the objective to get high, but also, to prevent withdrawal
symptoms, as a substitute of other substances and to potentiate
the effect of other drugs (mainly benzodiazepines and opioids).
In our sample, the inhaled and intravenous route were mainly
reported for those who use pregabalin and gabapentin to prevent
withdrawal syndrome, to come down and to get high. It is
important to consider the possibility of using the intravenous
route, and asking patients about it to prevent the transmission
of blood borne infections (Hepatitis B and C, and HIV).
TABLE 4 | Respondents that reported use of gabapentinoids (from total survey
respondents n = 10,062).
Unweighted N (%) Weighteda % (95% CI)
Lifetime use 1,003 (10.0%) 9.9 (9.2, 10.6)
Lifetime non-medical use 323 (3.2%) 2.9 (2.6, 3.3)
Last 12 month non-medical use 169 (1.7%) 1.5 (1.2, 1.7)
Last 90 day non-medical use 45 (0.4%) 0.4 (0.3, 0.6)
Last 30 day non-medical use 42 (0.4%) 0.4 (0.3, 0.6)
Last 7 day non-medical use 35 (0.3%) 0.4 (0.2, 0.5)
CI, Confidence Interval.
aResponses are weighted to represent the distribution of adults (ages 15+) in Spain by
region, gender, and age.
Another aspect to take into account may be the
polymedication risk. Pregabalin and gabapentin are usually
prescribed with other pain medications, mainly with opioids;
among 50–70% were reported in a recent paper (23). This
combination could increase the risk for overdose death (30).
Otherwise, the usefulness of the combination of pregabalin and
opioids for the treatment of some kind of pain is not clear, as
some researchers have described that pregabalin plus opioids
was associated with more pain severity and higher oral doses
of opioids; furthermore, pregabalin use was not associated with
improvements on mental health symptoms (31).
When prescribing these medications it is important to be
aware and monitor for signs of misuse and overdosification,
mainly in patients with risk factors for NMU (previous history
of substance use disorder and chronic pain). It is important to
remark that, although NMU of gabapentinoids is more frequent
in patients with previous substance use disorder, there are
described cases of a primary abuse in people without any of
the known risk factors (24), for this reason, it is important to
monitor for signs of NMU in all patients in treatment with
gabapentinoids. The detection of NMU could be complicated as
these medications are not detected in routine toxicology urine
controls. Furthermore, prescribers should be aware of the risk of
NMU, when patients request for specific drugs of higher doses,
when they obtain medications from different sources (doctor
shopping), when the medications are lost or stolen frequently or
they ask for new prescriptions too early (1).
The NMURx survey methodology is useful to identify under-
documented use and misuse of medication and can detect
changes in trends of substance use and misuse; also, it permits to
make comparisons among different countries. The large sample
size and post-stratification weighting applied creates estimates
that are representative of general populations. However, there
are some limitations related to online surveys, in first place
the reliance of participants to provide honest responses; also,
another limitation of the study is that respondents who have
acquired a gabapentinoid product from a family member, friend,
or dealer may not be aware whether it was initially obtained
with a prescription or from another source. However, these
limitations will apply to all surveys so still allow for comparison
across countries.
In conclusion, in spite of the risk of NMU, gabapentinoids
are useful medications in the treatment of neuropathic pain,
generalized anxiety disorder, and some forms of epilepsy.





















Gabapentin 124 65 (52.4%) 40 (32.3%) 12 (9.7%) 10 (8.1%) 13 (10.5%) 20 (16.1%)
Pregabalin 159 76 (47.8%) 45 (28.3%) 14 (8.8%) 9 (5.7%) 9 (5.7%) 28 (17.6%)
a Includes all survey respondents who report non-medical use of the product.
Respondents may check multiple options, percentages may not sum to 100.
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TABLE 6 | Route of administration by reason for non-medical use in Spain.





Dissolved in mouth (e.g.,












Gabapentin (e.g., Gabatur, Neurontin®, or generic), tablets/capsules
To self-treat my pain 65 47 (72.3%) 24 (36.9%) 19 (29.2%) 13 (20.0%) 12 (18.5%) 10 (15.4%)
To treat a medical condition, other than pain 40 27 (67.5%) 13 (32.5%) 14 (35.0%) 7 (17.5%) 9 (22.5%) 3 (7.5%)
For enjoyment/to get high 12 4 (33.3%) 5 (41.7%) 3 (25.0%) 1 (8.3%) 5 (41.7%) 2 (16.7%)
To come down 10 3 (30.0%) 5 (50.0%) 6 (60.0%) 1 (10.0%) 3 (30.0%) 0 (0.0%)
To prevent or treat withdrawal symptoms 13 5 (38.5%) 6 (46.2%) 7 (53.8%) 6 (46.2%) 4 (30.8%) 4 (30.8%)
Other reason 20 10 (50.0%) 6 (30.0%) 5 (25.0%) 6 (30.0%) 3 (15.0%) 5 (25.0%)
Pregabalin (e.g., Lyrica® or generic), tablets/capsules
To self-treat my pain 76 53 (69.7%) 19 (25.0%) 13 (17.1%) 12 (15.8%) 8 (10.5%) 5 (6.6%)
To treat a medical condition, other than pain 45 30 (66.7%) 21 (46.7%) 8 (17.8%) 4 (8.9%) 5 (11.1%) 1 (2.2%)
For enjoyment/to get high 14 2 (14.3%) 6 (42.9%) 8 (57.1%) 4 (28.6%) 2 (14.3%) 1 (7.1%)
To come down 9 1 (11.1%) 7 (77.8%) 3 (33.3%) 3 (33.3%) 2 (22.2%) 1 (11.1%)
To prevent or treat withdrawal symptoms 9 5 (55.6%) 6 (66.7%) 4 (44.4%) 4 (44.4%) 3 (33.3%) 1 (11.1%)
Other reason 28 17 (60.7%) 9 (32.1%) 7 (25.0%) 5 (17.9%) 4 (14.3%) 10 (35.7%)
a Includes all survey respondents who report each reason for non-medical use of the product.
Respondents may check multiple options, percentages may not sum to 100.
TABLE 7 | Reported method of drug acquisition in Spain.
Na Was prescribed
it by a doctor or
dentist
N (%)





















Bought it on the
internet without
a Rx N (%)
Bought it from a
dealer
N (%)
Gabapentin 124 76 (61.3%) 35 (28.2%) 30 (24.2%) 39 (31.5%) 33 (26.6%) 32 (25.8%) 38 (30.6%)
Pregabalin 159 111 (69.8%) 51 (32.1%) 40 (25.2%) 33 (20.8%) 41 (25.8%) 39 (24.5%) 46 (28.9%)
a Includes all survey respondents who report non-medical use of the product.
Respondents may check multiple options, percentages may not sum to 100.
TABLE 8 | Last purchase characteristics in Spain.
Na Number/volume
purchased
Strengthb Total price paid
(e)






































STD, Standard deviation; IQR, Interquartile Range.
a Includes all survey respondents who report non-medical use of the product and “Bought
it from a dealer” or “Bought it on the internet”.
bStrength: MG per tablet/capsule, MCG/h per patch, MG per oral film, MG/ML per
liquid, MCG per lollipop, MCG per lozenge, MG per suppository; All non-numeric entries
were excluded.
Respondents have option to check ‘I’m not sure’ under strength.
Professionals prescribing these medications should be aware and
actively search for signs of misuse and diversion.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.
ETHICS STATEMENT
The studies involving human participants were reviewed
and approved by the Colorado Multiple Review Board
(Protocol Number: 13-2394) and locally by the Parc de Salut
Mar Ethics Committee (Protocol Number: 2017/7331/I).
Written informed consent to participate in this study
was provided by the participants’ legal guardian/next
of kin.
AUTHOR CONTRIBUTIONS
FF, PD, DW, NS, MG, IM, MA, and RD were responsible to
prepare and adapt the country protocols. MG and RD were
Frontiers in Psychiatry | www.frontiersin.org 8 April 2021 | Volume 12 | Article 676224104
Fonseca et al. Non-medical Use of Gabapentinoids in Spain
responsible for the project concept and study design. FF, WL, EP,
and MF contributed to drafting the manuscript. MF, NS, and MT
were responsible for the final revision. All authors have read and
approved the final submitted manuscript.
FUNDING
This work was supported by the Researched Abuse, Diversion
and Addiction-Related Surveillance (RADARS) System.
The RADARS System is supported by subscriptions
from pharmaceutical manufacturers, government, and
non-government agencies for surveillance, research, and
reporting services. RADARS System is the property of Denver
Health and Hospital Authority, a political subdivision of
the State of Colorado. Authors were employed by Denver
Health and Hospital Authority during this work. Denver
Health retains exclusive ownership of all data, databases and
systems. No subscriber participated in the conception, analysis,
drafting, or review of this manuscript. Instituto de Salud
Carlos III–FEDER-Red de Trastornos Adictivos UE-FEDER
2016 (RD16/0017/0010 and RD16/0017/003); AGAUR-Suport
Grups de Recerca (2017 SGR530) and Acció instrumental
d’Intensificació de Professionals de la Salut - Facultatius
especialistes (PERIS: SLT006/17/00014).
REFERENCES
1. Evoy KE, Morrison M, Saklad SR. Pregabalin and gabapentin abuse: a
systematic review. Drugs. (2017) 77:403–26. doi: 10.1007/s40265-017-0700-x
2. Calandre EP, Rico-Villademoros F, Slim M. Alpha2delta ligands,
gabapentin, pregabalin, and mirogabalin: a review of their clinical
pharmacology and therapeutic use. Expert Rev Neurother. (2016) 16:1263–77.
doi: 10.1080/14737175.2016.1202764
3. Chiappini S, Schifano F. A decade of gabapentinoid misuse: an analysis of the
Europeanmedicines agency’s ’suspected adverse drug reactions’ database.CNS
Drugs. (2016) 30:647–54. doi: 10.1007/s40263-016-0359-y
4. Kwok H, KhuuW, Fernandes K, Martins D, Tadrous M, Singh S, et al. Impact
of unrestricted access to pregabalin on the use of opioids and other CNS-
active medications: a cross-sectional time series analysis. Pain Med. (2017)
18:1019–26. doi: 10.1093/pm/pnw351
5. Tran-Van-Minh A, Dolphin AC. The alpha2delta ligand gabapentin inhibits
the Rab11-dependent recycling of the calcium channel subunit alpha2delta-2.
J Neurosci. (2010) 30:12856–67. doi: 10.1523/JNEUROSCI.2700-10.2010
6. Frampton JE. Pregabalin: a review of its use in adults with generalized anxiety
disorder. CNS Drugs. (2014) 28:835–54. doi: 10.1007/s40263-014-0192-0
7. Bockbader HN, Wesche D, Raymond M, Chapel S, Janiczek N, Burger
P. A comparison of thepharmacokinetics and pharmacodynamics
of pregabalin and gabapentin. Clin. Pharmacokin. (2010) 49:661–9.
doi: 10.2165/11536200-000000000-00000
8. Bonnet U, Scherbaum N. How addictive are gabapentin and pregabalin?
A systematic review. Eur Neuropsychopharmacol. (2017) 27:1185–215.
doi: 10.1016/j.euroneuro.2017.08.430
9. Mersfelder TL, NicholsWH. Gabapentin: abuse, dependence, and withdrawal.
Ann Pharmacother. (2016) 50:229–33. doi: 10.1177/1060028015620800
10. Schjerning O, Rosenzweig M, Pottegård A, Damkier P, Nielsen J. Abuse
potential of pregabalin: a systematic review. CNS Drugs. (2016) 30:9–25.
doi: 10.1007/s40263-015-0303-6
11. Schwan S, Sundström A, Stjernberg E, Hallberg E, Hallberg P. A signal for an
abuse liability for pregabalin—results from the Swedish spontaneous adverse
drug reaction reporting system. Eur J Clin Pharmacol. (2010) 66:947–53.
doi: 10.1007/s00228-010-0853-y
12. Kapil V, Green JL, Le Lait MC, Wood DM, Dargan PI. Misuse of the c-
aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK.
Br J Clin Pharmacol. (2014) 78:190–1. doi: 10.1111/bcp.12277
13. Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM, Morrison MD.
Abuse and misuse of pregabalin and gabapentin: a systematic review update.
Drugs. (2021) 81:125–56. doi: 10.1007/s40265-020-01432-7
14. Coutens B, Mouledous L, Stella M, Rampon C, Lapeyre-Mestre M, Roussin
A, et al. Lack of correlation between the activity of the mesolimbic
dopaminergic system and the rewarding properties of pregabalin in mouse.
Psychopharmacology. (2019) 236:2069–82. doi: 10.1007/s00213-019-05198-z
15. Peng XQ, Li X, Li J, Ramachandran PV, Gagare PD, Pratihar D, et al.
Effects of gabapentin on cocaine self-administration, cocaine-triggered relapse
and cocaine-enhanced nucleus accumbens dopamine in rats. Drug Alcohol
Depend. (2008) 97:207–15. doi: 10.1016/j.drugalcdep.2007.09.019
16. Ponton R. Pregabalin misuse: preventing potential problems in New Zealand.
N Z Med J. (2018) 131:50–54. Available online at: https://assets-global.
website-files.com/5e332a62c703f653182faf47/5e332a62c703f6a7b62fd37e_
Ponton-FINAL.pdf
17. Anton RF, Latham P, Voronin K, Book S, Hoffman M, Prisciandaro J,
et al. Efficacy of gabapentin for the treatment of alcohol use disorder in
patients with alcohol withdrawal symptoms: a randomized clinical trial.
JAMA Intern Med. (2020) 180:728–36. doi: 10.1001/jamainternmed.202
0.0249
18. Kranzler HR, Feinn R,Morris P, Hartwell EE. Ameta-analysis of the efficacy of
gabapentin for treating alcohol use disorder. Addiction. (2019) 114:1547–55.
doi: 10.1111/add.14655
19. Torjesen I. Pregabalin and gabapentin: what impact will reclassification
have on doctors and patients? BMJ. (2019) 364:l1107. doi: 10.1136/bmj.
l1107
20. Peckham AM, Ananickal MJ, Sclar DA. Gabapentin use, abuse,
and the US opioid epidemic: the case for reclassification as a
controlled substance and the need for pharmacovigilance. Risk
Manag Healthc Policy. (2018) 11:109–16. doi: 10.2147/RMHP.
S168504
21. Black JC, Rockhill K, Forber A, Amioka E, May KP, Haynes CM, et al. An
online survey for pharmacoepidemiological investigation (survey of non-
medical use of prescription drugs program): validation study. J Med Internet
Res. (2019) 21:e15830. doi: 10.2196/15830
22. Ng FL, Rockhill K, Black J, May KP, Whittington MD, Wood DM, et al.
UK survey of non-medical use of prescription drugs (NMURx) as a valuable
source of general population illicit drug use data. Postgrad Med J. (2018)
94:627–33. doi: 10.1136/postgradmedj-2018-135798
23. Evoy KE, Covvey JR, Peckham AM, Reveles KR. Gabapentinoid misuse, abuse
and non-prescribed obtainment in a United States general population sample.
Int J Clin Pharm. (2021). doi: 10.1007/s11096-020-01217-8. [Epub ahead
of print].
24. Tambon M, Ponté C, Jouanjus E, Fouilhé N, Micallef J, Lapeyre-
Mestre M, et al. Gabapentinoid abuse in France: evidence on health
consequences and new points of vigilance. Front Psychiatry. (2021) 12:639780.
doi: 10.3389/fpsyt.2021.639780
25. European Monitoring Centre for Drugs and Drug Addiction. European Drug
Report 2017: Trends and Developments. (2017). Publications Office of the
European Union. Available online at: https://www.emcdda.europa.eu/system/
files/publications/4541/TDAT17001ENN.pdf (accessed February 22, 2021).
26. Observatorio Español de las Drogas y las Adicciones. Encuesta Sobre
Alcohol y Otras Drogas en España, EDADES 2019/20. Madrid: Ministerio
de Sanidad. Delegación del Gobierno para el Plan Nacional sobre Drogas
(2021). p. 93. Available online at: https://pnsd.sanidad.gob.es/profesionales/
sistemasInformacion/sistemaInformacion/pdf/2019_Informe_EDADES.pdf
(accessed February 27, 2021).
27. Baandrup L, Ebdrup BH, Rasmussen JØ, Lindschou J, Gluud C, Glenthøj BY.
Pharmacological interventions for benzodiazepine discontinuation in chronic
benzodiazepine users. Cochrane Database Syst Rev. (2018) 3:CD011481.
doi: 10.1002/14651858.CD011481.pub2
Frontiers in Psychiatry | www.frontiersin.org 9 April 2021 | Volume 12 | Article 676224105
Fonseca et al. Non-medical Use of Gabapentinoids in Spain
28. Caniff K, Telega E, Bostwick JR, Gardner KN. Pregabalin as adjunctive therapy
in benzodiazepine discontinuation. Am J Health Syst Pharm. (2018) 75:67–71.
doi: 10.2146/ajhp160712
29. Lang N, Sueske E, Hasan A, Paulus W, Tergau F. Pregabalin exerts
oppositional effects on different inhibitory circuits in human motor cortex:
a double-blind, placebo-controlled transcranial magnetic stimulation study.
Epilepsia. (2006) 47:813–9. doi: 10.1111/j.1528-1167.2006.00544.x
30. Bykov K, Bateman BT, Franklin JM, Vine SM, Patorno E. Association of
gabapentinoids with the risk of opioid-related adverse events in surgical
patients in the United States. JAMA Netw Open. (2020) 3:e2031647.
doi: 10.1001/jamanetworkopen.2020.31647
31. Nielsen S, Gisev N, Leung J, Clare P, Bruno R, Lintzeris N, et al. Clinical
correlates and outcomes associated with pregabalin use among people
prescribed opioids for chronic non-cancer pain: A five-year prospective
cohort study. Br J Clin Pharmacol. (2020). doi: 10.1111/bcp.14715. [Epub
ahead of print].
Conflict of Interest: FF has received during the last 3 years travel grants from
Lundbeck, Otsuka, Indivior, Pfizer, Gilead, Angelini, and Servier; and she
has received grant/research support from Indivior and Servier. MT has been
consultant/advisor and/or speaker for Gilead Sciences, Merck Sharp and Dohme
Corp, Indivior, Mundipharma Pharmaceutics, Servier, and Adamed. NS received
honoraria for several activities (advisory boards, lectures, manuscripts) by the
factories AbbVie, Camurus, Hexal, Janssen-Cilag, MSD, Medice, Mundipharma,
Reckitt-Benckiser/Indivior, and Sanofi-Aventis. During the last 3 years he
participated in clinical trials financed by the pharmaceutical industry. IM served
as Board Member for Angelini, Camurus, CT Sanremo, D&A Pharma, Gilead,
Indivior, Lundbeck, Molteni, MSD, and Mundipharma. MA over the past 3 years
has interacted directly or through the University of Bordeaux Foundation with
Camurus, Mundipharma, Accord Healthcare, Indivior for expert advice and/or
funding donation grants.
The remaining authors declare that conflicts of interest had no role in the design
of the study, data collection, analyses, and interpretation, in the writing of the
manuscript, or in the decision to publish the results.
Copyright © 2021 Fonseca, Lenahan, Dart, Papaseit, Dargan, Wood, Guareschi,
Maremmani, Auriacombe, Farré, Scherbaum and Torrens. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Psychiatry | www.frontiersin.org 10 April 2021 | Volume 12 | Article 67622406
SYSTEMATIC REVIEW
published: 07 May 2021
doi: 10.3389/fpsyt.2021.657397
Frontiers in Psychiatry | www.frontiersin.org 1 May 2021 | Volume 12 | Article 657397
Edited by:
Nicolas Simon,
Aix Marseille Université, France
Reviewed by:
Nicolas Franchitto,
Université Toulouse III Paul
Sabatier, France
Oussama Kebir,







This article was submitted to
Addictive Disorders,
a section of the journal
Frontiers in Psychiatry
Received: 22 January 2021
Accepted: 15 March 2021
Published: 07 May 2021
Citation:
Schifano F, Chiappini S, Miuli A,
Mosca A, Santovito MC, Corkery JM,
Guirguis A, Pettorruso M, Di
Giannantonio M and Martinotti G
(2021) Focus on Over-the-Counter
Drugs’ Misuse: A Systematic Review




Focus on Over-the-Counter Drugs’
Misuse: A Systematic Review on
Antihistamines, Cough Medicines,
and Decongestants
Fabrizio Schifano 1, Stefania Chiappini 1,2*, Andrea Miuli 2, Alessio Mosca 2,
Maria Chiara Santovito 2, John M. Corkery 1, Amira Guirguis 3, Mauro Pettorruso 2,
Massimo Di Giannantonio 2 and Giovanni Martinotti 2
1 Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical
Sciences, University of Hertfordshire, Hatfield, United Kingdom, 2Department of Neuroscience, Imaging and Clinical
Sciences, “G. D’Annunzio” University, Chieti, Italy, 3 Swansea University Medical School, Institute of Life Sciences 2, Swansea
University, Swansea, United Kingdom
Background: Over the past 20 years or so, the drug misuse scenario has seen the
emergence of both prescription-only and over-the-counter (OTC) medications being
reported as ingested for recreational purposes. OTC drugs such as antihistamines,
cough/cold medications, and decongestants are reportedly the most popular in being
diverted and misused.
Objective: While the current related knowledge is limited, the aim here was to
examine the published clinical data on OTC misuse, focusing on antihistamines
(e.g., diphenhydramine, promethazine, chlorpheniramine, and dimenhydrinate),
dextromethorphan (DXM)- and codeine-based cough medicines, and the nasal
decongestant pseudoephedrine.
Methods: A systematic literature review was carried out with the help of Scopus,
Web of Science databases, and the related gray literature. For data gathering
purposes, both the Preferred Reporting Items for Systematic Reviews andMeta-analyses
(PRISMA) and PROSPERO guidelines were followed (PROSPERO identification
code CRD42020209261).
Results: After completion of the selection, eligibility, and screening phases, some 92
articles were here taken into consideration; case reports, surveys, and retrospective case
series analyses were included. Findings were organized according to the specific OTC
recorded. Most articles focused here on DXM (n = 54) and diphenhydramine (n = 12).
When specified, dosages, route(s) of administration, toxicity symptoms (including both
physical and psychiatric ones), and outcomes were here reported.
Conclusion: Results from the systematic review showed that the OTC misusing issues
are both widespread worldwide and popular; vulnerable categories include adolescents
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and young adults, although real prevalence figures remain unknown, due to a lack of
appropriate monitoring systems. Considering the potential, and at times serious, adverse
effects associated with OTCmisusing issues, healthcare professionals should be vigilant,
and ad hoc preventative actions should be designed and implemented.
Keywords: drug abuse, drug misuse, prescription drug misuse, pharming, drug diversion, over the counter drug
misuse, addiction, OTC
INTRODUCTION
Since generally being considered safe, over-the-counter (OTC)
medicines are available without a prescription and can be
purchased directly from related pharmacies/stores (1, 2). OTC
medicines are meant to treat a variety of illnesses and symptoms,
including pain, coughs and colds, diarrhea, nausea, etc. OTC
availability, while encouraging self-care, has contributed to a
public perception of safety and a lack of awareness relating
to their potential for misuse, dependence, and harm (3–6).
Indeed, some OTC medicines have active ingredients possessing
a misusing potential at higher-than-recommended dosages (7)
and are becoming increasingly popular for the possibility of their
diversion in order to reach central psychoactive effects (8–11).
Currently, there is minimal information about the prevalence of
OTC misuse, abuse, and dependence (8–10, 12). Indeed, current
lack of knowledge may partly be due to poor sales’ monitoring
because of OTCs’ favorable legal status. However, the so-called
“pharming” phenomenon (13–15) has been requiring attention
at different levels because of increased treatment admissions,
dangerous behavior, more emergency room visits, drug-related
deaths, and overdoses (11, 16, 17). Most implicated drugs include
certain cough suppressants, sleep aids, and antihistamines,
which can at times be ingested in combination with remaining
recreational psychotropics and/or prescription drugs and/or
alcohol (17, 18). Overall, the misuse of OTC drugs is considered
as more socially acceptable, less stigmatizing, and safer than
the intake of illicit substances, also due to their likely lack of
detection in standard drug screens (16). OTC drugs’ intake
may involve snorting or injecting the crushed tablets’ powder
to amplify the effects of a drug or ingesting these molecules
for a purpose different from the therapeutic one. This may
be the case for dextromethorphan (DXM) and codeine-based
cough mixtures, being possibly misused at high dosages for
recreational or euphoric effects; conversely, loperamide is at
times being ingested for self-medicating withdrawal symptoms
(7, 16, 18–20). OTC misuse has also been associated with notable
drug interactions, physical and mental health effects, individual
variation in responses, and significant socioeconomic impact
for the users, their family, and the wider community (13–15).
Currently, most OTCmisusing data are obtained through clinical
records (e.g., case reports and case series) and surveys.
Aims of the Study
Thus, the current review aimed at (i) examining the current
literature on the misuse of OTC drugs, focusing on the following
OTCs: among antihistamines, diphenhydramine (DPH),
promethazine, chlorpheniramine, and dimenhydrinate (DH);
DXM- and codeine-based cough medicines; and the nasal
decongestant pseudoephedrine; (ii) illustrating patterns of
OTCs’ misuse, psychopathological effects, and harms associated;
and (iii) better understanding the psychotropic molecular
mechanisms underlying their recreational use.
METHODS
Systematic Review Procedures
A systematic electronic search was conducted from October
2020 to December 2020 and was set without a timeframe on
the following scientific search engines: PubMed, Scopus, and
Web of Science (WoS). The gray literature was also checked
for relevant information. The following search strategies
were used, respectively, in PubMed: (“diphenhydramine” OR
“promethazine” OR “chlorpheniramine” OR “dimenhydrinate”
OR “dextromethorphan” OR “pseudoephedrine” OR codeine-
based cough medicines) AND (“abuse” OR “misuse” OR
“craving” OR “addiction”) NOT review NOT (animal
OR rat OR mouse) NOT “in vitro;” in Scopus: [TITLE-
ABS-KEY (“Diphenhydramine”) OR TITLE-ABS-KEY
(“Promethazine”) OR TITLE-ABS-KEY (“Chlorpheniramine“)
OR TITLE-ABS-KEY (“Dimenhydrinate”) OR TITLE-
ABS-KEY (“Dextromethorphan”) OR TITLE-ABS-KEY
(“Pseudoephedrine”) OR TITLE-ABS-KEY (codeine-based
cough medicines) AND TITLE-ABS-KEY (“Abuse”) OR TITLE-
ABS-KEY (“Misuse”) OR TITLE-ABS-KEY (“Craving”) OR
TITLE-ABS-KEY (“Addiction”) AND NOT TITLE-ABS-KEY
(Review) ANDNOTTITLE-ABS-KEY (animal) ORTITLE-ABS-
KEY (rat) OR TITLE-ABS-KEY (mouse) AND NOT TITLE-
ABS-KEY (“in vitro”)]; and WoS: (“diphenhydramine” OR
“promethazine” OR “chlorpheniramine” OR “dimenhydrinate”
OR “dextromethorphan” OR “pseudoephedrine” OR codeine-
based cough medicines) AND (“abuse” OR “misuse” OR
“craving” OR “addiction”) NOT Review NOT (animal OR
rat OR mouse) NOT “in vitro.” The systematic review
was structured in accordance with the Preferred Reporting
Items for Systematic Reviews and Meta-analyses (PRISMA)
(21) and PROSPERO guidelines (22). All data collected
were tabulated on an Excel sheet to enable easy comparison
and analysis.
Data Synthesis Strategy
The selection and eligibility phase of the articles was carried
out by three independent reviewers (AM, AMo, and MCS),
who screened articles based on title and abstract; the first
screening was followed by full text reviews, using predetermined
criteria for inclusion and exclusion. Eligible articles were
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considered if the published studies met all the following
criteria: (i) original articles (open-label or double-blind trials,
prospective or retrospective observational studies, case series
and case reports); (ii) studies involving all age individuals
misusing the OTC drugs selected. There were no other
restrictions on the type of study population or publication
time period. Exclusion criteria were as follows: (i) nonoriginal
research articles (e.g., review, letter, commentary, editorial,
book chapter, professional or clients’ opinions); (ii) non full-
text articles (e.g., meeting/conference abstracts); (iii) languages
other than English; (iv) animal/in vitro studies; (v) articles
mentioning OTC drugs only as an example in the context
of OTC drugs misuse; and (vi) articles not dealing with the
misuse of the OTC drugs selected (e.g., DPH, promethazine,
chlorpheniramine, and DH; DXM- and codeine-based cough
medicines; and pseudoephedrine). Individual studies were also
manually searched to identify additional citations. A final,
between reviewers, cross-check was carried out, supervised
by SC and MP, with both doubtful cases and possible
inclusion/exclusion disagreements resolved through discussion
with GM, MDG, and FS.
Protocol and Registration
Current research methods were approved by PROSPERO
(identification code CRD42020209261).
FIGURE 1 | PRISMA flow diagram.
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Risk of Bias
The assessment of risk of bias was made in accordance with the
Cochrane risk of bias 2 (RoB 2) tool (23).
RESULTS
In removing duplicate articles (n = 566) from a total of 2,136
papers (PubMed = 393; Scopus = 1,372; WoS = 362; additional
sources = 9), some 15,70 records resulted to be relevant for
screening. Those considered not relevant to the subject while
considering both the title and the abstract (n = 1,103; e.g.,
animal/in vitro studies; articles only mentioning OTC drugs,
or not regarding OTC misuse/abuse, or not giving a clear
description of related symptoms), those not written in English (n
= 136), and those that were non-original articles (n = 87) were
eliminated. Out of the 244 remaining full-text articles assessed
for eligibility, some 125 papers did not match the inclusion
criteria and 27 were not available. Hence, 92 articles were taken
into consideration and properly analyzed (Figure 1). Findings
were organized according to the specific OTC recorded, reported
in alphabetical order in Supplementary Table 1; conversely, the
most relevant characteristics of the misusing potential of the
range of OTC drugs commented are summarized in Table 1.
Dextrometorphan
DXM resulted to be the most reported misused drug,
with n = 54 related papers having been here identified
(Supplementary Table 1). Indeed, it was recorded in two
retrospective studies (24, 25), in 10 case series (26–35), and in
several case reports (24, 25, 36–77). Most represented users were
male adolescent and young adults; DXM was mostly used alone
(28, 36, 37, 40, 44, 45, 54, 57, 66) or in DXM-containing cough
mixtures (26, 29, 30, 39, 41, 42, 47, 50, 52, 53, 62, 64, 68, 71, 72, 74,
76). Concomitant drugs included both licit and illicit substances,
such as alcohol (25, 30, 31, 35, 52, 53, 55, 60, 71, 76); cannabis
(25, 31, 35, 48, 60); sedatives drugs, e.g., benzodiazepines
(35); diethylamide lysergic acid (LSD) (35); opioids, e.g.,
morphine, heroin (25, 35, 54); ecstasy (35); cocaine (35); and
phencyclidine/ketamine (34, 35). Dosages varied among cases,
up to super-high dosages (up to 4,920mg) (31, 35, 36, 61).
The only route of administration (ROA) here recorded was the
oral one. Autonomic (e.g., mydriasis, tachycardia, palpitations)
(30, 33, 35, 42, 44, 46, 47, 51, 67, 70, 71), gastrointestinal
(32, 35, 42, 47), neurological [e.g., amnesia, nystagmus, ataxia,
seizures, and dystonia; (24, 26, 29, 30, 32, 34, 35, 39, 43–
46, 49, 51–53, 56, 59, 67)], and psychiatric symptoms, such as
euphoria, agitation/irritability, confusion, hallucinations, and
delusions, have been recorded (24, 25, 27–31, 33–38, 40–
50, 52–54, 56, 58, 60, 61, 63, 66, 67, 70–74, 76). DXM
misusers’ psychiatric history frequently included alcohol
and substance use disorders (SUD) (25–27, 29, 31, 32, 34–
37, 40, 43, 45–48, 50, 53, 55–62, 64–67, 69, 76), mood
disorders (29, 31, 32, 35, 37, 38, 41, 46, 56–65, 67, 68, 71),
and schizophrenia (37, 53, 69). Regarding the outcome, most
cases required hospitalization with supportive treatments and
antipsychotics [e.g., haloperidol (43, 47, 71, 73, 75)], risperidone
(74), and olanzapine (54, 61) administration. A DXM-related
suicide has been recorded (31).
Chlorpheniramine and Codeine
Chlorpheniramine and codeine were recorded as having been
misused in two papers (respectively, 68 and 69), as constituents
of BRON, a Japanese codeine-based cough suppressant, together
with methyl-ephedrine and caffeine (78, 79). BRON abuse has
been associated with both psychotic/affective symptoms and
dependence/withdrawal issues (78). Moreover, a case of severe
intoxication of a codeine-based cough mixture determining a
respiratory acidosis and requiring hospitalization was recorded
(80) (Supplementary Table 1).
Dimenhydrinate
DH misuse was described in eight articles
(Supplementary Table 1), including five case reports (81–
85) and three case series (86–88), mostly involving adults or
adolescents (88). Most important psychiatric comorbidities
described were represented by mood disorders (82, 84),
SUD (83–87), and schizophrenia (85, 87). Massive dosages,
up to 5,000mg, of DH have been recorded in a few cases
(84, 85, 87). DH administration was always oral, except for
one case where the molecule was administered intramuscularly
in association with opiates and benzodiazepines (83). The
symptoms recorded ranged from recreational stimulating
effects (87) to emotional lability, agitation, anxiety, and drug-
induced delirium with paranoia, thought incoherence, and
visual/auditory hallucinations (81, 86). The physical effects
reported were mild and included mydriasis, tachycardia,
hypertension, flushing, restlessness, dystonic reactions, and
ataxia (81, 82, 84–86, 88), while one case reported generalized
seizures (87). Withdrawal symptoms have been recorded after
the abrupt interruption of chronic use and included irritability,
anxiety, and craving (82, 84, 87). When reported, treatment was
almost supportive (81–83, 85, 88); in two cases, benztropine
was required to treat dyskinesia and related movement, muscle
control, and balance symptoms (81, 84).
Diphenhydramine
DPH misuse was reported in 12 articles, including 10 case
reports (17, 89–97); the remaining two included, respectively,
a case series (98) and a retrospective review study (99)
(Supplementary Table 1). Apart from the retrospective review
study focusing on all Mandrax R© (DPH + Methaqualone)
abuse cases (n = 67, male) retrieved from the United States
(US) Army during January–June 1972, users were here mostly
represented by female (F/M, 9/6). A high number of users
were adolescents, aged between 13 and 18 years (17, 94, 96–
98). Reported psychiatric comorbidities mostly included
SUD (17, 89–92, 95), schizophrenia/psychotic symptoms
(89, 91, 92), and mood disorders (17, 90, 91). DPH was
taken in most cases orally, but both intramuscular (IM) (90)
and intravenous (IV) (96–98) administrations were reported
as well. Super-high dosages were recorded, up to 2,000mg
daily (91–93, 98). In a few cases, DPH was misused together
with alcohol (91, 99), lorazepam (98), and cannabis (99).












































Oral • Chlorpheniramine acts primarily as
a potent H1 antihistamine drug
• Moderate anticholinergic activity
• Chlorpheniramine has been found
to act as a serotonin
reuptake inhibitor
• ACUTE EFFECTS: psychiatric effects: (i) sedating
and anxiolytic properties; (ii) its abuse has been
related to pleasurable feelings such as euphoria
and stimulating effects; (iii) it may be associated
with psychotic symptoms in predisposed
individuals (e.g., people with mental illnesses or
individuals concomitantly abusing other drugs)
• CHRONIC EFFECTS: dependence
• Drug dependence is recorded after
long-term use




“Triple c” refers to Coricidin®
cough and cold tablets; the
combination of codeine, methyl
ephedrine chlorpheniramine, and
caffeine is marketed as Bron®;








Codeine (opioid) Oral, IV • It is a selective agonist of the
mu-opioid receptor; it is a natural
isomer of methylated morphine,
requiring metabolic activation by
O-demethylation to morphine
by CYP2D6
• ACUTE EFFECTS: psychiatric effects: euphoria,
elation, analgesia, calmness; physical effects:
respiratory depression, extreme somnolence
progressing to stupor or coma, skeletal muscle
flaccidity, cold and clammy skin, and sometimes
bradycardia and hypotension. The triad of coma,
pinpoint pupils, and respiratory depression is
strongly suggestive of opiate poisoning. In severe
overdosage, death may occur
• CHRONIC EFFECTS: dependence
• Codeine has an identified abuse
liability potential, given its effect and
development of tolerance within a
short timeframe on regular or
excessive use
• Codeine-dependence was here
recorded, and associated with daily
use of codeine
Street names: “Captain Cody,”
“Cody,” “Little C,” “Schoolboy,”
“Doors & Fours.” Common
brand names for codeine and
codeine containing
combinations: Aspalgin® for
aspirin and codeine; Nurofen














• At high doses, acting as a NMDA
receptor antagonist, DXM and its
potent metabolite dextrorphan




• DXM also exhibits binding activity
at serotonergic receptors
• Neurobehavioural effects begin within 30–60min
of ingestion and persist for approximately 6 h
• They are dose-related, starting from a mild to
moderate stimulation with restlessness and
euphoria (100–200mg), to a state characterized
by hallucinations, paranoia, perceptual
distortions, delusional beliefs, ataxia, and
out-of-body experiences (>1,000mg)
• ACUTE EFFECTS: (i) psychiatric effects: euphoria,
altered mental status, mania, mood lability,
irritability, dysphoria, insomnia; (ii) physical effects:
tachycardia, hypertension, vomiting, mydriasis,
diaphoresis, nystagmus, dystonia, loss of motor
coordination;
• CHRONIC EFFECTS: (i) toxic psychosis and
cognitive deterioration; (ii) folate deficiency and
neuropathy; (iii) since DXM is produced as the
crystalline hydrobromide salt, bromism is a rare
consequence that has been identified in heavy
chronic abusers of DXM (neurotoxic effects,
resulting in somnolence, psychosis, seizures,
and delirium
• Although DXM is not thought to
have addictive properties, its







• EMCDDA: regarded as NPS
Street names: “Bromage,”
“Brome,” “Candy,” “Dex,”
“Dextro,” “DM,” “Drex,” “DXM,”
“Red Devils,” “Robo,” “Rojo,”
“Skittles,” “Triple C,” “Tussin,”
“Velvet,” and “Vitamin D,” “Poor
Man’s Ecstasy”; the practice of
using large amounts of DXM to
achieve psychoactive effects is
known as “robotrippin.”
Common brand names are:
Balminil DM®, Benylin DM®,
Bronchophan®, Buckleys D®,




































































































• It is a first generation
H1-antihistamine
• Diphenhydramine also acts as a
potent anticholinergic agent
• It can acutely block the cell
membrane pump mechanism of
central 5-hydroxytryptophane and
peripheral noradrenaline neurons
• ACUTE EFFECTS: (i) psychiatric effects: euphoria,
altered mental status, hallucinations, and/or
psychosis; (ii) physical effects: tachycardia,
xerostomia, mydriasis, blurred vision, ileus,
urinary retention, CNS depression, agitation, and
hyperactivity
• CHRONIC EFFECTS: dependence
• Reported cases of DPH
dependence have resulted from
usage of large doses (often over
1,000mg per day) over periods of
months or years. Withdrawal
symptoms include craving,
worsening of insomnia, rhinorrhoea,
nausea, irritability, restlessness,
abdominal cramps, sweating, and
diarrhea. Gradual tapering has
been the only described
detoxification treatment plan






Oral • It is a phenothiazine derivative and
a H1 receptor antagonist; It also
acts as a direct antagonist at
muscarinic (M1) and dopamine (D2)
receptors. It is classified as a
first-generation antihistamine
molecule which easily penetrates
the blood-brain barrier and is
associated with adverse effects
such as sedation
• ACUTE EFFECTS: from mild sedation and CNS
depression to profound hypotension, respiratory
depression, unconsciousness, and sudden
death; overdosage might determine an
antimuscarinic delirium, agitation and neuroleptic
malignant syndrome
• it can be used to enhance effects of other
co-ingested substances, e.g., opioids
• CHRONIC EFFECTS: NR
• EMCDDA: regarded as NPS
• Dependence might develop after
long-term use of promethazine
cough mixtures (containing opioids)
Promethazine mixed with a soft
drink and/or alcohol is known as
“purple drank,” “lean,” “syzzurp,”
“Texas tea”; Phenergan® and









exerting a stimulating action on
alpha, beta1-, and
beta2-adrenergic receptors
• ACUTE EFFECTS: stimulant effects, e.g.,
euphoria, insomnia, diminished sense of fatigue,
anorexia, and accelerated thinking; psychotic
symptoms with auditory and visual hallucinations,
persecutory delusions, fear, disorganized behavior
might develop after high-dose consumption
• CHRONIC EFFECTS: dependence
• Dependence might be developed
after long-term use
• Withdrawal symptoms include:
dysphoria, restlessness, abnormal
perceptions
• Due to the possibility to be used to
manufacture the class A controlled
drug methylamphetamine,
restrictions have been in place in
the UK to manage the risk of
products containing
pseudoephedrine and ephedrine; in
the US, a prescription is not
needed in most States, and in
remaining States there are limits on







acetylsalicylic acid diluted in




CNS, central nervous system; DH, Dimenhydrinate; DPH, Diphenhydramine; EMCDDA, European Monitoring Centre for Drugs and Drug Addiction; GABA, Gamma-Amino-Butyric Acid; H, Histamine; IN, Intranasal; IV, Intravenous;
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A polydrug overdose (e.g., DH together with bupropion,
citalopram, acetaminophen, omeprazole, and naproxen) was
recorded (94). DPH recreational use was associated with
relaxation, calmness, and sleep improvement (90, 92, 96, 98, 99).
Acute intoxication was associated with psychotic symptoms,
psychomotor agitation, restlessness, and disorientation (89, 92–
96, 98, 99). Withdrawal, consisting in both physical (e.g.,
bowel and bladder incontinence, hypertension, hypertonia, and
extrapyramidal symptoms) and psychological (e.g., anxiety,
irritability, rebound insomnia, and craving) symptoms have been
recorded (17, 89, 90, 92, 95, 98, 99). DPH-induced intoxication
was associated with signs and symptoms of anticholinergic
toxicity, such as fever, mydriasis, flushed skin, dry mouth, dry
eyes, decreased sweating, urinary retention, and dyskinesia
(92–94, 98). A severe toxicity case was associated with cardiac
conduction abnormalities and increased QT interval (90).
On-drug cases of violent behavior, including suicide, have
been reported (97, 99). Treatment required hospitalization
and supportive care; drugs used were antipsychotics,
such as fluphenazine and quetiapine, benzodiazepines,
and benztropine (89, 90, 92, 93).
Promethazine
A few papers recorded here the misuse of promethazine; a
retrospective analysis of data from the American Association
of Poison Control Centres (AAPCC) National Poison Data
System (NPDS) from January 2002 to December 2012 reported
354 promethazine intentional misuse/abuse cases (100)
(Supplementary Table 1). All cases involved adolescents and
young adults who misused promethazine orally. In most
cases (n = 259) promethazine abuse was associated with
other substances, such as DXM, codeine, phenylephrine,
pseudoephedrine, caffeine, etc. Intoxication symptoms ranged
from mild to severe effects, up to seizures and coma, but no
fatalities have been reported. Agitation, confusion, slurred
speech, and hallucinations were described as well. Promethazine-
alone abuse cases were mostly managed in healthcare facilities,
while promethazine in coformulationmostly required emergency
department (ED) care management (100). Moreover, further
cases of nonmedical use of promethazine were here identified
from (i) the Danish Poison and Information Centre (DPIC)
and related registers used within the State Serum Institute
of Denmark (SSI) (101); (ii) a prospective database of
poisoning admissions (January 1987-May 2007) to a UK
regional toxicology service (102); and (iii) a prospective study
regarding patterns of misuse of heroin injectors (103). Drug-
induced delirium was the most represented psychiatric effects;
this was managed with antipsychotics and benzodiazepines
(101, 102). Interestingly, the use of promethazine injection
in opioid users was reported as a substitute for heroin
or to increase the effects of an inadequate heroin dosing
(103). A case of drug-induced delirium deriving from the
coingestion of high-dose promethazine, cyproheptadine, and
fluvoxamine in a young girl was recorded (104). Finally, a
case of promethazine dependence and withdrawal after 2-
year continuing use of a promethazine–cough mixture was
described (105).
Pseudoephedrine
Seven articles, including six case reports (106–111) and one
case series (112), described the misuse of pseudoephedrine
(Supplementary Table 1). Cases mostly involved male adults
(age range, 18–45 years) (F/M, 3/7) suffering from mood
disorders (107, 109–111). One paper recorded an SUD
[e.g., alcohol, cannabis, and heroin; (112)]. Massive dosages
[e.g., 3,000–4,500mg of pseudoephedrine/day; (107)] and
IV administrations (108, 111, 112) have been associated
with the misuse of pseudoephedrine. Physical symptoms
associated with pseudoephedrine high dosage ingestion included
stimulating effects such as decreased appetite, dry mouth,
palpitations (106, 107, 112), and motor symptoms [e.g., gait
and balance disorder, postural instability, generalized dystonia,
hypokinesia, bradykinesia, psychomotor retardation; (106–108,
112)]. Pseudoephedrine effects were dose dependent and ranged
from euphoria, insomnia, diminished sense of fatigue, and
accelerated thinking, to psychotic symptoms with auditory
and visual hallucinations, persecutory delusions, fear, and
disorganized behavior (106, 109–111). Withdrawal symptoms
have been recorded after the abrupt interruption of the long-
term use (106, 107). Some cases required hospitalization and
treatment with antipsychotics, e.g., haloperidol (106, 109–111);
benzodiazepines (108); and antidepressants, e.g., amitriptyline
(106, 108). No fatalities have been recorded.
DISCUSSION
This systematic review has illustrated a range of both themes
and data regarding the misuse/abuse of some selected OTC
drugs, including DXM, DPH, DH, codeine-based cough syrups,
promethazine, and pseudoephedrine. Their misuse potential may
be particularly significant in adolescents and young adults (10,
12, 113). OTC recreational intake appeared to be associated
with high/very high dosages (17, 27, 30, 31, 35, 36, 40, 42, 45,
46, 55, 58, 61, 66, 76, 79, 84, 85, 88, 90–93, 104, 107, 114);
idiosyncratic routes of administration (e.g., snorting; IM; IV; 39,
69, 88–90, 100, 103); and associated with ingestion of both licit
[e.g., alcohol, prescription opioids, benzodiazepines, other OTCs;
(25, 35, 49, 52–55, 60, 61, 72, 76, 83, 91, 94, 99, 101, 102)] and
illicit (e.g., cannabis, cocaine, ketamine, etc.) drugs (30, 31, 34,
35, 48, 58, 60, 61, 88, 99). OTC drugs were obtained by various
means (8–11), including family and friends (63), multiple doctor
prescriptions (27, 36, 63, 90, 93), illegal online pharmacies/shops
(36, 42, 70, 77), and theft/burglary from hospitals, residences,
and pharmacies (27, 105, 110). DXM pills named “Snurf” were
also reported to have been acquired online and in having been
marketed as a legal high (70).
Overall, two main populations of OTC misusers were
identified (11): (a) patients already suffering from a health
condition and/or a psychiatric disorder who became dependent
on their prescription/OTC drugs due to prolonged/high-dosage
use (115), e.g., DXM-based cough mixtures started for sinusitis,
cough, nasal congestion, and then continued for years at
higher dosages (27, 58). Other examples have included DH
prescribed for emesis in pregnancy and then continued for
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12 years at a higher dosage without a prescription (82),
DPH use initiated to assist with initial insomnia and then
continued for 6 months up to 1,600mg daily (92), and
pseudoephedrine self-administered to lose weight then causing
addiction (106); (b) individuals, including substance abusers, not
in treatment for a medical disorder or illness who may have
started to misuse/abuse with OTC medications for recreational
purposes (36, 40, 43, 45, 70, 116).
Out of a total of n = 185 OTC misusers described in
case reports/series surveys (24, 25, 77, 78, 99–103), male
subjects were the most represented (F/M = 51/134), with an
SUD history having been recorded in 53 of them (53/185
= 28.6%). A range of psychiatric diagnoses were reported
(45/185 misusers, 24.3%), including mood disorders (e.g., bipolar
disorder, depression, dysthymia; N = 26), anxiety disorders (e.g.,
adjustment disorder, anxiety; N = 5), psychotic disorders (e.g.,
schizoaffective disorder, schizophrenia, psychosis, delusional
disorder; N = 11), attention deficit and hyperactivity disorder
(ADHD, N = 1), eating disorders (e.g., bulimia; N = 1),
and personality disorders (e.g., dependent disorder; N = 1).
Regarding the outcome, most cases recorded were associated
with a full recovery after hospitalization, with treatment having
been either supportive (32, 44–46, 65) or symptomatic, with the
latter consisting of benzodiazepines and antipsychotics (25, 27,
28, 43, 47, 49, 51, 54, 61, 67, 68, 71, 73–75, 79, 111, 115). A full
detoxification procedure was recorded in cases of dependence
and withdrawal (17, 82, 92, 95, 98, 105, 107, 109, 115); examples
included buprenorphine 2 mg/day to treat a sudden opiate
(codeine) withdrawal symptoms (114), naltrexone as a relapse
prevention agent for DXM dependence (63), and topiramate
for DXM craving (56). Some cases required specific actions
in the Emergency Unit (80). Finally, it has been suggested
here that drug use treatment would benefit from counseling,
behavioral therapies support, and rehabilitation treatment to
better overcome drug craving (11, 18, 27, 28, 34, 36, 46, 48, 53, 59,
60, 78, 84, 110, 117). OTC-related fatalities were here related to
either cases characterized by unusually high dosages (24, 31, 96)
or to suicide/self-aggression (31).
The cough-suppressant DXM resulted here to be the most
popular OTC being misused (Supplementary Table 1) due
to its dose-dependent sedative, dissociative, and stimulant
properties (16, 118–120). Indeed, DXM psychotropic effects
are mostly related to its active metabolite dextrorphan,
which, if used in large dosages, is able to antagonizes N-
methyl-D-aspartate (NMDA) receptors, hence modulating the
excitatory neurotransmission; this results in the production
of specific dissociative, ketamine-like, experiences (19, 25,
31, 56, 118–121) (Supplementary Table 1 and Table 1). The
effects depend upon several factors, such as an individual’s
CYP2D6 subtype, body weight, as well as the degree of
tolerance to DXM, and the concomitant use of other CYP2D6
substrates, including antidepressants (fluoxetine, fluvoxamine,
nefazodone, paroxetine, sertraline, venlafaxine), antipsychotics
(clozapine, haloperidol, risperidone, thioridazine), β-blockers
(atenolol, metoprolol, propranolol), antiarrhythmics, and opioid
analgesics (codeine, tramadol, and methadone), which may
decrease the rate of DXM metabolism, resulting in a DXM
intoxication (13, 19, 47, 121, 122). Due to DXM catabolism
by repeated demethylation, which may lead to abnormal folate
demands for methyl group transfer, a folate deficiency has been
described in association with chronic DXM use (26, 39, 122).
In addition, dental caries cases were associated with the high
syrup content of cough mixtures (26). Although DXM is not
thought to have addictive properties, with chronic use, vulnerable
individuals may rapidly develop tolerance, dependence, and
withdrawal (35, 36, 56, 58, 63, 66, 76). Interactions with
other substances can often produce synergistic effects; in fact,
OTC cough formulations frequently contain, in addition to
DXM, other pharmaceutical agents such as chlorpheniramine,
acetaminophen, or pseudoephedrine, exhibiting different effects.
Indeed, individuals abusing with chlorpheniramine-containing
DXM formulations may also exhibit anticholinergic signs and
symptoms (25, 31, 42, 47, 49, 73, 74, 123). Conversely, the
antipyretic and analgesic acetaminophen produces delayed
hepatic injury (29, 62). Finally, interactions between DXM and
selective serotonin reuptake inhibitors (SSRIs) or monoamine
oxidase inhibitor (MAOI) might further increase the risk of a
serotoninergic syndrome occurrence (67, 68, 121, 124).
Although widely used and generally considered safe, cases
of antihistamine abuse and dependence have been recorded
(125). These molecules were originally marketed for their
antiallergy properties and are now made available as sleeping
aids. Antihistamines’ toxicity appears to be clinically related
to both central and peripheral acetylcholine antagonism. In
addition, specifically due to multiple potential mechanisms
of action, DPH (e.g., the antihistamine moiety of DH) can
acutely block the cell membrane pump mechanism of central
5-hydroxytryptophane and peripheral noradrenaline neurons,
causing the euphoria reported by some users (Table 1). At high
dosages, and taken together with other drugs (e.g., alcohol,
cannabis, and stimulants), DPH and DH might be used to
achieve a stimulant effect (87, 91, 92, 126, 127). Reported
cases of DPH dependence have resulted from long-term usage
of large doses (often over 1,000 mg/day). Gradual tapering
has been described to alleviate withdrawal symptoms (17,
125). Conversely, promethazine is used in cough syrups for
its antihistaminic, antiemetic, and sedative effects, available
with codeine in common cough suppressants (128); its abuse
potential appears related to its calming and sedating effect
and enhancement of other coingested substances (Table 1).
A recreational use of promethazine mixed with a soft drink
and/or alcohol (“purple drank”) is currently popular among
young people for its euphoric effects and easy accessibility
(19, 20, 129–131). Promethazine has been reported in SUD
clients and is misused as a substitute for another drug or to
increase the effects of inadequate dosing (i.e., to delay the onset
of opioid withdrawal or to potentiate the sedating effect of
benzodiazepines/Z-drugs) (13, 19, 20, 103, 129, 130, 132, 133).
Overdose of promethazine is associated with an antimuscarinic
delirium, agitation, and neuroleptic malignant syndrome (100,
102, 104, 133). Scott et al. (104) recorded a promethazine-
induced delirium treated with physostigmine intravenously,
which reversed both central and peripheral anticholinergic
effects, similarly to a polydrug overdose due to the ingestion
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of DPH (94). Chlorpheniramine is used as a cheap sleep aid
and/or as an anxiolytic due to its antimuscarinic properties;
its abuse has been related to pleasurable feelings, which
reinforces the repetitive use and the possibility of developing
drug dependence (Table 1). It may, however, be associated with
psychotic symptoms in predisposed individuals [e.g., people
with mental illnesses or individuals concomitantly abusing
other drugs; (42, 43, 114, 115)].
Codeine was reported within the misusing scenario of
codeine-based cough and cold medicines and/or coingested with
other substances, e.g., DXM, DPH, ephedrine, pseudoephedrine,
methyl ephedrine, chlorpheniramine, promethazine, caffeine
(26, 27, 34, 78–80, 100, 114, 134). Codeine is a natural
isomer of methylated morphine and, similarly to DXM, is a
prodrug, requiring metabolic activation by O-demethylation
to morphine by CYP2D6. Thus, codeine-related effects are
associated with CYP2D6 metabolism, e.g., ultrarapid CYP2D6
metabolizers produce an unexpectedly large amount of
morphine, with resulting life-threatening opioid toxicity. Its
recreational use is related to the agonism at mu receptors and
the subjective effects of euphoria, elation, analgesia, and “liking”
(114, 121). Codeine toxicity is characterized by respiratory
depression and extreme somnolence progressing to stupor
or coma (79); in severe overdosage cases, death may occur
(121) (Supplementary Table 1 and Table 1). Idiosyncratic
codeine administration procedures have been recorded, e.g.,
a misuser learned online how the codeine base might be
extracted through a process called cold water extraction
(CWE) to be then injected. Regular use of codeine is described
here together with the development of both tolerance (135)
and dependence (80, 114).
Decongestants, here recorded as being abused, both alone
and with coingestants, were ephedrine and its stereoisomer
pseudoephedrine (78, 79, 106–109, 111, 112), which are
sympathomimetic agents (136, 137) exerting a stimulating
action on both alpha- and beta-adrenergic receptors (136, 137)
(Supplementary Table 1 and Table 1). Indeed, ephedrine has
been reported to obtain weight loss or to enhance athletic
performance; both pseudoephedrine and ephedrine have been
recorded as used illicitly in the production of methamphetamine
(136, 138). The abuse was here associated with high dosage (106–
109) and IV administration (108, 111, 112). Dependence issues
have been recorded (106–109).
LIMITATIONS
One of the difficulties regarding the literature on prescription
drug misuse is both its heterogeneity and the issues in identifying
misusing practices; interpretation was easier for both those cases
reported by healthcare professionals, whose intervention was
needed, National/Regional PoisonData System information (100,
101), etc. According to UNODC, the misuse of medicines is
defined as “the problematic consumption outside of acceptable
medical practice or medical guidelines, when self-medicating at
higher doses and for longer than is advisable, for intoxicating
purposes and when risks and adverse consequences outweigh the
benefit” (8–11). However, levels of terminology variability and
inconsistency to describe the OTC phenomenon were identified
as well; this use was referred to as non-medical use, problem use,
harmful use, recreational use, self-medication, or inappropriate
use, which calls into question whether there is a consensus on
the negative consequences (i.e., problem, harm) of OTC use.
Indeed, some of these terms may not even necessarily refer to the
same issue (8).
CONCLUSIONS
The current systematic review showed that OTC misuse is
an increasingly relevant health issue associated with potential
harms, including drug-related toxicity, addiction, and fatalities.
Nowadays, the CoViD-19 pandemic has likely facilitated the
occurrence of these misusing practices, as more users turned
from street drugs to prescription/OTC products (14, 15). Indeed,
OTC drugs are both widely accessible and perceived because of
their favorable legal status as relatively safe, hence accepted in
a “pill-popping culture” (11). There is the need of both drafting
ad hoc treatment guidelines and planning preventative measures.
These measures should revolve around the implementation of
a range of associated issues, including scheduling amendments,
proper surveillance, enhanced detection of misuse in clinical and
pharmacy practice, and promotion of public health awareness
initiatives (9, 11, 16, 139–141). As an example, due to the recent
rise in opioid abuse and related overdose deaths worldwide,
efforts are focusing on strengthening public health surveillance
and limiting opioid prescribing (142, 143). Specifically, as
codeine-containing products misusing levels might be hampered
by their widespread and easy availability, upscheduling and
pharmacy-based interventions targeting users might limit the
purchase of codeine products without a prescription. The recent
introduction of new OTC combinations with non-opioid agents
may provide a safer alternative to these widely misused products
(144). In the case of the antidiarrheal loperamide, found to be
misused at high dosages and associated with cardiotoxicity, to
support its safe use, the Food and Drug Administration (FDA)
approved changes to the packaging for tablet and capsule forms
limiting each carton to no more than 48mg of loperamide and
requiring the tablets and capsules to be packaged in individual
doses (145). A range of professionals should be involved in
tackling the OTC misusing issues, including (i) physicians,
especially general practitioners (GP), who can help OTCmisusers
in early recognizing a drug-related problem and refer them
to the appropriate service (e.g., mental or addiction services);
they should also take note of rapid increases in the amount of
medication needed or frequent, unscheduled refill requests and
uncovering possible “doctor shopping” practices. Physicians will
continue to have a role in educating users to ensure that they use
medications appropriately, following the prescribed directions,
while being aware of potential interactions with other licit/illicit
drugs (11, 16, 18, 116, 135, 141). Conversely, pharmacists
should be watchful for prescription falsifications or alterations,
being at the frontline in recognizing prescription drug abuse
issues. Moreover, prescription drug monitoring programs could
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assist healthcare professionals in identifying patients who are
getting prescriptions from multiple sources (11, 13, 16–18, 141,
144, 146). Finally, abuse prevention campaigns might provide
valuable resources on raising awareness and preventing medicine
abuse [https://stopmedicineabuse.org/; (144)].
DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included
in the article/Supplementary Material, further inquiries can be
directed to the corresponding author/s.
AUTHOR CONTRIBUTIONS
FS, SC, and GM conceived the idea of this paper. AM, MCS, and
AMo extracted the data. FS, MP, GM, AG, and MDG supervised
all stages of the process andwere consulted to resolve any possible
disagreement. SC, AM, and JMC drafted the first version and
revised it after contributions from FS, AG, and GM. All authors
contributed to the article and approved the submitted version.
FUNDING
GM received funds from the European Project entitled Analysis,
Knowledge dissemination, Justice implementation, and Special
Testing of Novel Synthetic Opioids—JUST-2017-AG-DRUG.
SUPPLEMENTARY MATERIAL




1. FDA. Understanding Over-the-Counter Medicines. Food and Drug
Administration (2018). Available from: https://www.fda.gov/drugs/buying-
using-medicine-safely/understanding-over-counter-medicines (accessed
January 17, 2021).
2. MHRA. Guidance Medicines: Reclassify Your Product. Medicines and
Healthcare products Regulatory Agency (2020). Available from: https://
www.gov.uk/guidance/medicines-reclassify-your-product#:~:text=’Over
%2Dthe%2Dcounter%20,in%20the%20UK%20medicines%20regulations
(accessed January 17, 2021).
3. Cooper RJ. ’I can’t be an addict. I am’ Over-the-counter
medicine abuse: a qualitative study. BMJ Open. (2013) 3:e002913.
doi: 10.1136/bmjopen-2013-002913
4. Hughes C. A retrospective evaluation of over-the-counter (OTC) drug-
related overdoses at Accident and Emergency Departments in Northern
Ireland. In: Abstract at the BPC- Manchester, UK (September 1, 2003) (2003).
p. R45–5.
5. Wazaify M, Shields E, Hughes CM, McElnay JC. Societal perspectives
on over-the-counter (OTC) medicines. Fam Pract. (2005) 22:170–6.
doi: 10.1093/fampra/cmh723
6. Cooper RJ. Over-the-counter medicine abuse-a review of the literature. J
Subst Use. (2013) 18:82e107. doi: 10.3109/14659891.2011.615002
7. NIDA. Over-the-Counter Medicines DrugFacts. National Institute on Drug
Abuse (2017). Available from: https://www.drugabuse.gov/publications/
drugfacts/over-counter-medicines (accessed January 10, 2021).
8. Barrett SP, Meisner JR, Stewart SH. What constitutes prescription
drug misuse? Problems and pitfalls of current conceptualizations.
Curr Drug Abuse Rev. (2008) 1:255–62. doi: 10.2174/18744737108010
30255
9. Casati A, Sedefov R, Pfeiffer-Gerschel T. Misuse of medicines in the
European Union: a systematic review of the literature. Eur Addict Res. (2012)
18:228–45. doi: 10.1159/000337028
10. Novak SP, Håkansson A, Martinez-Raga J, Reimer J, Krotki K, Varughese
S. Nonmedical use of prescription drugs in the European Union. BMC
Psychiatry. (2016) 16:274. doi: 10.1186/s12888-016-0909-3
11. UNODC. The Non-Medical Use of Prescription Drugs. Policy direction
issues. Discussion paper. United Nations OFFICE on DRUGS and
Crime (2011). Available from: https://www.unodc.org/documents/
drug-prevention-and-treatment/nonmedical-use-prescription-drugs.
pdf (accessed January 10, 2021).
12. Fingleton NA, Watson MC, Duncan EM, Matheson C. Non-prescription
medicine misuse, abuse and dependence: a cross-sectional survey
of the UK general population. J Public Health. (2016) 38:722–30.
doi: 10.1093/pubmed/fdv204
13. Chiappini S, Guirguis A, Corkery JM, Schifano F. Understanding the use of
prescription and OTC drugs in obtaining highs and the pharmacist role in
preventing abuse. Pharm J. (2020) 305:7943. doi: 10.1211/PJ.2020.20208538
14. Chiappini S, Guirguis A, John A, Corkery JM, Schifano F. COVID-19: The
hidden impact on mental health and drug addiction. Front Psychiatry. (2020)
11:767. doi: 10.3389/fpsyt.2020.00767
15. Chiappini S, Schifano F. What about “Pharming”? Issues regarding the
misuse of prescription and over-the-counter drugs. Brain Sci. (2020) 10:736.
doi: 10.3390/brainsci10100736
16. Levine DA. “Pharming”: the abuse of prescription and over-
the-counter drugs in teens. Curr Opin Pediatr. (2007) 19:270–4.
doi: 10.1097/MOP.0b013e32814b09cf
17. Gracious B, Abe N, Sundberg J. The importance of taking a history of over-
the-counter medication use: a brief review and case illustration of “PRN”
antihistamine dependence in a hospitalized adolescent. J Child Adolesc
Psychopharmacol. (2010) 20:521–4. doi: 10.1089/cap.2010.0031
18. NIDA. National Institute of Health (NIH). Research Report Series.
Prescription Drug Abuse. National Institute on Drug Abuse (2011).
19. NIDA. Cough and Cold Medicines. National Institute on Drug Abuse
(2020). Available from: https://teens.drugabuse.gov/drug-facts/cough-and-
cold-medicines (accessed January 10, 2021).
20. NIDA. Misuse of Prescription Drugs. Overview. National Institute on Drug
Abuse (2020). Available from: https://www.drugabuse.gov/publications/
research-reports/misuse-prescription-drugs/overview (accessed January 10,
2021).
21. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew
M, et al. Preferred reporting items for systematic review and meta-
analysis protocols (PRISMA-P) 2015 statement. Syst Rev. (2015) 4:1.
doi: 10.1186/2046-4053-4-1
22. Bernardo WM. PRISMA statement and PROSPERO. Int Braz J Urol. (2017)
43:383–4. doi: 10.1590/s1677-5538.ibju.2017.03.02
23. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: assessing risk
of bias in included studies. In: Cochrane Handbook for Systematic Reviews
of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017 (2017).
Available from: www.training.cochrane.org/handbook (accessed December
20, 2020).
24. Forrester MB. Dextromethorphan abuse in Texas, 2000-2009. J Addict Dis.
(2011) 30:243–7. doi: 10.1080/10550887.2011.581986
25. Ritter D, Ouellette L, Sheets JD, Riley B, Judge B, Cook A, et al. “Robo-
tripping”: Dextromethorphan toxicity and abuse. Am J Emerg Med. (2020)
38:839–41. doi: 10.1016/j.ajem.2019.10.001
26. Au WY, Tsang J, Cheng TS, Chow WS, Woo YC, Ma SK, et al. Cough
mixture abuse as a novel cause of megaloblastic anaemia and peripheral
neuropathy. Br J Haematol. (2003) 123:956–8. doi: 10.1046/j.1365-2141.2003.
04694.x
Frontiers in Psychiatry | www.frontiersin.org 10 May 2021 | Volume 12 | Article 65739716
Schifano et al. Focus on Over-the-Counter Drugs’ Misuse
27. Ghosh AK, Peh LH. Dextromethorphan: abusing the overused. Singapore
Med, J. (2011) 52:134–5.
28. Hapangama A, Kuruppuarachchi K. Dextromethorphan abuse. React Wkly.
(2011) 18:109–110. doi: 10.2165/00128415-201113640-00066
29. Kirages TJ, Sulé HP, Mycyk MB. Severe manifestations of
coricidin intoxication. Am J Emerg Med. (2003) 21:473–5.
doi: 10.1016/S0735-6757(03)00168-2
30. Logan BK. Combined dextromethorphan and chlorpheniramine
intoxication in impaired drivers. J Forensic Sci. (2009) 54:1176–80.
doi: 10.1111/j.1556-4029.2009.01127.x
31. Logan BK, Yeakel JK, Goldfogel G, Frost MP, Sandstrom G, Wickham DJ.
Dextromethorphan abuse leading to assault, suicide, or homicide. J Forensic
Sci. (2012) 57:1388–94. doi: 10.1111/j.1556-4029.2012.02133.x
32. Murray S, Brewerton T. Abuse of over-the-counter
dextromethorphan by teenagers. South Med J. (1993) 86:1151–3.
doi: 10.1097/00007611-199310000-00014
33. Nordt SP. “DXM”: a new drug of abuse? Ann Emerg Med. (1998) 31:794–5.
doi: 10.1016/S0196-0644(98)70250-1
34. Tsang JS, Au WY. Cough mixture abuse and rhabdomyolysis. Hong Kong
Med J. (2012) 18:68–9.
35. Ziaee V, Hamed EA, Hoshmand A, Amini H, Kebriaeizadeh A, Saman K.
Side effects of dextromethorphan abuse, a case series. Addicti Behav. (2005)
30:1607–13. doi: 10.1016/j.addbeh.2005.02.005
36. Akerman SC, Hammel JL, Brunette MF. Dextromethorphan abuse
and dependence in adolescents. J Dual Diagn. (2010) 6:266–78.
doi: 10.1080/15504263.2010.537515
37. Alam LY, Nelson A, Bastiampillai T. Cough syrup psychosis: Is
it under-recognised? Aust N Z J Psychiatry. (2013) 47:1209–10.
doi: 10.1177/0004867413495927
38. Amaladoss A, Brien SO. Cough syrup psychosis. CJEM. (2011) 13:53–6.
doi: 10.2310/8000.2011.100216
39. Au WY, Cheng TS, Siu TS, Tam S. Cerebellar degeneration and
folate deficiency due to cough mixture abuse. Haematologica.
(2005) 90(Suppl.):ECR28.
40. Bernstein LB, Albert D, Baguer C, Popiel M. Long-term
dextromethorphan use and acute intoxication results in an episode
of mania and autoenucleation. J Addict Med. (2020) 14:e133–5.
doi: 10.1097/ADM.0000000000000568
41. Bostwick JM. Dextromethorphan-induced manic symptoms in
a bipolar patient on lithium. Psychosomatics. (1996) 37:571–3.
doi: 10.1016/S0033-3182(96)71523-2
42. Boyer EW. Dextromethorphan abuse. CMJ. (2008) 53:109–10.
doi: 10.4038/cmj.v53i3.256
43. Butwicka A, Krystyna S, Retka W, Wolańczyk T. Neuroleptic malignant
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Opioid analgesics andmaintenance treatments, benzodiazepines and z-drugs, and other
sedatives and stimulants are increasingly being abused to induce psychoactive effects
or alter the effects of other drugs, eventually leading to dependence. Awareness of
prescription drug abuse has been increasing in the last two decades, and organizations
such as the International Narcotics Control Board has predicted that, worldwide,
prescription drug abuse may exceed the use of illicit drugs. Assessment of prescription
drug abuse tackles an issue that is hidden by nature, which therefore requires a
specific monitoring. The current best practice is to use multiple detection systems
to assess prescription drug abuse by various populations in a timely, sensitive, and
specific manner. In the early 2000’s, we designed a method to detect and quantify
doctor shopping for prescription drugs from the French National Health Data System,
which is one of the world’s largest claims database, and a first-class data source
for pharmacoepidemiological studies. Doctor shopping is a well-known behavior that
involves overlapping prescriptions from multiple prescribers for the same drug, to obtain
higher doses than those prescribed by each prescriber on an individual basis. In addition,
doctor shopping may play an important role in supplying the black market. The paper
aims to review how doctor shopping monitoring can improve the early detection of
prescription drug abuse within a multidimensional monitoring. The paper provides an
in-depth overview of two decades of development and validation of the method as
a complementary component of the multidimensional monitoring conducted by the
French Addictovigilance Network. The process accounted for the relevant determinants
of prescription drug abuse, such as pharmacological data (e.g., formulations and
doses), chronological and geographical data (e.g., impact of measures and comparison
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between regions), and epidemiological and outcome data (e.g., profiles of patients and
trajectories of care) for several pharmacological classes (e.g., opioids, benzodiazepines,
antidepressants, and methylphenidate).
Keywords: doctor shopping, prescription drug abuse, claims database, signals detection, addictovigilance,
opioids, benzodiazepines, methylphenidate
INTRODUCTION
Opioid analgesics and maintenance treatments, benzodiazepines
and z-drugs, and other sedatives and stimulants are increasingly
being abused to induce psychoactive effects or alter the effects
of other drugs, eventually leading to dependence (1). Awareness
of prescription drug abuse has been increasing in the last two
decades, and organizations such as the International Narcotics
Control Board has predicted that, worldwide, prescription drug
abuse may exceed the use of illicit drugs (2). Prescription drug
abuse is now qualified as an epidemic in economically developed
countries, particularly in North America (1, 3, 4).
Many studies pointed out an increasing trend of prescription
drug abuse across European countries, highlighting the need
for a specific monitoring (5–9). Several factors may explain this
trend, such as a greater ease in obtaining prescription drugs than
illicit drugs, a lower risk of arrest for trafficking, a higher social
acceptability of their abuse, their higher purity, and their more
predictable doses (6).
Assessment of prescription drug abuse tackles an issue
that is hidden by nature, which therefore requires a specific
monitoring. A single data source is rarely enough to assess
such a complex phenomenon (10). The current best practice
is to use multiple detection systems to assess prescription
drug abuse by various populations in a timely, sensitive,
and specific manner (11). By using various tools to mine
epidemiological data, assess the pharmacological properties of
the drugs, and assess the social contexts where the drugs are
used, these systems demonstrated their usefulness to detect
emerging trends earlier and intervenemore quickly to protect the
public from associated risks (12). Among these tools, assessing
doctor shopping through overlapping prescriptions, multiple
prescribers, or pharmacy shopping was implemented in several
countries (13–19). Therefore, the paper aims to review how
doctor shopping monitoring can improve the early detection of
prescription drug abuse within a multidimensional monitoring.
The paper provides an in-depth overview of two decades of
development and validation of the method as a complementary
component of the multidimensional monitoring conducted by
the French Addictovigilance Network.
RELEVANCE OF DOCTOR SHOPPING AS A
PROXY FOR PRESCRIPTION DRUG ABUSE
Drug-abusing patients may develop drug-seeking behavior to
meet their need. Among them, doctor shopping has long been
described, in several countries (e.g., North America, Europe,
Asia, and Oceania) and for several pharmacological classes
(e.g., opioids, stimulants, and benzodiazepines) (13–19). Doctor
shopping involves overlapping prescriptions from multiple
prescribers for the same drug, to obtain higher doses than those
prescribed by each prescriber on an individual basis. Doctor
shopping is based on circumventing the optimal one-to-one
patient-prescriber relationship, and therefore on a lack ofmedical
management, because one given prescriber does not know that
other prescribers are also prescribing the same drug. The lack of
medical management in addition to high doses increase the risks
for adverse outcomes, such as high-risk use, overdose, and death
(13, 20–24).
Amongmany divertedmeans for obtaining prescription drugs
(e.g., friends or relatives, black market, or internet), doctor
shopping is reported as one of the most frequent ones (25–27).
In addition, obtaining prescription drugs from a dealer raises the
question of how dealers obtain the prescription drugs they sell
(28). Although the question is difficult to answer with a strong
evidence, field studies suggest that doctor shopping may play an
important role in supplying the black market (29–32). Notably,
without regard to the final consumer (i.e., whether the patient
himself or a subsequent purchaser), the concern for the lack of
medical management remains, along with the risks associated
with it.
HOW TO QUANTIFY DOCTOR SHOPPING?
Doctor shopping is difficult to monitor because the patient
often attempts to hide the abuse and the prescribers may not
even realize that they have been deceived. These observations
underline the limitations of interviewing the prescribers or
patients, and therefore, highlight the added value of claims
databases to quantify doctor shopping objectively. Several teams
from different countries have developedmethods to detect doctor
shopping in claims databases (13–19). The methods face two
main challenges: a proper design of the method to accurately
detect drug-abusing patients and the use of a data source that is
representative of the population of interest.
First Challenge: The Design of the Method
The method must be both specific (i.e., must not red flag
non-abusing patients) and sensible (i.e., must not miss real
drug-abusing patients). Nevertheless, there is no standard
definition of doctor shopping, and therefore, no gold standard
method. Most studies assessing doctor shopping rely on the
number of prescribers or pharmacies visited, without regard
to successive and overlapping prescriptions (33). Such methods
may overestimate abuse, because successive prescriptions from
different prescribers may be legitimately needed, particularly in
cancer and palliative care (34), or in similar situations when a
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general practitioner refers a regular patient to a specialist (35).
Other situations involving successive prescribers may not be
related to abuse or restricted to psychoactive prescription drugs,
but rather related to prescriber factors (e.g., inconvenient hours
or locations, long waiting times, or personal characteristics of the
prescriber), illness factors (e.g., persistence of symptoms, lack of
understanding, or lack of confidence in diagnosis or treatment),
or psychological factors (e.g., anxiety leading to dose stockpiling)
(36, 37).
Conversely, overlapping prescription is at the core of the
safety concern, because it is the reason for the lack of
medical management. Interestingly, a study compared the
diagnostic odds ratios for opioid overdose of nine definitions
of pharmacy shopping, using a multistate Medicaid claims
database in the USA (38). The overdose rate was higher in
patients with overlapping prescriptions than in patients with
only pharmacy shopping. In addition, another study quantified
episodes of multiple prescriber for benzodiazepines using a two-
year cohort in Japan. Consecutive overlapping prescriptions had
the best accuracy to detect patients with potentially questionable
prescribed quantities, and predict patients with episodes of
multiple prescriber in the subsequent year (19).
In the early 2000’s, we designed a method to detect and
quantify doctor shopping for prescription drugs, accounting
for overlapping prescriptions (14, 39–45) (Figure 1). To detect
overlapping prescriptions, the method relies on periods of
prescriptions, defined as the period between the first and last
dispensing for each prescriber of each patient (i.e., the period
during which a patient consults a prescriber). If there is a longer
delay than a predefined threshold between two consecutive
dispensings, the period of prescriptions is interrupted. During
an interruption, a prescription from another prescriber is
not considered as overlapping to avoid the overestimation
of doctor shopping. If there are overlapping periods of
prescriptions, there is a lack of medical management, and a
share of the drug prescribed is considered to be obtained
by doctor shopping. The method provides aggregated drug-
level indicators (e.g., total quantity and proportion obtained by
doctor shopping) and population-level indicators (e.g., number
and proportion of patients with doctor shopping behavior),
and individual patient-level indicators (e.g., individual quantity
obtained by doctor shopping) (Figure 2). Taken together, these
complementary indicators enable to assess the extent of abuse
and abuse potential of prescription drugs, and characterize
profiles of patients with doctor shopping behavior and their
trajectories of care.
Notably, the method deliberately relies on a strict design
to specifically detect overlapping prescriptions rather than the
number of prescribers or pharmacies visited. In addition, the
quantity obtained by doctor shopping is not the entire quantity
received by a patient with doctor shopping behavior, but only
the quantity received in addition to what is dispensed with
only one prescriber. The underlying reason for this design is
that the patient may legitimately need the drug for a medical
use at the quantity prescribed by one prescriber. This design
helps to rule out the hypothesis of pseudoaddiction [i.e., doctor
shopping driven by insufficient dosing (46)], because it enables
to discriminate patients who receive high doses in addition to a
treatment considered legitimate (14, 45).
Second Challenge: A Representative Data
Source
To enable an accurate quantification of doctor shopping, the
database must be representative of the population of interest.
In addition, the database must identify each health professional
and health care consumer by a consistent pseudonym over time
and across geography. Given that claims databases were initially
designed for medicoadministrative purposes, it is far from trivial
in practice. For example, in the USA, health insurance plans
only cover residents by states or focus on a specific subset of
the population (e.g., Medicaid covers low-income populations,
while private insurances are employment-based). Notably, the
use of a non-representative population may bias the results,
because socioeconomic status is associated with abuse (47–49).
In addition, some regulation [e.g., the 42 CFR part 2 in the USA,
which aims to ensure confidentiality of records from federally
funded drug and alcohol treatment centers (50)] may further
complicate the use of claims databases.
In this regard, the French National Health Data System
is a first-class data source for pharmacoepidemiological
studies, as one of the world’s largest claims database, whose
representativeness is almost perfect (51–53). The National
FIGURE 1 | Method to detect and quantify doctor shopping for prescription drugs, accounting for overlapping prescriptions. *The quantity obtained by doctor
shopping is calculated as Qd–Qd/n, where Qd is the quantity dispensed, n is the number of overlapping periods of prescriptions, and Qd/n is the quantity that would
have been dispensed with only one prescriber.
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FIGURE 2 | Complementary indicators provided by the method.
Health Data System prospectively merges pseudonymized
records of claims from all the French health insurance plans,
the national hospital-discharge database, and the national death
registry (54). Because the coverage by a health insurance plan is
mandatory in France, the French National Health Data System
covers almost 100% of the 67 million inhabitants, from birth to
death, independently of the socioeconomic status and region of
residence. In addition, each health professional and health care
consumer is identified by a consistent pseudonym over time and
across geography. As a result, the French National Health Data
System enables a nationwide and exhaustive quantification of
doctor shopping.
In the last two decades, the French National Health Data
System has been extensively used for pharmacoepidemiological
research, including some large-scale studies that have led tomajor
public health interventions (55, 56). Among them, many studies
have focused on psychoactive prescription drugs (57–63).
VALIDATION OF DOCTOR SHOPPING AS A
PHARMACOLOGICAL TOOL
Before using doctor shopping as a proxy for prescription drug
abuse, there is a need for an in-depth customized validation
process within the health system of interest. The lack of a
gold standard method makes a classical statistical validation
process impossible (i.e., sensitivity, specificity, and predictive
values). Therefore, an empirical approach is required to assess
the external validity of the proxy in a given health system for
several pharmacological classes. Such a process should rely on
linking doctor shopping to relevant determinants of prescription
drug abuse, such as pharmacological data (e.g., formulations
and doses), chronological and geographical data (e.g., impact of
measures and comparison between regions), and epidemiological
and outcome data (e.g., profiles of patients and trajectories
of care).
In the last two decades, we have conducted such an
empirical validation of our method (14, 39–45) (Table 1).
The process has provided solid evidence that the method
is a relevant proxy for prescription drug abuse within the
French health system, because it has always demonstrated
an excellent external validity. In particular, the method
demonstrated to be a useful pharmacological tool, able to
provide detailed results by discriminating drugs, formulations,
and doses.
Detecting Prescription Drugs With a High
Abuse Potential
The method was first developed for buprenorphine maintenance
treatment (14, 39), which was expected to have a high abuse
potential in the real-life setting. In France, a wide access
to maintenance treatments is ensured by an office-based
setting for the majority of patients (64, 65). In parallel of
a marked decrease in lethal heroin overdoses, a concern
emerged along with observations of abuse (e.g., injection of
crushed tablets, snorting, association with benzodiazepines
such as flunitrazepam, and deaths) and an increasing
buprenorphine black market (14). Interestingly, evidence of
multiple prescribers for buprenorphine maintenance treatment
was also described, but without quantifying the buprenorphine
maintenance treatment involved, nor accounting for overlapping
prescriptions (66).
A study was conducted among the 3,259 patients who
received buprenorphine maintenance treatment in a population
of two million inhabitants in South East France in 1999 and
2000. The method found that 225,351 defined daily doses
(DDD) were obtained by doctor shopping, corresponding to
18.7% of the quantity dispensed (14). Doctor shopping was
highly concentrated on a minority of patients (i.e., 8.5% of
patients accounted for 45.4% of the quantity obtained by
doctor shopping).
As a result, the health insurance implemented a prescription
monitoring program for opioid maintenance therapies in 2004,
for both public health and economic concerns. Patients who
received >32 mg/day of buprenorphine maintenance treatment
(i.e., twice the maximum recommended dose) were proposed
a contract of care, including the choice of a single prescriber
and pharmacist for buprenorphine maintenance treatment.
Patients with particularly high doses who did not respond to
the convocation, or did not respect their contract of care,
could be prosecuted, or excluded from the health insurance
plan. A second assessment of doctor shopping from 2000
to 2005 in the same population found that the prescription
monitoring program led to a decrease in doctor shopping,
without decreasing the access to buprenorphine maintenance
treatment (39).
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TABLE 1 | Empirical validation of the method accounting for overlapping prescription, in the last two decades, in France.











3,259 225,351 DDD were obtained by doctor shopping,
corresponding to 18.7% of the quantity dispensed.
Doctor shopping was highly concentrated on a minority
of patients (i.e., 8.5% of patients accounted for 45.4% of
the quantity obtained by doctor shopping).








Doctor shopping increased from 2000 (i.e., 14.9% of the
quantity dispensed) to 2004 (i.e., 21.7% of the quantity
dispensed), and decreased in 2005 (i.e., 16.9% of the
quantity dispensed) following the implementation of a
prescription monitoring program.
The number of patients remained stable from 2000
to 2005.




Benzodiazepines 128,230 Benzodiazepines were ranked according to their abuse
potential in real-life setting.
The proportion obtained by doctor shopping was the
highest for flunitrazepam 1mg (i.e., 42.8% of the quantity
dispensed), then for diazepam 10mg (i.e., 3.2% of the
quantity dispensed), and clorazepate 50mg (i.e., 2.7% of
the quantity dispensed).






410,525 Tianeptine ranked first among antidepressants for the
proportion obtained by doctor shopping (i.e., 2.0% of the
quantity dispensed), and was close to benzodiazepines
with a well-known abuse potential in real-life setting.















The quantity obtained by doctor shopping in
Provence-Alpes-Côte d’Azur (i.e., 213 DDD/1,000
inhabitants) was two-fold higher than in Rhône-Alpes
(i.e., 115 DDD/1,000 inhabitants) and in Midi-Pyrénées
(i.e., 106 DDD/1,000 inhabitants).
A signal emerged for oxycodone in Midi-Pyrénées.






1,257,246 The proportion obtained by doctor shopping was the
highest for the highest doses of morphine (i.e., 8.4% of
the quantity dispensed for morphine 200mg) and
oxycodone (i.e., 2.8% of the quantity dispensed for
oxycodone 80mg), and for nasal and transmucosal
fentanyl (i.e., respectively 4.1 and 3.3% of the quantity
dispensed).
Soeiro et al. (44) 2010 and 2016 67 million
inhabitants in
France
Oxycodone 67,838 in 2010
212,753 in 2016
There was a three-fold increase in doctor shopping in
line with population exposure.
The quantity obtained by doctor shopping increased with
the dose for both immediate-release and
extended-release tablets.
Soeiro et al. (45) 2016 67 million
inhabitants in
France
Methylphenidate 63,739 Patients with heavy doctor shopping behavior were
older, received more concomitant dispensing of
antipsychotics and opioid maintenance treatments, and
had more prescribers.
DDD, defined daily dose.
Ranking Prescription Drugs Within a
Pharmacological Class Known for Abuse
The method demonstrated its ability to rank prescription drugs
according to their abuse potential in the real-life setting. A
study was conducted among the 128,230 patients who received
benzodiazepine in a population of one million inhabitants in
South West France in 2003. The method found a much higher
proportion obtained by doctor shopping for flunitrazepam 1mg
(i.e., 42.8% of the quantity dispensed), then for diazepam 10mg
(i.e., 3.2% of the quantity dispensed), and clorazepate 50mg (i.e.,
2.7% of the quantity dispensed) (40) (Figure 3).
Interestingly, although flunitrazepam has pharmacological
characteristics prone to abuse [e.g., rapid onset of action,
liposolubility, and additive effects with alcohol (67, 68)],
there is no evidence of any important experimental difference
for its abuse potential compared to other benzodiazepines
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FIGURE 3 | Validation of doctor shopping as a pharmacological tool through its ability to rank prescription drugs within a pharmacological class known for abuse
(e.g., benzodiazepines) and recover pharmacological determinants of abuse (e.g., formulation for methylphenidate and dose for oxycodone). SODAS: Spheroidal Oral
Drug Absorption System; IR: Immediate-release; OROS: Osmotic-Controlled Release Oral Delivery System; CB: Coated beads. See Table 1 in Soeiro et al. (45) for
details on formulations.
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(69). Nevertheless, a review of the literature found that the
two benzodiazepines with the highest abuse potential are
flunitrazepam and diazepam (70), particularly in opioid-abusing
patients, many of whom reported a preference for flunitrazepam
over other benzodiazepines (69).
Discriminating Prescription Drugs Within a
Pharmacological Class Not Known for
Abuse
The method also demonstrated its ability to discriminate
prescription drugs by specifically detecting tianeptine among
antidepressants (41). Back then, tianeptine was thought to
have no abuse potential, as mentioned in the French summary
of product characteristics before 2005, because there was no
evidence of such a risk on the data available before approval (71).
Nevertheless, the first reports of abuse with tianeptine emerged
in the literature (72–75).
A study was conducted among the 410,525 patients who
received an antidepressant in a population of five million
inhabitants in South East France in 2005. Tianeptine ranked first
among the antidepressants for the proportion obtained by doctor
shopping (i.e., 2.0% of the quantity dispensed), and was close to
benzodiazepines with a well-known abuse potential in the real-
life setting (41). In addition to reports from other data sources,
these findings led to a stricter regulation of tianeptine in France.
Interestingly, tianeptine is a selective serotonin reuptake
enhancer and an opioid agonist (76), with a chemical structure
close to amineptine, which was withdrawn in several countries
because of the abuse associated with hepatitis (77, 78).
In addition, psychostimulant effects of tianeptine appear at
high doses (75). These pharmacological properties makes




The method finally demonstrated its ability to recover
pharmacological determinants of abuse, such as a preference for
specific formulations and high doses for several pharmacological
classes (e.g., benzodiazepines, opioids, and methylphenidate)
(40, 42–45).
The effect of formulation is especially notable for
methylphenidate, which was available in five formulations, using
different extended-release technologies and ratio of immediate-
release/extended-release methylphenidate in France in 2016. On
the same year, a study was conducted among the 63,739 patients
who received methylphenidate in the 67 million inhabitants
in France. Patients with doctor shopping behavior preferred
formulations with a higher ratio of immediate-release/extended-
release methylphenidate (e.g., methylphenidate with Spheroidal
Oral Drug Absorption System and methylphenidate immediate-
release) over methylphenidate with Osmotic-Controlled Release
Oral Delivery System (OROS) (45) (Figure 3). Given that the use
of intravenous route for methylphenidate is frequent in France
(79–81), this pattern also suggests that a part of methylphenidate
obtained by doctor shopping may be used by intravenous route,
because methylphenidate OROS is the least preferred drug for
intravenous route in drug-abusing patients (82). Interestingly,
OROS increases the time for preparing due to the viscosity of the
preparation, which may be the reason for this preference (83).
Similarly, the effect of dose is especially notable for oxycodone,
which was available in 12 doses from 5 to 120mg in France in
2016. A study was conducted in 2016 among the 212,753 patients
who received oxycodone in the 67 million inhabitants in France.
There was a dose-response-like relationship between dose and
doctor shopping (i.e., the quantity obtained by doctor shopping
increased with the dose for both immediate- and extended-
release tablets) (44) (Figure 3). Interestingly, as soon as 2008, the
method detected a first signal for oxycodone, particularly in one
region (81), although no oxycodone abuse had been detected in
France back then. This finding underlines the usefulness of local
monitoring to assess the geographical specificities of abuse, which
may help to target public health interventions (84).
ADDED VALUE OF DOCTOR SHOPPING
MONITORING TO IMPROVE THE EARLY
DETECTION OF PRESCRIPTION DRUG
ABUSE WITHIN A MULTIDIMENSIONAL
MONITORING
In order to face the challenges of monitoring prescription drug
abuse, several authors and health authorities advocate for a
multidimensional proactive post-marketing monitoring (10–12).
Such a multidimensional monitoring is already operational in
France through the French Addictovigilance Network (85–90).
In addition to a spontaneous notification by health professionals
and pharmacoepidemiological studies from claims databases (91,
92), multiple ad hoc studies have been conducted nationwide,
such as: the OSIAP program, to detect forged prescription (93,
94); the OPPIDUM program, to detect psychoactive drug use in
drug-abusing patients (95, 96); the DRAMES program, to detect
deaths related to psychoactive drugs; the DTA program, to detect
deaths related to analgesic prescription drugs; or the chemical
submission program, to detect psychoactive drugs administered
without the victim’s knowledge (97).
The multidimensional monitoring conducted by the French
Addictovigilance Network enables the detection of signals by
crossing complementary data sources, which overcomes the
limitation of each data source taken individually (Figure 4).
In addition to the already existing programs of the French
Addictovigilance Network, the added value of doctor shopping
monitoring is its ability to exhaustively detect drug-abusing
patients in the general population, and for all the marketed
prescription drugs. This ability in not only theoretical, as
demonstrated by a nationwide quantification of doctor shopping
recently conducted in France for 220 psychoactive prescription
drugs from many pharmacological classes (e.g., opioids,
benzodiazepines, stimulants, antihistamines, gabapentinoids,
antidepressants, and antipsychotics) (98). Given its automatic
nature, the method can be implemented routinely, with minimal
costs and limited workforce. Interestingly, doctor shopping
monitoring is not impaired by under-declaration. Such features
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FIGURE 4 | Multidimensional monitoring conducted by the French Addictovigilance Network to detect signals by crossing complementary data sources.
make doctor shopping monitoring a complementary tool, which
is evenmore topical in the big-data era to assess prescription drug
abuse and detect emerging trends in the field of addictovigilance
as early as possible (99).
For example, the monitoring of tramadol conducted by
the French Addictovigilance Network detected an increasing
abuse (100, 101). Beside a regular increase in spontaneous
reports, tramadol has been used in combination or in alternation
with other opioids in drug-abusing patients according to
the OPPIDUM program; has ranked first among analgesics
for deaths in the DTA program; and has increased for
falsified prescriptions in OSIAP. These converging data are
further strengthened and complemented by the nationwide
quantification of doctor shopping in France (98). Notably,
tramadol ranked ninth among 220 psychoactive prescription
drugs for the quantity obtained by doctor shopping (i.e., 755,333
DDD). From 2010 to 2016, tramadol was one of the few opioids
for which both quantity and proportion obtained by doctor
shopping increased (i.e., +12% and +5%, respectively). In the
population approach, tramadol ranked first for the number of
patients with doctor shopping behavior (i.e., 44,088 patients).
Interestingly, tramadol is an atypical opioid analgesic that also
inhibits the reuptake of serotonin and norepinephrine (102).
In addition, O-desmethyltramadol, which is produced by the
polymorphic cytochrome P450 2D6, has a 200 to 500 higher
affinity for µ-opioid receptor than tramadol (103). In light of
the pharmacological properties of tramadol and international
data (104–106), these increasing trends are strong signals in the
French context.
DISCUSSION
The paper aims to review how doctor shopping monitoring can
improve the early detection of prescription drug abuse within a
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multidimensional monitoring. The paper provides an in-depth
overview of two decades of development and validation of the
method as a complementary component of the multidimensional
monitoring conducted by the French Addictovigilance Network.
In this context, doctor shopping monitoring has demonstrated
its added value to improve the early detection of prescription
drug abuse. Notably, the monitoring must also include a strong
pharmacological expertise, which is essential to both analyze
signals and interpret pharmacoepidemiological data.
While the method has been developed and validated in
France, the rationale is transposable in other health systems
with available claims databases. In practice, given the increasing
availability of claims databases in several countries, the main
issue is to integrate doctor shopping monitoring within a
multidimensional monitoring. In addition, the method must
undergo an in-depth customized validation process, accounting
for the specificities of the targeted health system (e.g., availability
of prescription drugs and illicit alternatives, cost of prescription
drugs and visits, prescription and control methods, and risks
involved for fraud).
Such pharmacoepidemiological monitoring is intended to
develop in the big-data era. Interestingly, it is nowadays
technically possible to implement a real-time doctor shopping
monitoring, assuming that a quick access to data is available,
which is currently the bottleneck.
Finally, as a public health mission, monitoring prescription
drug abuse must rely on free from conflict-of-interest
organizations to prevent private interest from interfering,
as it was the case in the opioid crisis (107, 108). This is even
more necessary given that such monitoring may lead to the
reconsideration of the safety of some prescription drugs in the
real-life setting, and trigger regulatory measures. Among them,
prescriptionmonitoring programs are efficient to mitigate doctor
shopping and its consequences (39, 109, 110). Nevertheless, the
consequences of such regulatory measures must be globally
assessed, because hardening the access to prescription drugs
may lead to switching to illicit drugs. The challenge is to
develop methods that maximize the detection and prevention of
prescription drug abuse, while minimizing any adverse impact
on legitimate medical treatments.
CONCLUSION
To conclude, doctor shopping monitoring is a useful component
for an efficient multidimensional monitoring to improve
the early detection of prescription drug abuse in the field
of addictovigilance.
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Introduction: The latest decade, an emerging issue has been the abuse potential of
the gabapentinoids pregabalin and gabapentin. The aim of our study was to assess this
safety signal combining two different methods of surveillance: search analytics big data
and the FDA spontaneous reporting system database.
Methods: Analysis of big data and the FAERS was used to detect pregabalin’s
and gabapentin’s abuse potential in comparison with two controls, clonazepam and
levetiracetam, and further, the correlation between these domains was investigated. Data
from the United States between 2007 and 2020Q2 were analyzed.
Results: The FAERS analysis revealed the following pattern of signals: clonazepam
> pregabalin ≥ gabapentin > levetiracetam, for both the primary term “drug abuse
and dependence” and the secondary terms (withdrawal, tolerance, overdose). The
Google domain pattern was slightly different: clonazepam ≥ gabapentin ≥ pregabalin≥
levetiracetam. A monotonic correlation was found between FAERS and Google searches
for gabapentin (r= 0.558; p< 0.001), pregabalin (r= 0.587; p< 0.001), and clonazepam
(r = 0.295; p = 0.030).
Conclusion: Our results revealed that there is preliminary evidence of a safety signal
for the abuse potential of pregabalin and gabapentin. Analysis of the FAERS database,
supplemented by big data search analytics, suggests that there is potential of using
these methods as a supplementary tool to detect drug abuse-related safety signals
in pharmacovigilance.
Keywords: pregabalin, gabapentin, big data, Google search analytics, disproportionality analysis, abuse potential,
safety signal, FAERS database
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INTRODUCTION
Gabapentinoids (pregabalin and gabapentin) are a class of
drugs that have been widely used-prescribed for neuropathic
pain, epilepsy, anxiety, and other psychiatric disorders,
while pregabalin showed promise as a treatment for alcohol
dependence (1, 2). Gabapentin and pregabalin have a similar
structure and are derivatives of the inhibitory neurotransmitter
GABA. Their proposed mechanism of action is the inhibition
of calcium currents via high-voltage-activated channels
containing the a2d-1 subunit (3). Since their first approval,
both gabapentinoids are widely prescribed medications in the
United States (4, 5).
The latest decade, an emerging issue has been the abuse
potential of both pregabalin and gabapentin. An increase in
non-medical use of gabapentinoids for recreational purposes
has been reported, especially in Europe (6, 7). Higher doses of
gabapentinoids use have been characterized by causing euphoria
effects and a range of experiences such as relaxation, improved
sociability, and sedative and psychedelic-like effects (8). From
the EudraVigilance database review on gabapentinoids, fatalities
were also reported associated with pregabalin and gabapentin
use and in most of the cases in combination with opioids (9).
Pharmacovigilance data from the Food and Drug Administration
Adverse Event Reporting System (FAERS) have shown adverse
drug events from gabapentinoid abuse with a higher prevalence
in young and male individuals (10). Both pregabalin and
gabapentin from 1st April 2019 have been classified as Schedule 3
controlled drugs under the Misuse of Drugs Regulations 2001,
and Class C of the Misuse of Drugs Act 1971 in the UK. On
the other hand, in the US, pregabalin is a Schedule 5 controlled
substance while gabapentin is a controlled substance only in
some States. In Australia, pregabalin and gabapentin are classified
as Schedule 4 (prescription only) medications; therefore there are
no special control measures on supply or possession yet (11).
Considering the abovementioned data on the relative well-
established abuse potential profile of the gabapentinoids, the
aim of our study was (i). to detect pregabalin’s and gabapentin’s
abuse potential in comparison with two controls, clonazepam
and levetiracetam and (ii). to investigate the correlation between
the search analytics and the FAERS domain. Our group
has recently published the methodology of combining these




Following the methodology of our previous analysis that
investigated mirtazapine’s abuse liability (12), herein, we
investigated the abuse liability of the gabapentinoids combining
pharmacovigilance and search analytics data from the
United States between 2007 and 2020Q2. Clonazepam, a
frequently used benzodiazepine with a well-known abuse
potential profile, was used as a positive control (12, 14), while
levetiracetam (a well-known antiepileptic with a low abuse
potential) (15) served as negative control.
TABLE 1 | Drug names and drug abuse-related terms.
Google FAERS










{Abuse, dependence} Drug abuse and
dependence (SMQ narrow
scope)
{Withdrawal} Drug withdrawal (SMQ
narrow scope)
{Overdose} Tolerance [drug tolerance
(PT) and drug tolerance
increased (PT)]
{Tolerance} Overdose [overdose (PT)
and intentional overdose
(PT)]
{High} Euphoria [euphoric mood
(PT), feeling abnormal
(PT), feeling drunk (PT),





In the FAERS database, the drugs are registered with their generic names; in Google
search analytics, a brand name was also used. Drug-abuse-related MedDRA terms were
selected in FAERS, and similar abuse-related search terms in the search analytics domain
(SMQ, standardized MedDRA query; PT, preferred term).
FAERS
The pharmacovigilance database of the FAERS consists
of individual safety reports originated mainly from the
United States. The structure and data mining algorithms of
FAERS have been described elsewhere (16). Briefly, reports can
be submitted by patients, the pharmaceutical industry, and
healthcare professionals, while adverse events are classified
with MedDRA terminology (16, 17). The freely available
pharmacovigilance tool OpenVigil-2.1-MedDRA (available at
http://openvigil.sourceforge.net/) was used in order to access
cleaned FAERS data, by removing duplicates and normalizing
drug names to the generic name of the drug (18). Similar to
our previous analysis, higher level terms were used, whenever
possible, to classify reports with drug-abuse-related adverse
events (12). The narrow scope of the Standardized MedDRA
Query (SMQ) “drug abuse and dependence” was used as
the primary term, and other terms related to drug abuse,
including overdose, tolerance, withdrawal, and euphoria-related
events, were used as secondary terms (Table 1) (12, 19).
Disproportionality analysis was conducted for the aggregated
period of 2007–2020Q2 for both the primary and secondary
terms, while correlation analyses were conducted using quarterly
data of the primary term.
Google Analytics
The Google search engine receives more than 5 billion of queries
per day (20). Although it does not provide detailed analytics,
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some indicators, such as the interest over time, are publicly
accessible. Usually, search queries contain terms related to the
generic and brand names of the drug, combined together with
some additional terms (e.g., “Can you get high of. . . ?”). We
combined analytics data retrieved using both the generic name
and a common brand name of each drug (Table 1).
An important aspect for retrieving analytics data from the
Google search engine is the context. We can define the search
context by limiting the returned results per category. The widest
category is the “general search term,” where Google returns
analytics from searches in all categories. However, since we were
studying a very specific area of interest, we could also restrict our
results in a more specific category (e.g., “medication”). Google
is using search semantics to classify each search query and
is expected that the more specific category will provide more
accurate results. However, depending on the search popularity
of some terms, there may not be enough results inside the
category context, because Google returns only results that can be
considered as big data volumes. In our study, we used only the
“prescription drug” category for the extraction of our data.
Next, we defined a set of six abuse-related search terms, similar
to the MedDRA abuse-related terms: {“abuse,” “dependence,”
“overdose,” “withdrawal,” “tolerance,” and “high”}. Table 1
indicates the relationship of the terms between the FAERS and the
Google domains. We used the term “high” as the corresponding
term of “euphoria,” as the second did not have enough data.
By default, Google does not return results for searches with
terms and queries made by a few people. Moreover special
characters (i.e., queries with apostrophes) were filtered—this is
a way of normalization that is also made by default. It is also
important that Google’s tools eliminate repeated searches from
the same person over a short period of time. We identified
queries containing combinations of the drug names and the
abuse-related terms from the set we defined in a previous
step. Finally, we filtered the results manually, by dropping out
queries unrelated to abuse. For example, while the search query
“clonazepam and high blood pressure” contains both the terms
“clonazepam” and “high,” it is not related to abuse. Instead, the
query “can you get high of pregabalin” is related to abuse and,
thus, included to our search results.
Statistical Analysis
The search interest over time is measured by the search
popularity score (SPS) in the Google domain. We used the SPS
score to collect metrics related to abuse liability. In the FAERS
domain, we used the reporting odds ratio (ROR) for abuse-
related adverse events. This methodology of analysis was recently
published from our group (12).
Search Interest Over Time
Google reports top searches for every search query. These are
terms (queries) that are most frequently searched with the main
term in the same search session and within the selected category,
country, or region (21).
The most popular queries are sorted by SPS. The value of
SPS is between 0 and 100. The most popular term (in our case
the main drug name, e.g., “Lyrica”) has a normalized score of
100, which is the maximum score. All other queries have a score
under this value. This indicator represents the total number of
searches divided by the total number of related searches on the
specific country or region at the given time range. This is the
default method used by Google in a tool called “Google Trends,”
to compare relative popularity between topics. For example, an
SPS of 50 is assigned to a query that has been searched half as
often as the top query. Queries with a search rate <1% are not
reported and are signed with a 0 SPS which is neither a percentage
value nor an absolute value of searches. Combining more than
one term or queries, the value can be above 100. Considering the
large number of queries, we can safely assume that all referred
statistics come from big data volumes.
We obtained the monthly SPS for all abuse-related terms for
each drug. We developed timelines representing the cumulative
search interest over time for the abuse-related terms beginning at
2007Q1 and ending at 2020Q2.
Disproportionality Analysis
Disproportionality analysis was conducted to investigate the
association between abuse-related events and the tested drugs
in comparison to all other drugs and all other events in the
FAERS database. The reporting odds ratio (ROR) was used to
quantify this association, and a larger ROR demonstrates a more
frequent co-reporting of the tested drug and the selected term as
well as a stronger safety signal. We detected safety signals when
the number of reports with the combination of the tested drug
and selected event was >3 and the lower boundary of the 95%
confidence interval of ROR was >1 (16). The disproportionality
analysis and RORs were calculated using the OpenVigil2.1-
MedDRA (18).
Correlation Between FAERS and Search
Analytics Domains
A correlation coefficient is a statistical metric that measures
the probability of two variables to change together. It describes
both the strength and the direction of the relationship. The
Pearson correlation coefficient is the most well-known metric,
which evaluates the linear relationship between two variables.
The Spearman correlation coefficient evaluates the monotonic
relationship between two continuous or ordinal variables. The
difference is that, in a monotonic relationship, the variables tend
to change in the same direction, increasing or decreasing their
values, but not necessarily at a constant rate, as in a linear
relationship. Unlike Pearson’s correlation, Spearman’s method




According to the analysis for the cumulative period, the
overall abuse-related terms had an average SPS of 8 for
Levetiracetam, 11.25 for pregabalin, 22.5 for gabapentin, and 45.5
for Clonazepam (Figure 1). Considering that Google is receiving
billion queries per day, even low values of SPS in the given time
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FIGURE 1 | Search Popularity Score (SPS) in the Google analytics domain for the four drugs.
range represent millions of queries about a topic (22). A non-
formal interpretation of these numbers could be as follows: e.g.,
for pregabalin, for every 100 search queries related to pregabalin,
there are 11.25 more queries (on top of the 100) related to
pregabalin and abuse related terms.
Figure 2 shows the search interest over time for pregabalin,
gabapentin, and clonazepam. The search volume for
levetiracetam was significantly low, and thus, there were
not enough data to be reported by the Google engine. While this
may sound as a serious limiting condition, instead it ensures
that the reported data are accurate and cannot be affected or
modified by a small number of people who perform search
queries producing “fake” trends.
The median values of search analytics over time were
82.5, IQR [53.25, 128] for pregabalin, 37, IQR [16.25, 47] for
gabapentin, and 203.5, IQR [145.25, 258] for clonazepam.
Disproportionality Analysis
During the period of 2007–2020Q2, there were in total 7430750
reports submitted in FAERS. The total number of reports (N)
was larger for pregabalin (N = 107,905) and gabapentin (N =
102,386), and about half for each of the controls, clonazepam (N
= 55,856), and levetiracetam (N= 43,842). For the primary term
“drug abuse and dependence” (N = 118,980), safety signals were
identified for both gabapentinoids (pregabalin: ROR 2.78 95% CI
[2.70–2.86]; gabapentin ROR 1.83 95% CI [1.76–1.90]), while the
positive control clonazepam had the largest signal (ROR 4.47 95%
CI [4.32–4.62]), and the negative control levetiracetam had a very
weak signal (ROR 1.10 95% CI [1.02–1.18]). The secondary terms
followed the same pattern of signals (clonazepam > pregabalin
≥ gabapentin > levetiracetam), except for euphoria-related
terms, for which pregabalin had the largest ROR and overdose-
related terms, for which the gabapentinoids and levetiracetam
demonstrated similar signals (Table 2). Figure 3 shows the
number of reported adverse events related to abuse terms in the
FAERS database.
Correlation Between FAERS and Search
Analytics Domains
A monotonic correlation was found between FAERS and Google
searches for clonazepam (r = 0.295; p = 0.030, Figure 4A),
gabapentin (r= 0.558; p< 0.001, Figure 4B), and pregabalin (r=
0.587; p < 0.001, Figure 4C). Since Google reports only volumes
with a significant number of searches, which can be considered as
big data volumes, we were not able to collect the amount of data
required for analysis for levetiracetam.
DISCUSSION
Based on extensive literature search, this is the first
study investigating the abuse potential of pregabalin and
gabapentin using two different pharmacovigilance methods:
disproportionality analysis in the FAERS and Google search
analytics. A positive control and a negative control were used,
the benzodiazepine clonazepam, with a well-known abuse profile
and the antiepileptic levetiracetam, with a previously unreported
abuse potential, respectively.
Signals in the FAERS Database
Our disproportionality analysis of the FAERS revealed the
following pattern of signals: clonazepam > pregabalin ≥
gabapentin > levetiracetam, both for the primary term “drug
abuse and dependence” and the secondary terms (withdrawal,
tolerance, overdose). Our results confirm previous findings
from the pharmacovigilance domain that highlight the abuse
potential of pregabalin. According to the review of the
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FIGURE 2 | Search interest over time for abuse-related terms in the search analytics domain. For the period 2007Q1 to 2020Q2, the search interest over time for
abuse-related terms is represented in timelines for each drug and is expressed as quarterly relative search volume for overall abused-linked terms.












ROR 2.78 95% CI
[2.70–2.86]; N = 4,558
ROR 1.83 95% CI
[1.76–1.90]; N = 2,924
ROR 1.10 95 %CI
[1.02–1.18]; N = 767
ROR 4.47 95% CI
[4.32–4.62]; N = 3,700
Drug withdrawal (N =
28,149)
ROR 3.76 95% CI
[3.56–3.96]; N = 1,463
ROR 2.09 95% CI
[1.95–2.25]; N = 796
ROR 1.54 95 % CI
[1.36–1.74]; N = 254
ROR 4.81 95% CI
[4.51–5.13]; N = 976
Overdose (N = 85,274) ROR 1.69 95% CI
[1.61–1.76]; N = 2,053
ROR 1.65 95% CI
[1.57–1.72]; N = 1,904
ROR 1.98 95% CI
[1.86–2.11]; N = 979
ROR 4.29 95% CI
[4.12–4.46]; N = 2,588
Drug tolerance (N =
1,965)
ROR 4.73 95% CI
[3.96–5.66]; N = 128
ROR 3.76 95% CI
[3.07–4.61]; N = 98
ROR 0.78 95% CI
[0.40–1.49]; N = 9
ROR 6.94 95% CI
[5.66–8.51]; N = 98
Euphoria-related events (N
= 280,097)
ROR 2.87 95% CI
[2.81–2.93]; N =
10,664
ROR 2.09 95% CI
[2.04–2.14]; N = 7,644
ROR 1.27 95% CI
[1.22–1.33]; N = 2,077
ROR 2.41 95% CI
[2.33–2.48]; N = 4,765
Each drug has been compared with all other drugs in the FAERS database. The study population consisted of 6993352 reports.
EudraVigilance database, adverse drug reactions were more
frequently reported for pregabalin use compared to gabapentin
(23). Pharmacovigilance data from FAERS have also shown
adverse drug events from pregabalin use and in general
gabapentinoid abuse with a prevalence in young and male
individuals (10). In contrast, from the EudraVigilance database
review, there were adverse drug reaction reports related to
abuse/dependence and misuse of pregabalin and gabapentin
with a prevalence in female adults (9). The last decade, apart
from gabapentinoid abuse there has also been reported extended
misuse, with a greater potential of misuse for pregabalin (9).
The misuse of pregabalin has been strongly linked to its
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FIGURE 3 | Number of reported adverse events in the FAERS database related to abuse.
FIGURE 4 | Correlation between FAERS and Google searches for (A) clonazepam (r = 0.295; p = 0.030); (B) gabapentin (r = 0.558; p < 0.001); (C) pregabalin (r =
0.587; p < 0.001).
strong sedative and psychedelic effects. It has been stated that
pregabalin misuse is more likely to occur in new users (24).
Besides being considered as less powerful than pregabalin,
gabapentin misuse was also associated with similar psychedelic
effects. A few substances have been reported for misuse in
combination with gabapentin, such as cannabis, alcohol, selective
serotonin reuptake inhibitors (SSRIs), LSD, amphetamine, and
gamma-hydroxybutyrate (GHB) (8, 25). There is agreement
from other studies that the majority of individuals that have
been reported for pregabalin abuse have a history of other
substance and medication abuse as well (11, 26). The differences
in the pharmacokinetic and pharmacodynamic profile of the
gabapentinoids should be carefully examined in order to
understand pregabalin’s higher abuse potential compared to
gabapentin (11, 25).
Signals in the Google Analytics Domain
The Google search analytics data are big data. Their volume,
velocity, and variety are far beyond any other dataset of
collected data, such as the adverse event reports. While they
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cannot be considered as a safe source for safety signals, their
recognition of the potential is rising (27), and their use in
pharmacovigilance is emerging. A recently published study of the
French Addictovigilance Network combined Google Trends with
the analysis of the global database of individual case safety reports
(VigiBase) (28). Our team has recently published this method
of combining different data sources of drug safety surveillance,
Google search analytics, and disproportionality analysis of the
US FAERS database (12) to detect safety signals. Data from this
timeline series from 2004Q1 to 2017Q2 revealed a consistent
association of abuse-related searches in the Google search engine
with the antidepressant mirtazapine, and a similar pattern of
association between abuse-related events and the drug was found
in FAERS. The results of this previous study already suggested
that search analytics and disproportionality analysis of FAERS
may be used combined as a supplementary pharmacovigilance
tool. Signals of gabapentinoid abuse found agreed with the signals
for the positive and negative control drugs (clonazepam and
levetiracetam). The generic pattern for FAERS was clonazepam
≥ pregabalin≥ gabapentin≥ levetiracetam. The Google domain
pattern was slightly different: clonazepam ≥ gabapentin ≥
pregabalin ≥ levetiracetam. This difference can be explained by
the fact that gabapentin was first approved for use in 1993 and in
2018 it was the eleventh most commonly prescribed medication
in the United States, with more than 46 million prescriptions
in 2018 and an increasing number of prescription over time
(5). On the other hand, pregabalin (FDA approved in 2004)
had an estimated number of 11.5 million prescriptions in 2018
in the United States being in ranking 70th among the most
commonly prescribedmedication (4). It should also be noted that
disproportionality analysis cannot quantify the true risk, which
should also be the case for the Google domain (29).
Correlation Between the Domains
A significant monotonic correlation was found between FAERS
and Google searches for gabapentin (r = 0.558; p < 0.001),
pregabalin (r = 0.587; p < 0.001), and clonazepam (r = 0.295; p
= 0.030). This relationship between two totally different domains
indicates that when one of the values changes in one domain,
there is a significant probability to change in the same way in the
other domain. Thus, changes of abuse-related searches on Google
for pregabalin, gabapentin, or clonazepam are accompanied
by analogous changes of abuse-related events in FAERS and
vice versa. There is no causality on this fact but, rather, a
similar behavior of two data domains. Interestingly, there were
not enough big data volumes for levetiracetam to develop the
timelines and, thus, no comparison could be made.
Study Limitations
Our study has some methodological considerations and
limitations. Disproportionality analysis cannot differentiate
between recreational, self-treatment, or mixed type of abuse;
however, it is a suitable tool to quantitate signals of abuse of
known and novel psychoactive substances. Further, the causal
relationship between drugs and the adverse event (abuse)
cannot be verified without a clinically performed causality
assessment, while confounders as comorbidity and concomitant
drugs cannot also be assessed properly. Regarding search
analytics, since Google only reports large datasets, terms such as
dependence, tolerance, and misuse have not provided substantial
numbers and were not included in the analysis. In addition, the
algorithms and their updates utilized by Google to analyze data
are not publicly available. Finally, there were not enough data
volumes before 2007.
CONCLUSION
Concluding, the present study revealed a safety signal for the
abuse potential of pregabalin and gabapentin using two different
methods of surveillance, the FAERS database analysis and big
data search analytics. We suggest that these methods can be used
in combination as a supplementary pharmacovigilance tool to
detect drug safety signals.
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